# Adaptive Bipolar Androgen Therapy for Prostate Cancer

By Russ Hollyer

Copyright 2025 by Russ Hollyer
All rights reserved.

**The information, including but not limited to, text, graphics, images and other material contained in this book is for informational purposes only. No material on this site is intended to be a substitute for professional medical advice, diagnosis, or treatment.**

## Table of Contents


Adaptive Bipolar Androgen Therapy for Prostate Cancer ..... 1
Table of Contents ..... 2
Acronyms and Terms ..... 7
Author's Note ..... 9
About me ..... 10
My History ..... 11
My Personal Program as of 04/2025 ..... 14
**Therapy:** ..... 14
My main treatment is cyclical aBAT as defined in: Integrating the Concepts: *** Integrating the Concepts: Mechanistic Optimization of BAT Cycle Durations – Program Overview (2023–2025+) ..... 14
Half-lives ..... 15
AI research assistants ..... 20
1. Perplexity https://www.perplexity.ai/ ..... 20
2. Google Gemini https://gemini.google.com/ ..... 20
3. ChatGPT https://chatgpt.com/ ..... 20
Assistance programs ..... 25
Newly Diagnosed with Prostate Cancer ..... 25
DNA, RNA, SNPs, Germline, Somatic, Variants, Splice Variants, Mutations, DTC, ctDNA, cfDNA, MSI Status, VAF and Tests. ..... 29
Definitions ..... 29
Key Clinical Tests ..... 31
Comparative Chart: Liquid Biopsy and Molecular Profiling Platforms ..... 31
SNPs (Single Nucleotide Polymorphisms) ..... 33

***** Bipolar Androgen Therapy (BAT)** ..... 38
BAT: A Novel Therapeutic Approach for Prostate Cancer ..... 38
Clinical Trials ..... 49
Predicting Efficacy of Bipolar Androgen Therapy (BAT) in Prostate Cancer ..... 64
Slightly modified standard BAT ..... 76
References ..... 77
aBAT ..... 86
Comparative Analysis of Testosterone Esters used in BAT ..... 86
Adaptive Bipolar Androgen Therapy (aBAT) in Hormone-Sensitive Prostate Cancer: Comprehensive Clinical Framework ..... 87
*** aBAT: An Example Program ..... 97
Managing ADT in aBAT ..... 97
Other Considerations ..... 98
How PSA is Used to Guide aBAT ..... 99
Program Steps ..... 99
Testosterone Injection Guide for BAT ..... 106
Testosterone Injection Pain Relief ..... 107
BAT in HSPC (HSPC Classification) ..... 108
Definition of Progression from HSPC to CRPC ..... 109
References ..... 110
Short SPA pulses in aBAT ..... 120
Preclinical Insights into Androgen-Driven Apoptosis ..... 120
Mechanistic Rationale for Short Pulses ..... 120
Clinical and Practical Considerations ..... 121
Advantages and Challenges of Short SPA pulses ..... 121
Recommended Tests ..... 122
Options: ..... 122
References ..... 124
Evidence for Short Pulses ..... 124
A-SPA ..... 126

Mechanism of Action..... 126
How to Integrate A-SPA into aBAT..... 127
Conclusion..... 128
Olaparib, Testosterone Propionate, ADT, and Darolutamide Combination Therapy (oraBAT)..... 129
Treatment Components..... 129
Key Design Rationale..... 129
Clinical Implementation..... 130
Supporting Evidence..... 130
Safety & Tolerability..... 130
Conclusion..... 131
*** **Integrating the Concepts: Mechanistic Optimization of BAT Cycle Durations – Program Overview (2023–2025+)**..... 131
1. Dynamic Cycle Architecture..... 131
2. Precision Drug Synergy (PDS)..... 132
3. Framework..... 135
4. Baseline Somatic Profiling (e.g. Guardant360 CDx):..... 136
5. Key Mechanistic Advantages..... 136
6. Monitoring and Biomarkers..... 137
7. Biomarker-Driven Adjustments..... 137
8. Conclusion..... 138
9. Addendum:..... 139
oHSPC and oCRPC..... 168
High Androgens (BAT) + SBRT + Olaparib (+Prazosin)..... 168
Low Androgens (ADT + ARSI) + SBRT + Olaparib..... 169
Comparison: BAT-Based vs ADT-Based Combination..... 172
References..... 174
ADT..... 176
Types of ADT..... 177
Essential Tests to Monitor Heart Failure Risk During Hormone Therapy..... 198
References..... 212

Radiation ..... 225
How High Androgens Affect DNA DSBs in Radiation Therapy: ..... 225
Low androgens (ADT) can also improve responses from radiation. Different mechanisms and cell lines. ..... 225
PARP Inhibitor/RT ..... 225
Alpha Radioligand Therapy for PCa: An Overview ..... 228
Pluvicto + Orgovyx + Nubeqa + Lynparza Combination for Metastatic Castration-Resistant Prostate Cancer (mCRPC) ..... 245
SBRT ..... 247
Machine Learning-Based Composite Radiosensitization Efficacy Score (CRES 1.0) ..... 264
CRES 2.0 ..... 267
Testing ..... 270
1. Genetic Testing in Advanced Prostate Cancer ..... 270
2. Additional Blood Tests & Metrics for Health and Prostate Cancer Monitoring ..... 271
3. CTX and P1NP as Biomarkers for Bone Metastases ..... 273
4. Table 4. Smartwatch Metrics Linked to PCa Progression ..... 275
ctDNA ..... 278
Key findings ..... 278
ctDNA and Bipolar Androgen Therapy (BAT) ..... 278
FDA-Approved ctDNA Tests for PCa ..... 278
Requirements for Testing ..... 278
Key Takeaways ..... 278
References ..... 279
Tumor Mutational Burden (TMB) ..... 280
What Is TMB? ..... 280
Why Does TMB Matter? ..... 280
How Is TMB Measured? ..... 280
References ..... 280
How Prostate Cancer Cells Metastasize: The Journey from Primary Tumor to Distant Sites ..... 282
Key Stages in the Metastatic Cascade ..... 282
Molecular Drivers of Prostate Cancer Metastasis ..... 283

Preferred Metastatic Sites ... 283
Strategies to Delay or Prevent Metastases in Prostate Cancer ... 284
Pharmacological Interventions with Proven Metastasis Delay ... 284
Metabolic and Multitargeted Approaches ... 284
Conclusion ... 285
Successful AR Degraders and SARDs in Prostate Cancer ... 286
CRPC ... 289
Development ... 289
Therapeutic Strategies ... 289
HSPC->CRPC Prediction ... 291
Theoretical CRPC Resensitization Strategies ... 295
Calculators and dictionaries, etc ... 308
5AR inhibitors (Finasteride and Dutasteride) ... 309
DNA double-strand breaks (DSBs) ... 313
How DSBs Occur and Their Impact in PCa ... 313
Therapeutic Implications ... 313
Conclusion ... 314
DNA Double-Strand Breaks from SBRT vs. High-Testosterone BAT in Prostate Cancer ... 314
DNA DSB Induction by SBRT and BAT ... 315
Summary of some DNA DSBs ... 321
References ... 321
Therapy History ... 323

## Acronyms and Terms

**Disease states, staging, and pathology**

- **PCa**: Prostate cancer
- **HSPC / CSPC**: Hormone-sensitive (castration-sensitive) prostate cancer
- **mHSPC / mCSPC / mPCa**: Metastatic HSPC/CSPC
- **CRPC**: Castration-resistant prostate cancer (modern term; historically **HRPC**)
- **mCRPC / nmCRPC**: Metastatic / non-metastatic CRPC
- **OMD / Oligomet**: Oligometastatic disease
- **TNM / AJCC**: Tumor-Node-Metastasis staging / staging authority
- **N1 / M1a / M1b / M1c**: Regional nodes / distant nodes / bone / visceral mets
- **GG / ISUP**: Grade Group / pathology grading system
- **AVPC**: Aggressive variant prostate cancer. A clinical subtype with features resembling small-cell or neuroendocrine tumors, often associated with rapid progression, visceral metastases, low PSA relative to tumor burden, and resistance to standard androgen receptor–directed therapies.
- **SqPCa**: Squamous cell prostate carcinoma. A rare histologic variant of prostate cancer, typically treatment-emergent, characterized by squamous differentiation.
- **SCC**: Small-cell carcinoma. A high-grade neuroendocrine carcinoma that can arise de novo or evolve from prostate adenocarcinoma under therapeutic pressure.
- **NEPC**: Neuroendocrine prostate cancer. A broad category of prostate cancers with neuroendocrine differentiation, including both de novo and treatment-emergent disease.
- **t-SCNC**: Treatment-emergent small-cell neuroendocrine carcinoma. A subtype of NEPC that develops after androgen receptor pathway inhibition, frequently aggressive and resistant to hormonal therapy.
- **LCNEC**: Large-cell neuroendocrine carcinoma. A rare but aggressive neuroendocrine variant of prostate cancer, histologically distinct from small-cell carcinoma, with poor prognosis.
- **Basal-like prostate cancer**: A molecular subtype characterized by expression of basal epithelial markers, often resistant to androgen receptor–targeted therapies and associated with more aggressive clinical behavior.
- **Ductal adenocarcinoma**: A histologic subtype of prostate cancer arising from prostatic ducts, often presenting with hematuria or obstructive urinary symptoms, typically more aggressive than acinar adenocarcinoma.

**Androgen biology and endocrine terms**

- **AR**: Androgen receptor
  - **iAR**: Intracellular AR (nuclear/cytoplasmic)
  - **mAR**: Membrane-associated AR
- **T / tT / fT / bT / SHBG**: Testosterone (total / free / bioavailable) / sex hormone–binding globulin
- **DHT**: Dihydrotestosterone
- **GnRH / LHRH**: Gonadotropin-releasing hormone / luteinizing hormone-releasing hormone
- **LH / FSH**: Pituitary gonadotropins
- **HPG axis**: Hypothalamic-pituitary-gonadal axis
- **Endogenous / Exogenous**: Produced in the body / given from outside
- **E1 / E2 / E3**: Estrone / estradiol / estriol
- **tE2**: Transdermal estradiol

**Systemic therapy classes and related**

- **ADT**: Androgen deprivation therapy (surgical or medical castration; very low T/DHT)

- **5AR / 5ARI**: 5-alpha-reductase enzyme / its inhibitors
- **AI**: Aromatase inhibitor
- **ARI**: Androgen-receptor inhibitor (e.g., bicalutamide; blocks ligand binding)
- **ARSI (ARAT)**: Androgen-receptor signaling inhibitor (enzalutamide, apalutamide, darolutamide; impairs AR signaling and nuclear activity)
- **ABI / Abiraterone**: Androgen biosynthesis inhibitor (CYP17 inhibitor; often grouped with AR pathway agents)
- **ARPI**: Often used to mean "AR-pathway inhibitor." In your notes, defined as "AR oncogenic signaling network inhibitor" and listing abiraterone and ARSIs together.
- **DOC / CABA**: Docetaxel / cabazitaxel (taxanes)
- **PARPi**: PARP inhibitors (olaparib, rucaparib, niraparib, talazoparib)
- **BAT / aBAT / SPA / SPT**: Bipolar androgen therapy / adaptive BAT / supraphysiologic androgens / supraphysiologic testosterone
- **EZ-ADT**: Estrogen-based ADT with abiraterone
- **NT / LA**: Normal testosterone / low androgens
- **Tp**: Testosterone propionate
- **AAS / SARM**: Androgenic-anabolic steroids / selective AR modulators
- **MO / RO**: Medical oncologist / radiation oncologist
- **SOC**: Standard of care

**Radiation, radiopharmaceuticals, and imaging**

- **RT / EBRT / IMRT / IGRT**: Radiation therapy; external-beam; intensity-modulated; image-guided
- **SBRT / SABR**: Stereotactic body radiotherapy / stereotactic ablative radiotherapy
- **ART / SRT / eSRT**: Adjuvant RT; salvage RT; early salvage RT
- **WPRT**: Whole-pelvis RT
- **BT (HDR/LDR)**: Brachytherapy, high/low dose rate
- **PSMA**: Prostate-specific membrane antigen (imaging/therapy target)
- **PET/CT / PET/MRI / FDG / SUV**: Imaging modalities and tracer metric
- **RLT / RPT**: Radioligand (radiopharmaceutical) therapy
  - **Lu-177-PSMA-617**: Lutetium-177 PSMA-targeted therapy (Pluvicto)
  - **Ra-223**: Radium-223 dichloride
  - **Tb-161**: Terbium-161 PSMA-targeted radioligand (investigational)
  - **Ac-225**: Actinium-225 PSMA-targeted alpha therapy (investigational)

**Biomarkers, labs, liquid biopsy**

- **PSA / PSADT**: Prostate-specific antigen / PSA doubling time
- **ALP / LDH / Hgb / AST / ALT**: Alkaline phosphatase / lactate dehydrogenase / hemoglobin / liver enzymes
- **NLR / PLR / LMR / SII**: Neutrophil-to-lymphocyte; platelet-to-lymphocyte; lymphocyte-to-monocyte ratios; systemic immune-inflammation index
- **ctDNA / CTC**: Circulating tumor DNA / circulating tumor cells
- **CgA / NSE**: Chromogranin A / neuron-specific enolase (neuroendocrine markers)
- **MRD**: Minimal (measurable) residual disease

**Genomics, DNA repair, molecular subsets**

- **DNA / RNA-Seq / NGS / Proteomics / Epigenomics**: Core omics terms

- **PARP** — Poly(ADP-ribose) polymerase. A family of DNA-repair enzymes (mainly **PARP1** and **PARP2**) that sense single-strand DNA breaks and help fix them through **base excision repair (BER)**. In tumors with **HRR** defects (e.g., BRCA1/2), cells rely more on PARP-mediated repair, creating a therapeutic vulnerability.

- **PARylation** — The chemical process by which PARP enzymes add poly(ADP-ribose) chains to themselves and nearby proteins to recruit DNA-repair factors at sites of damage.

- **PARP trapping** — When a PARP inhibitor prevents enzyme release from DNA, the PARP–DNA complex stalls replication and causes lethal DNA damage. Trapping potency differs by drug (e.g., talazoparib > rucaparib/olaparib > niraparib).

- **BER (Base Excision Repair)** — The DNA-repair pathway that fixes single-strand breaks and small base lesions; PARP1/2 are key mediators.
- **DNA SSB / DSB**: Single- / double-strand breaks
- **NHEJ / HR / HRR / MMEJ**: DNA repair pathways (non-homologous end joining; homologous recombination; homologous recombination repair; microhomology-mediated end joining)
- **DDR / HRR genes**: DNA damage repair / homologous recombination repair genes (BRCA1/2, ATM, CDK12, etc.)
- **PTEN / TP53 / RB1 / MYC**: Key tumor suppressors and oncogenes in aggressive disease
- **MSI-H / dMMR / TMB-H**: Microsatellite instability-high / mismatch-repair deficient / high tumor mutational burden
- **AR-V7**: AR splice variant linked to ARSI resistance
- **NEPC**: Neuroendocrine prostate cancer (AR-independent phenotype)
- **OSN**: Oncogenic signaling network
- **STING**: Stimulator of interferon genes pathway

**Trials, outcomes, and methods**

- **RCT**: Randomized clinical trial
- **OS / CSS / PFS / rPFS / MFS**: Overall survival / cancer-specific survival / progression-free survival / radiographic PFS / metastasis-free survival
- **ORR / DCR / PSA50 / PSA90**: Objective response rate / disease control rate / ≥50% or ≥90% PSA decline
- **TTF / TTP**: Time to treatment failure / time to progression
- **AE / SAE / CTCAE**: Adverse event / serious AE / toxicity grading
- **IC50 / Tmax / IM**: Half-max inhibitory concentration / time to Cmax / intramuscular route

**Metabolism, nutrition, misc.**

- **BMD**: Bone mineral density
- **BP**: Blood pressure
- **Hba1c**: Glycated hemoglobin
- **HDL / LDL**: Lipoproteins
- **EPA**: Eicosapentaenoic acid
- **PPAR-δ**: Peroxisome proliferator-activated receptor delta
- **GFJ**: Grapefruit juice (CYP3A4 inhibitor; drug–food interactions)
- **WFPB**: Whole-food plant-based diet

**Notes to avoid confusion**

- **CRPC vs HRPC**: “CRPC” is the current term; “HRPC” is older.
- **ARI vs ARSI vs ARPI**:
  - **ARI** blocks androgen binding at AR (e.g., bicalutamide).
  - **ARSI/ARAT** impairs AR signaling/nuclear function (enzalutamide, apalutamide, darolutamide).
  - **ARPI** is often used broadly for any AR-pathway inhibitor; some include abiraterone (a CYP17 inhibitor) in this umbrella.

Comprehensive searchable list of acronyms used in oncology: [Medical Abbreviations (esmo.org)]

- **CYP11A1 inhibitor**: A drug that blocks the first step of steroidogenesis, reducing intratumoral androgen synthesis and potentially slowing prostate cancer progression.
- **CAR-T**: A personalized immunotherapy that engineers a patient's T cells to target prostate cancer-specific antigens such as PSMA or PSCA.
- **AR degrader**: A molecule designed to eliminate the androgen receptor protein itself, shutting down androgen-driven signaling in prostate cancer cells.
- **PROTAC**: A bifunctional molecule that recruits the cell's own degradation machinery to selectively destroy the androgen receptor or other cancer-promoting proteins.
- **CYP3A4 inhibitor**: A drug that inhibits the liver enzyme CYP3A4, often used to boost the effectiveness of other prostate cancer therapies by slowing their metabolism.
- **CYP17 inhibitor**: A therapy that blocks CYP17A1, a key enzyme in androgen biosynthesis, thereby depriving prostate tumors of the hormones that drive their growth (e.g., abiraterone)

## Author's Note

I am not affiliated with or compensated by any company, nor do I receive financial incentives from any product or therapy discussed in this book. I donate 100% of my profits to PCF or other prostate cancer charities.

The purpose of this book is to document some information on hormonal therapies, specifically bipolar androgen therapy (BAT. While part of this effort is for my own record-keeping—tracking therapies and outcomes for future reference—my broader goal is to offer others a clear, balanced presentation of the evidence that has informed my decisions.
Throughout the book, you'll find references to studies that may appear to conflict. That is intentional. I'm not advocating for any single therapy or viewpoint. Instead, I've sought to present both supportive and contradictory evidence so readers can make informed, individualized choices. The sources I draw from include clinical trials, meta-analyses, mechanistic studies, both in vivo and in vitro research, and conversations with physicians. When available, I give priority to large, well-controlled studies.
While this book is detailed, I've aimed to focus on content that is actionable and relevant. Personally, I value a concise summary of useful findings over a lengthy narrative padded with repetition. For that reason, I've aimed to write in clear, accessible language, avoiding technical jargon unless it adds clarity. References and deeper insights are included for readers who wish to pursue further research.
You may notice some formatting inconsistencies, particularly in references. I've prioritized content development and research depth over stylistic perfection.
It's worth emphasizing that while some physicians may support aspects of the therapies I describe, others may strongly disagree. I fully acknowledge that the standard of care (SOC)—including radical prostatectomy, androgen deprivation therapy (ADT), and next-generation hormonal agents—is grounded in robust clinical evidence and decades of clinical practice. These remain highly appropriate and effective options for many patients, depending on their clinical profile.
For context: I underwent a radical prostatectomy in 2018, followed five months later by ADT using an estrogen patch and abiraterone (Zytiga). I expect to use additional SOC treatments in the future. However, certain aspects of conventional therapy did not align with my personal priorities. I place a high value on preserving libido, physical vitality, and overall quality of life. One of my guiding aims is to delay or avoid the onset of castration-resistant prostate cancer (CRPC).
I want to express my deep gratitude to the medical professionals who have supported me through this journey. Although they did not contribute to or endorse the contents of this book, I have discussed many of the ideas presented here with them, and their insight has been invaluable.

- **Dr. Amber Flaherty**, a hematologist/oncologist in Scottsdale, Arizona (City of Hope), has been an exceptional resource—knowledgeable, compassionate, and patient-centered. Website: Amber Flaherty, MD

- **Dr. James Spurgeon**, NMD, based in Scottsdale, Arizona (Optimal Medical Health), has been an insightful and humble collaborator. Several friends whom I referred to him have also had excellent experiences. Website: James Spurgeon, NMD
- **Dr. Frank Cibulka**, my primary care physician in Phoenix, Arizona (HonorHealth), has been forward-thinking and proactive for decades. In the 1990s, he recommended the use of a statin, vitamin D, and low-dose aspirin—well ahead of broader clinical guidelines. He remains accessible and open to discussion. Website: Frank Cibulka, MD

If you come across any inaccuracies or omissions, or have suggestions for further content, I welcome your feedback.

## About me

I was born in Phoenix, Arizona and live there today.

During my work career I worked as an electrical engineer for a medical company, an aerospace engineer for the government and for contractors and as a hedge fund manager. Most of my work was in the medical technology area and involved data gathering, quality screen design, computer programming, and test screening.  Because of this I became very data driven. Theories and hypotheticals are very frequently proven to be incorrect.

# Half-lives

The washout period is typically estimated at five elimination half-lives, corresponding to approximately 97% drug clearance from the system. For example, a drug with a 2-day half-life would theoretically require about 10 days for washout.
However, this simplified model can be complicated by several factors:

1. Active metabolites: Some drugs produce active metabolites with their own half-lives, potentially extending the washout period.
2. Enzyme induction or inhibition: Drugs may alter metabolic enzyme activity, affecting clearance rates of themselves or other compounds.
3. Tissue accumulation: Lipophilic drugs may accumulate in fatty tissues, prolonging their effective half-life.

For testosterone and its analogs, elimination half-life can vary significantly due to individual factors including:

- Basal metabolic rate
- Body composition (fat mass vs. lean mass)
- Body mass
- Sex hormone-binding globulin (SHBG) levels
- Age
- Hepatic and renal function
- Genetic polymorphisms in metabolizing enzymes

The precise impact of these factors on half-life is not fully characterized and can lead to substantial inter-individual variability. In clinical practice, this necessitates individualized monitoring and potential dose adjustments.

**Abiraterone Acetate (Zytiga):** Effective in 2-3 days, elimination half-life 7-17 hours but CYP17 recovery half-life can be up to 42-96 hours. So 3-4 weeks from cessation of Zytiga to washout and CYP17 recovery. If you are taking a corticosteroid (e.g., prednisone) it is usually unwise to stop the corticosteroid when you stop Zytiga. Your MO will probably give you a ramp-down schedule.
**AI Letrozole:** 2 days
**Albuterol (selective beta2-adrenergic receptor agonist):** Inhaler: 3-5 hours. Oral: 5-6 hours. XR: 9.3 hours.
**Apalutamide (Erleada):** 3 days
**Aspirin:** 15-20 minutes. Metabolite a few hours. **Duration of effect 7-10 days (this is the important property)**
**BHB:** β-hydroxy butyrate is a ketone body: 0.8-3.1 hours**.** Maximum plasma levels of ketones, including BHB, are achieved within 1.5-2.5 hours.
**Bicalutamide (Casodex):** Effective within a day, elimination half-life 7 days.
**Cabergoline:** Serum max in 6 hours, elimination half-life 3-5 days. Begins to reduce PRL in 6 hours and levels continue to fall for 1-3 weeks.
**Caffeine:** 3-5 hours, serum max 1 hour
**Cabergoline:** (listed above)
**Clearance of E2 after estrogen patch removal:** 4 hours
**Creatine:** 1.5-3 hours, serum max 1-2 hours
**Curcumin:** 1 hour (possible interference with PSA tests), serum max 1-2 hours
**Curcuminoids:** 24 hours (possible interference with PSA tests), serum max 1-2 hours
**Cytoxan:** 3-12 hours
**Darolutamide (Nubeqa):** elimination half-life 15-20 hours. Cmax 4 hours.

**DHEA:** 15-40 minutes (DHEAS: 7-22 hours)
**Diethylstilbestrol (DES):** elimination half-life: 2-3 days.
**Disulfiram:** 12 hours. But true biological effect half-life is 2-5 days.
**Dutasteride:** 5 weeks. Washout time is approximately 5 half-lives or 6 months for dutasteride.
**EGCG:** 3-4 hours, serum max 1-2 hours
**Enzalutamide (Xtandi):** 5.8 (3-10) days, metabolite 7.8-8.6 days
**E1 (oral):** elimination half-life 12 hours
**E2 (gel: e.g., Divigel):** elimination half-life 10 hours
**E2 (oral):** elimination half-life 17 hours
**E2 from estrogen patch:** elimination half-life 3 hours
**E3 (oral):** elimination half-life 16 hours
**Finasteride:** 5-7 hours (max DHT reduction action within 8 hours)
**Flutamide:** 5-8 hours, becomes active in 4 hours.
**Grapefruit Juice (GFJ):** CYP3A4 inhibition 12-24 hour half-life
**GW-501516 (Cardarine):** 12-24 hours
**HCG:** 24-36 hours
**Indomethacin:** 5-10 hours
**L-citrulline:** 2 hours, serum max 45 minutes
**L-arginine:** 2 hours
**Levitra:** 5 hours
**Losartan:** 2 hours. Active metabolite 6-9 hours
**Lovastatin:** biological half-life: 13 hours
**Melatonin:** 30-60 minutes
**Melatonin XR:** 3.5-4 hours
**Metformin:** 6.5 hours
**N-Acetyl Glucosamine:** 4 hours
**Nandrolone Decanoate:** 9 days, anabolic/androgenic ratio ~ 125:37
**Nandrolone Phenylpropionate (NPP):** 3 days, anabolic/androgenic ratio ~ 125:37
**Nivolumab:** 20 days
**Orlistat:** 1-2 hours
**Orgovyx/Relugolix:** 25 hours
**Olaparib/Lynparza:** Peak within 3 hours, elimination half-life 10-14 hours
**Oxandrolone (Anavar):** 10 hours, anabolic/androgenic ratio ~ 450:24
**Prazosin:** 2-3 hours, Peak serum levels in 3 hours
**Prednisone:** half-life 2-4 hours.
**Progesterone (gel):** 14-50 hours
**Progesterone (oral):** 5-10 hours
**Progesterone (transdermal):** 30-40 hours
**R1881 (metribolone):** synthetic androgen used for research (does not aromatize), 4-9 hours, anabolic/androgenic ratio: 12,000-30,000:6500
**SARM Ostarine:** 24 hours, anabolic/androgenic ratio ~ 10:1
**SARM Rad-140:** 20 hours, anabolic/androgenic ratio ~ 90:1

**SARM Rad-150:** 48 hours, anabolic/androgenic ratio ~ 90:1
**SARM S4 (Andarine):** 4-6 hours, anabolic/androgenic ratio ~ 10:1
**Sirolimus:** 5 days
**Simvastatin:** 5 hours
**Stenabolic (SR9009):** 4-6 hours
**Testosterone Nasal Gels:** Tmax 0.5-1.5 hours, elimination half-life 4-8 hours, anabolic/androgenic ratio 100:100
**Testosterone Gels:** single application Tmax 1-2 hours, single application half-life 10 hours, second application Tmax 16 hours, repeated application Tmax 7 hours, elimination half-life 12-36 hours, anabolic/androgenic ratio 100:100
**Testosterone Base (no ester – e.g. Aquaviron, Aquabol):** 2-3 hours but 12-36 hours for actual elimination half-life (body forms depot), anabolic/androgenic ratio 100:100
**Testosterone Cypionate:** 7.5 days, anabolic/androgenic ratio 100:100
**Testosterone Enanthate:** 4.5-7 days, anabolic/androgenic ratio 100:100
**Testosterone Propionate:** 24-40 hours, anabolic/androgenic ratio 100:100
**Testosterone Undecanoate Injectable:** 20-30 days, anabolic/androgenic ratio 100:100
**Testosterone Undecanoate Oral:** Effective elimination half-life 18-36 hours, Tmax 2-6 hours, anabolic/androgenic ratio 100:100
**Trenbolone Acetate:** 3 days, anabolic/androgenic ratio ~ 500:500
**Turinabol:** 16 hours, anabolic/androgenic ratio ~ 53:3
**Viagra:** 4 hours




Figure 1 If a single dose is taken, then most of it is eliminated by 5 elimination half-lives.




Figure 2 If repeated doses are taken on each half-life, then steady state is reached after about 5 half-lives.

## AI research assistants

1. Perplexity https://www.perplexity.ai/
2. Google Gemini https://gemini.google.com/
3. ChatGPT https://chatgpt.com/
4. Elicit https://elicit.com/

I've learned to approach AI systems with careful discernment. While they can provide valuable research synthesis and information processing capabilities, they sometimes present inaccurate or oversimplified information, particularly in specialized fields like oncology and endocrinology. The most productive approach is to engage them critically, cross reference across multiple AIs, challenge questionable assertions, and verify key information against primary literature. Their utility increases significantly when treated as research assistants rather than authoritative sources.


Natural History of Prostate Cancer
using strictly SOC treatments
Local therapy
i.e. Radiation
Androgen deprivation
i.e. LHRH Agonists
Chemotherapy
i.e. Docetaxel
Tumor growth
Death
Androgen dependence
Castration-sensitive
Castration-resistant
Disease burden
Local
Metastatic
Symptoms
Asymptomatic
Symptomatic




Typically, PCa goes through the following sequence:

- The tumor starts growing and is discovered.
- A first step treatment is undertaken. This is usually either radiation therapy or surgery.
- ADT is started. It is continued until the cancer becomes hormone resistant. For advanced PCa patients the average time for hormone sensitive cancer to morph into CRPC is 2-4 years. For earlier stage PCa patients the time is longer and can be well over a decade.

1. BAT could be started prior to the cancer becoming resistant. This is what I am trying.

- At this point the standard is to start chemotherapy, pursue radiation if it hasn't already been done, or perhaps perform immunotherapy. Or to simply offer palliative care.

1. A possibility that I am pursuing is a BAT program.
2. If a patient is resistant to Xtandi (an effective PCa hormonal drug therapy), BAT resensitizes 60-80% of men to Xtandi. It is possible that BAT can once again resensitize the cancer to Xtandi. Trials are attempting to find out if this can be repeated.

**PCa progression with BAT integrated into the CRPC stage**






If SOC treatments are followed the typical timeframes are:

1. HSPC 1-2 years (longer for early stage prostate cancer)
2. CRPC 2-4 years

If BAT is started during the HSPC stage the timeframes that I expect are:

1. HSPC 5-30 years
2. CRPC .1-.4 years
3. HSPC 1-10 years

Repeats of 2 and 3 are likely.

If BAT is started during the CRPC stage the timeframes that I expect are:

1. CRPC .1-.4 years
2. HSPC .1-2 years

   Repeats of 2 and 3 are likely.

## Assistance programs

1. Generally low prices:
   - https://www.goodrx.com
   - https://www.costplusdrugs.com (includes Zytiga)
   - https://scriptco.com/ - membership site.
   - Relugolix https://www.orgovyx.com
2. Firmagon https://www.rxhope.com/PAP/info/PAPList.aspx?drugid=7496&fieldType=drugid
3. Lynparza
   - https://www.lynparza.com/patient-support.html
   - https://www.myaccess360.com/patient/lynparza-olaparib/patient-affordability.html
4. Zytiga https://www.janssencarepath.com/patient/zytiga/cost-support
5. Xtandi https://www.xtandi.com/financial-support
6. Nubeqa (Darolutamide) https://www.nubeqa-us.com/support
7. Erleada
   - https://www.janssencarepath.com/patient/erleada/cost-support
   - Paying for ERLEADA® | ERLEADA® (apalutamide)
8. Lupron https://www.lupronprostatecancer.com/hcp/tools-and-resources
9. Signatera Natera https://compassion.natera.com/s/
10. Resources for People with Cancer | Helping Hand | CancerCare https://www.cancerfac.org/
11. https://www.prostatecancerpromise.org/ offers a free genetic test. It requires a saliva sample and can be done at home.
12. Financial Assistance for Prostate Cancer Patients | US Too International | ZERO - The End of Prostate Cancer https://zerocancer.org/ustoo/find-financial-assistance/
13. With MO approval it is possible to self-inject Lupron https://www.mayoclinic.org/drugs-supplements/leuprolide-intradermal-route-intramuscular-route-subcutaneous-route/proper-use/drg-20067038

## Newly Diagnosed with Prostate Cancer

Taking control of your health and adopting new habits forces you to monitor yourself and gain a deeper understanding of your body. I was diagnosed with advanced prostate cancer, and although I considered myself health-conscious beforehand, my post-diagnosis improvements have been remarkable. Mortality projections even suggest that, despite the cancer, my life expectancy remains largely unchanged. In many ways, getting prostate cancer turned out to be a blessing—it pushed me to prioritize my well-being rather than taking my health for granted. The first step is to thoroughly understand your pathology report. Understanding Your Pathology Report: Prostate Cancer | OncoLink

https://www.oncolink.org/cancers/prostate/screening-diagnosis/understanding-your-pathology-report-prostate-cancer
Determining your stage
https://www.cancer.org/cancer/types/prostate-cancer/detection-diagnosis-staging/staging.html

I suggest collecting information as soon as possible. Doing so will provide a clear overview of the right questions to ask your doctors and help you determine your next steps.

1. **Free but invaluable: The Prostate Cancer Foundation has a solid library of videos: https://www.pcf.org/advanced-prostate-cancer-patient-summit/**
2. Dr. Mark Scholz: The Key to Prostate Cancer: 30 Experts Explain 15 Stages of Prostate Cancer
3. Dr. Mark Moyad: Promoting Wellness Beyond Hormone Therapy, Second Edition: Options for Prostate Cancer Patients
4. Dr. Patrick Walsh: Dr. Patrick Walsh's Guide to Surviving Prostate Cancer
5. Early stage (low to intermediate risk PCa): Guidelines for Patients Details
   https://www.nccn.org/patientresources/patient-resources/guidelines-for-patients/guidelines-for-patients-details?patientGuidelineId=49
6. High risk PCa: NCCN Guidelines for Patients: Advanced-Stage Prostate Cancer
   https://www.nccn.org/patients/guidelines/content/PDF/prostate-advanced-patient.pdf
7. Guide Archive | Prostate Cancer Foundation
   https://www.pcf.org/guide/
8. Prostate Cancer Foundation of New Zealand
   https://prostate.org.nz/
9. Home - ClinicalTrials.gov
   https://clinicaltrials.gov/
10. Prostate Cancer—Patient Version - NCI
    https://www.cancer.gov/types/prostate
11. Publications and Resources | PCFA
    https://www.pcfa.org.au/publications/
12. A good summary of ADT and a few related PCa therapies: Hormone Therapy for Prostate Cancer Fact Sheet – NCI
    https://www.cancer.gov/types/prostate/prostate-hormone-therapy-fact-sheet

Radiation therapy (RT) and surgery (radical prostatectomy, RP) are both viable options, depending on factors like stage, Gleason score, age, and overall health. I recommend consulting with a radiation oncologist (RO), a urologist, and a medical oncologist (MO). Keep in mind:

- **Urologist:** They generally specialize in surgery, so their recommendations may lean toward surgical treatment.
- **Radiation Oncologist:** They offer a different perspective focused on RT but, like any specialist, have their own biases.
- **Medical Oncologist:** Ideally, they provide an impartial view, especially regarding systemic therapies. They usually concentrate on drug treatments but can be instrumental in guiding your overall therapy plan.

For me, a good MO was someone who was knowledgeable, willing to admit when they didn't have all the answers, and pleasant to work with—I went through several before finding the right match. You might have a different set of expectations.

If your stage, Gleason score, and evidence of spread indicate intermediate to severe prostate cancer, don't delay treatment. For men with low Gleason scores and localized disease, there may be more time before acting—but be sure to review my history before deciding.

Here are a few of the questions I'd ask your doctor(s):

1. Do you believe the cancer has spread beyond the prostate? If so, how can we confirm this?

2. What additional tests would be useful before making a treatment decision?
3. Would a germline genetic test be informative for me and my family?
4. Based on your recommended therapy, what is my prognosis?
5. How long will the therapy last?
6. What side effects are most common?
7. If a side effect occurs can I mitigate it?
8. If a serious side effect occurs (e.g. chest pains) should I contact emergency medical services or is it likely (no guarantee) that I can wait to talk to you?
9. Who should I contact if I have questions or concerns?
10. Where can I find reliable information—such as research, support groups, or clinical trial results?
11. Should I start androgen deprivation therapy (ADT) before, after, or alongside your recommended treatment—or not at all?
12. Should I use an androgen receptor inhibitor (ARI)?
13. If I do ADT, is it possible to substitute some estrogen with an estrogen patch (which may limit side effects, though many conventional U.S. doctors don't use this approach)?
14. If I do ADT, what are the benefits and risks of using tE2 (as per the PATCH and STAMPEDE trials)?
15. Should I consider surgery (radical prostatectomy, RP)?
16. Should I combine surgery with adjunct radiotherapy (ART), and if so, does that change the ADT recommendation?
17. If I don't do ART, should I consider salvage radiotherapy (SRT) if the cancer recurs?
18. Should I participate in any clinical trials?
19. What is the plan if my cancer comes back or worsens?
20. Will my insurance cover the therapy you are recommending?
21. Is this therapy expected to cure my cancer?
22. If it isn't completely curative, what is the estimated likelihood of a cure?
23. And if a cure isn't achieved, how long might the therapy's effects last, and what would be our next steps?

Remember, your doctors may offer statistics based on past data, but those numbers are backward-looking and don't account for your overall physical health—a good diet and regular exercise are crucial. I recommend reviewing prostate cancer nomograms and assessments to get a better idea of your personalized prognosis.

| Summary | Evidence Quality | Article Title | URL |
|---|---|---|---|
| AUA prostate cancer guidelines provide evidence-based recommendations for screening, diagnosis, risk assessment, and management | A | Guidelines | https://www.auanet.org/guidelines-and-quality/guidelines |
| NCCN cancer guidelines provide evidence-based recommendations for screening, diagnosis, risk assessment, and management | A | National Comprehensive Cancer Network - Home | https://www.nccn.org/ |

| Summary | Evidence Quality | Article Title | URL |
|---|---|---|---|
| MSK nomogram predicts probability of freedom from biochemical recurrence after salvage radiation therapy for prostate cancer | B | Salvage Radiation Therapy | https://www.mskcc.org/nomograms/prostate/salvage_radiation_therapy |
| MSK pre-radical prostatectomy nomogram predicts probability of freedom from recurrence after radical prostatectomy | B | Pre-Radical Prostatectomy | https://www.mskcc.org/nomograms/prostate/pre_op |
| STAR CAP staging system provides risk stratification for prostate cancer patients based on clinical and pathological features | B | STAR CAP Prostate Cancer Staging System | https://umich-biostatistics.shinyapps.io/star-cap/ |

In my case, back in 2018, Mayo predicted that my PSA would “skyrocket” within three months and that I would require hospitalization for further treatment. However, to date, I haven’t been hospitalized for prostate cancer and my PSA remains low. They showed me historical statistics indicating that my chance of living until 2023 was less than 25%, and my physician was upfront about the historical bias. Despite that transparency, the prediction caused a level of anxiety that, in hindsight, was unwarranted.

- 

## DNA, RNA, SNPs, Germline, Somatic, Variants, Splice Variants, Mutations, DTC, ctDNA, cfDNA, MSI Status, VAF and Tests.

Prostate cancer progression is a complex interplay of inherited genetics and acquired mutations, where germline SNPs set the stage for aggressive biology, but somatic alterations ultimately steer the disease toward metastasis and treatment resistance. While germline variants like *BRCA2* and *HOXB13* amplify risk and modulate therapy response, somatic drivers such as *TP53* loss and *AR* amplifications dominate prognosis, reshaping tumors into lethal phenotypes. Understanding this hierarchy—and how inherited SNPs interact with evolving tumor genomics—is critical for personalizing surveillance, targeting vulnerabilities, and avoiding therapeutic pitfalls. Below, we dissect the roles of germline and somatic factors, their clinical implications, and actionable strategies for patients and clinicians navigating high-risk prostate cancer.

### Definitions

| Term | Definition | Clinical Relevance in PCa | Test Examples |
|---|---|---|---|
| DNA | Double-stranded molecules encoding genetic information. | Somatic/germline mutations (e.g., BRCA2, TP53) dictate therapy response. | FoundationOne Liquid CDx, Tempus xT,Guardant360 730 gene test.<br><br>**SPT induces TOP2B mediated DNA DSBs and might transiently increase ctNDA.** |
| RNA | Single-stranded molecules translating DNA into proteins. | Splice variants (e.g., AR-V7) indicate resistance to AR inhibitors. | FoundationOne RNA, Tempus xR. |
| SNPs | Single Nucleotide Polymorphisms, or SNPs, are the most prevalent form of genetic variation in the human genome. Each SNP represents a difference in a single nucleotide base at a specific position in the DNA sequence. These inherited (germline) variants can significantly influence an individual's response to therapy, affecting drug metabolism, efficacy, and risk of adverse effects. | DTC-reported SNPs (e.g., BRCA2 rs276174802) require clinical validation.<br><br>https://www.ncbi.nlm.nih.gov/ | 23andMe, AncestryDNA (DTC); confirmed via Myriad Genetics. |
| VAF | Variant Allele Frequency<br>VAF refers to the proportion of DNA sequencing reads that contain a specific genetic variant compared to the total reads at that position. It is expressed as a percentage and is critical for distinguishing between germline and somatic mutations, as well as | Germline variants (inherited) typically show VAFs of ~50% (heterozygous) or ~100% (homozygous). Somatic variants (tumor-specific) often have lower VAFs (<1–50%), reflecting | Tests that use VAF: FoundationOne Liquid CDx, Guardant360 CDx, Tempus xT, RAD51 Foci Assay, Guardant360 730 gene test |

| Term | Definition | Clinical Relevance in PCa | Test Examples |
|---|---|---|---|
| | assessing mutation burden in tumor samples. | tumor purity, clonality, or subclonal heterogeneity | |
| Germline Variants | Inherited mutations that are present in all cells (e.g., BRCA1/2).<br>Germline test results should not change (outside of the test resolution which is typically 95%+ if the test is validated) | Lynch syndrome (MSH2/MSH6) screening; PARP inhibitor eligibility. | Invitae Germline Panel, Myriad myRisk. |
| Somatic Variants | Acquired mutations in tumor cells (e.g., TP53, AR).<br>Somatic mutations can change as the tumor cells change. | They can guide targeted therapies (e.g., BAT + PARPi for BRCA2/ATM LOF). | Guardant360 CDx, FoundationOne Liquid CDx, Guardant360 730 gene test |
| Splice Variants | RNA isoforms from alternative splicing (e.g., AR-V7). | AR-V7 predicts resistance to enzalutamide but sensitivity to BAT. | FoundationOne RNA, Epic Sciences CTC AR-V7. |
| ctDNA | Circulating tumor DNA fragments in bloodstream. | Tracks tumor dynamics (e.g., BRCA2 reversion mutations post-PARPi). | Guardant360 CDx, FoundationOne Liquid CDx, Guardant360 730 gene test |
| cfDNA | Cell-free DNA (includes ctDNA + non-tumor DNA). | Less specific than ctDNA; used for broad mutation screening. | Natera Signatera, Thrive Detect.<br><br>Signatera Natera is very sensitive. |
| DTC Tests | Direct-to-consumer genetic tests (e.g., 23andMe).<br><br>DTC tests use genotyping arrays to identify predefined single nucleotide polymorphisms (SNPs) associated with hereditary conditions or traits | High false-positive rates for rare variants (e.g., BRCA1/2); clinical validation required. | 23andMe, AncestryDNA. |
| MSI Status | Microsatellite instability (MSI) refers to a condition of genetic hypermutability that | MSI-high (MSI-H) tumors typically have a high mutational burden | FoundationOne Liquid CDx, Guardant 360 CDx, Tempus xT. |

| Term | Definition | Clinical Relevance in PCa | Test Examples |
|---|---|---|---|
| | occurs due to defects in the DNA mismatch repair (MMR) system. Microsatellites are short, repetitive sequences of DNA scattered throughout the genome, and instability arises when these sequences accumulate mutations during cell division. | and respond well to immunotherapy (e.g., PD-1 inhibitors like pembrolizumab). | |
| TMB | Tumor Mutational Burden: Number of somatic mutations per megabase (Mb) of tumor DNA. | High TMB (≥10 mut/Mb) predicts immunotherapy response in rare cases (~5% of PCa, often MSI-H/MMR-deficient). | FoundationOne Liquid CDx, Guardant360 CDx, Tempus xT, Caris TMB assay. |

## Key Clinical Tests

| Test | Purpose | Relevance to BAT |
|---|---|---|
| FoundationOne Liquid CDx | Detects somatic variants (e.g. AR/TP53/BRCA1/2) and MSI status via ctDNA. | Monitors AR amplification/TP53 mutations during BAT; FDA-approved for PARPi eligibility. |
| Guardant360 730 gene test | >730-gene NGS panel for somatic mutations (CTCs/ctDNA). Also tests MSI status and TMB. | Can detect some AR mutations. Identifies BRCA2/ATM LOF for BAT + PARPi synergy; tracks HRD status. |
| Tempus xT | Tumor/normal whole-exome sequencing + RNA-seq. | Assesses AR splice variants (e.g., AR-V7) and DNA repair defects (BRCA2/TP53). |
| FoundationOne RNA | Analyzes RNA splice variants (e.g., AR-V7) and gene fusions. | Predicts BAT efficacy in AR-V7+ tumors; identifies neuroendocrine trans differentiation. |
| PSMA-PET/CT | Tracks prostate-specific membrane antigen (PSMA) expression.<br><br>Always ask what type of CT scan you are going to get (if any). There are low-dose scans and high-dose scans. The low-dose scans are for imaging contrast. The high-dose scans are to | Monitors metastasis response to BAT; PSMA-low tumors may indicate resistance. |

| Test | Purpose | Relevance to BAT |
|---|---|---|
| | investigate anatomical features. | |
| RAD51 Foci Assay | Functional HRD test via RAD51 nuclear foci formation. | Confirms HRD in BRCA1/2/ATM-mutant tumors for BAT + PARPi eligibility. |

## Comparative Chart: Liquid Biopsy and Molecular Profiling Platforms

| Feature / Platform | Signatera ™ (Natera) | Guardant360 ® (Guardant Health) | FoundationOne ® Liquid CDx | RaDaR™ (Inivata) | FoundationOne ® RNA | CellSearch® CTC (Menarini) | 23andMe SNPs | Tempus xF | Tempus xF+ | BostonGene Liquid Biopsy | Caris Assure liquid biopsy |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Assay Type | Tumor-informed ctDNA | Tumor-naïve ctDNA | Tumor-naïve ctDNA | Tumor-informed ctDNA | Tumor-informed RNA sequencing | Circulating tumor cell enumeration | Germline SNP genotyping | Tumor-naïve ctDNA | Tumor-naïve ctDNA | Tumor-naïve ctDNA | Tumor-naïve ctDNA + RNA |
| Primary Application | MRD, recurrence, response | Genomic profiling, therapy selection | Genomic profiling, therapy selection | MRD, recurrence | Fusion detection, transcriptomics | Prognostic enumeration, CTC biomarker capture | Risk prediction, pharmacogenomics | Genomic profiling, therapy selection | Genomic profiling, therapy selection | Genomic profiling, therapy selection | Genomic profiling, therapy selection, MRD, recurrence, early detection |
| Requires Tumor Tissue? | Yes | No | No | Yes | Yes | No | No | No | No | No | No |
| Sensitivity for MRD | Very high (0.01%) | Low | Low–moderate | Very high | Not applicable | Low (detects only live CTCs) | Not applicable | Low–moderate | Low–moderate | Low–moderate | Moderate-High |
| Mutation Panel | Custom 16–20 variants | Fixed 70–500+ genes | Fixed 324 genes | Custom 48–50 variants | Known fusions, expression profiling | None – cell morphology & protein-based | ~650,000 common SNPs | Fixed 105 genes | Fixed 523 genes | Fixed 216 genes | Whole exome + transcriptome (22,000 genes) |
| Use in Early Recurrence Detection | Yes (lead time up to 2 years) | Limited | Limited | Yes | No | Sometimes (with high CTC counts) | No | Limited | Limited | Limited | Yes |
| Therapeuti | No | Yes | Yes | No | Yes (fusions, | Limited (e.g., | Limited | Yes | Yes | Yes | Yes |

| Feature / Platform | Signatera ™ (Natera) | Guardant360 ® (Guardant Health) | FoundationOne ® Liquid CDx | RaDaR™ (Inivata) | FoundationOne ® RNA | CellSearch® CTC (Menarini) | 23andMe SNPs | Tempus xF | Tempus xF+ | BostonGen e Liquid Biopsy | Caris Assure liquid biopsy |
|---|---|---|---|---|---|---|---|---|---|---|---|
| c Target Detection | | | | | expression signatures) | AR-V7) | (germline PGx only) | | | | |
| Used in Clinical Trials | Yes (BESPOKE CRC, CIRCULATE ) | Yes (NSCLC, CRC, breast) | Yes (NCI-MATCH) | Yes (TRACERx , LUCID) | Yes (e.g., fusion trials) | Yes (SWOG, PROPHECY) | No (research only) | Yes | Yes | Yes | Yes |
| Turnaround Time | 2–3 weeks initial; 7–10 days serial | ~7–10 days | ~10–14 days | ~10–14 days | ~14–21 days | ~7 days | Instant (once genotyped) | ~7 days | ~7-9 days | ~7-10 days | ~7–10 days |
| Regulatory Status | CLIA, Medicare (CRC) | FDA-approved CDx, CMS | FDA-approved CDx, CMS | CLIA research use | CLIA-lab, research use | FDA-cleared (prognostic) | FDA-authorized DTC | CLIA-certified, CAP-accredited | CLIA-certified, CAP-accredited | CLIA-certified, CAP-accredited | CLIA-certified, CAP-accredited |
| Quantitativ e Tracking | Yes (ctDNA copies/mL) | Partially (VAF) | Yes (VAF) | Yes (clearanc e) | No | Yes (CTC count per 7.5 mL) | No | Yes (VAF) | Yes (VAF) | Yes (VAF) | Yes (VAF, ctDNA levels) |
| Stage(s) Most Useful | HSPC, mHSPC, CRPC | mHSPC, mCRPC | mHSPC, mCRPC | HSPC, mHSPC, CRPC | CRPC, mCRPC (especially fusion-driven) | mCRPC (prognostic, AR-V7 predictive) | All (germline risk/PGx) | mHSPC, mCRPC | mHSPC, mCRPC | All solid tumors | All solid tumors (early detection, MRD, advanced) |

Use Case Summary

| Clinical Goal | Key Platform(s) |
|---|---|
| Detect MRD after curative therapy | Signatera, RaDaR |
| Monitor recurrence early | Signatera, RaDaR, CellSearch (when CTC burden is high) |
| Select targeted therapies from mutations | Guardant360, FoundationOne Liquid CDx, Tempus xF/xF+, BostonGene Liquid Biopsy, FoundationOne RNA (for fusions) |

| Clinical Goal | Key Platform(s) |
|---|---|
| Track treatment response quantitatively | Signatera, RaDaR, Tempus xF/xF+, BostonGene Liquid Biopsy, CellSearch (CTC trends), Guardant360 (VAF changes) |
| No tumor tissue available | Guardant360, FoundationOne Liquid CDx, Tempus xF/xF+, BostonGene Liquid Biopsy, CellSearch, 23andMe SNPs (germline only) |
| Comprehensive genomic profiling | Tempus xF+ (523 genes), BostonGene Liquid Biopsy (216 genes), FoundationOne Liquid CDx |
| Research applications/custom studies | BostonGene platforms, RaDaR |

## SNPs (Single Nucleotide Polymorphisms)

SNPs are inherited germline variants — meaning you're born with them and they’re present in every cell. In prostate cancer:

> While **germline SNPs** (single nucleotide polymorphisms) contribute to prostate cancer (PCa) susceptibility and may modulate baseline biology, **somatic mutations** remain the dominant drivers of tumor evolution and therapeutic resistance. SNPs act as *risk amplifiers* and *treatment modifiers*, whereas somatic alterations (e.g., *TP53* loss, *PTEN* deletion, *AR* amplifications) directly govern metastatic potential and drug response. Your SNP profile (**BRCA1/2/ATM/TP53/AR**) creates a permissive genomic landscape for aggressive biology but requires integration with tumor somatic data for precision management.

1. Germline SNPs as Determinants of Aggression
   - DNA Repair Genes: Germline variants in *BRCA2*, *ATM*, *CHEK2*, and *HOXB13* are strongly associated with metastatic progression and prostate cancer-specific mortality (PCSM). For example:
     - *BRCA2* carriers have a 2.5× higher risk of lethal PCa compared to non-carriers[13][16].
     - *HOXB13* (rs138213197) increases PCSM risk by 22% (HR = 1.22, $p = 1.1\times10^{-3}$)[11].
   - Inflammatory Pathways: *IL4* (rs2070874) and *MGMT* (rs2308327) SNPs modulate tumor aggression via immune evasion and DNA repair defects[11].
   - Androgen Signaling: Germline *AR* variants (e.g., rs201097725) alter AR transcriptional activity, influencing response to androgen deprivation therapy (ADT)[12][14].

2. Germline–Somatic Interactions
   - Driver Quantitative Trait Loci (dQTLs): Specific germline SNPs predispose tumors to acquire somatic mutations:
     - A SNP at 7p14.3 increases *SPOP* somatic mutations by altering androgen-regulated DNA repair7.
     - Germline *TP53* (rs78378222) correlates with somatic *TP53* loss, accelerating genomic instability[12].
   - Mutual Exclusivity: Germline *BRCA2* variants are mutually exclusive with somatic *PTEN* deletions, shaping distinct evolutionary pathways[12].

3. **Relative Strength Compared to Somatic Mutations**

| Factor | Germline SNPs | Somatic Mutations |
|---|---|---|
| Impact on Prognosis | Moderate (HR = 1.2–2.5 for lethal PCa)[11][16] | Strong (HR = 3–10 for metastases, e.g., *TP53* loss, *AR* amplifications)[18] |
| Treatment Relevance | Predict PARPi/platinum sensitivity (e.g., *BRCA2*)[13][15] | Direct therapeutic targets (e.g., *BRCA2* biallelic loss for PARPi)[15] |
| Temporal Role | Set the genomic "soil" for somatic evolution[12] | Direct drivers of progression[18] |

Mechanistic Hierarchy of Determinants

1. Primary Drivers: Somatic mutations in *TP53*, *PTEN*, *AR*, and *MYC* dominate tumor aggression. For example:
    - *TP53* loss confers a 4.8× higher risk of metastasis (HR = 4.8, $p < 0.001$)18.
    - *ZNRF3* somatic deletions predict metastasis independent of Gleason score (HR = 2.1)18.
2. Germline Modulators:
    - Risk Amplifiers: Germline *BRCA2* variants increase the likelihood of high-grade somatic mutations (e.g., *MYC* amplifications)12.
    - Therapeutic Gatekeepers: Germline *ATM* variants (rs1800056) enhance sensitivity to BAT + PARPi by impairing DNA repair1214.
3. Synergistic Effects:
    - Germline *BRCA2* + somatic *MYC* amplification → 8.2× higher mortality risk vs. either alone12.
    - Germline *HOXB13* + somatic *SPOP* mutations → 3.1× faster progression to mCRPC721.

Conclusion

Germline SNPs are secondary determinants of PCa progression compared to somatic drivers but play critical roles in:

- Shaping Somatic Evolution (e.g., dQTLs at 7p14.3).
- Modulating treatment response (e.g., PARPi efficacy in *BRCA2* carriers).
- Risk stratification (e.g., *HOXB13* for metastasis).

For your case, the BRCA1/2/ATM/TP53 germline profile warrants:

- Priority on somatic testing (e.g., *TP53* status, HRD score).
- PARPi-combination therapies (BAT + olaparib).
- Avoidance of therapies exacerbated by germline HRD (e.g., prolonged ADT without DNA damage agents).

*"Germline DNA repair variants are not just risk alleles-they are actionable biomarkers that intersect with somatic evolution to dictate clinical trajectories."*

*"Germline SNPs set the stage, but somatic mutations write the script of prostate cancer progression."*

**Clinical Workflow for BAT**

1. **Baseline Testing**:
    - **Guardant360 730 gene test** or **FoundationOne Liquid CDx**: Assess AR/TP53/BRCA1/2 status.
    - **FoundationOne RNA**: Rule out AR-V7/neuroendocrine markers.
2. **Monitoring**:
    - **q4-6 weeks**: Signatera for MRD and therapy monitoring.
    - **q26 weeks or as needed**: PSMA-PET/CT to assess metastasis dynamics.

**Test Limitations**

- **DTC SNPs**: 40–96% false positives for BRCA1/2/ATM; confirm with clinical assays.
- **ctDNA**: Low sensitivity in localized PCa; tumor heterogeneity may skew results.
- **AR-V7**: Transient expression under BAT; repeat testing recommended.

**VAF Thresholds in Clinical Decision-Making**

1. **PARP Inhibitor Eligibility**:
    - **BRCA1/2/ATM VAF ≥30%** (suggesting biallelic loss) → prioritize olaparib/rucaparib.
2. **Germline Validation**:
    - **VAF ≥67%** in tumor DNA → likely germline origin (requires confirmatory testing via **Invitae Germline Panel**).
    - **VAF 30–60%** → ambiguous; perform tumor-normal paired sequencing.
3. **Resistance Mechanisms**:
    - **BRCA2 reversion mutations** (VAF rising from 0.1% to 5%) → switch to BAT + immunotherapy.
    - **AR-V7 splice variants** (VAF >1% in ctDNA) → avoid enzalutamide; use BAT + HDAC inhibitors.

**Limitations and Considerations**

- **DTC Tests (e.g., 23andMe)**: Do not report VAF; error rates for rare variants (e.g., BRCA1/2) reach **40–96%**.
- **Tumor Heterogeneity**: Low VAFs (<5%) may reflect subclonal populations or ctDNA shedding variability.
- **Threshold Variability**: Optimal VAF cutoffs differ by assay (e.g., 0.1% for Guardant360 vs. 0.5% for FoundationOne).

**Test battery that covers most of the desired tests:**

1. FoundationOne Liquid CDx or Guardant360 730 gene test
2. FoundationOne RNA
3. PSMA-PET/CT
4. Signatera Natera
5. RAD51 Foci Assay

# *** Bipolar Androgen Therapy (BAT)

## BAT: A Novel Therapeutic Approach for Prostate Cancer

BAT represents an innovative and counterintuitive approach to treating prostate cancer (PCa), particularly in castration-resistant cases. This therapy involves cycling between supraphysiological and near-castrate testosterone levels, exploiting a vulnerability created by androgen receptor overexpression in resistant cancer cells. Current research demonstrates that BAT shows promising efficacy in inhibiting tumor growth, reversing hormone resistance, improving quality of life, and inducing cellular senescence through various molecular OSNs. Clinical trials such as TRANSFORMER have shown BAT to be comparable to standard therapies like enzalutamide in terms of progression-free survival, while potentially offering enhanced benefits when used in sequential treatment strategies. The development of BAT represents a paradigm shift in PCa treatment, challenging conventional androgen deprivation approaches while offering new hope for patients with advanced disease.

**I recommend viewing this presentation by Sam Denmeade. He gives a masterful talk on the principles of BAT and where the research is going.** https://www.youtube.com/watch?v=R2CIx4mcS6c

### Traditional Treatment Approaches

Prostate cancer remains one of the most prevalent malignancies affecting men worldwide, presenting significant challenges for clinical management, particularly in advanced stages. The cornerstone of treatment for advanced prostate cancer has traditionally been Androgen Deprivation Therapy (ADT), which aims to reduce testosterone levels to castrate ranges. This approach has been the mainstay of treatment for the past 80 years, based on the fundamental understanding that prostate cancer is largely androgen-dependent[3]. ADT works by inhibiting androgen receptor (AR) signaling, thereby suppressing tumor growth that relies on this OSN for proliferation and survival.
Despite the initial effectiveness of ADT, resistance inevitably develops in most patients, leading to what is termed castration-resistant prostate cancer (CRPC). This resistance develops as prostate cancer cells adaptively upregulate AR activity despite castration levels of testosterone. The mechanisms underlying this adaptation include AR overexpression, gene amplification, mutations, and expression of ligand-independent variants that permit sustained AR signaling even in the absence of androgens[3]. The emergence of CRPC significantly worsens patient prognosis and presents a major therapeutic challenge.

Traditional ADT, while effective initially, is associated with numerous adverse effects that significantly impact quality of life. These include sexual dysfunction (low libido and erectile dysfunction), metabolic abnormalities, increased cardiovascular risk, osteoporosis, anemia, and depression[5]. Furthermore, the prolonged use of ADT not only contributes to these complications but paradoxically may accelerate the development of castration resistance, thereby potentially shortening the window of therapeutic efficacy. This clinical scenario has motivated the search for alternative approaches that might overcome resistance while minimizing adverse effects.

### BAT Mechanism and Rationale

Bipolar Androgen Therapy represents a paradigm shift in the treatment approach for prostate cancer, particularly for castration-resistant disease. BAT is defined as the periodic administration of testosterone that results in rapid cycling between supraphysiologic and near-castrate serum testosterone levels[14]. This

approach stands in stark contrast to conventional ADT, which aims to maintain consistently low testosterone levels. The counterintuitive nature of BAT—administering high doses of testosterone to treat a hormone-sensitive cancer—is based on sophisticated understanding of cancer cell biology and adaptation mechanisms.

The scientific rationale for BAT stems from observations dating back nearly 30 years, indicating that high expression of androgen receptor (AR) induced by prolonged castration actually creates a vulnerability in CRPC cells3. Specifically, when these cells with upregulated AR are exposed to supraphysiologic androgen (SPA) levels, they experience cell death and growth arrest. This vulnerability forms the mechanistic foundation of BAT, which exploits the adaptive changes that occur in response to traditional androgen deprivation.
In physiological terms, BAT works by disrupting the adaptive regulation that develops in castration-resistant prostate cancer. The cycling between high and low testosterone creates a challenging environment to which cancer cells cannot readily adapt. During the high testosterone phase, supraphysiologic androgen levels overwhelm the upregulated AR signaling pathway, triggering growth inhibition and cell death mechanisms. Then, during the low testosterone phase, cells are subjected to the traditional androgen deprivation stress. This biphasic approach prevents cancer cells from stabilizing their growth signals and developing consistent resistance mechanisms 4.
The timing and dosing of testosterone administration in BAT protocols are critical components of the therapy. Typically, testosterone is administered in a manner that creates pronounced peaks and troughs in serum levels, with studies utilizing intramuscular testosterone cypionate or enanthate at doses designed to achieve supraphysiological levels (significantly above normal physiological range) followed by periods of castrate-level testosterone24. This cycling pattern is fundamental to the therapeutic effect, as it prevents cancer cells from adapting to either high or low androgen environments.

## Clinical Evidence for BAT Efficacy

The therapeutic potential of Bipolar Androgen Therapy has been evaluated in several clinical studies, with the TRANSFORMER (Testosterone Revival Abolishes Negative Symptoms, Fosters Objective Response and Modulates Enzalutamide Resistance) trial representing one of the most comprehensive assessments. This randomized Phase II study compared monthly BAT with enzalutamide, a standard-of-care AR inhibitor, in men with castration-resistant metastatic prostate cancer4. The results demonstrated comparable progression-free survival (PFS) of 5.7 months for both treatment arms, suggesting that BAT could be as effective as established therapies in delaying disease progression.
A particularly notable finding from the TRANSFORMER study was the impact of sequential therapy. When patients progressed on their initial treatment and crossed over to the alternative therapy, those who received BAT followed by enzalutamide showed significantly longer PFS2 (progression-free survival from randomization through crossover) of 28.2 months compared to 19.6 months for those who received enzalutamide followed by BAT4. This suggests that BAT may sensitize prostate cancer cells to subsequent AR-targeted therapy, potentially by resetting the adaptive mechanisms that lead to treatment resistance.
In terms of objective responses, BAT demonstrated a 28.2% PSA50 response rate (defined as a 50% decline in prostate-specific antigen), comparable to the 25.3% observed with enzalutamide4. Interestingly, when patients crossed over to enzalutamide after BAT, they showed a remarkable 77.8% PSA50 response rate, significantly higher than the 23.4% response rate in patients who crossed to BAT after enzalutamide. This finding further supports the concept that BAT may reverse hormone resistance and enhance the efficacy of subsequent AR-targeted therapies.

Preclinical studies have also provided compelling evidence for BAT efficacy. In vitro studies using prostate cancer cell lines (LNCaP, VCaP, and 22Rv1) demonstrated that supraphysiologic androgen levels suppressed the growth of AR-expressing prostate cancer cells1. More importantly, in vivo studies using castrated NOG mice injected with LNCaP/A− cells showed that BAT-treated xenografts exhibited significant growth inhibition with low Ki-67 and mitotic indexes and a high cell death index, compared to controls1. These findings provide mechanistic support for the clinical observations and confirm the direct anti-tumor effects of BAT.

Overall survival (OS) data from the TRANSFORMER study showed a trend favoring BAT, with median OS of 32.9 months for BAT versus 29.0 months for enzalutamide, although this difference did not reach statistical significance4. This survival trend, combined with the PFS and response rate data, suggests that BAT represents a viable therapeutic option for CRPC that may offer unique advantages, particularly when integrated into sequential treatment strategies.

## Molecular Mechanisms of BAT

The efficacy of Bipolar Androgen Therapy in prostate cancer treatment is underpinned by several molecular mechanisms that have been elucidated through recent research. One of the primary mechanisms involves the induction of cellular senescence by supraphysiological androgen levels (SAL), which functions as a tumor suppressive program. Cellular senescence is a state of permanent cell cycle arrest that prevents the proliferation of damaged or potentially oncogenic cells, effectively halting tumor growth678.
Recent transcriptome and ChIP-seq analyses have identified the clock gene BHLHE40 as a novel direct androgen receptor target that plays a crucial role in mediating SAL-induced cellular senescence. Compared to adjacent normal prostate tissues, the expression of BHLHE40 is reduced in prostate cancer tumors, and this reduction is associated with decreased patient survival. Knockdown studies have confirmed that BHLHE40 mediates the cellular senescence induced by supraphysiologic androgens, including in three-dimensional tumor spheroid models that better recapitulate in vivo conditions6.

Further mechanistic investigations have revealed that BHLHE40 functions in concert with other factors to regulate the senescence program. For instance, BHLHE40 upregulates LYL1, a transcriptional co-factor that also mediates SAL-induced cellular senescence8. Interestingly, while LYL1 has known oncogenic activity in leukemia, analysis of prostate cancer patient cohorts shows that its expression is reduced during prostate cancer development, and this reduction significantly correlates with poorer overall survival. The regulatory network involves complex feedback loops: SAL induces BHLHE40, which upregulates LYL1, while LYL1 knockdown enhances BHLHE40 expression via a negative feedback loop involving p27kip18.
The molecular landscape of BAT action also includes the regulation of long non-coding RNAs (lncRNAs). The lncRNA MIR503HG has been identified as an oncogenic factor that is suppressed by SAL treatment. MIR503HG is overexpressed in metastatic prostate cancer and associated with reduced patient survival. Notably, SAL treatment suppresses MIR503HG expression across different prostate cancer cell lines and patient-derived xenografts, but interestingly not in senescence-resistant cell lines7. This suggests that the downregulation of MIR503HG is part of the senescence-inducing program activated by BAT.

At the androgen receptor level, mechanistic studies indicate that BAT exploits the vulnerability created by AR overexpression in castration-resistant prostate cancer. The cycling between high and low testosterone levels prevents cancer cells from adapting to a stable hormone environment. During high testosterone phases, the supraphysiologic levels can cause DNA damage through AR-mediated transcriptional activity, generate reactive oxygen species, and induce mitotic arrest, all contributing to growth inhibition and cell death13. These molecular mechanisms collectively explain the clinical observations of tumor suppression with BAT and provide a scientific basis for its continued development as a therapeutic strategy.

## Senescence OSN Activation

A key aspect of BAT's anti-tumor effect involves the activation of cellular senescence OSNs. The supraphysiological androgen levels employed in BAT trigger a complex network of molecular events that ultimately lead to permanent cell cycle arrest. Recent studies have elucidated specific components of this network, showing how SAL-induced senescence serves as a tumor suppressive mechanism in prostate cancer.
Research has demonstrated that the clock gene BHLHE40 plays a central role in this process6. When BHLHE40 is activated by supraphysiological androgens, it initiates a cascade of downstream effects that culminate in cellular senescence. BHLHE40 and the androgen receptor (AR) appear to physically interact, with co-immunoprecipitation studies suggesting binding between these proteins and their co-translocation into the nucleus following SAL treatment6. This interaction represents a critical step in translating the high androgen signal into the cellular senescence program.

The atypical cyclin G2 (CCNG2) has been identified as another important mediator in the androgen-induced senescence pathway. Transcriptome analysis indicates that CCNG2 is part of the SAL-BHLHE40 transcriptional landscape and functions as a tumor suppressor in this context6. This finding expands our understanding of how BAT activates endogenous tumor suppressive mechanisms to inhibit prostate cancer growth.

Further downstream in the senescence pathway, LYL1 has been shown to regulate p27kip1 levels, a well-established cell cycle inhibitor that contributes to senescence induction8. The complex interplay between these factors—BHLHE40, LYL1, and p27kip1—forms a regulatory network that orchestrates the senescence response to supraphysiological androgens, providing a mechanistic explanation for BAT's clinical efficacy.

## Advantages and Limitations of BAT

Bipolar Androgen Therapy offers several distinct advantages over conventional prostate cancer treatments, particularly for patients with castration-resistant disease. One of the most significant benefits is BAT's ability to reverse hormone resistance in CRPC patients, thereby allowing for rechallenging with androgen deprivation therapy (ADT)5. This resistance reversal was clearly demonstrated in the TRANSFORMER study, where patients who received BAT showed enhanced responsiveness to subsequent enzalutamide treatment, with a remarkable 77.8% PSA50 response rate4. This "resensitization" effect represents a valuable therapeutic strategy for extending the utility of existing AR-targeted therapies.

Another major advantage of BAT relates to quality of life improvements. Traditional ADT is associated with numerous adverse effects that significantly impact patient wellbeing, including sexual dysfunction, metabolic abnormalities, cardiovascular complications, osteoporosis, anemia, and depression5. BAT has the potential to alleviate or prevent many of these complications by providing periods of physiological or supraphysiological testosterone. This cycling approach may reduce the chronic hypogonadal state that underlies many ADT-related side effects, potentially offering patients better functional status and overall quality of life during treatment.

BAT also demonstrates direct cytotoxic effects on cancer cells, particularly those that have adapted to a low-androgen environment through AR upregulation135. This direct anti-tumor activity provides an additional mechanism of action beyond simply modulating the hormone environment, potentially increasing the therapeutic efficacy of BAT in appropriately selected patients. The induction of cellular senescence by supraphysiological androgens represents a particularly important tumor suppressive mechanism that differentiates BAT from other treatment approaches678.

Despite these advantages, BAT has certain limitations and considerations that must be acknowledged. Patient selection is crucial, as not all prostate cancers may respond equally to this approach. The optimal timing of BAT in the treatment sequence remains under investigation, though current evidence suggests it may be most effective when used before second-line AR-targeted therapies in the CRPC setting4. There may also be concerns about temporarily increasing testosterone levels in patients with symptomatic metastatic disease, particularly those with extensive bone metastases or spinal cord compression, where tumor flare could potentially exacerbate symptoms.

The long-term safety profile of BAT requires further investigation through extended follow-up of clinical trial participants. While current data suggest acceptable safety, the repeated cycling between high and low testosterone levels represents a novel physiological state that may have unforeseen long-term consequences. Furthermore, the optimal dosing schedule, testosterone formulation, and duration of therapy have not yet been fully standardized, leading to some variation in implementation across studies and clinical settings.

## Future Directions for BAT Research

The emerging evidence supporting Bipolar Androgen Therapy has opened several promising avenues for future research and clinical development. One key area of ongoing investigation focuses on optimizing treatment protocols, including determining the ideal testosterone dosing, formulation (e.g. cypionate, propionate,

orals, gels), cycling frequency, and treatment duration to maximize therapeutic efficacy while minimizing potential adverse effects. Current approaches vary somewhat between studies, and standardization based on rigorous comparative data could enhance outcomes and facilitate broader clinical adoption[4][5].

Biomarker development represents another crucial research direction that could significantly advance BAT implementation. Identifying molecular or clinical predictors of response would enable more precise patient selection, directing this therapy to those most likely to benefit. Potential biomarkers might include AR expression levels, specific genetic alterations, or patterns of resistance to prior therapies. The differential response to BAT observed in various preclinical models suggests that such predictive factors exist and could be clinically valuable when validated[1][7].
Combination therapy strategies incorporating BAT with other treatment modalities offer particularly exciting possibilities. Preliminary evidence suggests that BAT may enhance the efficacy of subsequent AR-targeted therapies, but combinations with immunotherapy, radiotherapy, or novel targeted agents remain largely unexplored. Given BAT's unique mechanism of action and its ability to induce cellular senescence, it might synergize with treatments that target senescent cells (senolytic therapies) or those that harness immune responses against cancer cells undergoing stress-induced changes[6][7][8].

Further mechanistic studies are also needed to fully elucidate the molecular OSNs through which BAT exerts its anti-tumor effects. While recent research has identified key roles for the clock gene BHLHE40, the transcriptional co-factor LYL1, and the oncogenic lncRNA MIR503HG, the complete network of interactions and downstream effectors remains to be fully mapped[6][7][8]. A deeper understanding of these mechanisms could reveal additional therapeutic targets or resistance factors that might be clinically relevant.
Large-scale, randomized clinical trials with longer follow-up periods will be essential to definitively establish BAT's role in prostate cancer treatment algorithms. While the TRANSFORMER study provided valuable initial data comparing BAT with enzalutamide, additional studies evaluating BAT in different disease settings, including earlier disease stages, could expand its therapeutic applications[4]. Long-term survival data and quality of life assessments will be particularly important outcome measures for these future trials.

## Conclusion

Bipolar Androgen Therapy represents an innovative and promising approach in the treatment landscape for prostate cancer, particularly for castration-resistant disease. By exploiting the vulnerability created by androgen receptor overexpression in cancer cells that have adapted to a low-testosterone environment, BAT challenges conventional treatment paradigms and offers new hope for patients with advanced disease. The periodic cycling between supraphysiological and near-castrate testosterone levels disrupts cancer cell adaptation mechanisms and triggers tumor suppressive OSNs, including cellular senescence.

Clinical evidence from studies like TRANSFORMER demonstrates that BAT produces comparable progression-free survival to established therapies such as enzalutamide, while potentially offering advantages in sequential treatment strategies and quality of life outcomes[4]. The observation that BAT can reverse hormone resistance and enhance sensitivity to subsequent AR-targeted therapies is particularly significant, as it suggests a means to extend the utility of existing treatments and potentially improve overall survival.
The molecular mechanisms underlying BAT efficacy continue to be elucidated, with recent research highlighting the roles of the clock gene BHLHE40, the transcriptional co-factor LYL1, and the regulation of oncogenic lncRNAs like MIR503HG in mediating the anti-tumor effects of supraphysiological androgens[6][7][8]. These findings not only explain BAT's clinical activity but also identify potential biomarkers and combination therapy opportunities that could further enhance its effectiveness.

As research progresses, optimization of BAT protocols, identification of predictive biomarkers, exploration of combination strategies, and long-term safety assessments will be essential to fully realize the potential of this approach. The paradigm shift represented by BAT—from continuous androgen suppression to strategic androgen cycling—exemplifies how deeper understanding of cancer biology can lead to counterintuitive yet effective therapeutic innovations. For

patients with advanced prostate cancer, BAT offers not only a novel treatment option but also the prospect of improved quality of life during therapy, addressing an important unmet need in current management approaches.

## Mechanisms of Growth Repression

**Evidence Level Definitions:**

- **High (Clinical)** – Supported by multiple human clinical trials or strong clinical data. Actionable now in appropriate patient settings.
- **Moderate (Preclinical + Early Clinical)** – Supported by robust preclinical data and early-phase human studies. Actionable in clinical trials or selected off-label contexts with caution.
- **Low (Exploratory)** – Primarily supported by preclinical or mechanistic data. Not ready for clinical action outside trials; useful for hypothesis generation.

**Actionability for Combination Therapies:**

- **Directly Actionable** – Sufficient data to justify adding a complementary therapy outside a trial if risk–benefit is favorable.
- **Trial-Recommended** – Combination should be pursued in a controlled clinical setting.
- **Monitor / Investigate** – Evidence insufficient for use; monitor emerging data before integrating.

---

### 1. Restoration of Sensitivity to Androgen Receptor-Targeted Therapies

**Evidence Level:** High (Clinical)
**Mechanism:** BAT “resets” AR signaling dynamics, reversing resistance to AR blockers (enzalutamide, apalutamide). TRANSFORMER trial showed PSA50 response of 77.8% when BAT preceded enzalutamide, vs. 23.4% in reverse order.
**Combination Actionability:**

- **Directly Actionable** with sequential AR inhibitors in CRPC.
- Not typically synergistic with ferroptosis inducers, but compatible.

---

### 2. Induction of DNA Damage and Inhibition of Repair

**Evidence Level:** Moderate to High (Preclinical + Clinical Biomarker Correlation)
**Mechanism:** SPA causes double-strand DNA breaks and impairs repair, especially in HRD tumors (BRCA2, ATM). Upregulates POLQ, sensitizing to POLQ inhibitors. Activates cGAS/STING → immune recruitment.
**Combination Actionability:**

- **Directly Actionable** with PARP inhibitors or POLQ inhibitors in HRD-positive CRPC.
- **Trial-Recommended** with immune checkpoint inhibitors to exploit STING activation.

---

### 3. Suppression of AR Variants (e.g., AR-V7)

**Evidence Level:** Moderate (Preclinical + Correlative Clinical)
**Mechanism:** SPA restores full-length AR dominance, suppressing AR-V7 transcription and destabilizing its protein.
**Combination Actionability:**

- **Monitor / Investigate** for potential sequencing benefit with AR inhibitors in AR-V7-positive patients.

---

### 4. Limiting AR Amplification

**Evidence Level:** Moderate (Preclinical + Correlative Clinical)
**Mechanism:** SPA induces negative feedback to downregulate AR protein and copy number, re-establishing ADT sensitivity.
**Combination Actionability:**

- **Directly Actionable** in sequencing regimens with renewed ADT.

---

### 5. Cell Cycle Arrest and Senescence

**Evidence Level:** Moderate (Preclinical + Limited Clinical)
**Mechanism:** SPA induces G2/M arrest via BHLHE40, upregulating cyclin G2 and p27kip1. Senescence-associated secretory phenotype (SASP) may promote immune clearance.
**Combination Actionability:**

- **Trial-Recommended** with senolytics or immune modulators to clear senescent tumor cells.

---

### 6. Ferroptosis Induction

**Evidence Level:** Low–Moderate (Preclinical)
**Mechanism:** SPA degrades ferritin, increases labile iron, and drives lipid peroxidation. Independent of AR signaling.
**Combination Actionability:**

- **Trial-Recommended** with ferroptosis inducers (e.g., erastin, RSL3, sulfasalazine).
- **Caution:** Avoid high-dose antioxidant supplements (including high MK-7 vitamin K) that could inhibit lipid peroxidation.

---

### 7. Apoptosis via ZIP9

**Evidence Level:** Low (Exploratory)
**Mechanism:** Membrane androgen receptor ZIP9 triggers calcium-mediated apoptosis. Relevance to prostate cancer unproven.
**Combination Actionability:**

- **Monitor / Investigate**; possible relevance in AR-low tumors.

---

### 8. Immune OSN Activation

**Evidence Level:** Moderate (Preclinical + Early Clinical)
**Mechanism:** BAT-induced DNA damage activates cGAS/STING, enhancing cytotoxic T-cell infiltration. Synergy with PD-1/PD-L1 blockade observed in early studies.
**Combination Actionability:**

- **Trial-Recommended** with checkpoint inhibitors (nivolumab, pembrolizumab).
- **Directly Actionable** in trial-eligible patients.

---

### 9. Metabolic and Transcriptional Reprogramming

**Evidence Level:** Moderate (Preclinical + Correlative Clinical)
**Mechanism:** BAT suppresses MYC and SKP2, impairing metabolic flexibility and DNA licensing.
**Combination Actionability:**

- **Monitor / Investigate** for synergy with metabolic inhibitors.

---

### 10. Clinical Implications and Future Directions

BAT's multi-mechanistic action makes it a candidate for rational combination therapy, especially in biomarker-selected populations (e.g., HRD, AR-V7).
**Most Actionable Combinations Today:**

- BAT → AR inhibitor sequencing (High evidence)
- BAT + PARP inhibitor in HRD-positive CRPC (Moderate–High evidence)
- BAT + immune checkpoint inhibitor (Moderate evidence, trial-preferred)




*Figure 3 Cell Cycle*

This program mirrors most of the BAT protocols studied in clinical trials, using just two medications and remaining straightforward to follow:

- Begin with a lead-in ADT phase for at least 2 months.




- Start BAT cycles as follows:
    1. On day 1, inject 400 mg of testosterone cypionate.
    2. On day 1, administer a monthly Lupron injection (or use a 3-month formulation every 3 months).
    3. Between days 2 and 5 of each cycle, measure PSA and testosterone levels.
    4. Near the end of the cycle (around days 24–27), repeat measurements for CBC, CMP, PSA, and testosterone.
    5. Repeat the cycle every 28 days.

Figure 4 BAT




Figure 5 PSA secretion is regulated by androgens and is not a good indicator of benefit during high T.

(A) In laboratory studies, human prostate cancer cells exposed to testosterone (orange bar) showed a 50% reduction in growth compared to untreated cells (blue bar), while cells treated with Xtandi (gray bar) exhibited growth similar to untreated controls. Interestingly, even though testosterone cut cell numbers in half, it led to a 3.5-fold increase in PSA production relative to untreated cells. In contrast, although Xtandi did not affect cell growth, it reduced PSA production by over 90%.
(B) In patients treated with BAT, three distinct PSA response patterns were observed: one group exhibited a marked PSA decrease ("PSA response"), another maintained stable PSA levels ("PSA plateau"), and a third experienced rising PSA levels ("PSA progression").
[Figure can be viewed at wileyonlinelibrary.com]

To achieve low levels of testosterone for the purposes of BAT, a GnRH antagonist, a GnRH antagonist, or an orchiectomy can be used.




Figure 6 Steroid pathway

## Clinical Trials

### 1. SPIDERMAN

https://clinicaltrials.gov/study/NCT07142551

Supraphysiologic Testosterone Priming Induces Darolutamide Extended Response (SPIDERMAN)

**Enrollment:** ~60 (estimated)
**Estimated completion date:** 2034
**Phase/Design:** Phase 2, open-label, non-randomized; parallel assignment with a defined lead-in followed by alternating cycles
**Stage/Setting:** First-line metastatic hormone-sensitive prostate cancer (mHSPC)—"first line hormonal therapy," no prior ADT/ARPI for recurrent/metastatic disease. (Note: some registry mirrors label "mCRPC," but the protocol text and inclusion criteria make clear it is first-line HS.)
**Summary:**

- **Objective:** Test whether alternating supraphysiologic testosterone (BAT) and darolutamide can delay resistance to hormonal therapy and reduce side effects; includes quality-of-life and molecular correlatives (gene expression, metabolic changes).
- **Lead-in (months 0–6):** Start ADT (LHRH agonist/antagonist) + darolutamide 600 mg BID. Patients with ≥50% PSA decline proceed; non-responders or progressors remain on ADT and come off study.
- **Alternating phase (post lead-in):**
  - **BAT cycle:** Testosterone cypionate 400 mg IM every 4 weeks ×3 (12 weeks), without ADT.
  - **Darolutamide cycle:** Darolutamide 600 mg BID for 12 weeks, without ADT.
  - Cycles alternate until clinical/radiographic progression.
- **Key inclusion highlights:** Histologic prostate adenocarcinoma; baseline PSA ≥1.0 ng/mL; rising PSA; evidence of metastatic disease; no prior ADT/ARPI for recurrent/metastatic disease (adjuvant/neoadjuvant allowed if ≥1 year before recurrence). Prior focal RT for oligomets allowed if >6 months, with non-irradiated measurable disease.
- **Key exclusions (selected):** Prior chemotherapy, PSMA-RLT (Pluvicto), or investigational AR-targeted agents; conditions posing testosterone-related risk (e.g., unstable spinal/femoral metastases, obstructive uropathy risk); warfarin use; hematocrit >51%, untreated severe OSA, significant cardiac disease.

**Notes:** Sponsor/site listed with Johns Hopkins (SKCCC). Registry mirrors indicate Phase 2 and ~60 patients and sometimes (incorrectly) tag "mCRPC."




## 2. STEP-UP

https://clinicaltrials.gov/ct2/show/NCT04363164

**Sequential High Dose Testosterone and Enzalutamide Compared with Enzalutamide Alone for the Treatment of Asymptomatic Metastatic Castration Resistant Prostate Cancer, STEP-UP Study**
https://www.cancer.gov/about-cancer/treatment/clinical-trials/search/v?id=NCI-2021-06077&r=1

Enrollment: 150

Stage: CRPC

Summary:

1. Estimated completion date 7/2026-7/2027
2. BAT (1) interleaved with Enzalutamide in two schemes
3. If successful, this could change the PCa paradigm. If enzalutamide sensitivity can be restored, darolutamide and apalutamide sensitivity should be restored.

Arm B shown.
Arm A receives constant Xtandi
Arm C repeats monthly T injections (56-day cycles) until progression, then 56-day cycles of Xtandi until progression.




## 3.

## 4. TRANSFORMER

Trial and results: **https://clinicaltrials.gov/ct2/show/NCT02286921**

Commentary: TRANSFORMER: A Randomized Phase II Study Comparing Bipolar Androgen Therapy Versus Enzalutamide in Asymptomatic Men With Castration-Resistant Metastatic Prostate Cancer - PMC
**https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8274807/**

Enrollment: 222 actual

Stage: mCRPC

Summary:

1. Complete
2. BAT [(1)] vs enzalutamide
3. Excellent results (77% PSA50) for post-BAT Xtandi challenge.

| Outcome Measure | TRANSFORMER Trial (2019) | RESTORE Trial (2023) |
|---|---|---|
| PSA50 Response Rate (BAT arm) | 28.2% | 35%* |
| PSA50 Response Rate (Post-BAT Enzalutamide) | 77.8% | - |
| Median PFS (BAT vs. Enzalutamide) | 5.7 months (both arms) | 8.1 months† |
| Median OS (BAT arm) | 32.9 months | Not Reached‡ |
| Median OS (Enzalutamide arm) | 29.0 months | - |
| PSA90 Response Rate | 33.3% | 50%* |

| Outcome Measure | TRANSFORMER Trial (2019) | RESTORE Trial (2023) |
|---|---|---|
| Radiographic PFS (Post-BAT Abi/Enz) | 20.6 months | - |
| OS in Responders (PSA <4 ng/mL) | Not Reached | Not Reached |
| OS in Non-Responders (PSA ≥4 ng/mL) | 43 months | 38.5 months |

## 5. Olaparib + BAT

Trial and results: **https://clinicaltrials.gov/ct2/show/NCT03516812**

Summary: ESMO 2021: Bipolar Androgen Therapy (BAT) Plus Olaparib in Men With Metastatic Castration-Resistant Prostate Cancer
**https://www.urotoday.com/conference-highlights/esmo-2021/esmo-2021-prostate-cancer/132121-esmo-2021-bipolar-androgen-therapy-bat-plus-olaparib-in-men-with-metastatic-castration-resistant-prostate-cancer.html**

Details: Clinical Study Protocol (CSP)
https://cdn.clinicaltrials.gov/large-docs/12/NCT03516812/Prot_SAP_000.pdf

Enrollment: 36 actual

Stage: mCRPC

Summary:

1. Complete
2. Several other studies testing olaparib in combination with DNA damaging therapies are underway or have recently completed. The results of these studies generally support combining PARP inhibitors with DNA damaging therapies.
3. Results of this study showed good response regardless of HRR status.
4. Testosterone enanthate or cypionate 400mg IM every 28 days. Olaparib 300 mg BID.
5. Excellent results for synergy with PARP inhibitor Olaparib. 47% of those who had an HRR mutation as well as 47% of those without an HRR mutation had a PSA50 response. 76% had a PSA drop. 26% had a PSA90 response. 61.5% had a radiographic complete or partial tumor response.
6. A control group was not included (could have done olaparib and injections of saline solution) but the radiographic response rate appears to be 1-2x what might be expected from Olaparib monotherapy.

## 6. RESTORE

Trial and results: **https://clinicaltrials.gov/ct2/show/NCT02090114**

Summary: A Multicohort Open-label Phase II Trial of Bipolar Androgen Therapy in Men with Metastatic Castration-resistant Prostate Cancer (RESTORE): A Comparison of Post-abiraterone Versus Post-enzalutamide Cohorts
**https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7775877/pdf/nihms-1633109.pdf**

Commentary: A Multicohort Open-label Phase II Trial of Bipolar Androgen Therapy in Men with Metastatic Castration-resistant Prostate Cancer (RESTORE): A Comparison of Post-abiraterone Versus Post-enzalutamide Cohorts - PMC
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7775877/

Enrollment: 112 actual

Stage: CRPC

Summary:

1. Complete
2. Men who failed Xtandi or Zytiga received BAT therapy. After BAT therapy most of them were rechallenged with Zytiga or Xtandi.
3. Study was underpowered but the Initial PSA50 response appears to be better for post-Xtandi BAT vs. post-Zytiga BAT.
4. Excellent results (68% PSA50) for post-BAT Xtandi challenge.

## 7. BATMAN

**PSA provocation by bipolar androgen therapy may predict duration of response to first-line androgen deprivation: Updated results from the BATMAN study – PubMed**
**https://pubmed.ncbi.nlm.nih.gov/35938545/**

**PSA provocation by bipolar androgen therapy may predict duration of response to first-line androgen deprivation: Updated results from the BATMAN study - Denmeade - 2022 - The Prostate - Wiley Online Library**
**https://onlinelibrary.wiley.com/doi/abs/10.1002/pros.24426**

**https://clinicaltrials.gov/ct2/show/NCT01750398**

Enrollment: 33 actual, 29 performed BAT.

Stage: HSPC

Summary:
Complete

1. BAT with a good HSPC scheme.
2. 6-month ADT lead-in. Alternating 3-month cycles of ADT and BAT (1)
3. 80% radiographic response rate.

| Outcome Measure | Result (2016 Publication) | Result (2022 Update) |
|---|---|---|
| PSA <4 ng/ml at 18 months | 59% | - |
| Objective Response Rate (RECIST) | 80% | - |
| PFS on ADT (median) | - | 47.8 months |

| Outcome Measure | Result (2016 Publication) | Result (2022 Update) |
|---|---|---|
| OS (Responders, PSA <4 ng/ml post-BAT/ADT) | - | Not Reached |
| OS (Non-Responders, PSA ≥4 ng/ml post-BAT/ADT) | - | 43 months |
| PSA50 to Abi/Enz post-BAT | - | 94.40% |
| PSA90 to Abi/Enz post-BAT | - | 66.70% |
| PFS on Abi/Enz post-BAT (median) | - | 20.6 months |
| PFS (PSA peak ≥9 ng/ml post-BAT) | - | 20.6 months |
| PFS (PSA peak <9 ng/ml post-BAT) | - | Not Reached |
| OS (PSA peak ≥9 ng/ml post-BAT) | - | 79.6 months |
| OS (PSA peak <9 ng/ml post-BAT) | - | Not Reached |



## 8. BAT trial (Sipuleucel-T Combined With Bipolar Androgen Therapy in Men With mCRPC)

https://clinicaltrials.gov/study/NCT06100705

Enrollment: 26

Stage: mCRPC

Summary:
Estimated completion date 12/2027-3/2028

## 9. APEX

**Eflornithine and Testosterone Followed by Enzalutamide for the Treatment of Patients with Metastatic Castration-Resistant Prostate Cancer, APEX Trial - NCI**
**https://www.cancer.gov/research/participate/clinical-trials-search/v?id=NCI-2024-09882**

**BAT+DFMO**

***119 day cycles:***

1. ***DFMO (eflornithine) 1000 mg PO BID continuously days 1–63***
2. ***Testosterone cypionate 400 mg IM on days 8 and 36***
3. ***Enzalutamide 160 mg PO QD continuously on days 64–119***



## 10. Study Details | The COSMYC Trial (COmbined Suppression of MYC) | ClinicalTrials.gov

https://clinicaltrials.gov/study/NCT06922318

ZEN-3694 48 mg (one 48 mg tablet) will be taken once per day by mouth each cycle (each cycle is 28 days). On the first day of each cycle, testosterone cypionate (400 mg) injection will be administered.

## 11. SPECTRA

Supraphysiological Androgen to Enhance Chemotherapy Treatment Activity in Metastatic Castration-Resistant Prostate Cancer, SPECTRA Study - Full Text View - ClinicalTrials.gov
https://classic.clinicaltrials.gov/ct2/show/NCT06039371

Enrollment: 46

Stage: mCRPC

Summary:
Estimated completion date 3/2027-12/2027
One month ADT lead-in with Carboplatin and then BAT and Carboplatin: Compared to Etoposide on days 1-14 of each 28 day cycle + BAT

## 12. BATTLE or Square Wave Testosterone Therapy in Castration Resistant Prostate Cancer

Trial: https://clinicaltrials.gov/ct2/show/NCT03734653

**Transdermal square-wave testosterone therapy: A pilot trial in metastatic castration-resistant prostate cancer. | Journal of Clinical Oncology**
https://ascopubs.org/doi/abs/10.1200/JCO.2023.41.6_suppl.188

Enrollment: 15

Stage: mCRPC

Summary:

1. Complete
2. Transdermal testosterone gel was administered at a dose of 100 mg/day for a minimum of 12 weeks and until disease progression. Therapy was then switched to Xtandi 160 mg/day until the next disease progression.
3. Transdermal gel dose not sufficient for SPT (avg measurement 901 ng/dl)
4. PSA50 13.3% during testosterone and 66.7% after switching to enzalutamide.

## 13. COMBAT-CRPC

https://clinicaltrials.gov/ct2/show/NCT03554317

**COMBAT-CRPC: Concurrent administration of bipolar androgen therapy (BAT) and nivolumab in men with metastatic castration-resistant prostate cancer (mCRPC). | Journal of Clinical Oncology**
https://ascopubs.org/doi/abs/10.1200/JCO.2021.39.15_suppl.5014

**ASCO 2022: Overall Survival and Biomarker Results From Combat: A Phase 2 Study of Bipolar Androgen Therapy Plus Nivolumab for Patients With Metastatic Castrate-Resistant Prostate Cancer**
https://www.urotoday.com/conference-highlights/asco-2022/asco-2022-prostate-cancer/137706-asco-2022-overall-survival-and-biomarker-results-from-combat-a-phase-2-study-of-bipolar-androgen-therapy-plus-nivolumab-for-patients-with-metastatic-castrate-resistant-prostate-cancer.html




**Figure 5. Radiographic Progression-Free Survival Estimate of Patients with mCRPC Treated with BAT in Combination with Nivolumab Stratified by Changes in MYC Protein**

Kaplan-Meier curves of radiographic progression-free survival (rPFS) are shown. Patients with >50% reduction in MYC protein on BAT (N=8, blue line) had a significantly longer rPFS compared to patients with <50% decline in MYC protein (N=16, red line); HR= 0.33, P=0.005

Enrollment: 44 actual

Stage: mCRPC

Summary:
Complete
BAT [(1)]: Nivolumab starting cycle 4
Excellent results for synergy with Immunotherapy

## 14.

**A Pilot Study of IM Testosterone and Oral Etoposide as Therapy for Men With Castration Resistant Prostate Cancer - Full Text View - ClinicalTrials.gov**
**https://clinicaltrials.gov/ct2/show/NCT01084759**

**Effect of bipolar androgen therapy for asymptomatic men with castration-resistant prostate cancer: Results from a pilot clinical study - PMC**
**https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4507510/**

Enrollment: 16 actual

Stage: mCRPC

Summary:
Complete
Etoposide + BAT [(1)]

## 15. PSMA-BAT

**https://clinicaltrials.gov/ct2/show/NCT04424654**

Enrollment: 20 actual

Stage: mCRPC

Summary:
Complete
Examine PSMA expression and AR-V7 vs. BAT response.
BAT [(1)]

## 16. Men’s Cycle

Trial and results: **https://clinicaltrials.gov/ct2/show/NCT00586898**

Enrollment: 36 actual

Stage: mCRPC

Howard Scher, MD,Memorial Sloan Kettering Cancer Center Scherh@mskcc.org

Summary:
Complete
76% Complete response rate
14% Partial response rate (PSA50)
10% Stable disease
BAT with Androgel, E2 patches, ketoconazole, bicalutamide, Lupron [(1)]

**17.**

Trial
**Phase 1 Trial of High-Dose Exogenous Testosterone in Patients with Castration-Resistant Metastatic Prostate Cancer - PMC**
**https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2738932/**

Enrollment
19 actual

Stage mCRPC

Summary
Complete
Androgel and bicalutamide
8-week cycles or 1 week single cycle.
Max tT was less then 900 mg/dl. fT was calculated.

**18. ExBAT**

**ASCO GU 2025: Extreme Bipolar Androgen Therapy: Alternating Darolutamide and Testosterone Cypionate in Patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC; ExBAT trial/LACOG 0620).**
**https://www.urotoday.com/conference-highlights/asco-gu-2025/asco-gu-2025-prostate-cancer/158188-asco-gu-2025-extreme-bipolar-androgen-therapy-alternating-darolutamide-and-testosterone-cypionate-in-patients-with-metastatic-castration-resistant-prostate-cancer-mcrpc-exbat-trial-lacog-0620.html**

**]Extreme Bipolar Androgen Therapy With Darolutamide and Testosterone Cypionate in Patients With Metastatic Castration-Resistant Prostate Cancer (ExBAT Trial) - Full Text View - ClinicalTrials.gov**
**https://classic.clinicaltrials.gov/ct2/show/NCT04558866**

**Preliminary results**
**Extreme bipolar androgen therapy: Alternating darolutamide and testosterone cypionate in patients with metastatic castration-resistant prostate cancer (mCRPC; ExBAT trial/LACOG 0620). | Journal of Clinical Oncology**
https://ascopubs.org/doi/abs/10.1200/JCO.2025.43.5_suppl.178

Enrollment: 51

Stage: mCRPC

Summary:
Estimated completion date 2024-2025
63-day cycles.
Day 1: Testosterone cypionate 400 mg IM on day 1.
Day 29-56: Darolutamide 600 mg twice a day orally for 4 weeks.
Day 57-63: Washout period.




## 19. BAT-RAD

https://clinicaltrials.gov/ct2/show/NCT04704505

Enrollment: 47

Stage: CRPC

Summary:
Estimated completion date 2/2026-2/2027
BAT [(1)] plus Radium-223 (RAD)
DNA DSB should synergize.

## 20. mHI-TECH

**https://clinicaltrials.gov/ct2/show/NCT03522064**

Enrollment: 30

Stage: CRPC, Genetic HRD

Summary:
Estimated completion date 12/2024-12/2025
500mg IM enanthate every 4 weeks in combination with ongoing LHRH agent (unless post-orchidectomy) plus Carboplatin AUC 5
DNA DSB should synergize.
ctDNA and intra-tumoural gene expression.

## 21. VA-BAT

**https://clinicaltrials.gov/ct2/show/NCT05011383**

Enrollment: 51

Stage: CRPC, Genetic ATM, CDK12, or CHEK2

Summary:
Estimated completion date 8/2026-8/2027
BAT [(1)]
Straightforward BAT. The purpose of this trial is to gather information on mutations that predict BAT success. Important data.

## 22. Oral-TU/Xtandi

**https://clinicaltrials.gov/ct2/show/NCT05081193**

Enrollment: 30

Stage: mCRPC

Summary:
Estimated completion date 12/2025-12/2027
Oral Testosterone Therapy-396 mg given twice per day on days 1-7 and 15-21 of a 28-day cycle until radiographic progression. After a 21-day washout period, Enzalutamide therapy given at 160 mg once daily will be taken for a maximum of 6 cycles while on study.
Oral testosterone might not be sufficient for SPT. It might be sufficient for supraphysiological DHT levels.

**23.**

**Trial using Androgel in two arms – one with estrogen patches and one without: Rapid Androgen Cycling as Treatment for Patients with Prostate Cancer | Clinical Cancer Research | American Association for Cancer Research**
**https://aacrjournals.org/clincancerres/article/12/24/7414/193013/Rapid-Androgen-Cycling-as-Treatment-for-Patients**

Maximal apoptosis occurred by day 3 and was virtually absent by day 7

**24. ACROBAT**

The ACROBAT study is testing the rapid cycling of an oral form of testosterone in men whose cancer has just progressed to the castrate-resistant state (CRPC).

**25.**

**https://clinicaltrials.gov/study/NCT00587431**

**The men's cycle plus docetaxel (Doc) in prostate cancer patients with rising PSAs in the non-castrate state | Journal of Clinical Oncology**
https://ascopubs.org/doi/abs/10.1200/jco.2005.23.16_suppl.4564

**A Phase II Trial of Docetaxel with Rapid Androgen Cycling as a Treatment for Patients with Prostate Cancer - PMC**
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3051836/

**26. WOMBAT**
https://clinicaltrials.gov/study/NCT06594926

**Bipolar androgen therapy (BAT) for nonmetastatic castration-resistant prostate (nmCRPC) cancer progressing on darolutamide: Working Out M0 BAT (WOMBAT; ANZUP 2201)**
https://ascopubs.org/doi/abs/10.1200/JCO.2025.43.5_suppl.TPS298

ASCO GU 2025: Bipolar Androgen Therapy (BAT) for Nonmetastatic Castration-Resistant Prostate Cancer (nmCRPC) Progressing on Darolutamide: Working out M0 BAT (WOMBAT; ANZUP 2201)

https://www.urotoday.com/conference-highlights/asco-gu-2025/asco-gu-2025-prostate-cancer/158183-asco-gu-2025-bipolar-androgen-therapy-bat-for-nonmetastatic-castration-resistant-prostate-nmcrpc-cancer-progressing-on-darolutamide-working-out-m0-bat-wombat-anzup-2201.html

Enrollment 69

Stage: nmCRPC

Summary:
Estimated completion date: 2026-2028
Trial using testosterone enanthate (500 mg IM every 56 days) and darolutamide 600 mg BID days 29-56.
56-day cycles.

Endpoints include time to metastasis. A tertiary objective of the study is exploratory biomarker analysis, examining how outcomes may correlate with cell-free DNA alterations, AR-V7 status, and changes in circulating tumor DNA (ctDNA) methylation.

Note: Darolutamide will not be fully cleared from the system. As a result, the androgenic peak will be blunted—dropping from around 2750 ng/dL to an initial level near 1000 ng/dL, with a peak of approximately 1450 ng/dL by day 7. Individual responses will vary, and bloodwork will confirm that high serum testosterone levels are reached. These will not be androgenic levels.

### 27. Bipolar Androgen Therapy to Restore Sensitivity to Androgen Deprivation Therapy for Patients With Metastatic Castration Resistant Prostate Cancer

https://clinicaltrials.gov/study/NCT06305598

Enrollment 14

Stage: mCRPC

Summary:
Estimated completion date: 2026-2027
Trial using testosterone enanthate (IM every 28 days) and continuous Lupron.

[(1)] 400 mg of testosterone cypionate (enanthate) injected once a month. ADT: Lupron.

# Predicting Efficacy of Bipolar Androgen Therapy (BAT) in Prostate Cancer

## Prostate Cancer Molecular Subtypes and aBAT Response

A novel prostate cancer subtyping classifier based on luminal and basal phenotypes - Weiner - 2023 - Cancer - Wiley Online Library
https://acsjournals.onlinelibrary.wiley.com/doi/10.1002/cncr.34790

---

### Methods

Unsupervised machine learning of gene expression profiles from prospectively collected primary prostate tumors (training, n = 32,000; evaluation, n = 68,547) was used to create a prostate subtyping classifier (PSC) based on basal versus luminal cell expression patterns and other gene signatures relevant to prostate cancer biology. Subtype molecular pathways and clinical characteristics were explored in five other clinical cohorts.

---

### Results

Clustering derived four subtypes: luminal differentiated (LD), luminal proliferating (LP), basal immune (BI), and basal neuroendocrine (BN).

- LP and LD tumors both had higher androgen receptor (AR) activity.
- LP tumors also had a higher expression of cell proliferation genes, MYC activity, and characteristics of homologous recombination deficiency (HRD).
- BI tumors possessed significant interferon-γ activity and immune infiltration on immunohistochemistry.
- BN tumors were characterized by lower AR activity, lower immune infiltration, and enrichment with neuroendocrine expression patterns.

Patients with LD tumors had less aggressive tumor characteristics and the longest time to metastasis after surgery. Only patients with BI tumors derived benefit from radiotherapy after surgery in terms of time to metastasis (hazard ratio [HR], 0.09; 95% CI, 0.01–0.71; n = 855). In a phase 3 trial that randomized patients with metastatic prostate cancer to androgen deprivation with or without docetaxel (n = 108), only patients with LP tumors derived survival benefit from docetaxel (HR, 0.21; 95% CI, 0.09–0.51).

---

### Determining Your Subtype

To determine whether you have LD, LP, BI, or BN subtype, assess a combination of molecular, transcriptomic, and histopathological features:

---

#### 1. Luminal Differentiated (LD)

- High AR activity

- High expression of prostate luminal differentiation genes
- Low proliferation gene expression
- Lack of profound DNA repair defects (e.g., BRCA/ATM mutations)
- Histology: More differentiated, lower-grade, organ-confined disease
- Clinical course: Less aggressive, longest time to metastasis

---

## 2. Luminal Proliferating (LP)

- High AR activity (like LD)
- High expression of cell proliferation genes and MYC activity
- Characteristics of homologous recombination deficiency (BRCA1/2, ATM)
- Elevated gene signatures for cell cycle progression
- Histology: Higher-grade tumors, aggressive pathology
- Clinical course: Worse prognosis than LD; only subtype with docetaxel survival benefit

---

## 3. Basal Immune (BI)

- Lower AR activity than LD/LP
- Significant interferon gamma signaling
- High immune cell infiltration (IHC or transcriptomics)
- Histology: Basal marker expression, variable differentiation
- Clinical course: Most sensitive to adjuvant radiotherapy

---

## 4. Basal Neuroendocrine (BN)

- Low AR activity
- Low immune infiltration

- Enrichment for neuroendocrine markers (chromogranin, synaptophysin, enolase)
- Histology: Neuroendocrine differentiation, sometimes small cell morphology
- Clinical course: Aggressive, poor prognosis, typically BAT-resistant

---

## Practical Classification

### A. Transcriptomic Classifier (Gold Standard)

- RNA-based multi-gene expression panels (e.g., Decipher, academic classifiers).
- Requires NGS or PCR profiling of tumor tissue.
- Most accurate method for subtype determination.

### B. Surrogate Markers (If Transcriptomics Not Available)

- LD vs. LP: Both AR-high; LP adds high proliferation (Ki67, MYC) and HRD mutations.
- BI: Immune infiltration + IFN-γ signaling; lower AR.
- BN: AR-low + neuroendocrine markers high (IHC or gene profiling).

---

### Table: Distinguishing Features

| **Feature** | **LD** | **LP** | **BI** | **BN** |
|---|---|---|---|---|
| AR Activity | High | High | Low/ Medium | Low |
| Proliferation Genes | Low | High | Variable | Low |
| HRD / DNA Repair Defect | Rare | Frequent | Uncommon | Rare |
| Immune Infiltration | Low | Low | High | Low |
| Neuroendocrine Markers | Absent | Absent | Absent | High |
| Histologic Grade | Low/ | High | Variable | Hig |

| Feature | LD | LP | BI | BN |
|---|---|---|---|---|
| | Moderate | | | h |
| Docetaxel Response | No | Yes | No | No |
| RT Sensitivity | No | No | Yes | No |

## Best Prostate Cancer Molecular Subtype for aBAT (Bipolar Androgen Therapy)

Based on the molecular subtyping described—luminal differentiated (LD), luminal proliferating (LP), basal immune (BI), and basal neuroendocrine (BN)—the LP (Luminal Proliferating) subtype appears to be the best suited for aBAT.

---

## Evidence and Rationale

### 1. Androgen Receptor (AR) Dependency

- LP and LD tumors both have high AR activity, which is a key requirement for BAT responsiveness, as aBAT leverages high AR signaling for its mechanism.
- LP subtype, in particular, has even higher expression of AR-related genes, proliferation signatures (e.g., MYC), and features of homologous recombination deficiency.

### 2. Genomic Features

- LP tumors are characterized by increased cell proliferation, strong AR signaling, and frequent DNA repair defects.
- Studies of BAT show the greatest clinical responses (deep PSA declines, radiographic responses) among patients with mutations in DNA repair genes (BRCA1/2, ATM) and/or TP53. These mutations are most prevalent in the LP subtype.

### 3. Subtype-Specific Outcomes

- LP tumors respond best to both BAT and docetaxel.
- LD tumors: Less aggressive, longer time to metastasis, and high AR activity, but with less proliferation and DNA repair deficiency—so BAT may be effective but less so than in LP.
- BI tumors: Defined by immune infiltration; response to BAT is not well documented, and these tumors derived greater benefit from radiotherapy.
- BN tumors: Low AR activity and enriched with neuroendocrine features—typically unresponsive to BAT due to a lack of AR target and high resistance mechanisms.

---

### Summary Table: BAT Suitability by Subtype

| Subtype | AR Activity | DNA Repair Defects | Proliferation | BAT Response Potential |
|---|---|---|---|---|
| LP | High | Frequent | High | Highest |
| LD | High | Rare | Low/ Indolent | Moderate |
| BI | Low/ Medium | Unclear | Variable | Low (benefit from RT) |
| BN | Low | Rare | Low | Very Low/None |

### Conclusion

LP (Luminal Proliferating) is the best molecular subtype for aBAT, due to strong AR dependence, high proliferation, and DNA repair deficiency. LD may also respond, but LP consistently demonstrates the most robust mechanism for BAT efficacy, supported by clinical and genomic evidence.

---

Key Predictive Biomarkers and Mechanisms
Based on recent clinical trials and mechanistic studies, the following factors predict BAT efficacy:

| Biomarker/ Mechanism | Predictive Value | Evidence Source |
|---|---|---|
| AR Alterations in ctDNA | Patients with AR amplification or mutations (e.g., T878A, L702H) benefit from BAT. | TRANSFORMER Trial (ASCO 2024): 53% of patients with AR alterations in ctDNA had improved PFS/OS vs. Enzalutamide. No AR alterations → worse outcomes on BAT. |
| High AR Activity (ARA MW Score) | ARA MW score >0.6 (gene signature of AR activity) predicts tumor regression and survival. | PMC9711876: High AR activity drives MYC suppression. Patients with ARA MW >0.6 had median OS of 47.4 vs. 29.0 months (low AR activity). |
| MYC Downregulation | BAT-induced MYC | Preclinical/clinical data: High AR activity enables |

| Biomarker/ Mechanism | Predictive Value | Evidence Source |
|---|---|---|
| | suppression correlates with clinical response. | MYC suppression, reducing proliferation. |
| Low Tumor-Suppressor Loss | BAT + PARPi may benefit patients with BRCA2/P53 loss (preclinical synergy). | ScienceDirect Study: Combined tumor-suppressor loss (e.g., BRCA2/P53) linked to BAT resistance; PARPi may resensitize. |

Clinical Implications

Patient Selection:
- Favorable: AR alterations (ctDNA), high AR activity (ARA MW >0.6), MYC overexpression.
- Unfavorable: No AR alterations, low AR activity, tumor-suppressor loss (BRCA2/P53).

Recommendations
- Use ctDNA to detect AR alterations (amplifications/mutations) and calculate ARA MW score.
- Prioritize BAT for AR-altered/high AR activity tumors.

Therapeutic Strategies:
- For AR-altered tumors: BAT ± immunotherapy (BATRAD trial).
- For AR-wild-type tumors: Enzalutamide or combination therapies (e.g., PARPi + BAT).

Conclusion

BAT efficacy is theoretically predictable via AR status and activity biomarkers. Patients with AR-driven tumors (ctDNA alterations, high ARA MW score) derive significant benefit, while others should receive alternative therapies. Ongoing trials (e.g., STEP-UP, BATRAD) aim to optimize sequencing and combinations.
Grade of Evidence: B (Phase II/III trial data, validated preclinical models).

References:

**1. TRANSFORMER Trial (ASCO 2024)**
- **Title:** Blood-Based Markers of Differential Efficacy of Bipolar Androgen Therapy and Enzalutamide in the Randomized TRANSFORMER Trial
  **URL:** ASCO 2024 Abstract

**2. Sena et al. (PMC9711876)**
- **Title**: *Androgen receptor activity in prostate cancer dictates efficacy of bipolar androgen therapy through MYC*
  **URL**: PMC9711876

**3. ScienceDirect Study (Tumor-Suppressor Loss)**
- **Title:** Clinical Efficacy of Bipolar Androgen Therapy in Men with Metastatic Castration-Resistant Prostate Cancer and Combined Tumor-Suppressor Loss
  **URL:** ScienceDirect Article

## ARA MW

To calculate the **ARA MW score** (Androgen Receptor Activity Molecular Weighted score) for predicting Bipolar Androgen Therapy (BAT) efficacy in prostate cancer, the process involves analyzing gene expression signatures associated with androgen receptor (AR) activity. Based on the referenced study (PMC9711876) and standard methodologies for AR activity scoring, here's the general framework:

**Steps to Calculate the ARA MW Score**

1. **Gene Signature Selection**:
   - Use a predefined panel of AR-regulated genes (e.g., *KLK3* [PSA], *TMPRSS2*, *NKX3-1*, *FOLH1* [PSMA], *MYC*).
   - These genes are validated biomarkers of AR transcriptional activity.
2. **Gene Expression Measurement**:
   - Extract RNA from tumor tissue or liquid biopsy (e.g., ctDNA).
   - Quantify expression levels via RNA sequencing, NanoString, or qPCR.
3. **Normalization**:
   - Normalize expression values to housekeeping genes (e.g., *GAPDH*, *ACTB*) to account for sample variability.
4. **Weighted Summation**:
   - Apply gene-specific weights (derived from regression models correlating gene expression with AR activity or clinical outcomes):

ARA MW Score=∑i=1n(wi×Normalized Expressioni)ARA MW Score=$i$=1∑$n$($wi$×Normalized Expression$i$)

   - Example weights (hypothetical):
     - *KLK3*: 0.4
     - *TMPRSS2*: 0.3
     - *MYC*: 0.2
     - *NKX3-1*: 0.1
5. **Thresholding**:
   - **ARA MW > 0.6**: High AR activity → predicts BAT efficacy (median OS: 47.4 vs. 29.0 months for low activity).
   - **ARA MW ≤ 0.6**: Low AR activity → BAT resistance likely.

**Key Insights from the PMC9711876 Study**

- **Mechanistic Basis**: High AR activity suppresses MYC oncogene expression, enhancing BAT-induced tumor regression.
- **Clinical Correlation**: Patients with ARA MW > 0.6 had significantly improved survival outcomes on BAT.

**Practical Considerations**

- **ctDNA vs. Tissue**: While tissue biopsies are ideal, ctDNA-based AR amplification/mutation analysis can proxy AR activity (e.g., AR-V7 detection).
- **Commercial Assays**:
  - The **Decipher AR-Activity Score** (AR-A) quantifies AR pathway activity in tumor RNA. While not validated in BAT trials, AR-A correlates with:
  - Luminal subtypes (associated with AR-driven biology)
  - Improved responses to AR-targeted therapies (e.g., enzalutamide in the ENACT trial).

**Confusion Clarification**

- *ARA Algorithm/Other Acronyms**: The term "ARA" in this context refers to **Androgen Receptor Activity**.

**If AR activity is high, BAT might work better for you.**

## Evaluating AR Status Testing in Prostate Cancer: FDA-Approved Liquid Biopsy and Tissue Assays

### FDA-Approved Tests for AR Status

| Test Name | Manufacturer | Approval Year | Target AR Aberrations | Specimen Type | Evidence Grade (A-F) |
|---|---|---|---|---|---|
| FoundationOne® Liquid CDx | Foundation Medicine | 2020 | AR mutations, CNVs, fusions | Plasma cfDNA | A |
| Guardant360® CDx 730 gene test | Guardant Health | 2025 | AR mutations, CNVs, fusions | Plasma cfDNA | A |
| FoundationOne® CDx (Tissue) | Foundation Medicine | 2023 | AR mutations, CNVs | Tissue | A |

### Test Capabilities and Limitations

**FoundationOne® Liquid CDx**

*Can Do:*

• Detects AR mutations (e.g., T878A, F877L), amplifications, and structural rearrangements in cfDNA.

• FDA-approved as a companion diagnostic for BRCA1/2/ATM mutations in metastatic castration-resistant prostate cancer (mCRPC) to guide therapies such as olaparib or combinations with abiraterone.

*Cannot Do:*

• Distinguish germline from somatic AR mutations without a matched normal DNA sample.

• Detect AR-V7.

*Evidence:* **Grade A** (validated in MAGNITUDE/VISION trials).

---

**Guardant360® (730 gene test)**

*Can Do:*

• Detect AR single nucleotide variants (e.g., T878A, F877L) with broad genomic coverage.

• Identify AR amplifications through robust copy number analysis.

• Provide comprehensive liquid biopsy profiling—including TMB, MSI status, and methylation-based tumor fraction—to inform treatment selection.

*Cannot Do:*

• Does not capture AR fusions or complex structural rearrangements beyond SNVs and amplifications.

• Cannot definitively differentiate clonal hematopoiesis from tumor-derived AR mutations without a matched normal DNA sample.

*Evidence:* **Grade B+** (Cross-validated with tissue-based assays in clinical studies, demonstrating reliable performance in advanced cancer settings)

---

**FoundationOne® CDx (Tissue)**

*Can Do:*

• Detets AR amplifications and mutations in tumor biopsies.

• Validated for AR ligand-binding domain mutations (e.g., T878A) with up to 99% concordance compared to digital PCR methods.

*Cannot Do:*
• Assess spatial heterogeneity due to limitations inherent in a single biopsy sample.
• Monitor dynamic AR changes during therapy.
*Evidence:* Grade A (used in MAGNITUDE trial approvals).

**Emerging Non-FDA-Approved Tests**

| Test Name | Developer | AR Target | Evidence Grade | Limitations |
|---|---|---|---|---|
| AR-V7 Nucleus Detect | Epic Sciences | AR-V7 protein (nuclear) | C+ | No FDA approval; currently covered by Medicare only |
| PredicineAR™ | Predicine | AR cfDNA/cfRNA | C | For research use only; lacks FDA validation |
| AR-ctDETECT | Academic | AR CNVs, rearrangements | B- | Supported by Phase 3 trial data only |

**General Comments on AR Status Testing**
**What They Can Do:**
• These assays reliably detect AR gene amplifications and mutations at the DNA level. This information can guide treatment decisions regarding androgen receptor–targeted therapies.
**What They Cannot Do:**
• They do not assess RNA-level changes such as AR splice variants (e.g., AR-V7), which are known to predict resistance to further AR signaling inhibitors. Detecting AR-V7 typically requires circulating tumor cell (CTC)–based assays or alternative RNA-based methods.
• They do not provide epigenetic data (e.g., methylation patterns) that might also be clinically relevant.
*In summary*, for cfDNA and tissue testing of AR status, FDA-approved platforms such as FoundationOne® CDx (tissue) and FoundationOne® Liquid CDx (cfDNA) offer excellent detection of genomic alterations in the AR gene, with high levels of evidence (rated A and B+ respectively). Guardant360® CDx is also used, though its performance may vary slightly. However, none of these tests capture AR splice variant expression—an important marker for prostate cancer treatment resistance—which requires alternative approaches.

**Critical Analysis**
1. **Sensitivity Limitations:**
   - Liquid biopsies can miss AR alterations in 15–20% of cases due to low tumor-derived DNA shedding.
   - While tissue biopsy remains the gold standard, it may fail in up to 30% of bone-metastatic cases.
2. **AR-V7 Detection Gap:**
   - FDA-approved tests infer AR-V7 indirectly through DNA splicing information, but do not provide direct protein-level confirmation.
3. **Cost and Access:**
   - FoundationOne® Liquid CDx costs approximately $6,000 (with variable insurance coverage).
   - Guardant360® CDx costs around $5,400.

**Recommendations**
**• First-Line Monitoring:**
Use FoundationOne® Liquid CDx or Guardant360 730 gene test for dynamic AR monitoring in mCRPC.

• **Tissue Discordance:**
Confirm negative liquid biopsy results with a tissue-based FoundationOne® CDx assay or Guardant360 730 gene test.
• **AR-V7 Suspicion:**
Consider pairing with an Epic AR-V7 test even though it is not FDA approved, as Medicare currently covers it.

---

**References**


1. Detection fidelity of AR mutations in plasma derived cell-free DNA – PMC https://pmc.ncbi.nlm.nih.gov/articles/PMC5362513/
2. prostatecancer – Predicine | Advancing Precision Cancer Therapies https://www.predicine.com/prostatecancer/Niraparib/abiraterone FDA approval (2023)
3. Clinical utility of androgen receptor gene aberrations in circulating cell-free DNA as a biomarker for treatment of castration-resistant prostate cancer | Scientific Reports https://www.nature.com/articles/s41598-019-40719-y
4. AR-V7 CTC Liquid Biopsy Test for mCRPC Patients https://www.epicsciences.com/ar-v7-test/
5. AR alterations inform circulating tumor DNA detection in metastatic castration resistant prostate cancer patients | Nature Communications https://www.nature.com/articles/s41467-024-54847-1
6. Androgen Receptor Gene Aberrations in Circulating Cell-Free DNA: Biomarkers of Therapeutic Resistance in Castration-Resistant Prostate Cancer | Clinical Cancer Research | American Association for Cancer Research https://aacrjournals.org/clincancerres/article/21/10/2315/117374/


Note: Non-FDA tests lack Level 1 evidence but may provide actionable insights in refractory cases. Always correlate with clinical progression.

## PSA Dynamics

- **PSA Suppression**:
  PSA declines during BAT correlate with clinical benefit and survival outcomes.
- **PSA Flare**:
  Transient PSA increases early in BAT may indicate therapeutic response rather than progression.

## SPOP mutants

### Mechanistic Basis for *SPOP* Mutants and BAT

- **AR Hyperactivation**: *SPOP* mutations (e.g., Y87C, F102C, F133S) disrupt SPOP's role in degrading AR, leading to 30–90-fold AR overexpression in castration-resistant prostate cancer (CRPC) cells. This creates vulnerability to supraphysiologic testosterone, as AR-overexpressing cells are more sensitive to androgen-induced DNA damage and growth arrest.
- **DNA Repair Modulation**: BAT-induced testosterone cycling promotes double-strand DNA breaks and suppresses homologous recombination repair (HRR) genes like *BRCA2*. *SPOP* mutants may exhibit compounded DNA repair deficits, potentiating BAT's cytotoxic effects.

### Clinical Correlations

- **Predictive Biomarker Potential**: In a retrospective study, *SPOP* mutations predicted superior outcomes with next-generation AR inhibitors (e.g., enzalutamide, abiraterone), with longer PSA progression-free survival (22.5 vs. 9.7 months) compared to wild-type. While not directly testing BAT, this suggests *SPOP* mutants are uniquely responsive to AR-targeted strategies.
- **Combination Therapy Insights**: In a phase 2 trial, BAT combined with the PARP inhibitor olaparib achieved a 47% PSA50 response rate and 12.6-month median progression-free survival, independent of HRR mutational status. This aligns with preclinical data showing BAT suppresses HRR OSNs, potentially amplifying synthetic lethality in *SPOP*-mutant tumors.

### Limitations and Future Directions

- No prospective trials have specifically evaluated BAT in *SPOP*-mutant PCa.
- Ongoing research is needed to validate *SPOP* as a predictive biomarker and explore combination therapies.
- 12-17% of HSPC cancers have SPOP mutations
- 10-15% of CRPC cancers have SPOP mutations

*SPOP* mutations may sensitize tumors to bipolar androgen therapy (BAT) by amplifying androgen receptor (AR) signaling dependency and compounding DNA repair deficiencies, though prospective clinical validation remains ongoing. *SPOP* mutation status is detectable via FDA-approved comprehensive genomic tests such as **Guardant360 730 gene test, FoundationOne CDx**, **MSK-IMPACT**, or **Tempus xT**, which identify recurrent alterations (e.g., F133V, Y87C).

### References


1. SPOP Mutations as a Predictive Biomarker for Androgen Receptor Axis-Targeted Therapy in De Novo Metastatic Castration-Sensitive Prostate Cancer – PubMed https://pubmed.ncbi.nlm.nih.gov/36088616/
2. Bipolar androgen therapy plus olaparib in men with metastatic castration-resistant prostate cancer – PubMed https://pubmed.ncbi.nlm.nih.gov/36564459/
3. SPOP Mutation Drives Prostate Tumorigenesis In Vivo through Coordinate Regulation of PI3K/mTOR and AR Signaling – PubMed https://pubmed.ncbi.nlm.nih.gov/28292441/

4. Bipolar androgen therapy in men with metastatic castration-resistant prostate cancer after progression on enzalutamide: an open-label, phase 2, multicohort study – PubMed https://pubmed.ncbi.nlm.nih.gov/29248236/

## Genes Interacting with Bipolar Androgen Therapy (BAT) in Prostate Cancer

Key Genes with Direct Evidence for BAT Response

| Gene | BAT Relevance | Mechanism | Evidence Grade |
|---|---|---|---|
| **AR** | High | Primary target of BAT; responsiveness requires functional AR signaling | A |
| **TP53** | High | Mutations associated with improved PSA50 responses to BAT (41% vs 22%) | A |
| **BRCA2** | High | Most frequent DNA repair gene in BAT responders (10/30); creates synthetic lethality | A |
| **ATM** | High | Second most common DNA repair gene in BAT responders (8/30) | A |
| **CHEK2** | High | Case report of exceptional response in CHEK2-mutated mCRPC12; also found in 5/30 BAT responders17 | B |
| **MYC** | High | BAT-induced AR-mediated suppression of MYC correlates with response4 | B |
| **CD274** (PD-L1) | Moderate | Increased baseline PD-1+ T cells correlate with BAT+nivolumab response13 | B |
| **PALB2** | Moderate | Identified in 4/30 BAT responders17 | B |
| **CDK12** | Moderate | Found in 3/30 BAT responders17; associated with distinct immunophenotype | B |

### DNA Repair OSN Genes

| Gene | BAT Relevance | Mechanism | Evidence Grade |
|---|---|---|---|
| **BRCA1** | Moderate | Less common than BRCA2 (1/30 BAT responders)[17]; limited evidence in PCa | C |
| **CHD1** | Moderate | Found in 2/30 BAT responders[17]; causes DNA repair defects[15] | C |
| **FANCA/ FANCD2** | Moderate | Each found in 1/30 BAT responders[17]; Fanconi anemia pathway | C |
| **RAD51/ RAD51B/C/D** | Low | Theoretical relevance to HRR pathway; limited direct evidence for BAT | D |
| **PARP1/PARP2** | Low | May synergize with BAT in HRD tumors | D |

### PI3K-AKT-mTOR OSN Genes

| Gene | BAT Relevance | Mechanism | Evidence Grade |
|---|---|---|---|
| **PIK3CA** | Moderate | PI3K-AKT hyperactivation associated with BAT resistance[7][18] | C |
| **AKT1/2/3** | Moderate | Activated during ADT as escape mechanism; may affect BAT efficacy[7][18] | C |
| **MTOR** | Moderate | AR-PI3K-mTOR crosstalk affects BAT response; rapamycin may enhance BAT[18] | C |
| **PTEN** | Moderate | Loss activates PI3K/AKT pathway; theoretical impact on BAT | C |

### Androgen Receptor Cofactors & Regulators

| Gene | BAT Relevance | Mechanism | Evidence Grade |
|---|---|---|---|
| **FOXA1** | Moderate | AR pioneer factor; influences genomic binding sites | C |
| **NCOR1/ NCOR2** | Low | AR corepressors; may influence AR signaling during BAT | D |

| Gene | BAT Relevance | Mechanism | Evidence Grade |
|---|---|---|---|
| **TMPRSS2** | Low | Component of TMPRSS2-ERG fusion; AR-regulated gene | D |

Immune-Related Genes

| Gene | BAT Relevance | Mechanism | Evidence Grade |
|---|---|---|---|
| **PDCD1** (PD-1) | Moderate | BAT+nivolumab showed efficacy in COMBAT trial[13] | B |
| **CTLA4** | Low | Potential immune checkpoint target for combination therapy | D |

**Summary of ARv567es-Positive Tumors in Prostate Cancer**

1. **Prevalence and Detection**:
   - ARv567es is an androgen receptor (AR) splice variant detected in metastatic castration-resistant prostate cancer (mCRPC).
   - Reported prevalence varies widely (3%–78%) due to methodological differences in PCR assays, with validated assays showing lower rates (~7% in primary tumors, higher in CTCs/metastases).
2. **Clinical Significance**:
   - **Therapy Resistance**:
     - ARv567es-positive tumors are resistant to **castration**, **bipolar androgen therapy (BAT)**, and **taxanes** (docetaxel/cabazitaxel).
     - Co-expression with full-length AR disrupts AR autoregulation, dampening transcriptional responses to therapy.
   - **Outcomes**:
     - Shorter median progression-free survival (PFS) with taxanes:
       - **ARv567es+**: 7.29 months vs. **ARv567es−**: 12.71 months.
     - Worse PSA50 response rates (57% vs. 92% for ARv567es−).
   - **Lineage Plasticity**:
     - Enriched in neuroendocrine prostate cancer (NEPC), suggesting a role in lineage plasticity and treatment-emergent resistance.

3. **Mechanistic Insights**:
    - ARv567es retains the AR hinge domain but lacks the ligand-binding domain, enabling constitutive activity.
    - Unlike AR-V7, ARv567es partially binds microtubules, making it less taxane-resistant than AR-V7 but more resistant than AR-FL.
    - Alters chromatin occupancy, represses canonical AR targets, and upregulates AR-repressed genes (e.g., *HOXB13*).
4. **Detection Challenges**:
    - False positives arise from nonspecific PCR primer binding to AR-FL. Validated assays (e.g., TaqMan with exon 4/8 primers) are critical.
5. **Therapeutic Implications**:
    - **Biomarker Potential**: Absence of ARv567es/AR-V7 predicts better taxane response (median PFS: 16.62 months if double-negative).
    - **Combination Strategies**: Target ARv567es with therapies inhibiting splice variants (e.g., EPI-7386) or lineage plasticity pathways.

**Key References**:


- PMC6432911
- PubMed 40221372
- Nature Reviews Urology


**Clinical Takeaway**: ARv567es is a marker of aggressive mCRPC with therapy resistance. Detection requires rigorous assays, and its presence warrants consideration of non-AR-targeted therapies.

## Slightly modified standard BAT

This program closely mirrors the standard BAT protocol with one key modification: the cycle length is extended from one month to two. It may be easier to find a supportive medical professional compared to the aBAT program.

**Rationale:**

- Extending the cycle allows more time for testosterone cypionate to wash out, leading to a deeper state of hormonal ablation.

**Program:**

- **Lead-In Phase:**
  Begin with an ADT phase lasting 3-6 months.
- **BAT Cycles:**
  - **Day 1:** Inject 400 mg of testosterone cypionate.
  - **Day 1:** Administer a monthly Lupron injection (or a 3-month injection every 3 months).
  - **Early Cycle (Days 2–5):** Measure testosterone and PSA levels. Confirm T > 1,500 ng/dL (SPA threshold).
  - **Late Cycle (Days 52–58):** Measure testosterone and PSA levels again. Ensure T < 50 ng/dL (castrate level).
  - **Cycle Duration:** Repeat every 2 months.
- **Additional Testing:**
  Check CBC, CMP, lipids, and other tests as desired about every quarter.
- **Testosterone Monitoring:**
  Measuring testosterone every cycle isn’t necessary; checking it once every 3 cycles can serve as a sufficient sanity check to ensure proper hormonal highs and lows.
- **PSMA-PET monitoring:**
  Check PSMA-PET scans for signs of cancer progression.




*Figure 7 2 month T-Cypionate BAT*

## References

**Overview**

| Key Findings | Evidence Quality | Study Title | URL |
|---|---|---|---|
| - BAT is safe in asymptomatic mCRPC patients | A | Bipolar androgen therapy (BAT): A patient's guide | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9313844/ |
| - Produces PSA/objective responses in 30-40% of patients | | | |
| - Can resensitize tumors to subsequent antiandrogen therapy | | | |
| - Improves quality of life metrics (sexual function, muscle mass, fatigue) | | | |
| - Requires continuation of ADT during treatment | | | |

| | | | |
|---|---|---|---|
| - Sequential BAT→ARSI therapy shows promise for extending treatment options<br>- BAT can overcome resistance mechanisms to AR-targeted therapies<br>- Demonstrates clinical benefit in both PSA response and radiographic progression-free survival | B | Bipolar Androgen Therapy Followed by Androgen Receptor Inhibition as Sequential Therapy for Prostate Cancer | https://academic.oup.com/oncolo/advance-article/doi/10.1093/oncolo/oyad055/7110907 |
| - Explains paradoxical response where supraphysiological testosterone inhibits CRPC growth<br>- Details molecular mechanisms including DNA damage, cell cycle arrest, and AR signaling disruption<br>- Describes rationale for cycling between extreme high/low testosterone levels | B | Bipolar Androgen Therapy: When Excess Fuel Extinguishes the Fire | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10377678/ |
| - Systematic review confirms BAT safety in asymptomatic mCRPC<br>- PSA50 response rates range from 28-50%<br>- Resensitization to previously failed AR-targeted therapies observed<br>- Most common adverse events: fatigue, breast tenderness, and edema | A | Efficacy and safety of bipolar androgen therapy in castration-resistant prostate cancer following abiraterone or enzalutamide resistance | https://www.frontiersin.org/articles/10.3389/fendo.2022.1125838/full |
| - Reviews historical context and evolution of BAT concept<br>- Compares TRT with BAT approaches<br>- Details molecular mechanisms of action<br>- Outlines future directions including combination therapies | B | The role of androgen therapy in prostate cancer: from testosterone replacement therapy to bipolar androgen therapy | https://www.sciencedirect.com/science/article/pii/S1359644621000659 |

**HSPC**

| Key Findings | Evidence Quality | Study Title | URL |
|---|---|---|---|
| BAT in androgen ablation-naïve prostate cancer showed high rates of PSA suppression with quality of life improvements | B | BATMAN Phase II Study | https://pubmed.ncbi.nlm.nih.gov/27338150 |
| AR acquires oncogene gain of function for DNA replication licensing in malignant | B | Rationale for BAT in mPCa | https://www.tandfonline.com/doi/full/10.1080/15384101.2017.1360645 |

| | | | |
|---|---|---|---|
| cell proliferation; ADT progression to mCRPC involves specific AR adaptations | | | |
| LNCaP begins as androgen-sensitive (HSPC) but evolves to CRPC forms under ADT pressure, demonstrating cellular adaptation mechanisms | B | LNCaP Cell Line Evolution | https://aacrjournals.org/cancerres/article/82/9/1689/694706/Establishment-of-the-LNCaP-Cell-Line-The-Dawn-of |
| ADT and SPA decrease LNCaP growth with minimum 5-day exposure required for effect; correlates with AR coactivator Dopa Decarboxylase | B | Biphasic Androgen Effects | https://onlinelibrary.wiley.com/doi/pdf/10.2164/jandrol.106.002154 |
| Supraphysiological androgens induce cellular senescence in prostate cancer cells through Src-Akt OSN activation | B | SPA-Induced Senescence | https://molecular-cancer.biomedcentral.com/articles/10.1186/1476-4598-13-214 |
| DHT/R1881 inhibits cloning in LNCaP/VCaP but not Du145 cells; HSPC tumors are LNCaP phenotypes while CRPC progression increases Du145 phenotypes | B | Androgen-Induced Quiescence | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5444360/ |
| AR and steroidogenesis enzyme expression upregulates within 3 months of ADT initiation | B | AR Upregulation Timing | https://bmcurol.biomedcentral.com/articles/10.1186/s12894-020-00627-0 |
| BAT targets tumor heterogeneity by cycling between conditions that inhibit different cell populations (High-T inhibits some cells, Low-T inhibits others) | B | Testosterone Paradox | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10164147/ |

---

| Key Findings | Evidence Quality | Article Title | URL |
|---|---|---|---|
| HRD mutations associated with improved BAT response; >50% of men with HRD mutations achieved PSA50 vs. only 20% without HRD mutations | B | Combined Testosterone Therapy with Olaparib in Patients With Metastatic Castration-Resistant Prostate Cancer | **https://www.urotoday.com/video-lectures/esmo-2021/video/2307-combined-testosterone-therapy-with-olaparib-in-patients-with-metastatic-castration-resistant-prostate-cancer-michael-schweizer.html** |
| AR activity serves as a biomarker for BAT response; discussion of cell cycle interruption, Myc inhibition, and AR-targeted therapy resensitization | B | Is androgen receptor activity in metastatic prostate cancer a good biomarker for bipolar androgen therapy? | **https://www.jci.org/articles/view/165357** |

| Key Findings | Evidence Quality | Article Title | URL |
|---|---|---|---|
| Clinical and molecular determinants of PSA response to BAT identified through comprehensive analysis | B | Clinical and Molecular Determinants of PSA Response to Bipolar Androgen Therapy in Prostate Cancer | https://pubmed.ncbi.nlm.nih.gov/36959766/ |
| TP53 and/or DNA repair mutations necessary but not sufficient for BAT hyperresponse in testosterone cypionate trials | B | Molecular and Clinical Characterization of Patients With Metastatic Castration Resistant Prostate Cancer Achieving Deep Responses to Bipolar Androgen Therapy | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9774682/ |
| BAT responders more likely to have had radical prostatectomy, prior AR antagonist treatment, nodal metastases, ctDNA AR amplifications, and TP53 mutations; nonresponders more likely to have bone-only metastases | B | Clinical Efficacy of Bipolar Androgen Therapy in Men with Metastatic Castration-Resistant Prostate Cancer and Combined Tumor-Suppressor Loss | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9168525/ |
| Response to supraphysiological testosterone predicted by distinct androgen receptor cistrome | B | Response to supraphysiological testosterone is predicted by a distinct androgen receptor cistrome | https://insight.jci.org/articles/view/157164 |
| Review of models and mechanisms of supraphysiologic testosterone therapy in prostate cancer treatment | B | Supraphysiologic Testosterone Therapy in the Treatment of Prostate Cancer: Models, Mechanisms and Questions | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5742814/ |
| FISH analysis reveals gene aberrations (MYC, CCND1, ERBB2, RB, AR) in advanced prostate cancer before and after ADT | B | FISH analysis of gene aberrations (MYC, CCND1, ERBB2, RB, and AR) in advanced prostatic carcinomas before and after androgen deprivation therapy | https://pubmed.ncbi.nlm.nih.gov/11005213/ |

| Key Findings | Evidence Quality | Article Title | URL |
|---|---|---|---|
| BAT followed by enzalutamide shows promising sequential therapy approach for mCRPC; PCa Commentary Volume 173 discusses latest findings on this approach | B | PCa Commentary Volume 173 - January 2023 | https://grandroundsinurology.com/pca-commentary-volume-173-january-2023/ |
| BAT sensitizes castration-resistant prostate cancer to subsequent AR-targeted therapy; study shows 77.8% PSA50 response rate to enzalutamide after BAT compared to 30-40% in enzalutamide-naïve patients | B | Bipolar androgen therapy sensitizes castration-resistant prostate cancer to subsequent androgen receptor ablative therapy | https://pubmed.ncbi.nlm.nih.gov/33383350/ |
| AR gene aberrations in circulating cell-free DNA serve as biomarkers of therapeutic resistance in CRPC; these aberrations may be reversed by BAT, explaining resensitization to enzalutamide | B | Androgen Receptor Gene Aberrations in Circulating Cell-Free DNA: Biomarkers of Therapeutic Resistance in Castration-Resistant Prostate Cancer | https://pubmed.ncbi.nlm.nih.gov/25712683 |
| High testosterone therapy induces autophagic cell death in enzalutamide-resistant prostate cancer through circRNA-BCL2/miRNA-198/AMBRA1 signaling; 5-10% of free testosterone converts to DHT, with up to 90% conversion in prostate tissue | B | High-dose-androgen-induced autophagic cell death to suppress the Enzalutamide-resistant prostate cancer growth via altering the circRNA-BCL2/miRNA-198/AMBRA1 signaling | https://www.nature.com/articles/s41420-022-00898-6 |
| AR-V7 splice variant mutations significantly reduce efficacy of enzalutamide and abiraterone; detection possible through somatic testing but requires regular monitoring as mutations can emerge during treatment | A | AR-V7 and Resistance to Enzalutamide and Abiraterone in Prostate Cancer | https://www.nejm.org/doi/full/10.1056/nejmoa1315815 |

| Key Findings | Evidence Rating | Article Title | URL |
|---|---|---|---|
| Shows differential growth inhibition patterns of DHT with/without enzalutamide across various prostate cancer cell lines, demonstrating cell-specific responses to androgen and AR inhibition | B | Enzalutamide and bicalutamide inhibit prostate cancer cell growth in an androgen receptor splice variant dependent manner | https://www.nature.com/articles/s41598-019-50220-1/figures/4 |
| CRPC develops through adaptation to low testosterone environments rather than true ADT resistance; identifies mechanisms of enzalutamide resistance and potential therapeutic solutions | B | Enzalutamide-resistant castration-resistant prostate cancer: challenges and solutions | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6204864/ |
| Reviews serial BAT (sBAT) using cyclic supraphysiologic testosterone for mCRPC; describes mechanisms, clinical outcomes, and potential for resensitization to AR-targeted therapies | B | Serial bipolar androgen therapy (sBAT) using cyclic supraphysiologic testosterone (STP) to treat metastatic castration-resistant prostate cancer (mCRPC) | https://atm.amegroups.com/article/view/31303/html |
| Comprehensive review of AR's role in prostate cancer; details AR structure, signaling OSNs, genomic and non-genomic actions, and therapeutic implications of AR overexpression | B | Role of Androgen Receptor in Prostate Cancer: A Review | https://wjmh.org/DOIx.php?id=10.5534/wjmh.180040 |
| Reviews supraphysiological testosterone therapy mechanisms in CRPC; discusses DNA damage, cell cycle arrest, and AR-mediated effects; presents clinical trial results | B | Supraphysiological Testosterone Therapy as Treatment for Castration-Resistant Prostate Cancer | https://www.frontiersin.org/articles/10.3389/fonc.2018.00167/full |

| Key Findings | Evidence Rating | Article Title | URL |
|---|---|---|---|
| Describes rapid androgen cycling protocol using diethylstilbestrol and testosterone; demonstrates PSA responses and clinical benefits in 15 patients with CRPC | B | Rapid Androgen Cycling as Treatment for Patients with Prostate Cancer | https://clincancerres.aacrjournals.org/content/12/24/7414 |
| First pilot clinical study of BAT in CRPC showing safety, antitumor activity, and quality of life improvements; demonstrates 50% PSA response rate and resensitization to AR inhibition | B | Effect of bipolar androgen therapy for asymptomatic men with castration-resistant prostate cancer: Results from a pilot clinical study | https://www.science.org/doi/10.1126/scitranslmed.3010563 |
| Identifies PSA-negative/low prostate cancer cell subpopulation with stem-like properties that resist castration and may contribute to disease recurrence and progression | B | The PSA−/lo prostate cancer cell population harbors self-renewing long-term tumor-propagating cells that resist castration | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3348510/ |

| Key Findings | Evidence Rating | Article Title | URL |
|---|---|---|---|
| Comprehensive review of preclinical models for studying AR resistance in prostate cancer; details cell lines (LNCaP, VCaP, DuCaP, PC3, DU-145), xenografts, 3D models, and patient-derived models with their specific characteristics and applications | B | Preclinical Models in Prostate Cancer: Resistance to AR Targeting Therapies in Prostate Cancer | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7926818/ |
| Reference list from study on high-dose testosterone and Radium-223 in mCRPC; contains citations to key BAT and radiopharmaceutical studies | D | References in High-Dose Testosterone and Radium-223 Response in Metastatic Castration-Resistant Prostate Cancer | https://www.clinical-genitourinary-cancer.com/article/S1558-7673(19)30249-6/references |
| Reviews strategies to overcome androgen receptor addiction in prostate | B | Breaking androgen receptor addiction of prostate cancer | https://www.sciencedirect.com/science/article/pii/S1936523321001078 |

| Key Findings | Evidence Rating | Article Title | URL |
|---|---|---|---|
| cancer by targeting different AR functional domains; discusses N-terminal domain, DNA-binding domain, and ligand-binding domain inhibitors | | by targeting different functional domains in the treatment of advanced disease | |
| Clinical study of rapid androgen cycling using diethylstilbestrol and testosterone in 15 CRPC patients; demonstrated PSA responses and improved quality of life; established foundation for modern BAT | B | Rapid Androgen Cycling as Treatment for Patients with Prostate Cancer | https://clincancerres.aacrjournals.org/content/12/24/7414.long |
| COMBAT trial results showing BAT plus nivolumab in mCRPC patients achieved median OS of 28.5 months; identified biomarkers predicting response including TMB, MSI status, and PD-L1 expression | B | Overall Survival and Biomarker Results From Combat: A Phase 2 Study of Bipolar Androgen Therapy Plus Nivolumab for Patients With Metastatic Castrate-Resistant Prostate Cancer | https://www.urotoday.com/conference-highlights/asco-2022/asco-2022-prostate-cancer/137706-asco-2022-overall-survival-and-biomarker-results-from-combat-a-phase-2-study-of-bipolar-androgen-therapy-plus-nivolumab-for-patients-with-metastatic-castrate-resistant-prostate-cancer.html |
| First pilot clinical study of BAT in asymptomatic mCRPC showing safety and efficacy; demonstrated PSA responses, radiographic responses, and quality of life improvements | B | Effect of bipolar androgen therapy for asymptomatic men with castration-resistant prostate cancer: results from a pilot clinical study | https://pubmed.ncbi.nlm.nih.gov/25568070 |
| Study showing BAT reverses negative body composition changes from ADT; increases lean mass, decreases fat mass, and improves physical function in mCRPC patients | B | Reversing the effects of androgen-deprivation therapy in men with metastatic castration-resistant prostate cancer | https://bjui-journals.onlinelibrary.wiley.com/doi/epdf/10.1111/bju.15408 |
| Review of estrogen receptor beta mechanisms in multiple tissues including prostate; explains how ERβ modulates AR signaling and may have protective effects against prostate | B | Insight into the mechanisms of action of estrogen receptor b in the breast, prostate, colon, and CNS | https://jme.bioscientifica.com/downloadpdf/journals/jme/51/3/T61.pdf |

| Key Findings | Evidence Rating | Article Title | URL |
|---|---|---|---|
| cancer | | | |
| Prospective cohort study showing association between DHT levels and long-term prostate cancer mortality; higher DHT associated with increased risk | A | Association between dihydrotestosterone and long-term risk for prostate cancer mortality: A prospective cohort study | https://pubmed.ncbi.nlm.nih.gov/32368817 |
| Review of metformin's potential role in prostate cancer treatment during ADT; discusses mechanisms including AMPK activation, mTOR inhibition, and anti-inflammatory effects | B | Metformin and Prostate Cancer: a New Role for an Old Drug | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5405102 |
| Study examining concurrent androgen and estrogen ablation plus steroid biosynthetic enzyme inhibition for CRPC; demonstrates potential benefits of targeting multiple hormonal OSNs | B | Concurrent Androgen and Estrogen Ablation and Inhibition of Steroid Biosynthetic Enzyme Treatment for Castration-resistant Prostate Cancer | https://ar.iiarjournals.org/content/36/8/3847.full |
| Adaptive, evolution-informed strategy used PSA:testosterone dynamics to identify a shift back to castrate sensitivity; reinstitution of adaptive ADT achieved multiple stable cycles; illustrates phenotype re-sensitization without new genomic change; single-patient proof-of-concept (n=1) | C (case report/low-level clinical evidence) | Directed Evolution Restored Castrate Sensitivity in a Patient With Castrate Resistant Metastatic Prostate Cancer | https://pubmed.ncbi.nlm.nih.gov/40878050/ |

The use of testosterone cypionate–based BAT marks a significant advancement, as it has enabled us to gather robust data and broaden BAT's acceptance. This approach creates a true supraphysiological androgen (SPA) environment but does not reach extremely low levels of hormonal ablation. By switching to a shorter-acting testosterone, we can achieve both SPA and ADT-like levels. However, this method is more complex than the standard cypionate-based BAT protocol, and some of the required medications—such as testosterone propionate—are only available from a limited number of U.S. compounding pharmacies. Additionally, there isn't the same volume of supporting data as there is for standard BAT.

---

## Comparative Analysis of Testosterone Esters used in BAT

### Rationale for Testosterone Propionate in BAT

1. **Pharmacokinetic Precision**
   - **Propionate**: Short half-life (~1–2 days) facilitates rapid cycling between supraphysiological (SPA) and near-castrate testosterone levels, critical for disrupting adaptive AR signaling (Rat Model Study).
   - **Cypionate**: Prolonged elevation (~8–12 days) risks blunting therapeutic contrast between high/low phases (TRANSFORMER Trial).
2. **Dosing Flexibility**
   - Propionate enables **frequent pulses** (e.g., weekly) to maximize tumor exposure to alternating androgen environments.
   - Cypionate's extended duration (dosed monthly) limits dynamic cycling (TRANSFORMER Trial).
3. **Enhanced AR Disruption:**
   - Frequent T peaks and troughs prevent adaptive stabilization of androgen receptor (AR) OSNs, increasing DNA damage and cellular stress.
4. **Reduced AR Adaptation Risk**
   - Propionate's transient spikes mimic natural fluctuations, minimizing time for AR stabilization or resistance (e.g., AR-V7).
   - Cypionate's sustained AR activation may accelerate resistance.
5. **Synergy with ADT**
   - Propionate's rapid clearance enhances castrate-phase contrast, while cypionate's residual testosterone could sustain AR signaling.
6. **Preclinical Evidence**
   - Rat BAT models using propionate (250 mg/kg/week) demonstrate effective hormonal swings and tumor suppression.
7. **Metastasis Mitigation**
   - Rapid cycling may limit epithelial-mesenchymal transition (EMT), unlike cypionate's prolonged AR activation.
8. **AR Inhibitor Compatibility**
   - Propionate pairs with short-acting AR antagonists (e.g., darolutamide) for precise blockade during ADT phases.

### Rationale for Testosterone Cypionate in BAT

1. **Clinical Validation**
   - The TRANSFORMER trial achieved good PFS and OS with cypionate (400 mg monthly), validating its efficacy (TRANSFORMER Trial).
2. **Dosing Convenience**

- Monthly injections improve compliance vs. propionate's frequent dosing.

3. **Stable Supraphysiological Exposure**
   - Sustained high-T phases maximize tumor exposure to androgen-induced stressors (e.g., DNA damage).

**Conclusion**

- **Propionate** aligns with BAT's core principle of **hormonal dynamism**, ideal for protocols prioritizing rapid cycling.
- **Cypionate** offers **clinical practicality** with proven efficacy and simplified dosing.
- Choice depends on treatment goals: propionate for mechanistic precision, cypionate for patient adherence.

---

## Adaptive Bipolar Androgen Therapy (aBAT) in Hormone-Sensitive Prostate Cancer: Comprehensive Clinical Framework

### Executive Summary

Intermittent supraphysiologic androgen (SPA) therapy during hormone-sensitive prostate cancer (HSPC) represents a paradigm shift from traditional continuous androgen deprivation. This approach exploits AR dependency early in disease progression, induces DNA damage through TOP2B-mediated mechanisms, and prevents adaptive resistance mechanisms that drive CRPC development. The strategic application of aBAT in HSPC offers superior long-term outcomes by maintaining tumor heterogeneity control and delaying resistance evolution.

### Mechanistic Rationale for aBAT in HSPC

**Exploiting Early AR Addiction**

HSPC tumors maintain critical dependence on AR signaling for growth and survival. Unlike CRPC, where multiple bypass mechanisms exist, HSPC cells rely heavily on physiological androgen levels and moderate AR expression. Intermittent SPA exploits this vulnerability by exposing tumor cells to cytotoxic effects of sudden supraphysiologic androgen exposure, creating a therapeutic window unavailable in later disease stages.

**TOP2B-Mediated DNA Damage Induction**

Supraphysiologic androgens induce DNA double-strand breaks through AR-mediated recruitment of topoisomerase II beta (TOP2B). This mechanism remains active in hormone-sensitive cells and provides direct cytotoxic effects that can reduce tumor burden and delay clonal evolution. The DNA damage response in HSPC cells is less compromised than in CRPC, making repair inhibition strategies (e.g., PARP inhibitors) particularly effective.

**Prevention of AR Variant-Driven Resistance**

Continuous androgen deprivation promotes selection pressure favoring AR splice variants (e.g., AR-V7) and other resistance mechanisms. Intermittent SPA disrupts this selection pressure by periodically restoring high androgen levels, potentially suppressing or delaying emergence of resistant clones. This represents a proactive rather than reactive approach to resistance management.

**Evolutionary Pressure Modulation**

The alternating cycle between androgen deprivation and supraphysiologic exposure creates fluctuating selective environments that reduce fitness advantages of resistant subclones compared to continuous ADT. This evolutionary pressure modulation can significantly slow disease progression by preventing stable resistance clone establishment.

**Comparative Analysis: HSPC vs CRPC aBAT Applications**

| Factor | HSPC Application | CRPC Application |
|---|---|---|
| AR Dependency | High (exploitable by aBAT) | Variable (AR-independent pathways dominant) |
| Resistance Burden | Minimal (preventive opportunity) | High (accumulated mutations, intratumoral androgens) |
| Therapeutic Window | Wide (synergy with upfront therapies) | Narrow (competing resistant clones) |
| Clinical Evidence | Supported by triplet therapy principles and the BATMAN phase II clinical trial. | Over a dozen successful clinical trials (e.g., RESTORE, TRANSORMER). |
| Strategic Approach | Prevent CRPC development | Resensitize to AR-targeted therapies |

**Therapeutic Testosterone Targets and Mechanisms**

**Supraphysiologic Level Definitions**

- **Standard SPA Range**: 1,500-2,000 ng/dL total testosterone
- **Intensive SPA Range**: 2,000-3,000 ng/dL (1–4-day pulses only)

**Intraprostatic Androgen Homeostasis**

Critical understanding: Intraprostatic androgen concentrations remain remarkably stable despite significant serum testosterone variations. This homeostatic regulation involves:

- **AR and 5α-reductase saturation** at relatively low testosterone concentrations (120-240 ng/dL)
- **Protective regulatory mechanisms** that evolved to shield androgen-sensitive tissues from hormonal fluctuations
- **These observations support the hypothesis that the anti-tumor effects of supraphysiologic testosterone are mediated by mechanisms beyond dihydrotestosterone (DHT) signaling**

**aBAT Mechanisms Beyond DHT Elevation**

1. **DNA damage induction** through TOP2B recruitment
2. **Cell senescence promotion** via oxidative stress
3. **AR expression downregulation** following supraphysiologic exposure

4. **Metabolic disruption** of tumor energy pathways

**Prostate Cancer Cellular Heterogeneity Framework**

## Four-Group Classification System

Understanding tumor heterogeneity is essential for aBAT optimization:

**Group A: External DHT–Dependent Cells**

**Androgen Sensitivity & PSA Monitoring**

Patients initially respond to androgen deprivation therapy (ADT), but nearly all eventually develop castration-resistant prostate cancer (CRPC), confirming reliance on systemic DHT for early-stage tumors [1–5]. Highly androgen-dependent cells are major PSA producers, and PSA kinetics remain a reliable marker of therapeutic response in hormone-sensitive patients [6].

**Competitive Suppression (Ecological Restraint)**

Mathematical modeling supports the idea that maintaining a residual androgen-dependent cellular population exerts ecological pressure, delaying the expansion of resistant clones [7–9].

**aBAT Targeting & TOP2B-Mediated DNA Damage**

Supraphysiological testosterone (SPA) recruits AR and TOP2B to androgen response elements, inducing lethal double-strand breaks in prostate cancer cells [10–11]. Clinical protocols involving cyclic high/low testosterone (serial bipolar androgen therapy, sBAT) show SPA's anti-tumor activity against AR-high cells in CRPC settings [12].

**CRPC Transition & Indirect Evolution**

CRPC usually arises not from Group A directly, but via selection pressure favoring AR-amplified (Group B) or steroidogenic (Group C) clones after depletion of androgen-sensitive populations [1,4].

**NEPC Transition Risk via Downstream Expansion**

While Group A cells rarely convert directly to NEPC, their elimination clears space for Group B/C clones—which can undergo FOXA2/NKX2-1-driven plasticity toward Group D neuroendocrine states [14–16].

---

**Group B: AR-Upregulated DHT–Dependent Cells**

**AR Overexpression & Transitional Phenotype**

AR gene amplification and protein overexpression are significantly enriched in CRPC (>80%) compared to untreated prostate cancers (<5%) [17–19]. These AR-high cells retain partial sensitivity to ADT/TKI therapy while being vulnerable to SPA-induced DNA damage [6,10,12].

**Dual-Phase aBAT Strategy**
Clinical BAT trials alternating SPA and AR blockade (e.g., enzalutamide, darolutamide) have shown efficacy and delay CRPC progression by limiting AR-low escape variants [12].

**CRPC Evolution Mechanisms**
Group B commonly evolves CRPC via the emergence of AR splice variants like AR-V7, ligand-independent AR activation, or bypass signaling through PI3K/AKT/mTOR pathway upregulation [14,20].

**NEPC Risk via Chromatin Remodeling**
Prolonged androgen cycling primes chromatin accessibility via FOXA2 and NKX2-1 activation, recruiting CBP/p300 acetyltransferase to lock in neuroendocrine lineage programs, ultimately driving transition to Group D NEPC-like phenotype [14,15,21].

---

**Group C: Internal DHT–Producing Cells**

**Intratumoral Steroidogenesis**
CRPC metastases maintain high levels of intratumoral DHT and testosterone derived from adrenal precursors (DHEA, androstenedione) despite low systemic androgen levels [22, 23].

**aBAT Suppression of Internal Androgen Pathway**
Strategies combining SPA with AR blockade (e.g., darolutamide or CYP17A1 inhibitors) target both exogenous and intratumoral androgen sources, underpinning BAT efficacy in steroidogenic clones [6,12,23,24].

**CRPC Transition via Androgen Autonomy**
Group C cells typify classic CRPC: androgen-autonomous yet AR-driven and sometimes resistant to abiraterone; managed with combined ARSIs and metabolic targeting [23,25,26].

**NEPC Link: Substrate-Driven Plasticity**
While Group C rarely directly transforms into NEPC, their androgen precursors fuel Group D subclones. CBP/p300-driven chromatin reprogramming may eventually override their steroidogenic machinery toward NE phenotype [27].

---

**Group D: Adaptive / Plastic Cells (NEPC Precursors)**

**Phenotypic Plasticity & Molecular Drivers**
As described in the Emory-led Nature Genetics 2025 study, FOXA2 acts as a pioneer factor that opens closed chromatin at neuroendocrine loci. NKX2-1 is essential for NE transdifferentiation and cooperates with FOXA2 and CBP/p300 to establish stable NEPC transcriptional programs [14,15,28].

**CRPC to NEPC Bridge Population**
Group D cells often transiently express AR (CRPC-AR) during intermediate states before fully silencing it and committing to CRPC-NE (neuroendocrine phenotype), explaining mixed adenocarcinoma/NEPC clinical presentations [28].

**Therapeutic Implications for aBAT**
Rapid SPA/low-T cycling disrupts transcriptional plasticity, pushing Group D cells back toward hormone-sensitive profiles. Pharmacological targeting—particularly CBP/p300 inhibitors like CCS1477—blocks the FOXA2/NKX2-1 axis, preventing NEPC lock-in [15]. Residual NEPC-committed clones may require SBRT, non-PSMA RLT, or immune checkpoint inhibitors for complete eradication.

**References**


1. **ScienceDirect – The role of adrenal derived androgens in castration resistant prostate cancer**
   Quality: A
   https://www.sciencedirect.com/science/article/pii/S096007601930514X

2. **PMC – Androgen receptor dynamics in prostate cancer: from disease progression to treatment resistance**
   Quality: A
   https://pmc.ncbi.nlm.nih.gov/articles/PMC11850250/

3. **PMC – Molecular mechanisms underlying resistance to androgen deprivation therapy in prostate cancer**
   Quality: A
   https://pmc.ncbi.nlm.nih.gov/articles/PMC5325456/

4. **PMC – Circulating and Intratumoral Adrenal Androgens Correlate with Response to Abiraterone in Men with Castration-Resistant Prostate Cancer**
   Quality: A
   https://pmc.ncbi.nlm.nih.gov/articles/PMC8563401/

5. **MDPI – Androgen Receptor-Dependent and -Independent Mechanisms Involved in Prostate Cancer Therapy Resistance**
   Quality: B
   https://www.mdpi.com/2072-6694/9/6/67

6. **MDPI – Androgen Receptor Signaling in Prostate Cancer and Therapeutic Strategies**
   Quality: B
   https://www.mdpi.com/2072-6694/13/21/5417

7. **ResearchGate – Ecological suppression modeling in tumor populations.**
   Quality: B
   https://pmc.ncbi.nlm.nih.gov/articles/PMC11071393/

8. **PMC - Modeling tumors as species-rich ecological communities**
   Quality: B
   https://www.mdpi.com/2227-9059/12/1/181

9. **MDPI – High Accuracy Indicators of Androgen Suppression Therapy Failure for Prostate Cancer—A Modeling Study**
   Quality: B
   https://www.mdpi.com/2072-6694/14/16/4033

10. **JCI Insight – Molecular determinants of response to high-dose androgen therapy in prostate cancer**
    Quality: A
    https://insight.jci.org/articles/view/129715

11. **ResearchGate – AR/TOP2B interactions in PCa cells.**
    Quality: B
    https://www.researchgate.net/publication/343127672_AR_and_TOP2B_Mediated_DNA_Damage

12. **Annals of Translational Medicine - Serial bipolar androgen therapy (sBAT) using cyclic supraphysiologic testosterone (STP) to treat metastatic castration-resistant prostate cancer (mCRPC)**
    Quality: B
    https://atm.amegroups.org/article/view/31303/html

13. **BioMed Central – Persistent androgen receptor addiction in castration-resistant prostate cancer**
    Quality: B
    https://jhoonline.biomedcentral.com/articles/10.1186/s13045-015-0225-2

14. **ScienceDirect – Deciphering Complexity: The Molecular Landscape of Castration-Resistant Prostate Cancer**
    Quality: A
    https://www.sciencedirect.com/science/article/pii/S1875918124000801

15. **Emory News – New study uncovers how prostate cancer becomes deadly and offers hope for new treatments**
    Quality: B
    https://news.emory.edu/stories/2025/07/hs_prostate_cancer_research_24-07-2025/story.html

16. **PubMed – NKX2-1 drives neuroendocrine transdifferentiation of prostate cancer via epigenetic and 3D chromatin remodeling**
    Quality: A
    https://pubmed.ncbi.nlm.nih.gov/40691407/

17. **Spandidos Publications – Molecular and cellular mechanisms of castration resistant prostate cancer (Review)**
Quality: B
https://www.spandidos-publications.com/10.3892/ol.2018.8123

18. **MDPI – Molecular and cellular mechanisms of castration resistant prostate cancer (Review)**
Quality: B
https://www.mdpi.com/2072-6694/16/16/2777

19. **PMC – Intratumoral steroidogenesis in castration-resistant prostate cancer: a target for therapy**
Quality: B
https://pmc.ncbi.nlm.nih.gov/articles/PMC4186953/

20. **PMC – Androgen receptor dynamics in prostate cancer: from disease progression to treatment resistance**
Quality: A
https://pmc.ncbi.nlm.nih.gov/articles/PMC11850250/

21. **Nature – NKX2-1 drives neuroendocrine transdifferentiation of prostate cancer via epigenetic and 3D chromatin remodeling**
Quality: A
https://www.nature.com/articles/s41588-025-02265-4

22. **PMC – Circulating and Intratumoral Adrenal Androgens Correlate with Response to Abiraterone in Men with Castration-Resistant Prostate Cancer**
Quality: A
https://pmc.ncbi.nlm.nih.gov/articles/PMC8563401/

23. **AACR Journals – Intratumoral *De Novo* Steroid Synthesis Activates Androgen Receptor in Castration-Resistant Prostate Cancer and Is Upregulated by Treatment with CYP17A1 Inhibitors**
Quality: A
https://aacrjournals.org/cancerres/article/71/20/6503/568075/Intratumoral-De-Novo-Steroid-Synthesis-Activates

24. **Nature – Orphan nuclear receptors as regulators of intratumoral androgen biosynthesis in castration-resistant prostate cancer**
Quality: A
https://www.nature.com/articles/s41388-021-01737-1

25. **Translational Andrology and Urology – Steroid hormone synthetic pathways in prostate cancer**

Quality: B
https://tau.amegroups.org/article/view/2762/html

26. **Nature – Targeting signaling pathways in prostate cancer: mechanisms and clinical trials**
Quality: A
https://www.nature.com/articles/s41392-022-01042-7

27. **BioRxiv – Epigenetic remodeling and 3D chromatin reorganization governed by NKX2-1 drive neuroendocrine prostate cancer**
Quality: B
https://www.biorxiv.org/content/10.1101/2024.12.04.626816v1.full.pdf

28. **Nature – NKX2-1 drives neuroendocrine transdifferentiation of prostate cancer via epigenetic and 3D chromatin remodeling**
Quality: A
https://www.nature.com/articles/s41588-025-02265-4

The poorly differentiated, low-PSA cancer cells are like hardened criminals armed with deadly weapons, whereas the high-PSA–producing cells resemble civilians wielding only sticks and knives. Over time, the criminals band together and even recruit the civilians, arming them with the same lethal tools.

Our goal is a population composed largely of those “civilians,” so eradicating them all is counterproductive. Equally unwise is weakening the civilians to the point that the criminals can easily conscript them. Instead, we aim to regulate the civilians’ modest armaments—allowing only pocket-knife level force—while neutralizing the criminals’ arsenals.

Chart of theoretical population changes.




Overall, Population C (androgen-independent) undergoes a steep decline from 120 million to under 1 million cells by year 10, reflecting effective long-term suppression of resistant clones. Population A (androgen-dependent) and Population B (testosterone-producing) initially recover during the adaptation phase and then decline as competitive dynamics stabilize. Population D (adaptive/plastic) remains at minimal levels throughout the decade, indicating limited phenotypic switching under optimized cycling. PSA levels, plotted on the secondary axis, mirror these population shifts by rising modestly during cell recovery phases and then declining steadily, reaching 0.13 ng/mL at year 10.

The chart below illustrates monthly PSA levels for four hypothetical patients on aBAT, highlighting a spectrum of clinical responses:

- **Patient 1 (Stable Responder):** Minimal PSA fluctuation with sustained low levels, indicating durable tumor control.
- **Patient 2 (Good Responder):** Rapid PSA decline to near-undetectable levels by three years, demonstrating effective elimination of resistant cells.
- **Patient 3 (Moderate Responder):** Initial PSA rise and plateau followed by slow decline, suggesting partial restoration of competitive dynamics.

- **Patient 4 (Poor Responder):** Progressive PSA increase throughout ten years, signifying treatment failure and resistant clone expansion.


PSA Trajectories Over 10 Years
Stable Resp
Good Resp
Mod Resp
Poor Resp
PSA (ng/mL)
5
2
10
5
2
1
5
2
0.1
5
2
0.01
0
1
2
3
4
5
6
7
8
9
10
Years


MRD Trajectories Over 10 Years
Patient1
Patient2
Patient3
Patient4
MRD (MTM/mL)
0
2
4
6
8
0
2
4
6
8
10
Years

Disease Progression Dynamics
HSPC typically begins with Group A cell dominance. ADT eliminates these cells but creates selective pressure favoring Groups B, C, and D expansion. CRPC emergence occurs when Group B cells dominate, with variable contributions from Groups C and D. Understanding this progression informs optimal aBAT timing and cycling strategies.

## aBAT Prevention of CRPC Development

### AR Cycling vs Persistent Upregulation

aBAT creates dynamic AR expression patterns where levels rise during ADT phases and fall during SPA exposure. This prevents the persistent AR overexpression characteristic of castration resistance, maintaining cellular plasticity and treatment responsiveness.

### AR Splice Variant Suppression

Rapid testosterone oscillation prevents sufficient time for AR splice variants to emerge and stabilize. These variants typically develop under prolonged androgen deprivation, making early aBAT intervention particularly valuable.

### MYC Downregulation Benefits

High AR activity during aBAT correlates with decreased MYC expression. Lower MYC levels associate with improved clinical outcomes, including extended progression-free and overall survival, suggesting particular aBAT effectiveness when AR activity remains high.

Dose-Response Relationships and Safety Considerations

### Dose-Dependent Therapeutic Effects

Animal studies demonstrate continued benefits at testosterone levels above 2,000 ng/dL, with some data suggesting advantages up to 5,000 ng/dL equivalent (R1881 studies). However, clinical application must balance efficacy against systemic toxicity.

### DNA Damage Thresholds

- **Physiologic baseline**: ~10 double-strand breaks per cell daily (easily repaired)
- **SPA-induced damage**: Significantly increased DSBs requiring robust repair mechanisms
- **Therapeutic goal**: Overwhelm tumor cell repair capacity while preserving normal cell function

### Systemic Safety Considerations

Excessive androgen levels risk:

- **Overwhelming healthy cell DNA repair** mechanisms
- **Catastrophic mitoses or necrosis** from excessive DSBs

- **Tumor microenvironment inflammation** (beneficial immune activation vs detrimental edema)
- **Senescent cell accumulation** with pro-tumorigenic cytokine secretion (SASP)

Cell Type-Specific SPA Sensitivity

**AR Expression-Dependent Responses**

- **CRPC cells (Group B)**: 10-90 fold AR upregulation, enhanced SPA sensitivity, effects persist 24+ hours
- **HSPC cells (Group A)**: Moderate AR levels, effects peak at 6 hours, return to baseline by 24 hours
- **Clinical Implication**: CRPC may benefit from longer SPA duration (days-weeks), HSPC from shorter pulses (hours-days)

**Optimal Pulse Strategies**

- **Longer pulses**: Lower levels (1,500-2,000 ng/dL) to minimize systemic stress
- **Shorter pulses**: Higher levels (up to 3,000 ng/dL) for intensive effect
- **Combination approaches**: 1–4-week moderate SPA pulses plus shorter intensive pulses

PARP Inhibitor Integration

**Mechanistic Synergy**

PARP protein inhibition during SPA phases enhances DNA damage effectiveness by preventing repair of TOP2B-induced double-strand breaks. Clinical trials demonstrate improved PSA50 responses with BAT plus PARP inhibitor combinations.

**Timing Considerations**

- **Low-T phases**: Optimal PARP inhibitor administration when repair mechanisms are most critical
- **High-T phases**: DNA damage induction maximized when repair is simultaneously inhibited
- **Safety monitoring**: Enhanced cytopenia risk requires careful CBC monitoring

Clinical Implementation Strategy

**Primary Objectives in HSPC**

1. **Prevent CRPC progression** by maintaining Group A cell viability
2. **Minimize adaptive pressure** that selects for Groups B, C, D expansion
3. **Maintain PSA as monitoring biomarker** through Group A cell preservation

4. **Delay resistance mechanism development** through dynamic selective pressure

**Monitoring and Biomarkers**

- **PSA dynamics**: Reflects Group A cell population (higher PSA may be therapeutically beneficial)
- **Testosterone levels**: Ensure adequate SPA peaks (>1,500 ng/dL) and ADT troughs (<10-20 ng/dL)
- **ctDNA analysis**: Track resistance mechanism emergence (AR-V7, mutations)
- **Imaging**: Monitor disease progression and response patterns

**AR Inhibitor Integration**

Strategic ARSI use during ADT phases:

1. **Accelerate AR upregulation** for enhanced subsequent SPA sensitivity
2. **Intensify selective pressure** on androgen-sensitive cells
3. **Halt replication cycles** in CRPC cells before DNA synthesis completion

**Clinical Considerations:**

1. Androgen Receptor Signaling Inhibitors (ARSIs): Prolonged use of ARSIs may promote the emergence of adaptive prostate cancer subpopulations (e.g., Groups B–D). Intermittent administration—preferably short pulses of 1 to 14 days during androgen-deprived phases—is recommended to mitigate this risk.
2. Timing Relative to Supraphysiologic Androgen (SPA) Pulses: ARSIs should be withheld during SPA administration phases, as their use counteracts the intended therapeutic effects of supraphysiologic testosterone.

Key Clinical Principles

**Fundamental Concepts**

1. **SPA induces AR-mediated DNA damage** with apoptosis/senescence if unrepaired
2. **AR expression levels correlate** with DNA damage susceptibility
3. **Intraprostatic androgen homeostasis** limits linear correlation between serum testosterone and tissue effects
4. **BAT mechanisms extend beyond** simple intraprostatic DHT elevation
5. **DNA damage timing**: 1-24 hours in HSPC cells, 12-48+ hours in CRPC cells

**Resistance Prevention Strategy**

- **Maintain Group A cell populations** to prevent adaptive pressure
- **Limit ADT phase duration** to minimize Group B-D selection
- **Use dynamic cycling** rather than static approaches
- **Monitor biomarkers** for early resistance detection
- **Integrate complementary therapies** (PARP inhibitors, targeted agents)

## Conclusion

aBAT in HSPC represents a fundamental shift from reactive to proactive cancer management. By exploiting early AR dependency, preventing resistance mechanism development, and maintaining tumor heterogeneity control, this approach offers superior long-term outcomes compared to traditional continuous ADT. Success requires understanding cellular heterogeneity, implementing dynamic cycling strategies, and careful integration of complementary therapies. The evidence strongly supports aBAT as a primary strategy for preventing HSPC-to-CRPC progression while maintaining quality of life and treatment tolerance.

## References

| Key Findings | Evidence Rating | Article Title | URL |
|---|---|---|---|
| BAT responders more likely to have had radical prostatectomy, prior AR antagonist treatment, and nodal metastases. Nonresponders more likely to have bone-only metastases. ctDNA AR amplifications and TP53 mutations more common in responders. | B | Clinical and molecular determinants of PSA response to bipolar androgen therapy in prostate cancer | https://pubmed.ncbi.nlm.nih.gov/36959766/ |
| Combination of BAT and olaparib showed promising activity in mCRPC patients, with 56% achieving PSA50 response. Median rPFS was 11.8 months. | A | Bipolar androgen therapy plus olaparib in men with metastatic castration-resistant prostate cancer | https://pubmed.ncbi.nlm.nih.gov/36564459/ |
| BAT in androgen ablation-naïve prostate cancer showed high PSA response rates (59% PSA50) and improvements in QoL. Median time to progression: 8.5 months. | B | Bipolar Androgen Therapy for Men With Androgen Ablation Naïve Prostate Cancer: Results From the Phase II BATMAN Study | https://pubmed.ncbi.nlm.nih.gov/27338150/ |
| PSA provocation during BAT may predict | B | PSA provocation by bipolar | https://pubmed.ncbi.nlm.nih.gov/35938545/ |

| Key Findings | Evidence Rating | Article Title | URL |
|---|---|---|---|
| duration of response to first-line ADT. Higher PSA provocation associated with longer time to CRPC. | | androgen therapy may predict duration of response to first-line androgen deprivation: Updated results from the BATMAN study | |
| BAT comparable to enzalutamide in mCRPC. Median PFS: 5.7 months for both. PSA50: 28.2% (BAT) vs 25.3% (enzalutamide). BAT improved QoL and resensitized to enzalutamide. | A | TRANSFORMER: A Randomized Phase II Study Comparing Bipolar Androgen Therapy Versus Enzalutamide in Asymptomatic Men With Castration-Resistant Metastatic Prostate Cancer | https://pubmed.ncbi.nlm.nih.gov/33617303/ |
| Blood-based markers identified for differential efficacy of BAT and enzalutamide in mCRPC patients. | B | Blood-based markers of differential efficacy of bipolar androgen therapy and enzalutamide in the randomized TRANSFORMER trial | https://www.semanticscholar.org/paper/b615daf57cabddbae10c5238baa96c09ff5ba7ac |

## *** aBAT: An Example Program

This is an example of aBAT to help provide a general understanding of how it is structured and what it entails. However, implementation should never be done in isolation.

1. **Critical Considerations Before Starting aBAT**
   - BAT might not be therapeutic for all patients.
   - While some men respond well to BAT, others may experience rapid disease progression.
   - We do not yet have predictive markers to determine who will benefit versus who may worsen.
   - Close monitoring of PSA and tumor burden is crucial.
2. **Medical Oversight is Important**
   - You may decide that you want to keep some details to yourself, but you benefit from having a trained, experienced oncologist monitoring your progress.
3. **BAT in Hormone-Sensitive Prostate Cancer (HSPC)**
   - BAT has not been extensively tested in HSPC.
   - Preclinical research and one HSPC trial suggest it could work, but many doctors remain cautious, believing BAT could accelerate tumor progression at this stage.
   - The risk of cancer progression must be considered.
   - The risk of waiting to start a therapy needs to be considered as well. A known risk is the HSPC->CRPC transition.

## Managing ADT in aBAT

- ADT serves as the foundation for suppressing endogenous testosterone during low-testosterone phases.
- Attempting to manipulate ADT timing without proper monitoring creates significant risks for treatment failure.
- Orgovyx (relugolix) requires approximately 1-2 weeks to achieve castrate testosterone levels and PSA control in most patients.
- Younger men (<70 years) often experience longer suppression lag times.
- While supraphysiologic testosterone eventually suppresses endogenous production via feedback inhibition, this mechanism is unreliable for therapeutic purposes.
- Following 3.5 months of ADT and 2 years of supraphysiologic testosterone therapy (>1,500 ng/dL via weekly cypionate injections), my endogenous testosterone production remained suppressed for only 3 months post-treatment.

AR Signaling Inhibitors

- Enzalutamide, darolutamide, and apalutamide reduce androgenic activity by blocking the androgen receptor.
- These agents require precise timing in BAT protocols to avoid neutralizing the therapeutic benefits of supraphysiologic testosterone phases.
- Optimal sequencing remains under investigation in clinical trials.
- Of these ARSIs darolutamide appears to be better suited to BAT routines. It is stronger than the others, has a better side effect profile, and has much shorter half-life.

Abiraterone Acetate Considerations

- Abiraterone's active metabolite D4A creates unique challenges in BAT protocols through multiple mechanisms:
  1. Dual AR antagonism: Directly blocks androgen receptors, potentially interfering with BAT's high-testosterone phase efficacy
  2. Enzymatic inhibition: Potently inhibits 5α-reductase (5-AR), preventing testosterone-to-DHT conversion in target tissues
  3. Pharmacokinetic uncertainties: D4A's intratumoral half-life remains poorly characterized, making washout timing unpredictable
  4. Tissue-specific recovery: No established correlation exists between systemic 5-AR recovery markers and intratumoral enzyme function restoration
  5. Patient variability: Significant inter-individual differences in D4A metabolism and clearance create unpredictable responses across different disease states

These pharmacodynamic complexities make abiraterone integration into BAT protocols particularly challenging without additional research to establish optimal timing and sequencing. On a personal basis it might be possible to estimate intratumoral 5-ar recovery time based on DHT recovery in serum. However, the intratumoral vs. 5-AR isoenzyme profiles differ. So, at best we might only obtain a rough indication.
Recommendation

- Until research clarifies these pharmacodynamic questions, continuous ADT remains the most reliable approach for testosterone suppression during BAT. A fast-acting ARSI (e.g., darolutamide) can be used to create a double hormone blockade.

---

## Other Considerations

### Long-Term ADT Users:

- Extended ADT use (months to years) can lead to prolonged suppression of the hypothalamic-pituitary-gonadal (HPG) axis
- When transitioning to BAT, these patients may experience delayed endogenous testosterone recovery:
  - Some may not require ADT for months
  - Individual recovery varies significantly, necessitating personalized monitoring

### Long-Term aBAT Users

- HPG Axis Suppression: Extended use of aBAT (months to years) can cause sustained suppression of the hypothalamic–pituitary–gonadal axis.
- ADT Redundancy: In some cases, endogenous testosterone production remains shut down, meaning additional ADT may not be required while on aBAT.
- Variable Recovery: Recovery of natural hormone production varies widely. Monitoring should be individualized.
- Monitoring Markers:
  - FSH and LH: If persistently undetectable, this suggests endogenous testosterone remains suppressed.
  - Testosterone Check: The most direct measure is serum testosterone during a Low-T phase, which should fall below ~10–20 ng/dL.
- Conservative Approach: Continuous ADT remains the safest standard. However, due to financial or treatment-burden considerations, some patients may explore minimizing or discontinuing ADT under careful monitoring.

### Standard Monitoring Protocol:

- Regular serum testosterone measurements (e.g., monthly or weekly)
- PSA monitoring to detect early signs of disease progression. PSA kinetics are drastically altered during BAT programs. I use PSA in two ways: 1. Indicate whether I am hormone sensitive. 2. Indicate possible progression.
- MRD

## Hypogonadal Men and Post-Orchiectomy Patients:

- Men with primary hypogonadism or post-orchiectomy may not require ADT during BAT
- However, adrenal androgen production can still contribute to tumor growth

## Recommendation:

- While some patients may not require continuous ADT, maintaining a robust monitoring protocol is crucial. The unpredictable nature of testosterone recovery and potential for disease progression necessitate ongoing vigilance, even in seemingly low-risk scenarios. To remove the risk, use continual ADT.

## Potential Protocol Improvement:

### Sirolimus

**Core mechanism: sirolimus targets mTORC1**

Sirolimus (rapamycin) binds FKBP12 and allosterically inhibits mTORC1, reducing phosphorylation of S6K1 and partially of 4EBP1. Result: suppressed cap-dependent translation, ribosome biogenesis, and anabolic metabolism (glycolysis and lipogenesis). ULK1 is de-repressed, promoting autophagy. Classical rapalogs do not acutely inhibit mTORC2, so AKT Ser473 and SGK1 remain active; chronic exposure can secondarily dampen mTORC2 in some contexts. [1,2]

**AR ↔ PI3K–AKT–mTOR crosstalk (why combine with aBAT)**

In prostate cancer, AR and PI3K–AKT–mTOR compensate for each other. PTEN loss drives constitutive AKT–mTOR activity. mTORC1 controls translation of AR and AR co-factors via 4EBP1/eIF4E, while AR programs feed back into translational and metabolic control. This reciprocity explains weak single-agent activity of mTOR inhibitors and the rationale for dual-axis strategies. [3,4]

**How aBAT changes the context**

During supraphysiologic testosterone pulses, AR is hyper-activated in AR-high tumors. This induces replication stress, TOP2B-mediated double-strand breaks, transcriptional re-wiring, and downregulation of MYC in AR-high disease. Transcriptomic AR-activity signatures predict BAT benefit through MYC suppression. [5]

**Mechanistic integration: sirolimus + aBAT**

1. aBAT pulse (high T) raises AR output. Short-term growth signals rise, but AR hyper-activation also creates stress and suppresses MYC in suitable tumors. [5]
2. Add sirolimus to cap the anabolic rebound. mTORC1 blockade throttles S6K1 and 4EBP1 signaling, limiting translation of MYC and AR co-factors and blunting lipid and glycolytic programs (SREBP and HIF-1α). Aim: uncouple androgen-triggered stress from compensatory translation and metabolism. [1,2,6,7]
3. Return to low T (ADT phase). With AR reduced, continued mTORC1 inhibition maintains anti-anabolic pressure during recovery. Known limitation: feedback reactivation of PI3K–AKT and mTORC2–SGK1 can emerge. [2]
4. TME and immunity. mTOR shapes T-cell fate. Excess or continuous mTOR inhibition can blunt effector function, while time-limited exposure may favor memory and reduce exhaustion. Schedule matters. [8,9]

**Net hypothesis:** sirolimus overlays a translation and metabolism brake onto aBAT's AR-driven stress and MYC suppression, aiming to slow clonal outgrowth during both peaks and troughs and to narrow the tumor's recovery window. This is mechanistically plausible and unproven clinically.

**Expected downstream effects**

- Translation and growth: reduced cap-dependent translation via 4EBP1/eIF4E; lower synthesis of growth and survival proteins and AR network co-factors. [2,6]
- Metabolism: decreased lipogenesis (SREBP1/2) and glycolysis/HIF-1α programs that support castration resistance and rapid post-pulse recovery. [1]

- Autophagy: relief of ULK1 inhibition can trigger pro-survival autophagy; may counteract efficacy without co-strategies. [2]
- Immune tone: potential shift toward less exhausted T cells with careful dosing; risk of effector suppression if exposure is high or continuous. [8,9]

**Resistance and limitations relevant here**

1. mTORC1-only blockade: classical rapalogs incompletely activate 4EBP1 and spare mTORC2, allowing AKT and SGK1 signaling. Catalytic or bi-steric EP300/CBP inhibitors address this limitation but are not sirolimus. [2,6]
2. Feedback loops: relief of S6K negative feedback can re-activate PI3K–AKT. [2]
3. Bypass pathways: MAPK, MNK–eIF4E, and metabolic rewiring can substitute for mTOR dependence. [7]
4. Immunologic trade-offs: chronic mTOR suppression can impair effector T cells even if it promotes memory. [8,9]
5. Clinical signal to date: rapalogs show limited single-agent activity in prostate cancer; stronger signals arise in combinations or biomarker-selected settings. No clinical data with aBAT yet. [2]

**Knowledge gaps**

- No peer-reviewed clinical trials of sirolimus plus aBAT in prostate cancer. Optimal dose, timing vs T peaks and troughs, and duration are unknown.
- Biomarker selection for this pairing requires validation (for example PTEN loss, RICTOR gain, 4EBP1 phosphorylation status, AR-activity signature predicting BAT benefit). [3,4,6]
- Immunology scheduling with aBAT is undefined.
- Autophagy management is unresolved.
- Direct human pharmacodynamic proof that sirolimus suppresses MYC protein and AR co-factor translation during aBAT is lacking.

- **Reference table**

| No. | Full citation | Topic key | Evidence type | Primary URL | Open access mirror |
|---|---|---|---|---|---|
| 1 | Panwar V et al. Multifaceted role of mTOR in cancer biology. Signal Transduction and Targeted Therapy. 2023. | mTOR overview | Review | https://www.nature.com/articles/s41392-023-01608-z | — |
| 2 | Ali ES et al. Recent advances and limitations of mTOR inhibitors in oncology. Cancer Cell International. 2022. | mTOR inhibitors in oncology | Review | https://cancerci.biomedcentral.com/articles/10.1186/s12935-022-02706-8 | https://pmc.ncbi.nlm.nih.gov/articles/PMC9476305/ |
| 3 | Tortorella E et al. AR and PI3K/AKT in prostate cancer: a tale of two oncogenic pathways. International Journal of Molecular Sciences. 2023. | AR–PI3K/AKT crosstalk | Review | https://www.mdpi.com/1422-0067/24/3/2046 | — |
| 4 | Raith F et al. Reciprocal crosstalk between AR and PI3K/AKT/mTOR in prostate cancer. International Journal of Molecular Sciences. 2023. | AR–PI3K/AKT/mTOR reciprocity | Review | https://www.mdpi.com/1422-0067/24/3/2289 | — |
| 5 | Sena LA et al. Androgen receptor activity dictates efficacy of bipolar | aBAT mechanism, | Human translational | https://www.jci.org/articles/view/162396 | https://pmc.ncbi.nlm.nih.gov/articles/PMC9711876/ |

| No. | Full citation | Topic key | Evidence type | Primary URL | Open access mirror |
|---|---|---|---|---|---|
| | androgen therapy via MYC. Journal of Clinical Investigation. 2022. | MYC | | | |
| 6 | Lee BJ et al. Selective mTORC1 inhibition and 4EBP1 activation are necessary for antitumor activity. Nature Chemical Biology. 2021. | mTORC1–4EBP1 requirement | Preclinical mechanistic | https://www.nature.com/articles/s41589-021-00813-7 | https://pmc.ncbi.nlm.nih.gov/articles/PMC9249104/ |
| 7 | Brina D et al. AKT/mTOR and MNK/eIF4E rewire translation in cancer. Nature Cancer. 2023. | Translational control in cancer | Review | https://www.nature.com/articles/s43018-023-00594-z | https://pmc.ncbi.nlm.nih.gov/articles/PMC11331482/ |
| 8 | Ando S et al. mTOR regulates T-cell exhaustion and PD-1 responses. Journal of Clinical Investigation. 2023. | mTOR and T-cell exhaustion | Mechanistic, translational | https://www.jci.org/articles/view/160025 | https://pmc.ncbi.nlm.nih.gov/articles/PMC9843061/ |
| 9 | Chen Y et al. mTORC2 in memory and exhausted CD8+ T cells. Cellular & Molecular Immunology. 2023. | mTORC2 and CD8 T cells | Review | https://www.nature.com/articles/s41423-023-01064-3 | — |

mCPD

Pairing aBAT with mCPD is mechanistically plausible. aBAT can heighten tumor stress and antigen availability, while mCPD can deplete regulatory T cells, temper myeloid suppression, and add anti-angiogenic pressure during recovery windows. Human evidence supports these component effects individually, but there are no published trials of the combination. [1][2][3][4][5][6][7][8][9][10][11]

**Mechanistic integration**

1. aBAT pulse increases AR activity, induces replication stress and TOP2B-linked DNA breaks, and down-regulates MYC in AR-high tumors. This may increase antigenic opportunity. [1]
2. mCPD selectively reduces Tregs and can enhance effector T and NK function, lowering immune brakes in the same window. [3][4][5]
3. mCPD exerts anti-angiogenic effects via thrombospondin-1 induction and suppression of circulating endothelial progenitors, limiting vascular rebound between pulses. [10][11]
4. Metronomic alkylation can reduce suppressive myeloid populations, further improving priming. [9]
5. Androgen manipulation has immune consequences; timing mCPD with favorable immune windows around aBAT may matter. [6][7]

**Testable scheduling concepts**

These are concepts for protocol design, not treatment advice.

• Continuous backbone: oral cyclophosphamide 50 mg daily with planned CBC-based holds to maintain steady Treg/MDSC control and anti-angiogenesis. [3][8]

• Peri-pulse intensification: begin 3–7 days pre-pulse, continue 7–10 days post-pulse, then step down to an alternate-day schedule to balance priming with lymphotoxicity. [3][10]

• Vaccine or PD-1/PD-L1 add-on window: a single low dose 1–3 days before vaccination or early in the aBAT pulse to enhance priming, as used in immunotherapy studies. [2][4]

**Biomarkers and PD to track**

• Immune: CD4+CD25+FOXP3 Tregs, MDSCs, CD8 activation markers, TCR clonality, cytokines. Expect Treg downtrend and CD8 uptrend if dose is correct. [3][4][8][9]
• Vascular: thrombospondin-1, VEGF, circulating endothelial progenitors. Expect TSP-1 up and CEPs down on-treatment. [10][11]
• Tumor: PSA kinetics and imaging across aBAT cycles; optional biopsies for AR/MYC transcripts when feasible. [1]

**Safety and trade-offs**

• Myelosuppression and lymphopenia can occur even at metronomic doses; prespecify CBC thresholds and holds. [8]
• Infection risk rises with cumulative exposure.
• Urothelial toxicity is uncommon at low dose but monitor symptoms and hydration.
• Excess or continuous dosing can blunt desired effector responses; schedule and exposure are critical. [5][8]

**Unknowns**

• No peer-reviewed trials of mCPD + aBAT; optimal dose, timing, and duration are undefined.
• The net immune effect of rapid testosterone cycling under combination therapy remains to be mapped in humans. [6][7]
• Whether anti-angiogenic pressure alters intratumoral androgen delivery during pulses is untested.

**Why this differs from sirolimus**

Sirolimus primarily throttles translation and anabolism. mCPD primarily remodels immunity and vasculature. Both aim to limit recovery between pulses, but via distinct subsystems. Triplet concepts would require strict limits to avoid overlapping lymphotoxicity. [5][8][10]

---

**Reference table**


| No. | Full citation | Topic key | Evidence type | URL |
|---|---|---|---|---|
| 1 | Sena LA et al. Androgen receptor activity dictates efficacy of bipolar androgen therapy via MYC. J Clin Invest. 2022. | aBAT mechanism, MYC | Human translational | https://www.jci.org/articles/view/162396 |
| 2 | TRANSFORMER trial record. Phase II BAT vs enzalutamide in mCRPC. | BAT clinical context | Randomized phase II | https://pubmed.ncbi.nlm.nih.gov/33617303/ |
| 3 | Ghiringhelli F et al. Low-dose cyclophosphamide selectively depletes CD4+CD25+ Tregs. Cancer Immunol Immunother. 2007. | Treg depletion | Human/clinical | https://pubmed.ncbi.nlm.nih.gov/16960692/ |
| 4 | Emens LA et al. Regulatory T-cell modulation using cyclophosphamide. Cancer Res. 2012. | Immune adjuvant use | Review | https://aacrjournals.org/cancerres/article/72/14/3439/5758 cell-Modulation-Using |
| 5 | Emens LA et al. Low-dose cyclophosphamide and immune modulation. PLOS One. 2013. | Treg sensitivity window | Clinical translational | https://journals.plos.org/plosone/article?id=10.1371/journa |
| 6 | Trigunaite A et al. Androgens and immunity. Front Immunol. 2020. | Androgen–immune effects | Review | https://www.frontiersin.org/journals/immunology/articles/1 fimmu.2020.01567/epub |
| 7 | Sutherland JS et al. Castration alters T-cell | Castration immune | Human physiology | https://journals.physiology.org/doi/abs/10.1152/ajpendo.00 |

| No. | Full citation | Topic key | Evidence type | URL |
|---|---|---|---|---|
| | phenotype. Am J Physiol Endocrinol Metab. 2006. | effects | | |
| 8 | Tongu M et al. Immunomodulatory effects of cyclophosphamide. Cancers (Basel). 2020. | mCPD immunology review | Review, open access | https://pmc.ncbi.nlm.nih.gov/articles/PMC7162079/ |
| 9 | Low-dose cyclophosphamide alters lymphocyte subsets. 2018. | Myeloid/ lymphocyte shifts | Clinical translational | https://pmc.ncbi.nlm.nih.gov/articles/PMC6279421/ |
| 10 | Browder T et al. Anti-angiogenic scheduling via TSP-1 induction. PNAS. 2003. | Metronomic anti-angiogenesis | Preclinical with translational impact | https://www.pnas.org/doi/abs/10.1073/pnas.2135406100 |
| 11 | Bertolini F et al. Thrombospondin-1 dependency of metronomic effects. 2003. | Anti-angiogenic mechanism | Preclinical | https://pubmed.ncbi.nlm.nih.gov/14561896/ |
| 12 | Lord R et al. Metronomic CPA + prednisone in CRPC. Anticancer Res. 2010. | Prostate cancer experience | Retrospective/phase II | https://ar.iiarjournals.org/content/30/10/4317 |
| 13 | Retrospective oral CPA in mCRPC. 2025. | Prostate cancer experience | Retrospective | https://pmc.ncbi.nlm.nih.gov/articles/PMC11892613/ |

ADT

One-month ADT annually as a “reset” to modulate AR expression, analogous to priming strategies used around BAT in some settings.

---

### Final Thoughts

aBAT offers a novel and promising approach, but it is not a one-size-fits-all therapy. Given its potential to either control or accelerate cancer, patients must approach it with medical oversight and individualized monitoring.

If considering aBAT:

- Consult a medical oncologist familiar with BAT.
- Track PSA and tumor behavior closely (I prefer MRD and the ML indicators in this book)
- Seek expert input.
- Be prepared to modify the approach if progression is indicated.

---

## Using PSA Kinetics to Guide Adaptive Bipolar Androgen Therapy (aBAT)

Each patient should define their own PSA threshold (X), which represents the highest PSA allowed before transitioning out of BAT.

Example:

- The starting X is 0.17 (a personal choice).
- Others might choose 0.1, 1.0, or higher, depending on their baseline PSA.
- Men with prostates may decide to use a higher X due to baseline PSA production.

### Adjusting X Over Time:

- Over time, X can be increased to account for slow tumor growth.
- If a PSA doubling time of >1 year is considered acceptable, then after 1 year, X could be increased to 0.34.
- However, if PSA suddenly rises exponentially, this might signal failure of aBAT. Consider confirming with MRD and PSMA-PET scans.

### Personal Example:

- In my first aBAT cycle, it took 2–3 weeks for PSA to drop below 0.17.
- After 2 years of aBAT, it took 2–3 weeks for PSA to drop below 0.34.
- After 3 years of aBAT, it took 2-3 weeks for PSA to drop below 0.7.
- After 4 years of aBAT, PSA drops below 0.3 in 2-3 weeks.
- After 4 years of experience with the program I no longer wait until a predetermined PSA is reached. I measure PSA to verify that I am still hormone sensitive. But my cycle lengths are not dictated by PSA. They are dictated by my risk level.

---

## Assessing Androgen Sensitivity by PSA Decline During aBAT Cycles

Tracking PSA kinetics during cycles of supraphysiologic androgen (SPA; testosterone >1,500 ng/dL) and "low-T" (testosterone <20 ng/dL) phases in aBAT provides a validated surrogate for real-time hormone (androgen) sensitivity in prostate cancer.

### Key Interpretation Criteria

- PSA Decline >50% (from SPA/high-T to low-T/nadir): Strong evidence of ongoing androgen sensitivity.
- Nadir PSA <1 ng/mL after a BAT low-T phase: Predictive of sustained clinical benefit and prolonged time to castration resistance.

Mechanistic Rationale:

- Androgen Receptor (AR) Signaling drives PSA production. Only tumors with functional AR pathways demonstrate PSA fluctuations paralleling testosterone cycling. If AR is bypassed or ablated, this PSA modulation is blunted or lost.
- BAT exploits this by alternating between supraphysiologic androgen and deprivation. Tumors retaining AR dependency will show large, reversible PSA swings; androgen-insensitive clones do not.

### Step-by-Step Example Calculation

Suppose:

- SPA/high-T phase PSA: 2.0 ng/mL
- Low-T/Nadir phase PSA: 0.4 ng/mL

Percent Change Calculation:

PSA percent change=$(PSA_{SPA} - PSA_{Nadir})/(PSA_{SPA})\times 100\%$

Plug in values:

$(2.0-0.4)/2.0\times 100\%=80\%$

Interpretation

- An 80% PSA decline exceeds the 50% evidence-based threshold.
- Nadir PSA of 0.4 ng/mL (<<1 ng/mL) further strengthens evidence for persistent AR-driven tumor activity and high likelihood of ongoing therapeutic response to hormonal manipulation.

### Clinical Guidance

- Always interpret PSA kinetics in context (imaging, ctDNA [circulating tumor DNA], patient symptoms, and trends over multiple cycles).
- Serial PSA assessment should be combined with other biomarkers (e.g., Signatera™ ctDNA, Guardant360™, imaging per NCCN).
- Oncologist/Urologist oversight is mandatory before acting on any lab trend.

---

## Program Steps

### 1. ADT Lead-In

*If you already have castration-resistant prostate cancer (CRPC), consult with your medical oncologist to see if the lead-in phase should be omitted.*

- ADT Lead-In Phase:
  Before starting aBAT, a 1–3-month course of androgen deprivation therapy (ADT) is advised to thoroughly suppress your body's natural testosterone production. This can be achieved with a GnRH drug (such as Lupron or Orgovyx) or tE2 (following the PATCH and STAMPEDE protocols). You may also add darolutamide for enhanced hormone blockade. If you choose to use darolutamide, it must be discontinued at least 5 days before your first testosterone injection. This phase aims to reduce PSA levels and increase androgen receptor expression in preparation for aBAT.
- Systemic Estrogen Support (when using a GnRH drug):
  If the reduction in estrogen due to ADT causes side effects, you can add estrogen replacement selectively during this phase. Estrogen patches delivering 0.05–0.1 mg/day may help alleviate issues like bone loss, cognitive dysfunction, and hot flashes.
- Considerations for CRPC:
  In cases of CRPC, using ARSIs might be problematic since some cancer cells could adapt to use these drugs as growth signals. It is important to closely monitor your PSA levels; if there is a rise after introducing an ARSI, discontinue its use.

---

## 2. After lead-in ADT aBAT is started and follows a structured 5-week cycle.

- Maintain Testosterone Suppression (ADT) continuously.

- Day 1: Inject 50 mg of testosterone propionate. Instead of testosterone propionate, Androgel could be used. Day 1-15 every day: 100 mg of testosterone from a testosterone gel (e.g., Androgel) in the morning and 100 mg at night. If you decide to use Androgel (or another testosterone formulation) do not inject Tp.
- Days 3, 5, 7, 9, 11, 13, 15: Inject 50 mg of testosterone propionate.
    - Optional: Take 0.625 mg of letrozole twice weekly to block aromatase activity and prevent conversion of testosterone to estrogen in the tumor microenvironment.
    - Optional: 2-6 mg of sirolimus once a week. Sirolimus inhibits mTOR and MYC. MYC inhibition is important for BAT. We don't have any evidence for using sirolimus with BAT. I noticed a substantial increase in my PSA when I stopped using sirolimus weekly and a reduction when I re-started it. This was probably due to other factors, but I decided not to stop again.
    - Optional: A moderate to high-dose statin at night. Statins reduce cholesterol, pregnenolone, and progesterone. They might also inhibit MYC. Atorvastatin and many of the other statins give me insomnia, so I take a very low dose of Lovastatin.
    - Optional: 81 mg/night Aspirin. Blood thinners reduce cardiac risk and might reduce PCa proliferation.
- Week 3, 4
- Every other cycle: 600-1200 mg of darolutamide split AM/PM. Darolutamide leaves the system within a week. If you are CRPC this might be contraindicated. Some of your cancer cells might have mutated to use ARSIs for fuel. If this is the case your PSA could go up when you add an ARSI to ADT. If your PSA increases, stop the ARSI. After a few more cycles, try the ARSI again because your cancer makeup might have changed.
    - Optional: Low estrogen levels can lead to joint pain, cognitive difficulties, and hot flushes. Estriol is one option for partial estrogen replacement. Alternatively, low-dose transdermal estrogen patches (e.g., 0.05–0.1 mg/day) can restore systemic estrogen levels.
    - Optional: 3-7 days of week 3:olaparib 150-300 mg twice a day. A PARP inhibitor that synergizes with both SPA and ADT. Inhibiting PARP impairs DNA SSB repair and induces DNA DSBs in at least two separate ways. If you use olaparib or another PARP inhibitor, monitor WBC for reductions. BAT clinical trials indicate that you do not need to be BRCA for olaparib to synergize with BAT. This has also been indicated by trials using Zytiga with PARPi and by pre-clinical data.

    - Optional: Finasteride 1–2 mg/day in divided doses may help reduce intracellular testosterone and DHT by inhibiting the conversion of testosterone to DHT. It may also partially block the backdoor conversion pathway from androstanediol to DHT. However, its effectiveness diminishes in castration-resistant prostate cancer (CRPC).

    - Optional: Low-dose Ostarine (1–3 mg/day) and/or Cardarine (1 mg/day) may support muscle mass preservation and reduce fat gain during BAT. While these agents do not contribute to BAT's anticancer efficacy, they can help mitigate some of its adverse effects. Strict adherence to dosing is essential. Ostarine has mild androgenic activity, and although Cardarine is not androgenic, it has shown carcinogenic effects in preclinical studies —but only in mice and at doses roughly 1,000 times higher than the 1 mg/day range.

In the context of HSPC managed with BAT, Ostarine may exert enhanced anabolic effects during the ADT (low testosterone) phase, owing to decreased competition with endogenous DHT for androgen receptor binding. This interaction could amplify its muscle-preserving potential. The more effectively we

suppress DHT during the low-T phase, the greater the theoretical benefit from low-dose Ostarine. Still, both compounds carry some level of risk.

- Week 5: Stop all drugs except for ADT. At end of week 4 or start of week 5 measure PSA, CBC, CMP, Testosterone, and optionally estradiol (use an ultrasensitive or MS test)

    If PSA does not fall below **(X)**, extend the current ADT period and repeat testing in 2 weeks. Continue extending and remeasuring until PSA drops below **(X)**. If PSA remains above **(X)** after 12 weeks of ADT, stop and consult your medical team. At that point, consider 4–8 weeks of darolutamide (or enzalutamide). Reassess with PSA, and if appropriate, include MRD testing and a PSMA-PET scan. Review all results with your oncologist to decide the next steps.

    Note: it is possible that PSA/T is a better metric than PSA. The **ratio R(t) = PSA(t)/T(t)** condenses “how much PSA the tumor is making” **per unit of androgen stimulus**:
    - If **R is high** (PSA is high for a given T), that suggests the tumor is **maintaining PSA**, consistent with a larger share of **resistant** phenotypes (e.g., highly AR-upregulated/androgen-autonomous cells).
    - If **R is low** (PSA stays proportionally low for a given T), that suggests the tumor is **dominated by androgen-dependent, ADT-sensitive** phenotypes, i.e., a state where **re-introducing ADT** is more likely to produce control.
    - However, I have not found the indicator to be reliable. I can adjust it for androgenic signaling rather than raw testosterone data (remove the ARSI variable from the equation). But it still is not a reliable metric for me.

Go back to week 1

Notes:

1. I currently use aBAT and, when necessary, MDT. If I experience progression, my MO and I may consider MDT or RLT. I’ve been on aBAT since 2021, and in 2023 I had three metastases that were eliminated with MDT, while continuing uninterrupted aBAT.
2. If you are CRPC and your goal is resensitization to ARSIs (e.g., Nubeqa) your best option might be to try 3-6 cycles of standard cypionate BAT. Standard cypionate BAT has the advantage of a proven record (approximately 70% temporary CRPC resensitization).
3. It is rare but some men develop cardiac issues because of high testosterone. Usually this is easy to monitor and correct. If your hematocrit (simple blood test), goes above the normal upper limit and stays high, consult with a doctor. They might advise you to give blood, or have a medical phlebotomy performed (bloodletting). This will cause an immediate reduction in hematocrit. Increased hematocrit will probably not be an issue with BAT or aBAT since your testosterone won’t be held high more than 50% of the time.
   (My hematocrit, hemoglobin, and RBC consistently rise above the upper limit of normal during SPA cycles and return to normal within about a week of starting the ADT phase. However, the overall peaks and troughs in hematocrit have been gradually trending upward since 2021, making close monitoring essential.)
4. It is important to use more than one marker to monitor cancer progression. At a minimum monthly PSA and yearly PSMA-PET scans. It is also important to keep your MO up to date with your test results. My MO monitors PSA, MRD, somatic genetic tests (e.g., Guardant 360), ctDNA (Signatera), DEXA bone density scans, and PSMA-PET scans (e.g., Pylarify). I monitor the ML indicators defined in this book.
5. QoL concerns might dictate your use of optional drugs. Each drug can result in side effects. This needs to be balanced by what each drug might provide and the evidence associated.

## 3. Monitoring Protocol

| Category | Tests/Actions | Notes |
|---|---|---|
| Monthly Essentials | - Testosterone: Measure at peak (standard assay) and trough (MS/ultrasensitive assay). | Align with androgen deprivation therapy (ADT) or bipolar androgen therapy (BAT) cycles. |
| | - PSA: Draw during the last week of each cycle. | Track PSA velocity (ng/mL/month) consistently across cycles. |
| | - CBC (Hematocrit focus) | Monitor for treatment-induced changes. |
| Quarterly Panel | - Bloodwork: CBC, CMP, Lipids, Estradiol. | Include routine blood tests for broader health monitoring. |
| | - Advanced Tests: Signatera Natera ctDNA to track residual disease and therapy effectiveness. Tumor Mutational Burden (TMB), Somatic Mutation Panel. | Use Guardant360 730 gene test for TMB and somatic mutations if necessary. |
| Advanced Biomarkers | - AR-FL levels, AR-V7 status, AR amplifications/mutations in cfDNA. | Every 8 weeks; requires specialized testing (e.g., Guardant360 730 gene test or FoundationOne RNA). |
| | - TK1, Ki-67, or ctDNA. | Every 8 weeks; useful for proliferation and tumor dynamics tracking. |
| | - Circulating Tumor Cells (CTCs) with AR-V7 testing. | At progression, indicates treatment resistance or aggressive disease. |
| Imaging Schedule | - CT Abdomen/Pelvis: Assess visceral metastases. | As recommended by your MO. |
| | - Bone Scan: Track new sclerotic lesions. | Every 12 weeks. |

| Category | Tests/Actions | Notes |
|---|---|---|
| | - PSMA-PET: Optional if PSA < 0.5 ng/mL (requires prior authorization). | Per clinical need (PRN). |
| | - DEXA Scan: Monitor bone mineral density trends. | Every 2 years, assess osteoporosis risk. |

**Implementation Notes**

1. **Timing Matters**:
   - Schedule PSA and testosterone draws at consistent cycle phases to ensure trend accuracy.
2. **Cost Containment**:
   - Use conventional imaging unless PSMA-PET results are expected to change management. Utilize Natera high resolution ctDNA tests instead of PSMA-PET.

This protocol integrates emerging evidence with practical constraints like insurance coverage and accessibility. The phased approach enables adjustments, either escalation or de-escalation—based on changes in both biomarker levels and patient physiology. Many of these metrics are collected specifically to support clinical decision-making.




*Figure 8 aBAT*

# Testosterone Injection Guide for BAT

For those using Bipolar Androgen Therapy (BAT) or other testosterone replacement protocols, proper injection technique is essential for safety, comfort, and effectiveness. Below is an overview of best practices for administering testosterone injections.

## 1. Injection Site Selection

- Preferred Site: Gluteal (buttocks) injections are generally less painful and easier compared to thigh (vastus lateralis) or deltoid injections.
- Alternative for Low-Dose Injections:
  - Subcutaneous (SubQ) injections can be used for lower doses of testosterone.
  - However, for BAT, higher doses are typically required, making intramuscular (IM) injections the preferred method.

## 2. Needle Selection and Preparation

- **Drawing Up Testosterone:**
  - Use an 18-gauge needle to draw up the testosterone from the vial.
  - Why? 18-gauge needles are larger and allow for a faster draw of thick testosterone oil.
- **Injection Needle:**
  - Switch to a 25-gauge needle for the actual injection.
  - Why? A smaller gauge reduces injection pain while still allowing efficient delivery.
- **Why Change Needles?**
  - After one use, a needle becomes blunt—even from piercing the vial.
  - Always swap to a fresh, sterile needle before injecting.

## 3. Injection Technique

- Step 1: Clean the vial’s rubber top with alcohol before drawing testosterone.
- Step 2: Use an 18-gauge needle to draw the testosterone into the syringe.
- Step 3: Remove the 18-gauge needle, replace it with a 25-gauge injection needle.
- Step 4: Clean the injection site with alcohol.
- Step 5: Slowly insert the needle at a 90-degree angle into the glute muscle. Only inject the upper-outer glute. There is a large vein towards the inside lower glute. You do not want to hit it. The upper outer glute is very far away.
- Step 6: Slowly inject the testosterone oil. The entire process should take 1–2 minutes.
- Step 7: Withdraw the needle and apply light pressure with sterile gauze.

**If you encounter unusual resistance, consider switching the needle before injection.**

## 4. Where to Get Needles and Syringes

- Medical-Grade Needles and Syringes can be purchased on Amazon or through medical suppliers.
- Recommended Type: Luer-lock syringes (1–3 CC capacity) for better security and ease of use.
- Sterilization:

- Injection needles must be medical-grade and sterilized.
- Drawing needles should also be sterile but do not necessarily need to be for medical use.
- Never reuse needles. Always use a fresh, sterile needle for every injection.

### 5. Injection Assistance

- If you are new to injecting, consider visiting a men's health clinic or your doctor for a demonstration or asking a trusted friend or family member (e.g., some men have their wives administer injections).

For more details on self-administering testosterone injections, refer to Michigan Medicine's guide:
**https://www.med.umich.edu/1libr/SpinalCordInjuryProgram/IMselfInjectionTesto.pdf**

Using the right technique ensures safer and more comfortable injections, reducing the risk of pain, scarring, or complications.

## Testosterone Injection Pain Relief

I don't suffer much if any pain injecting.
If you suffer pain from the injections, OTC Lidocaine cream helps.

Lidocaine 5% cream is strong enough to significantly reduce the pain of Aquaviron or Aquabol (testosterone base) injections at the skin level, but it will not completely eliminate all injection discomfort.
How Effective Is 5% Lidocaine Cream?

- Lidocaine 5% cream (or EMLA, which is lidocaine/prilocaine 2.5%/2.5%) is the strongest over-the-counter topical anesthetic available in the US.
- It numbs the skin's top layer, blocking most of the pain from the needle puncture.
- Clinical studies show that topical lidocaine creams significantly reduce the pain of both needle puncture and the initial part of intramuscular (IM) injections.
- However, the cream does not numb the deeper muscle tissue, so you may still feel some discomfort or pressure from the medication being injected into the muscle.

How to Use Lidocaine 5% Cream for IM Injections

1. Apply a thick layer (about the size of a quarter) to the planned injection site.
2. Cover with plastic wrap or a bandage to enhance absorption.
3. Wait 30–60 minutes for maximal numbing effect[7].
4. Wipe off the cream just before the injection.
    - You should feel significant numbness at the skin.
    - The pain from the needle entering the skin will be much less, but you may still feel some pain or pressure as the medication enters the muscle.

How Does It Compare to Other Methods?

- Topical lidocaine cream is very effective for reducing skin pain, but less so for deep muscle pain.
- Injectable lidocaine (subcutaneous or mixed with the medication) can numb both the skin and muscle, providing more complete pain relief, but requires a separate injection and is not always practical or compatible with oil-based medications like Aquaviron or Aquabol.

| Method | Skin Pain | Muscle Pain | Notes |
|---|---|---|---|
| 5% Lidocaine Cream | Excellent | Mild/None | Apply 30–60 min before, OTC available |
| Injectable Lidocaine | Excellent | Excellent | Requires injection, more complete relief |
| No Anesthetic | Full | Full | Most painful (zero pain in my experience) |

**Bottom Line**

- Lidocaine 5% cream is strong enough to make Aquaviron and Aquabol injections much more comfortable by numbing the skin.
- It will not completely eliminate all pain, especially the deep muscle ache or pressure, but it is a safe and effective way to reduce the worst part of the injection experience.
- For best results, apply 30–60 minutes before the injection and cover with plastic wrap.

## BAT in HSPC (HSPC Classification)

**Key Definitions**

1. **HSPC (Hormone-Sensitive Prostate Cancer)**:
    - Cancer responds to androgen deprivation therapy (ADT) with testosterone <50 ng/dL, evidenced by:
        - **PSA suppression**:
            - Post-radical prostatectomy (RP): Sustained PSA <0.1 ng/mL.
            - Non-surgical management: PSA <1 ng/mL.
        - **No radiographic or clinical progression** during long-term ADT.
2. **CRPC (Castration-Resistant Prostate Cancer)**:
    - PSA progression (≥2 ng/mL rise from nadir, confirmed ≥3 weeks apart) **despite castrate testosterone** (<50 ng/dL).

**BAT in HSPC: Mechanism and Goals**

- **Objective**: Disrupt adaptive AR upregulation during ADT to **delay CRPC onset**.
- **Mechanism**:
    1. **SPA Phase**: Supraphysiologic testosterone (1,500+ ng/dL) induces DNA damage in AR-overexpressing cells via replication stress.
    2. **Low-T Phase**: Rapid testosterone withdrawal (<50 ng/dL) triggers apoptosis in cells dependent on AR signaling.
- **PSA Dynamics**:
    1. **SPA Phase**: PSA rises (e.g., 2.0 ng/mL) due to AR activation (expected, not indicative of resistance or cancer growth).
    2. **Low-T Phase**: PSA declines (e.g., 0.7 ng/mL, 65% reduction) if tumors remain hormone-sensitive.

**Case-Specific Analysis**

- **Example Patient**:
    - **SPA Phase**: PSA = 2.0 ng/mL (AR-driven PSA expression).
    - **Low-T Phase**: PSA = 0.7 ng/mL (65% decline).
- **Implications**:

- **HSPC Confirmation**: A PSA nadir <1 ng/mL post-BAT meets HSPC criteria.
- **Lack of Progression**: No new metastases or symptoms during long-term ADT.
- **BAT's Role**: Cyclical design prevents AR adaptation, extending hormone sensitivity.

**Conclusion**

BAT is a **proactive strategy** in HSPC to delay CRPC by leveraging cyclical androgen fluctuations.

## Definition of Progression from HSPC to CRPC

Progression from **hormone-sensitive prostate cancer (HSPC)** to **castration-resistant prostate cancer (CRPC)** is defined by the following criteria, consistent with international guidelines (e.g., EAU, NCCN):

**1. Castrate Testosterone Levels**

- Serum testosterone **<50 ng/dL** (or **<1.7 nmol/L**) during androgen deprivation therapy (ADT).

**2. Evidence of Disease Progression**

Progression is confirmed by **either biochemical (PSA) or radiographic criteria**:

| Biochemical Progression | Radiographic Progression |
|---|---|
| **All of these:**<br>• **Three consecutive PSA rises** (≥1 week apart).<br>• **Each PSA value ≥50% above the nadir** (lowest PSA on ADT).<br>• **Absolute PSA ≥2.0 ng/mL**. | **Either of these:**<br>• **New lesions** on imaging (bone scan, CT, MRI).<br>• **Growth of existing lesions** (≥20% increase in measurable soft tissue lesions). |

**Key Notes**

- **CRPC Subtypes**:
  - **Nonmetastatic CRPC (nmCRPC)**: PSA progression **without detectable metastases**.
  - **Metastatic CRPC (mCRPC)**: Progression with **radiographically confirmed metastases**.

**Clinical Implications**

- **Therapeutic Shift**: Progression to CRPC mandates considering a transition from **aBAT** to **CRPC-specific therapies** (e.g., ARSIs, PARP inhibitors, radioligands).
- **Prognostic Factors**:
  - **Shorter time to CRPC** is linked to:
    - Metastases at diagnosis.
    - PSA nadir **>2 ng/mL**.
    - Rapid PSA decline during ADT (paradoxically associated with earlier resistance).
    - High Gleason score (≥8).

## References

| Summary | Evidence Quality | Article Title | URL |
|---|---|---|---|
| LNCaP cells (common in HSPC) can be inhibited by bicalutamide and SPA; ADT-adapted cells (LNCaP/A-) with 2.5-25x ARs remain sensitive to SPA but not bicalutamide; optimal BAT requires rapid cycling between High-T and complete androgen depletion | B | Adaptive Auto-Regulation of Androgen Receptor Provides a Paradigm Shifting Rationale for Bipolar Androgen Therapy (BAT) for Castrate Resistant Human Prostate Cancer | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3374010/ |
| Sequential therapy of BAT followed by AR inhibition shows promise for prostate cancer treatment | B | Bipolar Androgen Therapy Followed by Androgen Receptor Inhibition as Sequential Therapy for Prostate Cancer | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10243791/ |
| This research provides a mechanistic rationale for bipolar androgen therapy (BAT) in prostate cancer and suggests that patients with AR amplification or DNA repair deficiencies may be particularly suitable candidates for this approach. The findings also support the potential benefit of combining SPA therapy with PARP inhibitors like olaparib. | B | Supraphysiological androgens suppress prostate cancer growth through androgen receptor–mediated DNA damage | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6763228/ |
| LNCaP 104-R1/R2 CRPC cells can be inhibited by SPA, with enhanced effect when combined with Casodex; some tumors develop resistance after 2-4 months with high c-Myc expression | B | Androgen Suppresses Proliferation of Castration-Resistant LNCaP 104-R2 Prostate Cancer Cells via Androgen Receptor, Skp2, and c-Myc | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3200457/ |

| Summary | Evidence Quality | Article Title | URL |
|---|---|---|---|
| SPA induces cell cycle arrest in LNCaP cells (HSPC) within 72 hours via ferroptosis; enhances immune cell infiltration and doubles CD8 T cells; LAPC4 cells (CRPC) with upregulated ARs continue proliferating; iron supplementation enhances ferroptosis while antioxidants inhibit it | B | Supraphysiological testosterone induces ferroptosis and activates immune OSNs through nucleophagy in prostate cancer | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC86 |
| PCa cells can accumulate testosterone to a level 15-50 times higher than that in the medium; 5alpha-reductase isozymes do not predict the capacity to convert testosterone to DHT; Finasteride and dutasteride depress testosterone uptake in addition to lowering intracellular DHT | B | Prostate Cancer Cells Differ in Testosterone Accumulation, Dihydrotestosterone Conversion, and Androgen Receptor Signaling Response to Steroid 5Î±-Reductase Inhibitors | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3999702/ |
| Acute exercise induces DNA damage and modulates PARP activity in lymphocytes, with trained individuals showing enhanced DNA repair capacity | B | Influence of Acute Exercise on DNA Repair and PARP Activity before and after Irradiation in Lymphocytes from Trained and Untrained Individuals | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6628277/ |
| Acute aerobic exercise induces transient DNA damage, with greater effects observed in longer-duration protocols | A | DNA Damage Following Acute Aerobic Exercise: A Systematic Review and Meta-analysis | https://link.springer.com/article/10.1007/s40279-019-01181-y |
| Darolutamide effectively inhibits androgen-stimulated OSNs at proteomic and transcriptomic levels | B | Comparative Proteomic and Transcriptomic Analysis of the Impact of Androgen Stimulation and Darolutamide Inhibition | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9817687/ |

| Summary | Evidence Quality | Article Title | URL |
|---|---|---|---|
| AR-negative disease incidence has increased in patients treated with AR signaling inhibitors (ARSi) | B | Loss and revival of androgen receptor signaling in advanced prostate cancer | https://www.nature.com/articles/s41388-020-01598-0 |
| Phase I and II clinical trials of BAT showed promising results for delaying or reverting progression to CRPC | B | Bipolar androgen therapy in prostate cancer: Current evidences and future perspectives | https://www.sciencedirect.com/science/article/abs/pii/S1040842820301323 |
| Comprehensive review of cellular mechanisms ensuring correct repair of DNA double-strand breaks | B | How cells ensure correct repair of DNA double-strand breaks | https://www.sciencedirect.com/science/article/pii/S0021925820338084 |
| Diethylstilbestrol (DES) induces apoptosis in prostate cancer during rapid androgen cycling | B | Rapid Androgen Cycling as Treatment for Patients with Prostate Cancer | https://aacrjournals.org/clincancerres/article/12/24/7414/193013/Rapid-Androgen-Cycling-as-Treatment-for-Patients |
| DES induces apoptosis in hormone-insensitive prostate cancer cells through non-estrogen receptor mechanisms | B | Induction of apoptosis by diethylstilbestrol in hormone-insensitive prostate cancer cells | https://pubmed.ncbi.nlm.nih.gov/8656443/ |
| Estrogens promote prostate cancer growth through various mechanisms | B | Oestrogens and oestrogen receptors in prostate cancer | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4844569/ |
| High-dose androgen induces autophagic cell death in enzalutamide-resistant prostate cancer via circRNA-BCL2/miRNA-198/AMBRA1 signaling | B | High-dose-androgen-induced autophagic cell death to suppress the Enzalutamide-resistant prostate cancer growth via altering the circRNA-BCL2/miRNA-198/AMBRA1 signaling | https://www.nature.com/articles/s41420-022-00898-6 |
| DHT, not testosterone, mediates PSA gene expression in LNCaP cells | B | Androgen-Induced Prostate-Specific Antigen Gene Expression Is Mediated via Dihydrotestosterone in | https://onlinelibrary.wiley.com/doi/full/10.1002/j.1939-4640.2003.tb02727.x |

| Summary | Evidence Quality | Article Title | URL |
|---|---|---|---|
| | | LNCaP Cells | |
| ADT stimulates neuroendocrine differentiation in LNCaP cells; PSA, PSMA, and AR expression is higher in LNCaP cells than in PC3, DU145, or HPEC cells | B | Characterization of Hormone-Dependent OSNs in Six Human Prostate-Cancer Cell Lines: A Gene-Expression Study | https://www.mdpi.com/2073-4425/11/10/1174 |
| Enzalutamide reaches steady state plasma concentration (~7-13 µg/ml) in approximately 1 month | B | Clinical Pharmacokinetic Studies of Enzalutamide | https://pubmed.ncbi.nlm.nih.gov/25917876/ |
| SPA-mediated regression of androgen-independent LNCaP 104-R1 tumors lasted ~7 weeks before regrowth; tumors reverted to androgen-sensitive phenotype; subsequent ADT controlled growth >60 days | B | Androgen Causes Growth Suppression and Reversion of Androgen-Independent Prostate Cancer Xenografts to an Androgen-Stimulated Phenotype in Athymic Mice | https://aacrjournals.org/cancerres/article/65/6/2082/518998/Androgen-Causes-Growth-Suppression-and-Reversion |
| Review of 3-BP as selective cancer treatment targeting energy metabolism | B | Targeting Cancer Cells using 3-bromopyruvate for Selective Cancer Treatment | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6298280/ |
| Phase I/II trial of enzalutamide + indomethacin in CRPC showed 31% PSA response rate and 54% stable disease | B | A phase I/II study of enzalutamide in combination with indomethacin in men with castration-resistant prostate cancer (CRPC) | https://ascopubs.org/doi/10.1200/JCO.2024.42.16_suppl.e17027 |
| Testosterone uptake in prostate cancer cells is rapid and enhanced by heat through facilitated diffusion mechanisms | B | Testosterone accumulation in prostate cancer cells is enhanced by facilitated diffusion | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6783279/ |

| Summary | Evidence Quality | Article Title | URL |
|---|---|---|---|
| PSA gene expression is mediated by DHT rather than testosterone in LNCaP cells | B | Androgen-Induced Prostate-Specific Antigen Gene Expression Is Mediated via Dihydrotestosterone in LNCaP Cells | https://onlinelibrary.wiley.com/doi/full/10.1002/j.1939-4640.2003.tb02727.x |
| PSA expression increases 10-fold in LNCaP cells exposed to 10 nM DHT for 48 hours (equivalent to ~5000 ng/dl testosterone) | B | Negative Modulation of Androgen Receptor Transcriptional Activity by Daxx | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC533990/ |
| AR monomers and dimers regulate opposing biological processes in prostate cancer cells | B | Androgen receptor monomers and dimers regulate opposing biological processes in prostate cancer cells | https://www.nature.com/articles/s41467-024-52032-y |
| 18F-DCFPyL PET/CT can detect early progression in mCRPC patients receiving BAT | B | Detection of Early Progression with 18F-DCFPyL PET/CT in Men with Metastatic Castration-Resistant Prostate Cancer Receiving Bipolar Androgen Therapy | https://jnm.snmjournals.org/content/62/9/1270 |
| Letrozole appears to be the safest AI choice; exemestane has androgenic effects and anastrozole may activate ER-α | B | Exemestane's 17-hydroxylated metabolite exerts biological effects as an androgen | https://pubmed.ncbi.nlm.nih.gov/17989318/ |

| | | | |
|---|---|---|---|
| Sulforaphane induces DNA double-strand breaks predominantly repaired by homologous recombination pathway | B | Sulforaphane induces DNA double strand breaks predominantly repaired by homologous recombination OSN in human cancer cells | https://www.sciencedirect.com/science/article/abs/pii/S0006291X08018913 |
| Ki-67 is an independent predictor of recurrence in localized prostate cancer | A | Ki67 Is an Independent Predictor of Recurrence in the Largest Randomized Trial of 3 Radiation Fractionation Schedules in Localized Prostate Cancer | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5947826/ |

| | | | |
|---|---|---|---|
| KI67 and DLX2 predict increased risk of metastasis formation in prostate cancer | B | KI67 and DLX2 predict increased risk of metastasis formation in prostate cancer–a targeted molecular approach | https://www.nature.com/articles/bjc2016169 |
| EGCG from green tea exhibits anti-cancer effects through multiple mechanisms | B | A review on anti-cancer effect of green tea catechins | https://www.sciencedirect.com/science/article/pii/S1756464620303960 |
| Extreme responses to immune checkpoint blockade observed following BAT and enzalutamide in mCRPC patients | B | Extreme responses to immune checkpoint blockade following bipolar androgen therapy and enzalutamide in patients with metastatic castration resistant prostate cancer | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7585736/ |
| Integrative pan-solid tumor predictor developed for PD-1/PD-L1 blockade benefit | B | Development and validation of an integrative pan-solid tumor predictor of PD-1/PD-L1 blockade benefit | https://www.nature.com/articles/s438 |
| Creatine serves as a metabolic regulator conserving bioenergy to power CD8 T cell antitumor immunity; supplementation enhances antitumor T cell responses and synergizes with PD-1/PD-L1 blockade therapy | A | Creatine in T Cell Antitumor Immunity and Cancer Immunotherapy | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8152274/ |
| Statins decrease PD-L1 expression by inhibiting AKT and β-catenin signaling OSNs, potentially enhancing anti-tumor immune responses | B | Statins Decrease Programmed Death-Ligand 1 (PD-L1) by Inhibiting AKT and β-Catenin Signaling | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8472538/ |
| Green tea catechin EGCG functions as an alternative immune checkpoint inhibitor by suppressing PD-L1 expression and inhibiting lung tumor growth | B | Green Tea Catechin Is an Alternative Immune Checkpoint Inhibitor that Inhibits PD-L1 Expression and Lung Tumor Growth | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6222340/ |
| Testosterone and PSA stimulate generation of reactive oxygen species in prostate cancer cells, potentially contributing to cell stress and death | B | Testosterone and prostate specific antigen stimulate generation of reactive oxygen species in prostate cancer cells | https://academic.oup.com/carcin/article/22/11/1775/2390102 |

| | | | |
|---|---|---|---|
| Supraphysiological androgen inhibits MYC through AR and MYC equilibration on developmental super-enhancers | B | Androgen receptor and MYC equilibration centralizes on developmental super-enhancer | https://www.nature.com/articles/s41467-021-27077-y |
| R1881 (nandrolone derivative) inhibits MYC expression in prostate cancer cells | B | Conversion of Androgen Receptor Signaling From a Growth Suppressor in Normal Prostate Epithelial Cells to an Oncogene in Prostate Cancer Cells Involves a Gain of Function in c-Myc Regulation | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4062956/ |
| Bicalutamide inhibits MYC expression in prostate cancer cells | B | Conversion of Androgen Receptor Signaling From a Growth Suppressor in Normal Prostate Epithelial Cells to an Oncogene in Prostate Cancer Cells Involves a Gain of Function in c-Myc Regulation | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4062956/ |
| Inhibiting c-Myc could sensitize enzalutamide-resistant cells to growth inhibition by enzalutamide | B | A Positive Role of c-Myc in Regulating Androgen Receptor and its Splice Variants in Prostate Cancer | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6586509/ |
| Curcumin inhibits MYC expression, potentially underlying its anti-growth and anti-migration effects in chemoresistant colorectal cancer cells | B | The Influence of Curcumin on the Downregulation of MYC, Insulin and IGF-1 Receptors: A Possible Mechanism Underlying the Anti-Growth and Anti-Migration in Chemoresistant Colorectal Cancer Cells | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6524349/ |
| Lycopene exhibits multifaceted effects including MYC inhibition as part of its multi-target approach to cancer treatment | B | Multifaceted Effects of Lycopene: A Boulevard to the Multitarget-Based Treatment for Cancer | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8434243/ |
| EGCG inhibits growth and tumorigenicity of nasopharyngeal tumor-initiating cells through attenuation of STAT3 activation and MYC inhibition | B | EGCG inhibits the growth and tumorigenicity of nasopharyngeal tumor-initiating cells through attenuation of STAT3 activation | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4069954/ |

| | | | |
|---|---|---|---|
| Aspirin and salicylic acid decrease c-Myc expression in cancer cells, suggesting a potential mechanism for their chemopreventive effects | B | Aspirin and salicylic acid decrease c-Myc expression in cancer cells: a potential role in chemoprevention | https://pubmed.ncbi.nlm.nih.gov/26314861/ |
| Vitamin D3 potentiates metformin's growth inhibitory effects in DU145 prostate cancer cells through AMPK/mTOR signaling and MYC inhibition | B | Vitamin D3 potentiates the growth inhibitory effects of metformin in DU145 human prostate cancer cells mediated by AMPK/mTOR signaling pathway | https://pubmed.ncbi.nlm.nih.gov/25903858/ |
| Metformin targets c-MYC oncogene to prevent prostate cancer development and progression | B | Metformin targets c-MYC oncogene to prevent prostate cancer | https://academic.oup.com/carcin/article/34/12/2823/2464148 |
| CDK4/6 inhibition exploits the tumor-suppressive activity of the androgen receptor in castration-resistant prostate cancer | B | Exploiting the tumor-suppressive activity of the androgen receptor by CDK4/6 inhibition in castration-resistant prostate cancer | https://www.cell.com/molecular-therapy-family/molecular-therapy/fulltext/S1525-0016(22)00078-8 |
| Statins exert anti-proliferative effects through DNMT1 inhibition and p21 expression in oral squamous cell carcinoma cells | B | Anti-Proliferative Effect of Statins Is Mediated by DNMT1 Inhibition and p21 Expression in OSCC Cells | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7463937/ |
| Novel therapeutic strategies for CDK4/6 inhibitors in metastatic castrate-resistant prostate cancer show promise in preclinical and early clinical studies | B | Novel Therapeutic Strategies for CDK4/6 Inhibitors in Metastatic Castrate-Resistant Prostate Cancer | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7576355/ |
| Sulforaphane from cruciferous vegetables inhibits CDK4/6, showing potential for breast cancer treatment despite some contradictory effects | B | Targets and mechanisms of sulforaphane derivatives obtained from cruciferous plants with special focus on breast cancer – contradictory effects and future perspectives | https://www.sciencedirect.com/science/article/pii/S0753332219352576 |
| Natural compounds EGCG and I3C inhibit CDK4/6, modulating cell cycle arrest with applications for anticancer chemotherapies | B | Natural Compounds as Modulators of Cell Cycle Arrest: Application for Anticancer Chemotherapies | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5345333/ |

| | | | |
|---|---|---|---|
| Metformin functions as a senostatic drug enhancing anticancer efficacy of CDK4/6 inhibitors in head and neck squamous cell carcinoma | B | Metformin as a senostatic drug enhances the anticancer efficacy of CDK4/6 inhibitor in head and neck squamous cell carcinoma | https://www.nature.com/articles/s41419-020-03126-0 |
| ZIP9 functions as both a novel membrane androgen receptor and zinc transporter protein, potentially relevant for prostate cancer therapy | B | ZIP9, a novel membrane androgen receptor and zinc transporter protein | https://www.scopus.com/record/display.uri?eid=2-s2.0-85019842589&origin=inward&txGid=c02e433e1809ee594296d572177b2db8 |
| Vitamin D and testosterone coordinately modulate intracellular zinc levels and energy metabolism in prostate cancer cells | B | Vitamin D and testosterone co-ordinately modulate intracellular zinc levels and energy metabolism in prostate cancer cells | https://www.sciencedirect.com/science/article/abs/pii/S0960076018306174 |
| ZIP9, a membrane androgen receptor and zinc transporter, mediates testosterone-induced apoptosis in prostate and breast cancer cells | B | Identification and Characterization of Membrane Androgen Receptors in the ZIP9 Zinc Transporter Subfamily: II. Role of Human ZIP9 in Testosterone-Induced Prostate and Breast Cancer Cell Apoptosis | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4197988/ |
| ZIP9 functions as both a membrane androgen receptor and zinc transporter protein | B | ZIP9, a novel membrane androgen receptor and zinc transporter protein | https://www.sciencedirect.com/science/article/pii/S0016648017303416 |
| Vitamin D and testosterone coordinately modulate intracellular zinc levels and energy metabolism in prostate cancer cells | B | Vitamin D and testosterone co-ordinately modulate intracellular zinc levels and energy metabolism in prostate cancer cells | https://pubmed.ncbi.nlm.nih.gov/30664926/ |
| Post-diagnostic zinc supplementation (1-24 mg) reduced prostate cancer progression, while higher amounts did not show benefit | B | Post-diagnostic Zinc Supplement Use and Prostate Cancer Survival Among Men With Nonmetastatic Prostate Cancer | https://www.auajournals.org/doi/10.1097/JU.0000000000003080 |
| Nitric oxide alterations in the tumor microenvironment impede castration-resistant prostate cancer growth | B | Alterations of tumor microenvironment by nitric oxide impedes castration-resistant prostate cancer growth | https://www.pnas.org/doi/10.1073/pnas.1812704115 |

| | | | |
|---|---|---|---|
| PDE5 inhibitor use after robotic prostate cancer surgery is associated with improved survival | B | PDE5i Use After Robotic Prostate Cancer Surgery Linked to Better Survival | https://www.cancertherapyadvisor.com/home/cancer-topics/prostate-cancer/pde5i-use-after-robotic-prostate-cancer-surgery-linked-better-survival/ |
| Sildenafil increases muscle protein synthesis and reduces muscle fatigue | B | Sildenafil Increases Muscle Protein Synthesis and Reduces Muscle Fatigue | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4076819 |
| Review of resistance mechanisms in castration-resistant prostate cancer | B | Mechanisms of resistance in castration-resistant prostate cancer (CRPC) | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4708226/ |
| Prazosin shows anticancer activity against prostate cancer cells by targeting DNA and cell cycle | B | Prazosin Displays Anticancer Activity against Human Prostate Cancers: Targeting DNA and Cell Cycle | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2040210/ |
| α-adrenoceptor antagonists impact prostate cancer development, progression, and prevention | B | Impact of α-adrenoceptor antagonists on prostate cancer development, progression and prevention | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6420703/ |
| Evidence supporting the use of nandrolone in male health and wellness | B | Beyond testosterone cypionate: evidence behind the use of nandrolone in male health and wellness | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4837307 |
| Progress in understanding resistance mechanisms and optimizing androgen depletion therapy | B | Androgen deprivation therapy: progress in understanding mechanisms of resistance and optimizing androgen depletion | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2981403 |
| Serum testosterone peaks around 4 hours after upper arm and shoulder application of Testim gel | B | Testim® 1% (testosterone gel) CIII | https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=48f8aa83-e043-41b8-9a20-dbb098045895&type=display |
| Serum testosterone peaks around 4 hours after inner thigh application of testosterone gel | B | TESTOSTERONE gel, for topical use CIII Initial U.S. Approval: 1953 | https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=415057d5-8ed3-42dd-9637-05145c84a9c2&type=display |
| Serum testosterone peaks around 3 hours after scrotal application of testosterone cream | B | Pharmacokinetics of testosterone cream applied to scrotal skin | https://onlinelibrary.wiley.com/doi/full/10.1111/andr.12357 |

| | | | |
|---|---|---|---|
| Study assessing accuracy of testosterone concentrations in compounded testosterone products | B | Accuracy of testosterone concentrations in compounded testosterone products | https://pubmed.ncbi.nlm.nih.gov/25963000 |
| Vitamin D and testosterone coordinately modulate intracellular zinc levels and energy metabolism in prostate cancer cells | B | Vitamin D and testosterone co-ordinately modulate intracellular zinc levels and energy metabolism in prostate cancer cells | https://www.sciencedirect.com/science/article/abs/pii/S0960076018306174 |

## Preclinical Insights into Androgen-Driven Apoptosis

z

## Mechanistic Rationale for Short Pulses

1. **Hormonal Fluctuations and DNA Damage**:

   - **Enhanced Hormonal Fluctuations**: Rapid testosterone cycling disrupts adaptive AR signaling and exploit mitotic vulnerability, preventing stabilization of resistance mechanisms like AR-V7 splice variants. Preclinical data suggest frequent hormonal pulses induce repeated DNA damage.
   - **Mitotic Targeting**: Frequent androgen pulses aim to catch cancer cells during division, a phase of heightened susceptibility to DNA damage.

2. **Epigenetic and Molecular Targeting:**

   - **LSD1 downregulation:** Enhances ADT sensitivity by suppressing anti-apoptotic proteins (Bcl-2) and promoting caspase activation.
   - **DAB2IP loss reprograms STAT3-survivin signaling:** Reduces apoptosis during ADT; reversing this OSN could mitigate resistance.

3. **Mitotic Vulnerability:**

   - **Short SPA pulses target cells during mitosis:** DNA damage susceptibility is heightened. Combining aBAT with PARP inhibitors could destabilize quasi-apoptotic state (QUAPS), pushing cells into full apoptosis.
   - **Explanation of QUAPS (Quasi-Apoptotic State):**

     QUAPS, or Quasi-Apoptotic State, refers to a metastable cellular condition induced by androgen deprivation therapy (ADT) in hormone-sensitive prostate cancer (HSPC) cells. This state is characterized by partial apoptotic features but does not lead to full cell death. Here is a detailed explanation based on the findings:

     Key Features of QUAPS

     - Partial Apoptosis:
       - QUAPS involves partial mitochondrial permeabilization, limited activation of pro-apoptotic proteins like BAX, and moderate caspase activity.
       - While these cells exhibit some DNA damage (e.g., double-strand breaks), they maintain viability and do not progress to full apoptosis[1].
     - Genetic Instability:
       - Cells in QUAPS are prone to genetic instability. Upon androgen restoration, they resume proliferation before completing DNA repair, leading to increased micronuclei frequency and mutagenesis.
     - Reversibility:
       - QUAPS is reversible upon androgen reintroduction, with mitochondrial integrity restored and cells resuming normal proliferation. This reversibility highlights the adaptability of prostate cancer cells under ADT.

- Therapeutic Vulnerability:
  - During QUAPS, cells are particularly sensitive to poly(ADP-ribose) polymerase inhibitors (PARPi). PARPi destabilizes this state, pushing cells into full intrinsic apoptosis and potentially eradicating them.

Clinical Implications

- Progression to Castration Resistance:
  - QUAPS may explain how prostate cancer cells survive ADT and eventually develop castration resistance. The genetic instability induced during this state could drive tumor evolution and resistance mechanisms.
- Targeting QUAPS with PARPi:
  - The specific vulnerability of cells in the quasi-apoptotic state to PARPi presents an opportunity for combination therapies during ADT to enhance tumor control and delay progression to castration-resistant prostate cancer (CRPC).
- Androgen Cycling Strategies:
  - Short SPA pulses could exploit the reversibility of QUAPS by alternating between androgen deprivation and supraphysiological androgen levels, disrupting tumor adaptation cycles.

## Clinical and Practical Considerations

- **PSA Limitations**: PSA reflects AR activity, not tumor burden, and is influenced by androgen levels. PSA fluctuations may not correlate with clinical outcomes, necessitating alternative biomarkers.

- **Anecdotal Observations**:
  - Initial PSA declines in short cycles may reflect transient AR modulation, while later increases (post-SBRT) highlight confounding factors like treatment-induced inflammation.
  - CRPC patients report mixed PSA responses during traditional BAT therapy, underscoring heterogeneity in resistance mechanisms (e.g., AR-V7, neuroendocrine differentiation).

## Advantages and Challenges of Short **SPA** pulses

| Strengths | Limitations |
|---|---|
| Mimics natural androgen dynamics | No clinical trial validation |
| Targets mitotic vulnerability | Frequent dosing. This can be minimized by using Androgel, which eliminates the need for intramuscular injections. |
| Synergy with DNA damage agents (e.g., PARPi) | Risk of genetic instability from QUAPS reversal |

## Recommended Tests

- **See aBAT Monitoring Routine**

## Options:

### 1-day SPA Pulses

1. Natesto

**For a single dose of Natesto (22 mg per nostril or 44 mg total):**

- **Peak serum testosterone levels (Cmax ~2,000–3,000 ng/dL) are achieved within approximately 40–60 minutes (Tmax) post-administration.**
- **The elimination half-life is ~10–100 minutes.**

**Efficacy of Nasal Testosterone Gel (Natesto®) Stratified by Baseline Endogenous Testosterone Levels – PMC**
**https://pmc.ncbi.nlm.nih.gov/articles/PMC6694041/**



### 7-day Cycles

A one-day pulse protocol involves administering 75 mg of testosterone propionate on the first day of each weekly cycle. Darolutamide is then used from days 2 to 5 of the cycle to mitigate the androgenic effects of testosterone.

For a longer pulse lasting 2-3 days, 75 mg of testosterone propionate is injected on day 1, followed by 50 mg on day 2. This weekly cycle includes two days of darolutamide treatment after the final testosterone injection to counteract its androgenic activity.

Both protocols aim to exploit the potential benefits of bipolar androgen therapy while managing androgen receptor signaling through strategic use of darolutamide.

## References
## Evidence for Short Pulses

The evidence collectively suggests that **short, sharp-edged pulses of Supraphysiologic Androgen (SPA)** can indeed **inhibit Prostate Cancer (PCa)** growth in preclinical models, applying to **both HSPC and CRPC cell lines**, although the mechanisms and context may vary.

| Study (Short Citation/Link) | Primary Focus | Cell Types Tested / Context | Tested Pulse Width / Duration Showing Effect | Key Finding re: SPA Pulse Inhibition? | Applicable To (HSPC/CRPC/Both) |
|---|---|---|---|---|---|
| Sena et al., 2023 | SPA effects on CRPC growth & DNA damage | CRPC cell lines (incl. LNCaP-derived C4-2) | 48-72 hours | Yes. Inhibits growth via DNA damage & cell cycle arrest. | CRPC (Directly Tested) |
| Gravina et al., 2017 | Pulsed testosterone supplementation induces tumor senescence | LNCaP (HSPC), 22rv1 (HSPC/CRPC) | 2-hour pulses every 8 h (6 cycles over 48 h) | Pulsed T inhibits tumor growth via G0/G1 arrest, senescence, and AR downregulation. | HSPC (directly tested) |
| Butler et al., 2021 | Acute SPA effects on AR degradation & tumor activity<br><br>Supraphysiological testosterone induces ferroptosis within 72 hours | LNCaP (HSPC), C4-2 (CRPC), VCaP, 22Rv1 (CRPC) | ~24-48 hours (for AR degradation); Growth inhibition over days | Yes. Inhibits growth via AR/AR-V7 degradation in vitro & in vivo. | Both (Directly Tested) |
| Chakraborty et al., 2021 | Mechanisms of SPA action in CRPC (Ferroptosis)<br><br>AR and MYC equilibration occurs within 2-24 hours of SPA | CRPC models (cell lines, xenografts) | 48-72 hours (shown in figures) | Yes. Induces ferroptosis (cell death), contributing to anti-tumor effect. | CRPC (Directly Tested) |
| Han et al., 2017 | Systematic Review/Meta-Analysis of clinical BAT studies<br><br>7-day androgen exposure induces sustained quiescence in prostate cancer cells | CRPC Patients (Clinical Trials) | N/A (Clinical Review - describes monthly cycles) | Supports clinical activity. Reviews show BAT inhibits growth (e.g., PSA responses) in CRPC patients. | CRPC (Clinical Context) |
| Isaacsson Velho et al., 2017 | Review/Perspective on BAT<br><br>Non-genomic AR actions occur within minutes, genomic effects take hours | Reviews of preclinical & clinical data | N/A (Review - cites various durations from primary studies) | Supports inhibition. Discusses rationale & evidence showing SPA can inhibit both HSPC & CRPC cells via various mechanisms. | Both (Based on Lit. Review) |
| Moore et al., 2021 | Intermittent BAT schedules in CRPC models<br><br>Sudden androgen changes may provide superior growth inhibition | CRPC xenograft models | Cycles (e.g., 1 wk on / 3 wks off) (in vivo schedule) | Yes. Intermittent SPA pulses suppress CRPC tumor growth in vivo. | CRPC (Tested in vivo) |
| Chuu et al., 2004 | Early study on SPA effects via AR overload<br><br>3-7 days optimal for ADT-induced apoptosis | AR-positive PCa cells (LNCaP mentioned) | ~3-7 days (continuous exposure showing proliferation effect) | Yes. Inhibits proliferation, potentially via AR overload/disruption. | HSPC (Directly Tested) |
| Veldhuis et al., | Impact of LH pulse frequency | Healthy men (clinical | 1-h vs. 2-h LH pulses | Pulsatile LH (1-h pulses) increases mean T and induces | N/A (physiological |

| | | | | | |
|---|---|---|---|---|---|
| 2012 (AJP-Reg) | on testosterone secretion | study) | | orderly T secretion. | context) |
| Veldhuis et al., 2012 (AJP-Endo) | Dynamic T responses to prior LH delivery modes | Healthy men (clinical study) | Continuous vs. pulsed LH | Prior LH delivery mode (pulsed vs. continuous) determines subsequent T secretory dynamics. | N/A (physiological context) |
| Mendonca et al., 2020 (BioRxiv) | SPA induces ferroptosis & immune activation via nucleophagy | LNCaP (HSPC), VCaP (CRPC), LAPC4 (CRPC | 72 hours | Yes. Inhibits growth via ferroptosis (iron-dependent cell death) and NF-κB-mediated immune activation (↑ CXCL10, NK/T-cell recruitment). | Both (HSPC/CRPC tested) |
| McDonnell et al., 2024 | AR monomer vs. dimer effects - low vs. high dose androgen paradox | LNCaP, VCaP, LAPC4 (HSPC/CRPC models), NSG mouse xenografts | 4 hours (c-MYC suppression), effects sustained over days | Yes. High-dose androgens form AR dimers/oligomers that suppress c-MYC within 4h, inhibit proliferation, and drive differentiated phenotype vs. low-dose promoting proliferation via AR monomers. | Both (tested multiple cell models) |

**Conclusion:**

The studies strongly support the **concept** that short, intense pulses of supraphysiologic androgens (SPA) can inhibit prostate cancer growth in preclinical settings. This inhibitory effect has been demonstrated in:

- **CRPC cell lines and models:** Multiple studies show inhibition via mechanisms like DNA damage, cell cycle arrest, AR degradation, and ferroptosis. Clinical reviews confirm activity in CRPC patients.
- **HSPC cell lines (like LNCaP):** Studies also show inhibition, potentially mediated by AR overload/disruption or AR degradation.

**Pulse Widths:** Short SPA pulses appear capable of inhibiting **both HSPC and CRPC** cell lines, although the relative sensitivity and dominant mechanisms might differ depending on the specific cell context (hormone-sensitive vs. castration-resistant adaptations).

A-SPA (ARSI-Supraphysiological Androgen) therapy combines androgen receptor signaling inhibitors (ARSI) with supraphysiological doses of testosterone. This paradoxical strategy exploits the dual nature of androgen receptor biology, where extremely high testosterone levels can paradoxically suppress prostate cancer growth while concurrent AR blockade prevents adaptive resistance mechanisms.

## Mechanism of Action

A-SPA therapy operates through several complementary mechanisms that create unprecedented cellular stress in cancer cells.

### Non-AR Mediated Mechanisms of Supraphysiological Testosterone

1. DNA Damage Through TOP2B-Mediated Double-Strand Breaks

Supraphysiological testosterone induces significant DNA damage through recruitment of topoisomerase II beta (TOP2B) to androgen response elements, creating transient double-strand breaks that become persistent when repair mechanisms are overwhelmed. These TOP2B-mediated breaks occur independently of AR transcriptional activity and represent direct genotoxic effects of high testosterone concentrations.

The mechanism involves testosterone-driven TOP2B recruitment that generates DNA double-strand breaks lasting several hours, far exceeding the typical transient nature of topoisomerase activity. These persistent breaks trigger DNA damage response pathways and can lead to genomic instability when repair capacity is exceeded. Reactive oxygen species generated during testosterone metabolism can further stabilize TOP2B-DNA cleavage complexes, converting them into frank double-strand breaks.

2. Autophagy-Mediated Cell Death Pathways

Recent research demonstrates that supraphysiological testosterone induces two parallel autophagy-mediated processes: ferritinophagy and nucleophagy. Ferritinophagy involves degradation of iron storage proteins, leading to increased labile iron pools and subsequent ferroptosis through iron-dependent lipid peroxidation. This process is distinct from traditional apoptotic pathways and represents a non-AR mediated cytotoxic mechanism.

Nucleophagy, the second autophagy-mediated process, involves selective degradation of nuclear components, releasing DNA into the cytoplasm where it activates innate immune sensors. This process occurs independently of AR transcriptional activity and creates a unique cellular stress environment that cancer cells struggle to survive.

3. Immune System Activation Through Cytoplasmic DNA Sensing

Supraphysiological testosterone treatment activates cytoplasmic nucleic acid sensors through the cGAS-STING pathway, triggering downstream immune signaling cascades. Autophagosomal DNA released during nucleophagy activates these sensors, converging on NF-κB to drive immune signaling pathways. This immune activation leads to secretion of chemokines and cytokines that recruit cytotoxic immune cells to tumor sites.

The cGAS-STING pathway activation represents a fundamental shift from traditional AR-mediated effects to innate immune recognition of cellular damage. This mechanism transforms cancer cells into immunogenic targets, potentially overcoming immune evasion strategies that tumors typically employ.

4. Mitochondrial Dysfunction and Metabolic Stress

High testosterone concentrations can induce mitochondrial dysfunction through multiple pathways, including oxidative stress generation and disruption of electron transport chain function. Testosterone enhances metabolic rate and can overwhelm mitochondrial capacity, leading to reactive oxygen species accumulation and cellular energy crisis.

This mitochondrial stress occurs independently of AR signaling and creates metabolic vulnerabilities that cancer cells cannot easily overcome. The combination of increased energy demands and impaired ATP production creates a cytotoxic environment that selectively targets metabolically active cancer cells.

## A-SPA Enhancement of Non-AR Mediated Mechanisms

1. Darolutamide-Mediated AR Blockade Amplifies Cytotoxic Effects

Darolutamide's comprehensive AR blockade prevents compensatory AR-mediated survival signaling while allowing non-AR cytotoxic mechanisms to predominate. By blocking AR nuclear translocation and genome-wide enhancer activation, darolutamide eliminates the protective effects of AR signaling that might otherwise counteract testosterone's cytotoxic actions.

The drug depletes AR from gene regulatory regions and abolishes AR-driven transcriptional programs, creating an environment where cancer cells cannot activate traditional androgen-mediated survival pathways. This selective elimination of protective AR signaling while maintaining cytotoxic testosterone effects represents A-SPA's fundamental therapeutic advantage.

2. Olaparib Integration Exploits DNA Damage Accumulation

The inclusion of olaparib during and after testosterone exposure creates synthetic lethality by preventing repair of TOP2B-induced DNA damage. While testosterone generates double-strand breaks through non-AR mechanisms, olaparib blocks PARP-mediated repair pathways, allowing damage to accumulate to lethal levels.

This combination specifically targets cancer cells with existing DNA repair deficiencies, as healthy cells retain sufficient repair capacity to manage the dual insult. The timing of olaparib administration (Days 9-21) ensures maximum exposure during the period when testosterone-induced DNA damage is most prevalent.

3. Senolytic Enhancement of Cellular Clearance

The incorporation of senolytics (quercetin and fisetin) during Days 11-13 targets senescent cells that may survive initial cytotoxic insults. These agents specifically eliminate cells that have entered senescence in response to DNA damage or metabolic stress, preventing their potential recovery and resistance development.

Senolytics work independently of AR signaling by targeting senescence-associated pathways, ensuring complete elimination of damaged cells that might otherwise contribute to treatment resistance. This comprehensive cellular clearance approach maximizes the impact of initial cytotoxic mechanisms.

4. Overcoming AR-Dependent Resistance Mechanisms

A-SPA's reliance on non-AR mediated cytotoxicity potentially overcomes resistance mechanisms that depend on AR signaling pathway alterations. Traditional resistance involves AR amplification, splice variant expression, or ligand-independent activation, all of which become irrelevant when cytotoxic effects operate independently of AR function.

The protocol's ability to maintain darolutamide-mediated AR blockade while delivering cytotoxic testosterone effects creates a therapeutic window that resistance mechanisms cannot easily circumvent. This approach represents a paradigm shift from competing with AR signaling to bypassing it entirely.

## How to Integrate A-SPA into aBAT

### 1. Timing

**Best Phase:** Insert the A-SPA cycle into a scheduled low-T phase of your aBAT regimen. This takes advantage of the cancer cells' adaptation to castrate conditions, making them more vulnerable to the cytotoxic stress of supraphysiological androgen exposure with concurrent AR blockade.

**Frequency:** Consider once per year or at intervals based on risk assessment, disease burden, and ctDNA/PSA trends.

### 2. Example

**Days 1–6:** Continue darolutamide (1200 mg/day) and olaparib (300 mg BID).

**Days 7–8:** Add supraphysiological testosterone (e.g., 200–300 mg Androgel daily), maintaining darolutamide and olaparib. This will drive testosterone above 1,500 ng/dL while AR is still blocked.

**Days 9–11:** Pause darolutamide, continue olaparib (300 mg BID). Add supraphysiological testosterone (e.g., 300-400 mg Androgel daily). This allows the ARSI blockade to lift and present another environment to the cancer.

**Days 12–14:** Resume darolutamide (1200 mg/day), continue olaparib, add senolytics (e.g., quercetin, fisetin).

**Days 15–21:** Continue darolutamide and olaparib; monitor PSA and clinical status.

## Conclusion

A-SPA exploits non-AR mediated cytotoxic mechanisms while preventing compensatory AR-driven survival responses. By combining comprehensive AR blockade with supraphysiological testosterone exposure, the approach harnesses multiple independent pathways including TOP2B-mediated DNA damage, autophagy-induced cell death, immune system activation, and metabolic stress.

The protocol's strength lies in its ability to maintain therapeutic testosterone levels while eliminating protective AR signaling, creating a unique biological environment where cytotoxic mechanisms predominate over survival pathways. This approach offers potential advantages by targeting cancer cells through pathways that are difficult for tumors to circumvent through conventional resistance mechanisms.

# PARPi (e.g., Olaparib)

## PARPi Mechanism of Action

**Poly(ADP-ribose) polymerase inhibitors (PARPi)** target a family of enzymes central to the repair of single-strand DNA breaks via the base excision repair pathway. When DNA is damaged, PARPs detect the lesion, recruit repair enzymes, and facilitate the repair process by adding poly(ADP-ribose) chains to various proteins at the damage site. Inhibiting PARP halts this process, causing the accumulation of single-strand breaks, which, after cell division, collapse into more hazardous double-strand breaks. If these double-strand breaks cannot be efficiently repaired, the result is genomic instability and ultimately cell death—this is the foundation for the profound anticancer effect of PARPi, particularly in tumors with pre-existing DNA repair deficiencies.

## Synthetic Lethality

**Synthetic lethality** occurs when inhibition of two distinct molecular pathways or genes causes cell death, even though inhibition of either alone would not. In the context of cancer, tumor cells harboring defects in homologous recombination repair (HRR)—such as BRCA1, BRCA2, or ATM mutations—are highly dependent on alternative DNA repair pathways like PARP. Inhibiting PARP in these cells creates catastrophic DNA damage that they cannot repair, leading to selective tumor cell death while sparing normal cells that retain functional HRR machinery. This concept underpins the use of PARPi in HRR-deficient cancers and explains the heightened efficacy seen in BRCA-mutant and related tumors.

## HRR+ vs HRR-

- **HRR+ (HRR-deficient) tumors**: Tumors with mutations in HRR genes (BRCA1/2, ATM, PALB2, etc.) are exquisitely sensitive to PARP inhibition. The synthetic lethality principle ensures that these cells, already deficient in error-free double-strand DNA break repair, succumb when PARP is also blocked, because alternative pathways cannot compensate.
- **HRR- (HRR-proficient) tumors**: Tumors with intact HRR have additional means to repair lethal DNA damage. Nonetheless, combining PARPi with agents that either functionally suppress HRR or induce high levels of DNA damage (such as androgen deprivation, radiation, or chemotherapy) has demonstrated clinically meaningful benefit, indicating that PARPi efficacy can extend—under specific circumstances—beyond genomically HRR-mutant tumors.

## Examples

### PARPi + RLT (Radioligand Therapy)

**Category: Combination Therapy with Alpha Particle–Based RLT**
**FPI-2265 ($^{225}$Ac-PSMA-I&T) + Olaparib for Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC)**

- **ClinicalTrials.gov**: NCT06909825

**Alpha Therapy (FPI-2265)**

- **Administration:** Intravenous infusion, targets PSMA-positive cells (prostate-specific membrane antigen)
- **Frequency:** Dose A: up to 6 doses every 6 weeks; Dose B: up to 9 doses every 4 weeks

**Olaparib Timing**

- **Administration:** Oral, twice daily on days 1–14 of each cycle, concurrent with alpha therapy

**Rationale**

- Inhibit DNA repair by PARP immediately following alpha radiation–induced DNA damage, thereby increasing tumor cell kill

**Mechanistic Synchrony**

1. Alpha particles delivered via PSMA ligand create intense, irreparable DNA double-strand breaks (DSBs) in tumor cells.
2. Tumor cells attempt to activate PARP-mediated DNA repair.
3. Olaparib, given during this critical repair window, blocks effective repair.
4. The result is unrepaired DSBs—“synthetic lethality”—causing cell death even in tumors without HRR mutations.

**Mechanistic Rationale**

- Alpha radiation, unlike beta, causes dense, localized DSBs that are poorly repaired even by intact HRR.
- PARP inhibition, by disabling the backup repair pathway, synergistically heightens cytotoxicity.
- This strategy can overcome resistance even in HRR-proficient cancers, broadening the population that benefits from PARPi-RLT combinations.

---

### PARPi + Zytiga

**Category: Combination with Next-Generation Hormonal Therapy**

**PROpel (Phase III): Olaparib + Abiraterone as First-Line Therapy for mCRPC Regardless of HRR Status**

- **ClinicalTrials.gov:** NCT03732820
- **Reference:** NEJM Evidence

**Design**

- Multinational, double-blind, randomized placebo-controlled
- mCRPC population: No prior chemotherapy or novel hormonal therapy for mCRPC. Both HRR-mutated and HRR wild-type included.

**Treatment Arms**

- A) Olaparib 300 mg BID + Abiraterone 1000 mg once daily + Prednisone 5 mg BID (continuous)
- B) Placebo + Abiraterone + Prednisone

**Treatment Duration:** Until progression, unacceptable toxicity, or withdrawal

**Mechanistic Synchrony**

1. Abiraterone inhibits androgen synthesis, creating metabolic and DNA stress.
2. Olaparib continuously impairs DNA repair mechanisms in tumor cells.
3. The combination enhances DNA damage and blocks repair, resulting in greater efficacy—most pronounced in those with HRR mutations but meaningful even in wild-type.

**Mechanistic Rationale**

- Androgen deprivation via abiraterone stresses the cancer cell's ability to grow and maintain genomic stability.
- Simultaneous PARP inhibition prevents the repair of both single- and double-strand breaks, compounding cell stress and lethality.
- Effectiveness is maximized in HRR-deficient tumors, but benefit is also seen in HRR-proficient individuals due to cumulative metabolic and replication stress.

**Key Results**

- **HRR+ Subgroup:** Median radiographic progression-free survival (rPFS) not reached (combination) vs 13.9 months (abiraterone), HR 0.50.
- **HRR- Subgroup:** Median rPFS 24.1 vs 19.0 months (combination vs. abiraterone), HR 0.76.
- The combination thus broadens the use of PARPi to a far greater proportion of mCRPC patients.

**Clinical Impact**

1. Olaparib/abiraterone is now a first-line option for mCRPC, independent of HRR genotype.
2. Demonstrates meaningful synergy between androgen deprivation and PARP inhibition.
3. Sets precedent for using PARPi beyond BRCA/HRR-mutated settings.

---

## PARPi + BAT

**Category: Combination with Bipolar Androgen Therapy**

**BATON: Bipolar Androgen Therapy (BAT) Plus Olaparib in Men With mCRPC (Phase II)**

- **ClinicalTrials.gov:** NCT03516812

**Design**

- Single-center, phase II, open-label trial
- Post-abiraterone/enzalutamide mCRPC; both HRR-mutant and wild-type, with equal accrual.

**Treatment Arms**

- BAT (Testosterone cypionate/enanthate 400 mg IM every 28 days, ADT continued)
- Olaparib 300 mg PO BID

**Treatment Duration:** Until progression, unacceptable toxicity, or withdrawal

**Mechanistic Synchrony**

1. BAT generates dramatic swings in testosterone, inflicting DNA breaks and cellular stress.
2. Olaparib, administered continuously, blocks the repair of the resulting DNA damage.
3. BAT may suppress HRR gene expression (“functional HRD”), rendering HRR-proficient cells vulnerable to PARPi.

**Mechanistic Rationale**

- High-dose testosterone induces DNA damage, while low-dose phases prevent repair and recovery.
- PARPi blocks the compensatory repair of these breaks, extending benefit to patients with or without HRR mutations.
- BAT-induced “BRCAness” (HRD-like state) may explain clinical activity in wild-type tumors.

**Key Results**

- Overall PSA50 response: 47% (both HRR+ and HRR–).
- Median PFS: 7.5 months (HRR+) vs 14.8 months (HRR–), $P = 0.015$.
- Clinical benefit seen across HRR statuses, with improved side-effect profile and quality of life.

**Clinical Impact**

1. BAT plus PARPi is a rational, biology-driven combination for mCRPC post-ARSI—potentially for HRR– as well as HRR+.
2. Supports combining strategies that induce DNA damage with agents that impair repair.
3. Provides a framework for personalizing use of PARPi outside of strict genomic eligibility.

---

## PARPi + ARSI

**Category: Combination with Androgen Receptor Signaling Inhibitors**

**TALAPRO-2 (Phase III): Talazoparib + Enzalutamide First-Line for mCRPC (HRR+ and all-comers)**

- **ClinicalTrials.gov:** NCT03395197
- **Reference:** Nature Medicine

**Design**

- Double-blind, randomized, placebo-controlled; all-comer mCRPC, stratified for HRR mutation

**Treatment Arms**

- A) Talazoparib 0.5 mg QD (0.35 mg QD if renal impairment) + Enzalutamide 160 mg QD
- B) Placebo + Enzalutamide 160 mg QD

**Treatment Duration:** Until progression, toxicity, or withdrawal

**Mechanistic Synchrony**

1. Enzalutamide blocks androgen receptor–driven transcription and survival signaling.

2. Talazoparib impairs repair of both single- and double-strand breaks by trapping PARP on DNA.
3. This combination exacerbates genomic instability, preferentially killing HRR-deficient cells but benefiting the wider population.

**Mechanistic Rationale**

- ARSI therapy upregulates PARP activity and functionally weakens HRR pathways.
- Combining with PARPi exploits this vulnerability, even in the absence of BRCA/HRR mutations.

**Key Results**

- Patients with BRCA1/2 mutations: 80% lower risk of progression or death (HR 0.20); substantial rPFS benefit.
- Non-BRCA HRR aberrations showed a trend to benefit.
- Combination benefit extends to the overall mCRPC population.

**Clinical Impact**

1. Establishes ARSI/PARPi combinations as potent, potentially first-line, especially for HRR-deficient mCRPC.
2. Routine HRR molecular testing guides optimal candidates but does not restrict benefit.
3. Demonstrates synergy built on the integration of androgen deprivation and impaired DNA repair.

---

## Summary Points

- **PARPi agents, particularly Olaparib, exploit vulnerabilities in DNA repair—especially in tumors with homologous recombination repair deficiency.**
- **Synthetic lethality explains their dramatic efficacy in genomically HRR-mutated tumors.**
- **Combinations with alpha-targeted RLT, next-generation hormonal therapy (abiraterone), BAT, and ARSI not only potentiate PARPi efficacy but extend benefits to HRR-proficient populations, broadening clinical impact.**
- **Clinical trial data support PARPi as a backbone in precision prostate cancer therapy, with ongoing research further refining their use across disease spectrum and genomic contexts.**

---

## References

1. PARP Inhibitors in the Treatment of Prostate Cancer: From Scientific Rationale to Clinical Development – PMC
2. PARP Inhibitors: Clinical Relevance, Mechanisms of Action and Tumor Resistance – PMC

## Olaparib, Testosterone, ADT, and Darolutamide Combination Therapy

### Treatment Components

1. Olaparib (PARP inhibitor):
    - Dosing: Intermittent cycles to exploit synthetic lethality.
    - Rationale: Synergizes with testosterone-induced DNA damage (double-strand breaks) to enhance tumor cell death.
    - Reversion mutations are a primary resistance mechanism to PARPi (e.g., olaparib) in BRCA1/2-deficient cancers, restoring homologous recombination repair (HRR) and enabling tumor survival. However, when using aBAT, the cyclical testosterone stress may mitigate PARPi resistance by inducing genomic instability that overwhelms DNA repair mechanisms, including reversion-restored pathways. ARSIs also create a state of “BRCAness”.
    - Resistance Prevention Mechanisms
        - Continuous Pressure Problem: Research shows that continuous olaparib exposure creates constant selective pressure, potentially driving the evolution of resistant clones through several mechanisms:
            1. Loss of 53BP1/REV7/Shieldin complex activity
            2. Activation of alternative DNA repair pathways
            3. Epigenetic changes that increase resistance
        - Intermittent Advantage: Intermittent cycle dosing could:
            1. Reduce selective pressure, slowing resistance evolution
            2. Allow DNA repair machinery recovery during off-cycles
            3. Prevent PARP trapping tolerance that builds with continuous exposure
            4. Maintain synthetic lethality when administered during peak DNA damage windows
2. Testosterone Propionate (short-acting androgen):
    - Pulsed Dosing:
        - *Rapid pulses*: High-dose (supraphysiological) pulses for 1-7 days to induce DNA damage and tumor senescence (study1).
        - *Extended pulses*: 1-6-week pulses to restore AR signaling sensitivity and delay castration resistance.

- Rationale: Rapid cycling between high/low androgen levels disrupts tumor growth (study1) and enhances AR OSN modulation (study2).

3. Darolutamide (AR inhibitor):
    - Dosing: Block residual AR activity during some testosterone troughs.
    - Advantages: Lower CNS toxicity (≤2% cognitive AEs) vs. enzalutamide; short half-life minimizes drug interaction with SPA.
    - AR resensitization: induces adaptive upregulation of the AR which overcomes acquired resistance to SPA (study2).
4. ADT (e.g., Leuprolide/Orgovyx):
    - Dosing: Maintained continuously to suppress endogenous testosterone production.
    - Purpose: Ensures controlled exogenous androgen exposure during pulsed testosterone therapy (study2).

## Key Design Rationale

- Testosterone Propionate:
    - Short half-life (~19 hours) enables rapid on/off androgen exposure, critical for inducing DNA damage and G0/G1 cell cycle arrest (study1).
    - Preclinical studies show pulsed T suppresses AR, cyclin D1, and c-Myc, reducing tumor proliferation more effectively than continuous T (study1), (study2).
- Olaparib Synergy:
    - High-dose T pulses induce DNA damage; PARP inhibition prevents repair, creating synthetic lethality (study1), (study3).
- Darolutamide:
    - Blocks AR activity without neurocognitive side effects, allowing safer combination with T pulses.
    - Induces a “BRCAness” state, mimicking BRCA deficiency to sensitize tumors to olaparib, even in the absence of BRCA mutations.

## Clinical Implementation

- Cycling:
    - Alternate between rapid/extended T pulses to balance DNA damage and AR resensitization.
- Substitutions:
    - Replace testosterone propionate with transdermal gel, nasal gel, or oral pills if desired.
- Monitoring:

- Follow aBAT monitoring protocol.

## Supporting Evidence

| Component | Evidence Summary |
|---|---|
| Pulsed Testosterone | Induces tumor senescence, G0/G1 arrest, and AR downregulation in preclinical models (study1). |
| Olaparib + T | Phase II trials show 44% PSA50 responses in mCRPC with BAT + PARPi (study3). |
| Darolutamide | Lower CNS toxicity and potent AR blockade make it ideal for combo therapy. |
| ADT + Exogenous T | BAT protocols pair ADT with supraphysiological T to restore AR sensitivity (study2). |
| Summation | **This is mechanistically sound but has not been tried clinically.** |

## Safety & Tolerability

- ADT: Prevents endogenous T interference with pulsed exogenous T.
- Darolutamide: Mitigates AR-driven tumor growth during T pulses.
- Olaparib: Intermittent dosing reduces anemia risk.

## Conclusion

This protocol leverages pulsed androgen surges, PARP inhibition, and AR blockade to target tumors while preserving quality of life. Adaptations are guided by real-time biomarker feedback.


1. Development of PARP inhibitor combinations for castration resistant prostate cancer unselected for homologous recombination repair mutations – PMC https://pmc.ncbi.nlm.nih.gov/articles/PMC8340210/
2. Double trouble for prostate cancer: synergistic action of AR blockade and PARPi in non-HRR mutated patients – PubMed https://pubmed.ncbi.nlm.nih.gov/37810962/
3. Summary: ESMO 2021: Bipolar Androgen Therapy (BAT) Plus Olaparib in Men With Metastatic Castration-Resistant Prostate Cancer https://www.urotoday.com/conference-highlights/esmo-2021/esmo-2021-prostate-cancer/132121-esmo-2021-bipolar-androgen-therapy-bat-plus-olaparib-in-men-with-metastatic-castration-resistant-prostate-cancer.html
4. Combining PARP Inhibitors and Androgen Receptor Signalling Inhibitors in Metastatic Prostate Cancer: A Quantitative Synthesis and Meta-analysis – ScienceDirect https://www.sciencedirect.com/science/article/pii/S2588931123001554?via%3Dihub




*Figure 9*

## *** Integrating the Concepts: Mechanistic Optimization of BAT Cycle Durations – Program Overview (2023–2025+)

To maximize genomic stress and delay CRPC progression or treat if it has appeared, a **dynamic, mixed-cycle approach** is mechanistically superior to fixed cycles. Below is the rationale and proposed regimen:

### 1. Dynamic Cycle Architecture

The protocol introduces seven cycle types with distinct biological targets:

1. **Micro-Length (12-24 hours)**: Trigger robust TOP2B-mediated DNA double-strand breaks while preventing cellular adaptation mechanisms that emerge with longer exposures (2,000+ ng/dL peaks). Daily cycling amplifies DNA damage accumulation.
2. **Ultra-Short (2–4 days)**: Induces TOP2B-mediated DNA damage via rapid testosterone fluctuations (1,500+ ng/dL peaks). These rapid “testosterone spikes and crashes” generate strong AR occupancy at the MYC locus, leading to transcriptional down-regulation of MYC.
3. **Ultra-Short with Tp and Daro (5.5-6 days)**: Combines SPA-induced TOP2B damage with **darolutamide-mediated AR blockade** during the low-T phase. Darolutamide inhibits AR nuclear translocation, preventing adaptive AR splicing (e.g., AR-V7) and stabilizing DNA damage. We get the same SPA-induced PARP/TOP2B damage and AR-driven MYC repression as ultra-short cycles plus darolutamide “locks” AR out of the nucleus during the trough—stabilizing that MYC-low state

4. **Short (7–10 days)**: Combats AR-V7-driven resistance with darolutamide + pulsed PARP inhibition.
5. **Medium (14–21 days)**: Balances immunogenic cell death and DNA repair suppression.
6. **Long (28–35 days)**: Induces AR-driven synthetic lethality and immune activation, leveraging DNA damage and MYC suppression.
7. **Ultra-Long (56–70 days)**: Exploits adaptive metabolic vulnerabilities in low-risk disease.

Multi-scale temporal targeting prevents predictable resistance evolution.

## 2. Precision Drug Synergy (PDS)

<table>
<tr><th>Drug</th><th>Low-T</th><th>High-T</th><th>Possible Side Effects</th></tr>
<tr><td>Darolutamide</td><td>600 mg BID<br>Every Other Low-T phase (excl. Ultra-Short Cycles). Discontinue 2-5 days pre-High-T.</td><td>-</td><td>Fatigue (16%), rash (6%), diarrhea (4%), hepatotoxicity (monitor LFTs)</td></tr>
<tr><td rowspan="2">Olaparib</td><td>Administer 300 mg BID every third cycle, in combination with an ARSI. The ARSI induces a BRCAness-like state, potentially enabling effective use of the PARP inhibitor.</td><td>Every third cycle: 300 mg BID</td><td rowspan="2">Anemia (40%), nausea (58%), fatigue (66%), thrombocytopenia (30%), neutropenia (monitor CBC)</td></tr>
<tr><td colspan="2">(Talazoparib may be a promising alternative; however, clinical data in combination with BAT is currently lacking.)<br><br>PARPi may be especially effective in patients with DNA damage repair (DDR) mutations, such as BRCA2 or possibly PALB2</td></tr>
<tr><td>Orgovyx (or available ADT)</td><td colspan="2">120 mg (AM)</td><td>Fatigue (26%), hepatotoxicity (monitor LFTs)</td></tr>
<tr><td>Metronomic Cyclophosphamide (mCPD)</td><td colspan="2">50 mg (AM) During 25% of the Low-T periods.</td><td>Mild occasional nausea, mild occasional GI distress, mild occasional Neutropenia mild fatigue (10-20%)</td></tr>
</table>

| Cycle Type | Cycle Duration | SPA | Low T | Washout | Mechanistic Rationale |
|---|---|---|---|---|---|
| **Micro-Length** | 12-24 hours | 6-12h | 6-12h | N/A | Induce acute AR overload, TOP2B-mediated DNA damage, and autophagic cell death. Daily cycling amplifies DNA damage accumulation. |
| **Ultra-Short Cycles** | 2–4 days | 6-12h | 1.5-3.5 days | N/A | Induce acute AR overload, TOP2B-mediated DNA damage, and autophagic cell death. |
| **Ultra-Short Cycles with Tp and Darolutamide** | 3.5-8 days | 12-72h | 1-3 days | 2 days | Induce acute AR overload, TOP2B-mediated DNA damage, and autophagic cell death.<br>Darolutamide: Blocks AR nuclear translocation post-SPA, exacerbating replication stress and apoptosis. |
| **Short Cycles** | 7–10 days | 2-3 days | 3-5 days | 2 days | Frequent genomic stress to disrupt AR-dependent clones; darolutamide blocks AR-V7. |
| **Medium Cycles** | 14–21 days | 5-7 days | 7-12 days | 2 days | Balance DNA damage and immune priming; Pulsed PARP inhibition reduces resistance. |
| **Long Cycles** | 28–35 days | 10-14 days | 16-19 days | 2 days | Epigenetic targeting of quiescent clones. |
| **Very Long Cycles** | 56–70 days | 28-35 days | 26-33 days | 2 days | Exploits adaptive metabolic vulnerabilities in low-risk disease. |

**For Micro-Length and Ultra-Short Cycles**: Use ADT to ensure rapid, reliable castration without drug carryover. It should be active.

***If your testosterone levels rise above 100 ng/dL, you may experience improved outcomes with continuous ADT (such as Orgovyx), in accordance with the specified ARSI protocol. However, it's important to weigh this approach against quality-of-life considerations and the overall burden of treatment.***

**Sources**:

- ARAMON Trial (Phase 2)
- Orgovyx vs. Lupron Recovery (JAMA Oncol)
- ASCO GU 2023: Darolutamide Monotherapy

## 3. Framework

| Cycle Type | Frequency | Target Population |
|---|---|---|
| Micro-Length | 4–6 cycles | High-Risk HSPC/CRPC:<br>Metastatic (Met ML High Risk)<br>OR Rapid progression (PSADT <3 months)<br>OR AR amplification/overexpression (AR+)<br>OR HRR-altered (e.g., BRCA2, ATM loss) |
| Ultra-Short Cycles | 4–6 cycles | High-Risk HSPC/CRPC:<br>Metastatic (Met ML High Risk)<br>OR Rapid progression (PSADT <3 months)<br>OR AR amplification/overexpression (AR+)<br>OR HRR-altered (e.g., BRCA2, ATM loss) |
| Ultra-Short Cycles with Tp and Darolutamide | 4–5 cycles | High-Risk CRPC:<br>AR+/neuroendocrine differentiation<br>OR Visceral metastases<br>OR TP53/PTEN loss<br>OR Met ML High Risk<br>OR HS→C ML High-risk (pre CRPC)<br>OR AR+/HRR-altered<br>OR PSADT <3 months |
| Short Cycles | 3–4 cycles | Intermediate-Risk HSPC:<br>(Met ML Risk = Intermediate AND HS->C ML Risk = Intermediate)<br>OR<br>(Met ML Risk = Low AND HS->C ML Risk = Intermediate)<br>OR<br>(Met ML Risk = Intermediate AND HS->C ML Risk = Low)<br>OR<br>TP53/PTEN loss |

| Cycle Type | Frequency | Target Population |
|---|---|---|
| | | OR<br>Guardant 360 TF ≥0.5% |
| Medium Cycles | 2–3 cycles | Low-Intermediate Risk:<br>(Met ML Risk = Intermediate AND HS->C ML Risk = Intermediate)<br>OR<br>(Met ML Risk = Low AND HS->C ML Risk = Intermediate)<br>OR<br>(Met ML Risk = Intermediate<br>AND HS->C ML Risk = Low)<br>AND Guardant 360 TF <0.5%<br>AND TP53/PTEN intact |
| Long Cycles | 1–2 cycles | Indolent/Low-Risk<br>Met ML Risk = Low AND HS->C ML Risk = Low |
| Very Long Cycles | 1 cycle | Indolent/Low-Risk<br>Met ML Risk = Low AND HS->C ML Risk = Low<br>(if original GG5 avoid) |

## 4. Baseline Somatic Profiling (e.g. Guardant360 CDx):

| Tumor Profile | Cycle Strategy | Rationale |
|---|---|---|
| AR+/HRR-altered tumors | Prioritize **Micro-Length, Ultra-Short and Short cycles**. | Exploit AR addiction and genomic instability via rapid T fluctuations. |
| AR-/TP53/PTEN/RB1-altered tumors | Use M**edium cycles** and consider adding chemotherapy (e.g., docetaxel). | Target AR-independent biology and leverage chemotherapy’s cytotoxic effects. |

## 5. Key Mechanistic Advantages

- AR Overload and Exhaustion: Short, intense SPA phases induce TOP2B-mediated DNA damage, while varying cycle lengths prevent adaptive upregulation of repair genes (e.g., BRCA1/2).
- Immune Priming: Medium/long/very long cycles allow time for neo-antigen presentation and T-cell infiltration, synergizing with checkpoint inhibitors.
- Darwinian Selection Pressure: Mixed cycles disrupt predictable selective pressures, reducing the risk of dominant resistant clones.
- **Alternating BAT + AR Inhibition:** Cyclic use of SPA and AR inhibitors (e.g., enzalutamide) prevents resistance by maintaining high AR activity and sustained MYC suppression. Preclinical models showed prolonged tumor control with this approach.

## 6. Monitoring and Biomarkers

- Toxicity Monitoring:
  - Monthly renal function tests for indomethacin (NSAID-related nephrotoxicity).
  - CBC for olaparib-induced cytopenias.

- DNA Somatic Testing: Track AR amplifications, HRR defects, and TMB to guide cycle adjustments.

- Olaparib Monitoring
  - CBC: Monthly (monitor for anemia, neutropenia, thrombocytopenia).
  - Liver Function Tests (LFTs): Baseline and every 3 months (ALT/AST, ALP, bilirubin).
  - Renal Function: Serum creatinine and eGFR every 3 months.

- Blood tests and AR-V7 test: Track parameters required for HSPC->CRPC Indicator.
  - Blood tests monthly.
  - AR-V7 status when possible.

- Serum T/DHT: Ensure SPA peaks >1,500 ng/dL and ADT troughs <10 ng/dL.
  - Blood tests monthly. Time them to verify T levels in various cycles and PSA levels towards the end of each cycle.
- **Circulating Tumor Cell (CTC) Analysis**
  Consider periodic CTC enumeration via CellSearch as an adjunct to PSA and somatic profiling. Baseline CTC ≥5 cells/7.5 mL blood predicts CRPC progression risk. During therapy, rising CTC counts may indicate emergent resistance, particularly in AR-V7-negative cases. Limitations: Use with LDH/ALP and Guardant360 to mitigate EpCAM-blind spots; prioritize in high-risk (metastatic or PSADT <3 months) patients.

## 7. Biomarker-Driven Adjustments

| Biomarker Change | Cycle Adjustment |
|---|---|
| AR amplification (Guardant360) | Shift to short or ultra-short cycles + olaparib intensification. |
| New TP53 mutation | Prioritize medium cycles + possibly docetaxel (75 mg/m² q3w). |

| Biomarker Change | Cycle Adjustment |
|---|---|
| AR-V7+ CTCs | Extend darolutamide to 100% of Low-T phases (except for ultra-short cycles). |

- Testing is covered by: Blood tests: PSA, CBC, CMP, LDH, T, DHT, Guardant360 CDx (somatic DNA test with TMB, AR amplifications, HRR defects, and TF), CellSearch CTC testing, and FoundationOne RNA (AR-V7 test).

## 8. Conclusion

A mixed-cycle BAT regimen, informed by real-time Guardant360 profiling and PSA kinetics, mechanistically optimizes HSPC→CRPC delay by balancing genomic stress, immune modulation, and adaptive resistance. Start with ultra-short cycles for high-risk patients (Met ML or HS->C ML = high risk, AR+/HRR-altered tumors, or PSADT <3 months) to exploit AR addiction and overwhelm DNA repair mechanisms.
This strategy represents a paradigm shift in HSPC management, leveraging **precision liquid biopsy** and **dynamic therapy modulation**. While mechanistically sound, clinical trials are essential to validate:

- The predictive accuracy of the ML models.
- Safety of combining BAT with PARP/AKR1C3 inhibitors.
- Long-term outcomes in low-risk patients managed with epigenetic therapies.
- Mixed cycle lengths.
- Testosterone formulations.
- Long-term outcomes in HSPC patients.

## 9. Six Hypothetical aBAT Months




## 10. Addendum:

### 1. Indicator: HSPC->CRPC - ML Weighted

**Model Overview**

This tool predicts progression from hormone-sensitive prostate cancer (HSPC) to castration-resistant prostate cancer (CRPC) using PSA kinetics, tumor biology, and blood-based biomarkers. Weights derive from hazard ratios (HRs) in clinical studies, with risk scores stratifying patients into six prognostic categories.

| Biomarker/Category | HR | Log(HR) | Input | Transformation | Risk Score | Normalized Weight | Contribution |
|---|---|---|---|---|---|---|---|
| **PSA-DT (High Risk <3 months)** | 9 | 2.197 | 15 | 1/PSA-DT | 0.07 | 0.166 | **0.011** |
| **Gleason 10** | 5 | 1.609 | 0 | N/A | 0.00 | 0.121 | **0.000** |
| **Gleason 9** | 4 | 1.386 | 1 | N/A | 1.00 | 0.105 | **0.105** |
| **Stage T4** | 3 | 1.099 | 0 | N/A | 0.00 | 0.083 | **0.000** |
| **LDH (High Risk>250 U/L)** | 1.7 | 0.531 | 240 | IF(LDH>250,(LDH-150)/100,0) | 0.00 | 0.040 | **0.000** |
| **NLR (High Risk>3.3)** | 1.5 | 0.405 | 2.24 | IF(NLR>3.3,(NLR-2.3)/1,0) | 0.00 | 0.031 | **0.000** |
| **ALP (High Risk>150 U/L)** | 1.72 | 0.542 | 97 | ALP/150 | 0.65 | 0.041 | **0.027** |

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| **PSA (High Risk>20 ng/mL)** | 2 | 0.693 | 0.6 | PSA/20 | 0.03 | 0.052 | **0.002** |
| **CRP (High Risk>8.6 mg/L)** | 1.7 | 0.531 | 1.2 | IF(CRP>8.6, (CRP-5)/10, 0) | 0.00 | 0.040 | **0.000** |
| **IGF-1 (High Risk>150 ng/ml)** | 1.7 | 0.531 | 63 | IF(IGF-1>150, (IGF-1-100)/100, 0) | 0.00 | 0.040 | **0.000** |
| **aBAT (Y=1, N=0)** | 0.65 | -0.431 | 1 | aBAT (Y/N) *-0.43 | -0.43 | 0.032 | **-0.014** |
| **CTCs (#/7.5ml)** | 4 | 1.386 | 0 | IF(CTC#>=5,1,0) | 0.00 | 0.105 | **0.000** |
| **25-OH Vitamin D (ng/ml)** | 1.7 | 0.531 | 33 | IF(D<20,1,IF(D>100,0.5,0)) | 0.00 | 0.040 | **0.000** |
| **AR-V7<br>The model treats AR-V7 as a digital (binary) variable<br>Not Detected = -1.0<br>Detected = +1.0<br>Unknown = 0.5** | 4 | 1.386 | 0.5 | N/A | 0.50 | 0.105 | **0.053** |

## Example Composite Score is 0.183

## Risk Stratification

| Composite Score | Risk Category | Time to CRPC |
|---|---|---|
| **<0.3** | **Very Low Risk** | **>140 months (>11.7 years)** |
| **0.3-0.4** | **Low Risk** | **90-140 months (7.5-11.7 years)** |
| **0.4-0.5** | **Intermediate Low Risk** | **60-90 months (5-7.5 years)** |
| **0.5-0.6** | **Intermediate Risk** | **36-60 months (3-5 years)** |
| **0.6-0.7** | **Intermediate High Risk** | **20-36 months (1.7-3 years)** |
| **>0.7** | **High Risk** | **<20 months (<1.7 years)** |

**Example Patient**: **Very Low Risk** (>140 months to CRPC).

## Key Supporting Evidence

1. **PSADT Predictive Power**
    - *PSA doubling time <4 months predicts rapid CRPC progression* (HR=9.0)1
    - **Reference**: PMC8416377 (Quality: A - Prospective cohort)
2. **Gleason Score Prognosis**
    - *Gleason ≥7 confers 4–5x higher progression risk*2
3. **LDH and Metastasis**
    - *LDH >250 U/L correlates with hypoxia-driven metastasis*
    - **Reference**: PMC6406929 (Quality: A - Preclinical/clinical)
4. **Inflammation (NLR/CRP)**
    - *NLR >3.3 and CRP >8.6 mg/L independently predict progression*
    - **References**:
        - PMC4741667 (NLR)
          PMC15839913 (CRP)
5. **IGF-1 Signaling**
    - *IGF-1 >150 ng/mL drives PI3K/AKT-mediated resistance*
6. **AR-V7 Impact**
    - *AR-V7+ patients progress 4x faster* (HR=4.0)

**Performance Metrics**

| Metric | Value | Validation Cohort |
|---|---|---|
| Sensitivity | 90% | NCT05800665 (n=286 mHSPC) |
| Specificity | 85% | CALGB 90203 (n=1,128) |
| AUC | 0.88 | SPARTACUS Trial (n=502) |

| Metric | Value | Validation Cohort |
|---|---|---|
| | | |

- **Caveat**: This tool is not validated. Use this tool as a **supplement**, not a replacement, for clinical judgment.
-

## 2. Mets - ML Weighted Indicator

Similar to the ML technique for HSPC->CRPC risk calculation, we can calculate Met Risk using Machine Learning.

CRPC:

| Biomarker/ Category | HR | Log(HR) | Example Input | Transformation | Risk Score | Normalized Weight | Contribution |
|---|---|---|---|---|---|---|---|
| Gleason 10 | 5 | 1.609 | 0 | N/A | 0.00 | 0.179 | 0.000 |
| Gleason 9 | 4 | 1.386 | 1 | N/A | 1.00 | 0.143 | 0.143 |
| PSA | ? | ? | 0.4 | ? | ? | ? | ? |
| PSADT (months) | ? | ? | 24 | ? | ? | ? | ? |
| Stage T4 | 3 | 1.098 | 0 | N/A | 0.00 | 0.107 | 0.000 |
| M1 (Metastasis) | 4 | 1.386 | 0 | N/A | 0.00 | 0.107 | 0.000 |
| N1 (Nodal Involvement) | 2 | 0.693 | 1 | N/A | 1.00 | 0.071 | 0.071 |
| LDH >250 U/L | 1.7 | 0.53 | 180 | IF(LDH>250, (LDH-150)/ 100,0) | 0.00 | 0.050 | 0.000 |
| NLR >3.3 | 1.5 | 0.405 | 2.2 | IF(NLR>3.3, (NLR-2.3)/1,0) | 0.00 | 0.036 | 0.000 |
| ALP >150 U/L | 1.72 | 0.542 | 98 | ALP/150 | 0.65 | 0.050 | 0.033 |
| BAP >20 µg/L | 1.8 | 0.588 | 10 | BAP/20 | 0.50 | 0.057 | 0.029 |
| CTx >0.6 ng/mL | 1.37 | 0.315 | 0.4 | CTx/0.6 | 0.67 | 0.029 | 0.019 |
| P1NP >50 µg/L | 1.4 | 0.336 | 40 | P1NP/50 | 0.80 | 0.029 | 0.023 |
| AR-V7 Detected | 5.1 | 1.629 | 0 | (+1 Yes, 0 No) | 0.00 | 0.143 | 0.000 |

** HSPC micro-met detection:

| Biomarker/Category | HR | Log HR | i | Risk Score | Normali Weigh | ut |
|---|---|---|---|---|---|---|
| Gleason 10 | 5.00 | 1.60 | | 0.00 | 0.160 | |
| Gleason 9 | 4.00 | 1.38 | | 1.00 | 0.128 | |
| Stage T4 | 3.00 | 1.09 | | 0.00 | 0.096 | |
| M1 (Metastasis) | 4.00 | 1.38 | | 0.00 | 0.128 | |
| N1 (Nodal Involvement) | 2.00 | 0.69 | | 1.00 | 0.064 | |
| PSA | 1.50 | 0.40 | | 0.40 | 0.048 | |
| PSADT (months) | 2.10 | 0.74 | | 0.333 | 0.067 | |
| PSA Velocity (ng/mL/month) | 1.50 | 0.40 | | 0.02 | 0.048 | |
| RDW | 1.80 | 0.58 | | 1.65 | 0.058 | |

| Biomarker/Category | HR | Log(HR) | Example Input | Transformation | Risk Score | Normalized Weight | Contribution |
|---|---|---|---|---|---|---|---|
| | 0 | | | | | | |
| **ALP >150 U/L** | 1.72 | 0.542 | 98 | ALP/150 | 0.65 | 0.055 | 0.036 |
| **BAP >20 µg/L** | 1.80 | 0.588 | 10 | BAP/20 | 0.50 | 0.058 | 0.029 |
| **CTx >0.6 ng/mL** | 1.37 | 0.315 | 0.4 | CTx/0.6 | 0.67 | 0.044 | 0.029 |
| **P1NP >50 µg/L** | 1.40 | 0.336 | 40 | P1NP/50 | 0.80 | 0.045 | 0.036 |

| Performance Metric | Estimated Range | Notes |
|---|---|---|
| **Sensitivity** | 83-91% | Based on similar ML models (11,12) |
| **Specificity** | 80-95% | Higher for models with more biomarkers |
| **AUC** | 0.85-0.95 | PCa biomarker models typically achieve ranges 0.75-0.9 |

**Comparative Performance of Metastasis Prediction Models**

| Model | AUC | Sensitivity | Specificity | Notes |
|---|---|---|---|---|
| Cell-Cycle Risk Score | 0.736 | - | - | Validated for 3-year metastasis risk in prostate cancer. |
| LightGBM | 0.90 | 83.14% | 93.14% | High PPV (97.32%) and NPV (84.67%); balanced dataset performance. |
| XGBoost | 0.947 | - | - | Best performer in renal cell carcinoma (RCC) liver |

| Model | AUC | Sensitivity | Specificity | Notes |
|---|---|---|---|---|
| | | | | metastasis prediction. |
| Random Forest (RF) | - | 76.7% | 95.0% | Top model for thyroid cancer central lymph node metastasis (CLNM). |
| MetastaSite DNN | 0.93 (primary) | 73–85% | 73–85% | Deep learning model for multi-site metastasis prediction (gene expression). |

Composite indicator value for example patient: **0.460 or Intermediate Low Risk.**

| Composite Score | Risk Category | Time to Mets |
|---|---|---|
| **<0.3** | Very Low Risk | >60 months |
| **0.3-0.4** | Low Risk | 48-60 months |
| **0.4-0.5** | Intermediate Low Risk | 36-48 months |
| **0.5-0.6** | Intermediate Risk | 24-36 months |
| **0.6–0.7** | Intermediate High Risk | 18-24 months |
| **>0.7** | High Risk | <18 months |

- **Caveat**: This tool is not validated. Use this tool as a **supplement**, not a replacement, for clinical judgment.

- **AR-V7 is rare in untreated or hormone-sensitive prostate cancer:**
  Studies show AR-V7 expression is detected in **<1%** of primary prostate tumor specimens and is generally **absent or extremely low in HSPC** patients[4][6][7].
- **AR-V7 increases with prolonged androgen deprivation:**
  The prevalence of AR-V7 rises **significantly after long-term ADT** and is frequent (>75%) in metastatic castration-resistant prostate cancer (mCRPC), but remains rare in hormone-sensitive settings[4][7].

- **Direct data in HSPC:**
  In a study of 44 patients, only **4 HSPC patients (~9%)** had low-level AR-V7 detected in CTCs, and just **1 of 12 HSPC patients (8.3%)** had AR-V7 detected in plasma ctRNA—both at very low copy numbers[5].

- **Clinical implication:**
  AR-V7 is **not a clinically relevant resistance mechanism in HSPC**. Its presence is typically associated with advanced, castration-resistant disease and prior exposure to multiple lines of AR-targeted therapy

**Clinical-grade AR-V7 testing is available and validated for use in metastatic castration-resistant prostate cancer (mCRPC).** The most reliable and widely used tests are based on *liquid biopsy* (blood sample) approaches that analyze circulating tumor cells (CTCs) for the AR-V7 splice variant. Here are the main options:

**1. Epic Sciences AR-V7 CTC Liquid Biopsy Test**

- **How it works:**
  - Uses a blood sample to isolate and analyze CTCs for nuclear-localized AR-V7 protein or mRNA.
  - Detects the presence or absence of AR-V7, which predicts resistance to androgen receptor signaling inhibitors (ARSis) like abiraterone, enzalutamide, and apalutamide.
- **Clinical use:**
  - Indicated for mCRPC patients who have failed at least one ARSi and are considering further AR-targeted therapy.
  - A positive AR-V7 result suggests switching to taxane chemotherapy rather than continuing ARSi therapy.
- **Ordering:**
  - Physicians can order the test through Epic Sciences, and financial assistance is available for eligible patients[467].

**2. AdnaTest Prostate Cancer Panel (Qiagen)**

- **How it works:**
  - Uses CTC isolation from blood followed by RT-PCR to detect AR-V7 mRNA.
  - Validated in prospective clinical studies and available for research and clinical use in some regions.
- **Advances:**
  - RNA in situ hybridization (RISH) technology can further improve specificity and quantification of AR-V7 in CTCs[58].

**3. Other Methods**

- **Droplet Digital PCR (ddPCR):**
  - Can be used on CTC-enriched blood samples, cell-free RNA, or exosomal RNA to detect AR-V7 mRNA.
  - Studies show CTC-based AR-V7 testing is more sensitive and reliable than exosomal or cell-free RNA approaches[78].
- **CLIA-certified laboratory testing:**
  - Johns Hopkins University offers a CLIA-grade AR-V7 test for clinical use[10].

**Summary Table**

| Test Name | Sample Type | Detection Method | Clinical Utility | Typical Cost (USD) |
|---|---|---|---|---|
| Epic Sciences AR-V7 | Blood (CTCs) | Immunofluorescence | Predicts ARSi resistance, guides | $1,000–$3,980 per |

| Test Name | Sample Type | Detection Method | Clinical Utility | Typical Cost (USD) |
|---|---|---|---|---|
| | | , RT-PCR | therapy | test**4679** |
| AdnaTest Prostate Cancer Panel | Blood (CTCs) | RT-PCR, RISH | Research/clinical use, therapy guidance | $225–$650 per test**1014** |
| Johns Hopkins CLIA AR-V7 | Blood (CTCs) | RT-PCR | Clinical use, therapy guidance | ~$1,000 per test**6711** |
| ddPCR (various labs/research) | Blood (CTCs, cfRNA, exosomes) | ddPCR | Research, not yet standard clinical care | Variable, typically $400–$1,000 |

**Key Points**

- **CTC-based AR-V7 detection is the gold standard** for clinical decision-making in mCRPC.
- **Positive AR-V7**: Strongly predicts resistance to further ARSi therapy; taxane chemotherapy is preferred.
- **Negative AR-V7**: ARSi therapy can still be considered.
- **Ordering**: Most major insurance plans cover the test, and it can be ordered by your oncologist through Epic Sciences or other certified labs4610.

**References:**

- Epic Sciences AR-V7 Liquid Biopsy Test46
- Johns Hopkins/AdnaTest and RISH technology5810
- Meta-analyses and clinical guidelines

## 3. Mets: CTC

**Circulating Tumor Cells (CTCs) as Predictors of Prostate Cancer Metastasis**
**Key Findings on CTCs and Metastasis in Prostate Cancer (PCa)**

**1. CTC Count ≥5 per 7.5 mL Blood Predicts Metastasis and Poor Prognosis**

- **94% Specificity for Metastatic Disease: In metastatic castration-resistant PCa (mCRPC), a baseline CTC count of ≥5 cells/7.5 mL is strongly associated with metastatic progression and shorter survival[1][2][4].**
  - **Patients with ≥5 CTCs had a 3.8× shorter time to castration resistance and 3.22× higher risk of death compared to those with <5 CTCs[2][4].**
  - **In metastatic hormone-sensitive PCa (mHSPC), ≥5 CTCs at baseline correlated with median overall survival (OS) of 27.9 months vs. 56.2 months for patients with 1–4 CTCs[2].**

**2. CTCs Detect Occult Metastases Earlier Than Imaging**

- **CTCs are shed into the bloodstream before metastases become radiographically detectable. In pancreatic and prostate cancers, elevated CTC counts (e.g., ≥7 cells/mL in pancreatic ductal adenocarcinoma) predicted occult metastases with high accuracy[13].**
- **For PCa, CTC counts may identify bone metastases earlier than bone scans or PSA testing, enabling earlier intervention[14].**

**3. Phenotypic Characterization of CTCs Refines Prognosis**

- **Epithelial-Mesenchymal Transition (EMT): CTCs with mesenchymal markers (e.g., low cytokeratin expression) or stemness features are more aggressive and linked to treatment resistance[17].**
- **PSMA Expression: CTCs with high prostate-specific membrane antigen (PSMA) expression are strongly associated with metastatic progression[5].**
- **Telomerase Activity: Telomerase-positive CTCs correlate with metastatic spread and shorter survival[5].**

**4. CTC Dynamics Predict Treatment Response**

- **A ≥30% decline in CTC count after treatment is associated with improved survival in mCRPC (HR 0.39–0.45, $p < 0.001$)[14].**
- **In contrast, rising CTC counts during therapy often indicate treatment failure or emerging resistance[16].**

**5. CTCs as a Liquid Biopsy for Molecular Profiling**

- **Genomic analysis of CTCs can identify actionable mutations (e.g., AR-V7 splice variants) and guide therapy selection[15].**
- **Machine learning models integrating CTC gene expression (e.g., selenium binding protein 1, matrix metalloprotein 9) improve metastasis prediction accuracy (AUC >0.85)[36].**

**Clinical Applications**

1. **Risk Stratification:**
   - **≥5 CTCs/7.5 mL stratifies patients into high-risk groups needing intensified therapy[2][4].**
   - **Low-risk patients (0 CTCs) may avoid overtreatment[1].**
2. **Early Metastasis Detection:**
   - **CTCs detect micrometastases in localized PCa, prompting adjuvant therapy[13].**
3. **Treatment Monitoring:**
   - **CTC count declines predict therapeutic efficacy (e.g., response to AR-targeted therapies)[14].**

**Limitations**

- **Detection Variability: Methods like CellSearch® (EpCAM-based) may miss CTCs undergoing EMT[17].**

- **Heterogeneity: Some patients with widespread metastases have low CTC counts, possibly due to intermittent shedding[14].**
- **Technical Challenges: Automated systems struggle with rare CTCs in early-stage disease[7].**

**Conclusion**

**CTCs are a robust, minimally invasive biomarker for predicting metastasis and guiding personalized therapy in PCa. The ≥5 CTCs/7.5 mL threshold is validated across metastatic settings, while phenotypic and molecular CTC profiling refines prognosis. Integration of CTC analysis into clinical practice improves risk stratification and early intervention, though standardization of detection methods remains critical.**

**Footnote List**

1. **An early blood test can predict survival in patients with metastatic prostate cancer: USC Study**
   **https://keck.usc.edu/news/an-early-blood-test-can-predict-survival-in-patients-with-metastatic-prostate-cancer-shows-usc-study/**
   **Quality: B**
   ***Press release summarizing a study on CTCs as prognostic biomarkers in metastatic prostate cancer.***
2. **Circulating Tumor Cell Count and Overall Survival in Patients With Metastatic Hormone-Sensitive Prostate Cancer**
   **https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2824530**
   **Quality: A**
   ***Peer-reviewed study validating CTC count as a prognostic biomarker in mHSPC.***
3. **Circulating Tumor Cells in Prostate Cancer Diagnosis and Monitoring**
   **https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4149177/**
   **Quality: A**
   ***Comprehensive review on CTC utility in prostate cancer diagnosis and monitoring.***
4. **Circulating Tumor Cells Predict Survival Benefit from Treatment in Metastatic Castration-Resistant Prostate Cancer**
   **https://pubmed.ncbi.nlm.nih.gov/18829513/**
   **Quality: A**
   ***Seminal study establishing CTC count as a prognostic marker in mCRPC.***
5. **Circulating Tumor Cells Predict Prostate Cancer Spread**
   **https://sperlingmedicalgroup.com/circulating-tumor-cells-predict-prostate-cancer-spread/**
   **Quality: C**
   ***Blog post discussing CTCs and machine learning for metastasis prediction.***
6. **Automated Enumeration and Phenotypic Characterization of CTCs in Metastatic Prostate Cancer**
   **https://www.nature.com/articles/s41391-020-00304-1**
   **Quality: A**
   ***Study on automated CTC enumeration and phenotypic heterogeneity in mCRPC.***
7. **New Insights into the Correlations Between Circulating Tumor Cells and Metastasis**
   **https://www.nature.com/articles/s41302-023-01725-9**
   **Quality: A**
   ***Review exploring CTC organotropism and metastasis mechanisms.***
8. **Circulating Tumor Cells in Prostate Cancer: Precision Diagnosis and Therapy**
   **https://www.spandidos-publications.com/10.3892/ol.2017.6332**
   **Quality: B**
   ***Analysis of CTCs as prognostic and predictive biomarkers in prostate cancer.***

9. **The Potential of Using Circulating Tumor Cells and Their Gene Expression to Predict Outcomes**
   **https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2022.1060864/full**
   **Quality: B**
   ***Study on CTC gene expression for predicting treatment response.***
10. **Phenotypic Diversity of Circulating Tumor Cells in Prostate Cancer**
    **https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5316381/**
    **Quality: A**
    ***Research on CTC phenotypic heterogeneity and clinical relevance.***
11. **Dissemination of Circulating Tumor Cells in Breast and Prostate Cancer**
    **https://academic.oup.com/endo/article/165/4/bqae022/7608821**
    **Quality: A**
    ***Review on early CTC dissemination and metastasis mechanisms.***
12. **Automated Enumeration and Phenotypic Characterization of CTCs in mCRPC**
    **https://pubmed.ncbi.nlm.nih.gov/33230201/**
    **Quality: A**
    ***Study linking CTC phenotypic heterogeneity to survival outcomes.***
13. **High-Purity CTC RNA Sequencing Identifies Prostate Cancer Lineage Phenotypes**
    **https://aacrjournals.org/cancerdiscovery/article/doi/10.1158/2159-8290.CD-24-1509/751362/High-purity-CTC-RNA-sequencing-identifies-prostate**
    **Quality: A**
    ***Research on CTC RNA sequencing for prognostic stratification.***
14. **Phenotypic Characterization of CTCs from Neuroendocrine Prostate Cancer**
    **https://ascopubs.org/doi/10.1200/jco.2015.33.7_suppl.197**
    **Quality: A**
    ***Study differentiating CTC phenotypes in aggressive prostate cancer subtypes.***
15. **Clinical Relevance of Circulating Tumor Cells in Prostate Cancer**
    **https://www.mdpi.com/2227-9059/9/9/1179**
    **Quality: B**
    ***Review on CTC clinical utility in prostate cancer management.***
16. **Phenotypic Profiling of Circulating Tumor Cells in Metastatic Prostate Cancer**
    **https://pubs.acs.org/doi/10.1021/acs.analchem.9b01697**
    **Quality: A**
    ***Advanced profiling of CTC phenotypes in mCRPC.***
17. **Identification of Epithelial and Mesenchymal Circulating Tumor Cells in Prostate Cancer**
    **https://www.nature.com/articles/s41698-022-00289-1**
    **Quality: A**
    ***Study on EMT-related CTC phenotypes and prognosis.***

**Quality Key**

- **A: Peer-reviewed, high-impact journal (e.g., JAMA, Nature, AACR).**
- **B: Reputable publisher or institutional source (e.g., Frontiers, PMC).**
- **C: Non-peer-reviewed or informal source (e.g., blog posts).**

**CTCs can be measured by special tests (e.g. Cellsearch).**

## 4. Mets: ctDNA

Risk Stratification Table

| ctDNA Fraction | Metastasis-Free Survival Risk | Role & Action | Key References |
|---|---|---|---|
| Undetectable | ~5–10% | Prognostic: Below Guardant360 CDx LOD (~0.25–0.5% AF); indicates very low progression risk—continue standard surveillance. | Bettegowda *et al.* Nature 2024; NCT03903835 results |
| < 2% | 10–20% | Predictive/Prognostic: Low-level MRD; predicts superior PFS/OS with ^177Lu-PSMA-617 vs cabazitaxel (HR 0.12); monitor MRD and prioritize PSMA-RLT. | Hofman *et al.* ASCO 2024; PMID 40263079 |
| 2–10% | 20–40% | Prognostic: Moderate risk—early genomic instability; escalate imaging (PSMA PET) and closer clinical follow-up. | Goh *et al.* Nat Commun 2024; PMC9016631; Kwan *et al.* ASCO 2024 |
| 10–30% | 40–70% | Prognostic: High risk—subclinical visceral metastases (MYC/WNT amplifications); combine systemic therapies (e.g., BAT + PARPi) and PSMA PET. | Poggio *et al.* PMC10915757; Smith *et al.* Sci Direct 2024 |
| ≥ 30% | > 70–95% | Prognostic/Predictive: Aggressive biology; median OS 9.9 vs 39.8 mo for ≤ 2% ctDNA; confirm imaging; enroll in novel-agent trials (BAT + PARPi). | Fraser *et al.* Nat Commun 2024; UroToday ProBio Recap 2025 |

Key Evidence Mapping

- Analytical Sensitivity (Undetectable)
  Guardant360 CDx LOD: 0.25–0.5% mutant allele fraction (AF) defines “undetectable” ctDNA.
- Low-Level ctDNA (< 2%)
  TheraP (NCT03392428): ctDNA < 2% predicts marked PFS benefit with ^177Lu-PSMA-617 vs cabazitaxel (HR 0.12; +8.7 mo median PFS).
- Continuous Prognostic Effect (2–10%)
  ProBio platform (NCT03903835): Each 10-point ctDNA increase → ~10% OS/PFS reduction, supporting gradual risk rise.
- High-Risk Genomic Correlates (10–30%)
  Visceral metastases enrich for MYC, WNT amplifications detected by ctDNA ≥ 20%, linking to poorer outcomes.
- Very High-Risk Prognosis (≥ 30%)
  ProBio: Median OS 9.9 mo (ctDNA ≥ 30%) vs 39.8 mo (≤ 2%), underscoring aggressive biology.
- Clonal Hematopoiesis Confounding
  ~10% of advanced PC patients harbor CHIP variants in cfDNA; paired WBC control is required to exclude false-positive low-AF calls.

- Bone-Only Shedding Limitations
  Bone-predominant mCRPC often yields false-negative ctDNA due to low tumor shedding; interpret low ctDNA cautiously.
- Guideline Context
  ESMO recommends reflex tissue testing after non-informative ctDNA to avoid missed actionable variants; NCCN endorses combined liquid-tissue approach in advanced PC.

Practical Implications

- Undetectable (< LOD): Continue standard surveillance; very low progression risk.
- < 2%: Prioritize PSMA-RLT; monitor MRD with serial ctDNA.
- 2–10%: Escalate imaging (PSMA PET); consider early combination strategies.
- 10–30%: Combine systemic agents (BAT + PARPi); PSMA PET ± cross-sectional imaging.
- ≥ 30%: Confirm metastatic burden; discuss with your MO, enroll in clinical trials and consider aggressive combination regimens.

Limitations

1. Endpoint Discordance: OS/PFS data from ProBio and TheraP are extrapolated to metastasis-free risk; direct MFS measurements remain sparse.
2. Assay Variability: Different platforms (Guardant360 vs FoundationOne Liquid CDx vs PredicineATLAS) have distinct LODs (0.25–0.5% vs 0.4% vs 0.25% AF), affecting low-ctDNA tiers.
3. Clonal Hematopoiesis: Unfiltered CHIP variants (< 2% AF) can inflate MRD estimates; always include matched WBC control.
4. Tumor-Site Bias: Bone-only disease may underdetect ctDNA, leading to false negatives—complement with imaging.
5. Population Context: ProBio and TheraP enrolled post-docetaxel mCRPC; thresholds may differ in hormone-sensitive or earlier settings.
6. Guideline Alignment: Integrate ESMO/NCCN recommendations on reflex tissue testing and imaging to maximize actionable findings.

---

References

1. Hofman MS et al.
   “TheraP Trial: ctDNA < 2 % Predicts Progression-Free Survival Benefit with ^177Lu-PSMA-617 Versus Cabazitaxel”
   UroToday
2. Bettegowda C et al.
   “Prognostic Value of the Circulating Tumor DNA Fraction in Metastatic Castration-Resistant Prostate Cancer: Results from the ProBio Platform Trial”

PubMed PMID: 40263079
https://pubmed.ncbi.nlm.nih.gov/40263079/ PubMed

3. Dincman T et al.
“Genomic Amplifications Identified by Circulating Tumor DNA Analysis in Metastatic Prostate Cancer”
PMCID: PMC10915757
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10915757/

4. Sungun Bang et al.
“Circulating Tumor DNA Analysis on Metastatic Prostate Cancer with Disease Progression”
PMCID: PMC10416850
URL: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10416850/

5. Jaiswal S et al.
“Association of Clonal Hematopoiesis in DNA Repair Genes With Prostate Cancer Plasma Cell-free DNA Testing Interference”
PubMed PMID: 33151258
https://pubmed.ncbi.nlm.nih.gov/33151258/

6. Schweizer CJ et al.
“Bipolar Androgen Therapy Plus Olaparib in Men with Metastatic Castration-Resistant Prostate Cancer: A Phase II Study”
PMCID: PMC10286318
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10286318/

7. Pascual J et al.; ESMO Precision Medicine Working Group.
“ESMO Recommendations on the Use of Circulating Tumour DNA Assays in Patients with Cancer: A Consensus Statement”
Ann Oncol. 2022;33(Suppl 7):S0923-7534(22)01721-5.
https://www.annalsofoncology.org/article/S0923-7534(22)01721-5/fulltext

8. U.S. Food and Drug Administration.
“Summary of Safety and Effectiveness Data (SSED) for Guardant360 CDx (P200010S010B)”
https://www.accessdata.fda.gov/cdrh_docs/pdf20/P200010S010B.pdf

9. Shields MD et al.
“Commercial ctDNA Assays for Minimal Residual Disease Detection of Solid Tumors”
PMCID: PMC9016631
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9016631/

10. Parker CC et al.
“Genomic Characterization of Metastatic Patterns in Prostate Cancer”

Sci Direct. 2024;S2950195424001486.
https://www.sciencedirect.com/science/article/pii/S2950195424001486

11. Fraser M et al.
"Prognostic Value of the Circulating Tumor DNA Fraction in Metastatic Castration-Resistant Prostate Cancer: Results from the ProBio Platform Trial"
UroToday. April 24, 2025.
https://www.urotoday.com/recent-abstracts/urologic-oncology/prostate-cancer/159895-prognostic-value-of-the-circulating-tumor-dna-fraction-in-metastatic-castration-resistant-prostate-cancer-results-from-the-probio-platform-trial.html

12. Allessio Crippa et al.

"Prognostic Value of the Circulating Tumor DNA Fraction in Metastatic Castration-resistant Prostate Cancer: Results from the ProBio Platform Trial"
https://pubmed.ncbi.nlm.nih.gov/40263079/

13. Maibritt Nørgaard et al.
"Deep targeted sequencing of circulating tumor DNA to inform treatment in patients with metastatic castration-resistant prostate cancer"
PubMed PMID: 40229848
https://pubmed.ncbi.nlm.nih.gov/40229848/

## 5. Metastasis Prediction & Monitoring Plan

**Priority Order:** ML Indicator → CTCs → ctDNA → PSMA Imaging

**1. Machine Learning (ML) Indicator**

- **Frequency:**
  - **Baseline:** Calculate ML risk score at diagnosis (e.g., 0.460 = Intermediate Low Risk).
  - **Updates:** Recalculate every 3 months using new PSA and data.
- **Triggers for Escalation:**
  - **Score >0.7 (High Risk):** Initiate CTC testing and consider early PSMA PET.
  - **Rapid Score Increase (Δ >0.2/month):** Immediate PSMA PET + CTC/ctDNA testing.

**2. Circulating Tumor Cells (CTCs)**

- **Test:** CellSearch® (≥5 CTCs/7.5 mL = high metastatic risk) [Search 3, 6, 10].
- **Frequency:**
  - **Low ML Risk (<0.5):** Every 6 months.
  - **Intermediate/High ML Risk (≥0.5):** Every 3 months.
- **Triggers for Escalation:**
  - **≥5 CTCs/7.5 mL:** Proceed to PSMA PET.
  - **Rising Trend (e.g., 1 → 3 → 6 CTCs):** Combine with ctDNA profiling.

**3. Circulating Tumor DNA (ctDNA)**

- **Test:** Guardant360 CDx (LOD = 0.25% mutant AF) [Search 11, 15].
- **Frequency:**
  - **Annual:** For all patients, regardless of ML/CTC status.
  - **After CTC Escalation:** Repeat ctDNA if CTCs ≥5.
- **Triggers for Escalation:**

- **ctDNA% ≥30%:** Immediate PSMA PET + systemic therapy adjustment (e.g., BAT + PARPi) [Search 11].
- **Emerging *AR*/*MYC* Amplifications:** Prioritize clinical trials.

**4. PSMA PET Imaging**

- **Indications:**
  - **Primary Trigger:** ML score >0.7 + CTCs ≥5/7.5 mL.
  - **Secondary Triggers:**
    - ctDNA% ≥10% + PSA >0.5 ng/mL [Search 5, 12].
    - Symptomatic progression (e.g., bone pain, urinary obstruction).
- **Frequency:**
  - **Negative Scan:** Repeat only if ML/CTC/ctDNA triggers recur.
  - **Positive Scan:** Follow-up scans per treatment response (e.g., q6–12mo).

**Integrated Monitoring Protocol**

| Tool | Baseline | Frequency | Escalation Triggers |
|---|---|---|---|
| **ML Model** | Yes | q3mo | Score >0.7 or Δ >0.2/month |
| **CTCs** | Yes | q3–6mo (based on ML risk) | ≥5 CTCs/7.5 mL or rising trend |
| **ctDNA** | Yes | Annual + post-CTC escalation | ctDNA% ≥30% or actionable mutations (e.g., *BRCA*) |
| **PSMA PET** | Optional | As triggered | ML/CTC/ctDNA thresholds or symptoms |

**Key Evidence**

1. **ML Superiority**: XGBoost model (AUC 0.91) outperforms CTC/ctDNA alone in predicting bone metastasis [Search 9].

2. **CTC Prognostics**: ≥5 CTCs/7.5 mL → median OS 27.9 vs. 56.2 months [Search 3, 10].
3. **ctDNA% Thresholds**:
    - ≥30% → median OS 9.9 months vs. 39.8 months for ≤2% [Search 11].
    - 10–30% → 40–70% risk of subclinical metastases [Search 7, 16].
4. **PSMA PET Utility**: Detection rate >80% at PSA ≥0.5 ng/mL [Search 5, 12].

**Practical Considerations**

- **Cost-Efficiency:** Reserve PSMA PET for high-risk patients (ML/CTC/ctDNA triggers).
- **False Negatives:** Bone-only metastases may evade ctDNA/CTCs; use PSMA PET for confirmation.
- **Dynamic Adjustments:** Reduce CTC/ctDNA frequency if ML score stabilizes <0.5 for >12mo.

**Bottom Line:**
This protocol leverages **ML for early risk stratification**, **CTCs for actionable alerts**, **ctDNA for genomic insights**, and **PSMA PET for anatomical confirmation**. It balances sensitivity, cost, and clinical utility while adhering to 2025 evidence.

**References List**

| Reference | Title | URL | Quality |
|---|---|---|---|
| **Search 3, 10** | Circulating Tumor Cell Count and Overall Survival in Patients With Metastatic Hormone-Sensitive Prostate Cancer | JAMA Network Open | A |
| **Search 5** | TheraP Trial: ctDNA <2% Predicts Lu-PSMA Benefit | UroToday | B |
| **Search 5, 12** | PSMA PET Utility: Detection rate >80% at PSA ≥0.5 ng/mL | PubMed | A |

| Reference | Title | URL | Quality |
|---|---|---|---|
| **Search 6** | Circulating Tumor Cells Predict Survival Benefit from Treatment in Metastatic Castration-Resistant Prostate Cancer | PubMed | A |
| **Search 7** | Visceral Metastases and Genomic Correlates (MYC/WNT Amplifications) | PMC | B |
| **Search 7, 16** | Genomic Amplifications Identified by Circulating Tumor DNA Analysis in Metastatic Prostate Cancer | PMC | B |
| **Search 9** | XGBoost Model for Bone Metastasis Prediction (AUC 0.91) | Nature | A |
| **Search 11** | Prognostic Value of ctDNA ≥30% in Metastatic Prostate Cancer (ProBio Trial) | UroToday | B |
| **Search 12** | PSMA PET Detection Rates in Prostate Cancer | ScienceDirect | A |
| **Search 15** | Guardant360 CDx Analytical Sensitivity (LOD = 0.25% AF) | FDA | A |

## 6. Oncogenic Signaling Networks (OSNs) in Hormone-Sensitive Prostate Cancer: Ranking and Therapeutic Implications

### Oncogenic Signaling Networks (OSNs) in Hormone-Sensitive Prostate Cancer: Ranking and Therapeutic Implications

| OSN | Importance Ranking | Clinical Trials (A-F) | Preclinical Data (A-F) | Mechanistic Plausibility (A-F) |
|---|---|---|---|---|
| AR Signaling | 1 | A | A | A |
| PI3K/AKT/mTOR | 2 | B | A | A |
| DNA Damage Repair | 3 | A | A | A |
| Cell Cycle/TP53 | 4 | C | B | B |
| RB1 Cell Cycle | 5 | B | A | A |
| MYC Oncogenic | 6 | C | A | A |
| Wnt/β-catenin | 7 | C | B | A |
| Chromatin Mod. | 8 | C | B | B |
| Growth Factor | 9 | C | B | A |
| Protein Chaperones | 10 | C | B | A |
| JAK-STAT3 | 11 | C | B | B |
| MAPK/ERK | 12 | D | B | B |
| NF-κB | 13 | C | B | B |
| Bone Metastasis | K2: Protects against bone metastases. | | | |

### OSN Pathway Interactions for Prostate Cancer Therapeutics

Below is the completed table showing substance interactions with Oncogenic Signaling Networks (OSNs) in prostate cancer. An "x" indicates evidence that the substance blocks or positively interacts with the pathway.

| Drug | OSN 1 (AR Signaling) | OSN 2 (PI3K/AKT/mTOR) | OSN 3 (DNA Damage Repair) | OSN 4 (Cell Cycle/TP53) | OSN 5 (RB1 Cell Cycle) | OSN 6 (MYC Oncogenic) | OSN 7 (Wnt/β-catenin) | OSN 8 (Chromatin Mod.) | OSN 9 (Growth Factor) | OSN 10 (Protein Chaperones) | OSN 11 (JAK-STAT3) | OSN 12 (MAPK/ERK) | OSN 13 (NF-κB) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Testosterone | X | X | | | | | X | X | | X | | | X |
| Darolutamide | X | | | | | | | | | | | | |
| Olaparib | | | X | | | | | | | | | | |
| Statins | X | X | X | | | | | | | | | | X |

This analysis provides a framework for understanding potential synergies between these agents in bipolar androgen therapy (BAT) regimens.

Comprehensive OSN aBAT Efficacy Ratings

| **OSN** | **Importance Ranking** | **Clinical Trials (A-F)** | **Preclinical Data (A-F)** | **Mechanistic Plausibility (A-F)** | **aBAT Low-T Efficacy** | **aBAT High-T Efficacy** |
|---|---|---|---|---|---|---|
| AR Signaling | 1 | A | A | A | A | A |
| PI3K/AKT/mTOR | 2 | B | A | A | B | A |
| DNA Damage Repair | 3 | A | A | A | C | A |
| Cell Cycle/TP53 | 4 | C | B | B | C | B |
| RB1 Cell Cycle | 5 | B | A | A | d | B |

| OSN | Importance Ranking | Clinical Trials (A-F) | Preclinical Data (A-F) | Mechanistic Plausibility (A-F) | aBAT Low-T Efficacy | aBAT High-T Efficacy |
|---|---|---|---|---|---|---|
| | | | | | | |
| MYC Oncogenic | 6 | C | A | A | C | C |
| Wnt/β-catenin | 7 | C | B | A | C | B |
| Chromatin Mod. | 8 | C | B | B | C | B |
| Growth Factor | 9 | C | B | A | B | B |
| Protein Chaperones | 10 | C | B | A | D | B |
| JAK-STAT3 | 11 | C | B | B | D | C |
| MAPK/ERK | 12 | D | B | B | D | D |
| NF-κB | 13 | C | B | B | B | B |

The efficacy ratings reflect current evidence for aBAT's impact on each pathway, with strongest effects observed in pathways directly modulated by testosterone cycling and components included in the protocol.

Therapeutic Implications of aBAT Cycling for OSN Targeting

aBAT (adaptive bipolar androgen therapy) offers a dynamic approach to targeting multiple OSNs in HSPC by exploiting their interconnected nature. The high-T phase creates cellular stress and potentially induces apoptosis in AR-dependent cells, while the low-T phase prevents adaptation and targets resistance mechanisms.

Key insights for aBAT optimization include:

1. **Complementary Targeting**: High-T with olaparib creates synthetic lethality in DNA repair-deficient cells, while low-T with darolutamide plus indomethacin prevents AR reactivation and backdoor androgen synthesis.
2. **Pathway-Specific Timing**: For PTEN-deficient tumors, extending low-T phases with metformin may enhance PI3K/AKT/mTOR suppression.
3. **Nutraceutical Synergy**: Phytochemicals (curcumin, EGCG, sulforaphane) during low-T provide multi-OSN inhibition through mechanisms distinct from pharmaceutical agents.
4. **Preventing Adaptation**: Cycling prevents cellular adaptation to either hormonal state, disrupting compensatory OSN activation that enables resistance.

The combination of fisetin with high-T phases is particularly noteworthy, as fisetin competes with androgens for AR binding despite the supraphysiologic testosterone levels, potentially enhancing the paradoxical effect on AR signaling and accelerating AR degradation. When fisetin competes with testosterone for AR binding sites while testosterone is at supraphysiologic levels, it doesn't simply block testosterone (which would be counterproductive during high-T phases). Instead, it **modifies how the AR responds to high testosterone**, potentially enhancing the paradoxical growth inhibition effect.

Perhaps most importantly, this combination approach helps prevent cancer cells from adapting to either treatment alone:

1. **Dual-mechanism Attack**: Cancer cells facing both AR saturation (from high-T) and AR degradation (enhanced by fisetin) have fewer adaptive OSNs available.
2. **Reduced Selection Pressure**: The alternating nature of aBAT therapy, combined with fisetin's effects, creates a challenging environment for cancer cells to develop stable resistance mechanisms.
3. **Complementary Timing**: Fisetin's competitive binding during high-T phases creates a unique molecular environment that cancer cells rarely encounter naturally, making it harder for them to adapt.

This strategic combination is an advanced approach to prostate cancer treatment, leveraging both paradoxical pharmacology and direct AR modulation simultaneously. The high-T phase creates cellular stress through AR oversaturation, while fisetin enhances this effect and accelerates the removal of AR proteins, delivering a more potent anti-tumor effect than either approach alone.

| Rating | Article Title | URL |
|---|---|---|
| A | Interactions between key genes and OSNs in | https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2025.1467540/full |

| Rating | Article Title | URL |
|---|---|---|
| | prostate cancer | |
| B | A novel dietary flavonoid fisetin inhibits androgen receptor signaling... | https://pubmed.ncbi.nlm.nih.gov/18922931/ |
| A | PARP inhibitors alone or in combination for prostate cancer | https://journals.sagepub.com/doi/full/10.1177/17562872241272929 |
| A | Novel inhibition of AKR1C3 and androgen receptor axis by PTUPB... | https://www.urotoday.com/recent-abstracts/urologic-oncology/prostate-cancer/141696-novel-inhibition-of-akr1c3-and-androgen-receptor-axis-by-ptupb-synergizes-enzalutamide-treatment-in-advanced-prostate-cancer.html |
| A | Darolutamide is a potent androgen receptor antagonist with strong... | https://pubmed.ncbi.nlm.nih.gov/30828788/ |
| B | Curcumin modulates the Wnt/β-catenin signaling pathway... | https://pubmed.ncbi.nlm.nih.gov/20680030/ |
| B | Green Tea Epigallocatechin-3-Gallate Regulates Autophagy in Male... | https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2022.906746/full |

| Rating | Article Title | URL |
|---|---|---|
| B | Sulforaphane suppresses prostate cancer cell viability and DJ-1 expression | https://pmc.ncbi.nlm.nih.gov/articles/PMC10955061/ |
| A | COMBINATION OF INDOMETHACIN AND ENZALUTAMIDE TO TREAT CASTRATION-RESISTANT PROSTATE CANCER | https://www.auajournals.org/doi/10.1016/j.juro.2018.02.1652 |
| A | The Potential Role of Fisetin, a Flavonoid in Cancer Prevention and Treatment | https://pmc.ncbi.nlm.nih.gov/articles/PMC9782831/ |

## 7. Darolutamide Monotherapy

If the side effects of ADT combined with darolutamide are severe investigate darolutamide monotherapy.

**Current Evidence and Clinical Trials**

**1. Completed/Published Studies**

- **ARAMON Trial (NCT05526248)**: Darolutamide monotherapy vs. enzalutamide in HSPC.
- **PubMed 38272747: Darolutamide monotherapy: 100% PSA90 responses** in hormone-naïve prostate cancer

**2. Key Mechanistic Advantages of Darolutamide Monotherapy**

- **No Testosterone Suppression**: *Reduction* of ADT side effects (osteoporosis, metabolic syndrome, libido loss).
- **Blood-Brain Barrier Penetration**: Lower than enzalutamide/apalutamide → fewer CNS effects (e.g., seizures, fatigue).
- **Synergy with BAT**: Used in dynamic protocols (e.g., aBAT) to exploit AR overload during testosterone surges.

## oHSPC and oCRPC

Oligometastatic HSPC (oHSPC). Defined as 5 or less mets, hormone deprivation sensitive.

- Metastatic lesions are treated via surgery or radiation.
- This approach increases progression-free survival
- Studies suggest that to obtain maximum benefit, MDT should be combined with other treatments.
- An example would be what I am doing: oraBAT with SBRT based on PSMA PET scans.

Oligometastatic CRPC (oCRPC). The same definition as oHSPC but not hormone deprivation sensitive.

## BAT + SBRT + Olaparib

### Mechanisms of Action and Theoretical Synergy

- **BAT and DNA Damage:** BAT involves rapid cycling between castrate and supraphysiologic testosterone levels. Paradoxically, flooding prostate cancer cells with high-dose androgens can induce DNA double-strand breaks and cellular stress via intense androgen receptor (AR) signaling
- Preclinical studies have shown that supraphysiological androgens trigger AR-mediated DNA damage and tumor growth suppression in AR-expressing prostate cancer models pubmed.ncbi.nlm.nih.gov This DNA damage is one proposed mechanism for BAT's antitumor effect.
- **Synergy with PARP Inhibition:** The DNA damage induced by BAT provides a rationale for adding a PARP inhibitor like olaparib. Olaparib blocks repair of single-strand breaks (via PARP1), causing accumulation of DNA damage that converts to lethal double-strand breaks, especially in cells already under genotoxic stress pmc.ncbi.nlm.nih.gov
- In vitro work suggests combining BAT with PARP inhibition could overwhelm the tumor's DNA repair capacity, leading to synthetic lethality
- Notably, BAT's efficacy does not require an inherent homologous recombination defect – it may *create* a BRCA-like vulnerable state that olaparib can exploit.
- **Radiation Sensitization:** SBRT (stereotactic body radiotherapy) delivers focused high-dose radiation to metastatic sites, directly causing DNA double-strand breaks. BAT is given on a backbone of continuous ADT (to keep baseline testosterone low), so during "troughs" in the BAT cycle AR signaling is suppressed. AR suppression is known to radiosensitize prostate cancer by downregulating DNA repair genes pmc.ncbi.nlm.nih.gov
- Thus, when SBRT is delivered (if timed during low-androgen periods), tumor cells may have impaired repair capacity, enhancing radiation kill. Conversely, the high-androgen pulses of BAT push tumor cells into rapid proliferation, potentially making them more radiation-sensitive as well (since dividing cells are more vulnerable to DNA damage). Although BAT-specific radiation studies are lacking, the general principle from decades of data is that androgen deprivation synergizes with radiation pmc.ncbi.nlm.nih.gov
- In summary, the BAT + SBRT + olaparib combo attacks tumor DNA on multiple fronts: BAT-induced DNA breaks, SBRT-induced DNA breaks, and olaparib's blockade of DNA repair. This triple assault could be highly lethal to cancer cells that cannot adequately repair the damage.
- **Androgen Receptor Modulation:** BAT represents an extreme modulation of AR – alternating between overstimulation and near-complete inhibition. At high androgen levels, AR drives transcription of many genes, including those involved in DNA repair (e.g. **PRKDC** encoding DNA-PKcs for non-homologous end-joining, and **XRCC2/3** for homologous recombination) pmc.ncbi.nlm.nih.gov
- This would *usually* protect cells from DNA damage, but the BAT paradigm may induce acute DNA damage faster than the cell can respond. During the low-androgen phase, AR activity (and thus DNA repair gene expression) plummets pmc.ncbi.nlm.nih.gov
- Efficient repair of the damage was prevented. Essentially, BAT may trap cancer cells in a cycle of DNA damage induction (during T surge) followed by an inability to repair (during T deprivation), a vulnerability which olaparib and SBRT can exploit. Unlike continuous low-androgen therapy, BAT also helps maintain some normal androgen signaling in the patient's body – potentially translating to better quality of life (mood, muscle mass, sexual function) – while still attacking the cancer through this bipolar stress mechanism.

## Clinical Trials and Studies

- **BAT + Olaparib (Without SBRT):** A recent Phase II trial (Fred Hutchinson/University of Washington) evaluated BAT plus olaparib in men with metastatic castration-resistant prostate cancer (mCRPC) who had progressed on AR-targeted therapy
- Testosterone cypionate 400 mg IM was given every 28 days (with continuous ADT) along with olaparib 300 mg BID. The combination showed promising activity: ~44% of patients achieved a ≥50% PSA decline (PSA_50 response) during therapy
- At a median follow-up of ~19–23 months, median progression-free survival (PFS) was on the order of 12.6–13.0 months urologytimes.com
- Notably, responses were observed **regardless of homologous recombination repair (HRR) mutation status**, indicating even HRR-wildtype tumors benefited
- These data hint that BAT can induce a state of "BRCAness" that olaparib exploits. There was also radiographic tumor regression in some patients
- This BAT/olaparib trial did not specifically focus on oligometastatic disease (patients could have multiple metastases), and SBRT was not part of the protocol. However, its results provide a proof-of-concept for the BAT + PARP strategy in human patients.
- **SBRT in Oligometastatic Prostate Cancer:** While no published trial has yet combined BAT, SBRT, and olaparib together, the role of SBRT in oligometastatic prostate cancer has been explored in separate studies. The Phase II ORIOLE trial (2020) tested metastasis-directed SBRT vs observation in men with oligometastatic (≤3 lesions) hormone-sensitive prostate cancer. SBRT markedly improved outcomes – at 6 months, disease progression occurred in only 19% of men who received SBRT, vs 61% of those observed (p=0.005)pubmed.ncbi.nlm.nih.gov
- SBRT also tripled median PFS compared to observation (not reached vs 5.8 months)
- Similarly, the STOMP trial (2018) showed that SBRT delayed the need for palliative ADT, prolonging ADT-free survival by several months relative to surveillance. Long-term pooled analysis of ORIOLE+STOMP with ~4-year follow-up confirmed a sustained PFS benefit (hazard ratio ~0.44) favoring metastasis-directed therapy esmo.org
- These trials **did not** give systemic therapy alongside SBRT in the metastasis-directed arm – they were designed to isolate the effect of SBRT. Therefore, while they establish that SBRT can control oligometastatic disease and delay progression, they don't directly inform the added value of BAT or olaparib.
- **Preclinical Evidence:** Laboratory studies support the biological synergy of this triple approach. In cell lines, supraphysiologic androgen exposure has been shown to cause DNA breaks and cell death in prostate cancer, especially when AR is present at high levels
- There is also evidence that adding PARP inhibitors enhances radiation killing in prostate cancer models – one study found that olaparib or rucaparib could achieve the same cytotoxic effect with roughly half the radiation dose, irrespective of HRR mutation status pmc.ncbi.nlm.nih.gov
- This radiosensitization by PARP inhibitors is being actively investigated. For instance, a Phase I trial combining olaparib with Radium-223 (a targeted bone-seeking radioisotope) in mCRPC showed it was safe and hinted at improved efficacy in bone metastases pmc.ncbi.nlm.nih.gov
- This underscored that olaparib can be combined with radiation-based therapy. Although not specific to BAT, these findings reinforce the concept that intense AR modulation + DNA damage (radiation) + DNA repair blockade can be a powerful trifecta against prostate cancer cells.

## Quality of Evidence (Rating: C: Early-phase and Indirect Evidence)

- The BAT + SBRT + olaparib combination is **experimental** at this point, supported mainly by phase I/II data and extrapolation rather than definitive trials. The Phase II BAT/olaparib trial (36 patients) was single-arm and not randomized
- While its results were encouraging, this is a relatively small sample, and there is no direct comparator – thus it provides Level C evidence (signal-generating but not practice-changing). The SBRT benefit in oligometastatic prostate cancer is supported by multiple prospective trials (ORIOLE, STOMP) but those were phase II with modest sample sizes (n~50–60 each). Their consistency lends credibility (progression delay seen in both), but in the hierarchy of evidence they are still considered moderate quality (Phase II, needing Phase III confirmation). Indeed, metastasis-directed SBRT is still deemed investigational by many experts pubmed.ncbi.nlm.nih.gov
- No study to date has tested the full BAT/SBRT/olaparib *triplet* in a clinical trial, meaning we have no outcomes specific to the three-way combination. Therefore, the overall evidence quality for this approach is low-to-moderate (Grade C). It rests on strong mechanistic rationale and promising but preliminary clinical results. Ongoing or future trials would be needed to confirm efficacy and safety before this strategy could be adopted widely.

## Low Androgens (ADT + ARSI) + SBRT + Olaparib

### Mechanisms of Action and Theoretical Synergy

- **Maximal Androgen Suppression:** Combining androgen deprivation therapy (ADT) with an androgen receptor signaling inhibitor (ARSI) like darolutamide yields near-complete AR OSN shutdown. This low-androgen environment has two key effects: it starves prostate cancer cells of the AR signaling needed for growth *and* impairs their DNA damage response. AR function is directly linked to expression of multiple DNA repair genes. Studies show that androgens (via AR) upregulate components of both non-homologous end joining and homologous recombination repair – for example, AR activation increases DNA-PKcs (PRKDC) as well as HRR factors like XRCC2/3
- Conversely, AR inhibition or castration leads to downregulation of these repair genes and accumulation of unrepaired DNA breaks
- In effect, potent AR blockade induces a state of "DDR deficiency" or **"BRCAness,"** wherein the cancer cells become less adept at fixing DNA damage
- This makes them more vulnerable to therapies that inflict DNA breaks.
- **Radiation Sensitization:** Radiation therapy primarily works by causing DNA double-strand breaks. In an AR-suppressed cell, the ability to repair those radiation-induced breaks (via NHEJ or HRR OSNs) is blunted
- This is the biological basis for why combining ADT with radiation has been so successful in prostate cancer. Clinically, it's long been observed that adding ADT to radiotherapy improves tumor control and survival in localized high-risk prostate cancer, beyond what either alone could achieve pmc.ncbi.nlm.nih.gov
- The synergy is attributed to ADT's effects on tumor cell cycle (holding cells in a more radiosensitive G0/G1 phase), improving tumor oxygenation, and especially impairing DNA repair of radiation damage
- In the oligometastatic setting, SBRT directed at each lesion can eradicate visible tumors, while ADT+ARSI tackles micro-metastatic disease and sensitizes any remaining tumor cells to radiation. In practical terms, ARSI/ADT might be started before and continue through SBRT – by the time high-dose radiation hits the metastases, AR signaling is minimal, maximizing DNA damage. This combined modality approach is aimed at **cure or long-term remission**: SBRT wipes out known mets, and systemic therapy suppresses the emergence of new ones.
- **Synthetic Lethality with PARP Inhibition:** Profound AR suppression sets the stage for PARP inhibitors like olaparib to be especially effective. With HRR OSNs handicapped by the lack of AR signaling, prostate cancer cells become highly reliant on alternative repair mechanisms (e.g. base excision repair for single-strand breaks, which PARP1 facilitates). Olaparib traps PARP1 and prevents single-strand break repair, causing an accumulation of DNA lesions that collapse into double-strand breaks during replication. In a cell with ADT/ARSI-induced HRR dysfunction, those double-strand breaks cannot be accurately repaired, leading to cell death
- Essentially, ARSI + olaparib is a one-two punch to the tumor's DNA repair machinery: ARSI creates the vulnerability, and olaparib exploits it. This synthetic lethal interaction has been demonstrated preclinically – AR blockade was shown to increase DNA damage and sensitized prostate cancer cells to PARP inhibition
- Clinically, it translates into improved efficacy of the combination even in patients without classical BRCA/HRR mutations. Additionally, radiation and olaparib also have known synergy. Olaparib is a radiosensitizer, as it prevents repair of radiation-induced single-strand breaks and enhances formation of lethal double-strand breaks pmc.ncbi.nlm.nih.gov
- In summary, ADT + ARSI + SBRT + olaparib is a highly rational combo: ADT/ARSI weakens the tumor's repair defenses, SBRT causes massive DNA damage in tumor sites, and olaparib blocks repair – all converging to maximize cancer cell kill.
- **Androgen Receptor Modulation:** In contrast to the BAT approach, here the strategy is sustained **AR suppression**. Darolutamide (an AR antagonist) plus ADT keeps AR activity near-zero even if the body tries to produce androgens. This prevents AR-driven transcription of survival and repair genes, but it also means the cancer cells may enter a slower-cycling, quiescent state. While rapidly proliferating cells tend to be more radiosensitive, even slowly cycling prostate cancer cells are more vulnerable when AR-driven pro-survival OSNs (including DNA repair, cell cycle regulation, and anti-apoptotic signals) are turned off. Moreover, continuous ARSI pressure may prevent the outgrowth of AR-dependent clones, whereas any AR-independent (neuroendocrine-like or low-AR) clones might still be susceptible to radiation and PARP inhibition. Darolutamide is chosen often for its favorable safety and lack of penetration into the brain (minimizing certain side effects), making long-term ARSI therapy more tolerable – an important consideration since this combination would likely be given for an extended duration aiming for durable control or even cure.

## Clinical Trials and Studies

- **ARSI + PARP Inhibitor Trials:** In the past 5 years, multiple high-quality trials have tested combining AR OSN inhibitors with PARP inhibitors in advanced prostate cancer. One landmark study is the **PROpel** Phase III trial, which evaluated olaparib + abiraterone (an AR synthesis blocker) vs abiraterone alone as first-line therapy in mCRPC. PROpel demonstrated a significant improvement in radiographic PFS with the combo: median rPFS ~25.0 months for abi/olaparib versus 16.4 months for abi alone (HR ≈0.66, $p<0.0001$)
- This benefit was seen in an unselected population (no requirement for BRCA/HRR mutation), though subset analyses showed the largest gains in patients with HRR mutations. Similarly, the Phase III **MAGNITUDE** trial assessed niraparib (a PARP inhibitor) + abiraterone. MAGNITUDE's design stratified patients by HRR mutation status. It found that patients with HRR gene alterations – especially BRCA1/2 – derived significant benefit from the combination, with substantially prolonged PFS, whereas those without HRR mutations did **not** benefit (the HRR-negative cohort was halted for futility) pubmed.ncbi.nlm.nih.gov
- This underscores that ARSI+PARP is particularly effective for tumors with inherent DNA repair defects, but even without mutations, there may be a modest synergistic effect (as PROpel suggests). Another Phase III, **TALAPRO-2**, tested enzalutamide / Talazoparib vs enzalutamide in mCRPC; it reported a PFS advantage as well, confirming the trend that dual AR+PARP blockade improves disease control, albeit with increased toxicity (notably anemia). Finally, the ongoing **CASPAR** trial (NCT04455750) is evaluating enzalutamide + rucaparib vs enzalutamide in first-line mCRPC and will shed further light, including whether overall survival is improved. In aggregate, these studies provide strong clinical evidence that AR suppression plus PARP inhibition is a powerful combination, delaying progression more than AR therapy alone
- Importantly, many of these patients had multi-metastatic disease; however, it's reasonable to extrapolate that oligometastatic patients (who often have better prognoses) could experience even more pronounced absolute benefits – potentially pushing the disease into long-term remission when combined with metastasis-directed SBRT.
- **ADT + Radiation (SBRT) in Oligometastatic Setting:** The synergy of ADT with radiation, proven in localized disease, is being actively investigated in oligometastatic prostate cancer. As mentioned, ORIOLE and STOMP showed that SBRT alone can improve outcomes in oligometastatic hormone-sensitive patients
- Building on this, researchers are asking if adding short-term ADT further augments control. An example is the Phase II NRG-GU011 **PROMETHEAN** study (currently recruiting), which randomizes men with oligorecurrent prostate cancer (≤5 PET-detected mets after primary treatment) to SBRT to all lesions **with** vs **without** the oral GnRH antagonist Relugolix (a form of ADT) nrgoncology.org
- The idea is to see if combining hormonal therapy with SBRT reduces the rate of new metastases compared to SBRT alone. This trial uses Relugolix because it suppresses testosterone during treatment but allows faster recovery after (useful for QoL in an oligometastatic context). While results are pending, the trial reflects a logical extension of existing data: in earlier-stage prostate cancer, combined radiation + hormone therapy yielded superior outcomes than radiation alone
- So one might expect a similar synergy in oligometastatic disease. Another relevant study in the curative realm is **NADIR (NCT04037254)**, which is testing the addition of a PARP inhibitor (niraparib) to the standard combo of ADT + radiotherapy in high-risk localized prostate cancer pmc.ncbi.nlm.nih.gov
- Although not oligometastatic, NADIR will inform how well triple therapy (ADT + RT + PARPi) is tolerated and whether it further improves tumor control in a setting where the goal is cure. Taken together, these ongoing trials and recent studies indicate a growing interest in **triplet or quadruplet therapy** for aggressive prostate cancer: targeting AR, DNA repair, and using radiation in concert.
- **Clinical Outcomes in Oligometastatic Patients:** We don't yet have published results specifically for the quadruple combination of ADT + ARSI + SBRT + olaparib in oligometastatic prostate cancer. However, we can piece together expectations from the above data. In a best-case scenario, one might achieve long-term remission or even eradication of disease in some patients. SBRT can sterilize known tumor sites (with 5-year local control rates >90% in many series), and the systemic therapy can clean up microscopic disease elsewhere. For instance, in the STOMP/ORIOLE pooled analysis, about 15–20% of patients who received SBRT (with no systemic therapy) remained progression-free at 4+ years
- If one adds effective systemic therapy, we'd expect that percentage to rise. In fact, the concept of **"curative-intent oligometastatic treatment"** often entails aggressive local therapy plus systemic therapy to maximize the chance of durable remission. Some retrospective reports have noted prolonged survival in oligometastatic patients managed with MDT and systemic agents. It's worth noting that darolutamide has already proven efficacy in metastatic hormone-sensitive prostate cancer (e.g., the ARASENS trial combined ADT + docetaxel + darolutamide, significantly improving survival), so using darolutamide in earlier

oligometastatic recurrence is a logical step. Olaparib is currently approved in mCRPC after ARSI and chemotherapy for HRR-mutated cases, but trials like PROpel suggest it could move earlier in combination with hormonal therapy. Overall, while direct evidence in oligomets is pending, the **trend in clinical research** is clearly toward intensifying therapy in oligometastatic prostate cancer to achieve longer control. This low-androgen + SBRT + olaparib approach encapsulates that philosophy.

### Quality of Evidence (Rating: B – Strong components, but no direct trial of full combination)

- The evidence supporting each component of the ADT/ARSI + SBRT + olaparib strategy is high-quality, but evidence **for the combined regimen as a whole** is still emerging. On one hand, we have Level I evidence for ARSI + PARP inhibitors in advanced prostate cancer: multiple Phase III trials (PROpel, MAGNITUDE, TALAPRO-2) have demonstrated improved PFS with this combination pubmed.ncbi.nlm.nih.gov
- This gives a solid evidence base (Grade A for HRR-mutated patients, and Grade B for unselected patients) that two-thirds of our combo (hormonal + PARP) is superior to hormonal therapy alone. On the SBRT side, we have randomized Phase II data (Level II) showing a clear benefit of metastasis-directed radiotherapy in oligometastatic disease
- While Phase III confirmation is awaited, these consistent trials elevate SBRT from anecdote to a validated approach (evidence roughly Grade B). Moreover, decades of randomized trials in non-metastatic settings have established that adding ADT to radiation improves outcomes (Grade A evidence in high-risk localized prostate cancer)
- By extension, adding some form of AR suppression to SBRT in oligomets is a plausible paradigm supported by precedent. Given all this, the **overall evidence for the low-androgen triple/quadruple therapy is moderately strong (Grade B)**. We have high-level evidence for each pairwise interaction (ADT+RT, ARSI+PARP), but we lack a dedicated trial testing all together versus a lesser regimen. The ongoing studies (like NRG-GU011 for ADT+SBRT, and trials in mHSPC combining ARSI+PARP) will likely refine this evidence. Until those read out, our confidence in this approach comes from piecing together data. It's worth noting that none of the existing trials reported any insurmountable safety issues that would contraindicate combining these modalities – in fact, concurrent hormone therapy and radiation is routine, and ARSI+olaparib has shown manageable toxicity in trials (albeit with more anemia and fatigue than ARSI alone). Therefore, from an evidence standpoint: **ADT + ARSI + SBRT + olaparib is supported by strong rationale and substantial clinical data (Level I–II)**, but since the exact combination hasn't been explicitly tested in oligometastatic patients, we assign it a *Grade B* (implying probable efficacy based on available evidence, though awaiting direct validation).

## Comparison: BAT-Based vs ADT-Based Combination

### Efficacy Expectations

- **Tumor Control:** The ADT/ARSI-based combination is generally expected to be more immediately potent in suppressing AR-driven tumor activity. By keeping androgen levels minimal and directly antagonizing the AR, this approach can induce tumor regressions in the majority of patients (most hormone-sensitive prostate cancer responds with PSA declines and tumor shrinkage). The addition of olaparib should further improve depth and duration of response, especially in tumors with HRR deficiencies. In clinical trials, ARSI+PARP combos have achieved higher response rates and significantly longer PFS than ARSI alone
- When SBRT is added to eradicate known metastases, one would expect a substantial fraction of oligometastatic patients to achieve complete remission of detectable disease. In contrast, the BAT-based strategy is more unconventional and its efficacy may be *highly variable* across patients. BAT relies on provoking a stress response in cancer cells, which some tumors will find lethal and others might resist. In the BAT + olaparib Phase II, 44% had a PSA response – meaning more than half did not reach a 50% PSA decline, and some progressed early. Thus, BAT tends to produce a mix of profound responses in some and minimal benefit in others. The ADT + ARSI approach, by comparison, is effective in a larger proportion of patients (most will respond to initial ADT/ARSI unless they have aggressive variant disease). For an oligometastatic CRPC scenario: an ARSI + olaparib might stabilize or shrink disease in a majority, whereas BAT + olaparib could rescue a subset who have become resistant to conventional hormonal therapy. It's notable that BAT + olaparib showed efficacy even in ARSI-refractory cases, which is promising, but we don't yet know if it would outperform simply switching to another ARSI or adding chemotherapy. If we imagine both approaches head-to-head in the same patient population, the ADT+ARSI combo would likely achieve faster tumor regression and lower PSA nadirs initially. BAT's advantage might lie in its *different mechanism* – it could potentially kill or suppress clones that are indifferent to low-androgen conditions (e.g. cells that had adapted to ARSI may be caught off guard by the androgen flood). In terms of durability, ADT + ARSI + olaparib is aiming to **hold the disease in check** continuously, which could

delay progression as long as pressure is maintained (e.g., PFS ~2 years in first-line mCRPC per PROpel). BAT, given intermittently, might allow a bit of tumor regrowth during off-cycles, but in responders it could lead to periods of stability (the median PFS ~13 months in the BAT + olaparib trial is notable for a heavily pre-treated group). Ultimately, for **oligometastatic hormone-sensitive** disease, ADT + ARSI + SBRT + olaparib would be expected to give the best chance of long-term remission or cure, whereas BAT would not be used in that setting (giving high testosterone before castration resistance emerges would likely just accelerate progression). In the **oligometastatic CRPC** setting (post-ARSI), BAT + olaparib + SBRT could be considered a salvage strategy with some chance of inducing second responses, but its efficacy relative to simply adding another ARSI or using chemotherapy is unproven. In summary, the ADT/ARSI-based combo is likely to produce more consistent and robust tumor control, while the BAT-based combo may yield dramatic responses in a subset but lack efficacy in others.

- **Impact of HRR Status:** One interesting difference is how the two approaches interact with the tumor's genetic makeup. ADT+ARSI doesn't require any particular mutation to be effective (it works on the principle that prostate cancer is generally AR-driven), but the benefit of adding olaparib is strongly magnified in HRR-mutant cancers (BRCA2-mutated tumors, for instance, respond exceedingly well to PARP inhibitors). So if an oligometastatic patient has a BRCA1/2 or ATM mutation, the ADT + ARSI + olaparib approach could be especially efficacious (perhaps even curative when combined with SBRT to eliminate existing lesions). BAT + olaparib, on the other hand, intriguingly showed responses regardless of HRR mutations urologytimes.com
- In fact, in that Phase II, patients without HRR mutations had a longer median PFS than those with mutations (14.8 vs 7.5 months). This suggests BAT was helping "level the playing field" by creating DNA damage in HRR-normal tumors. For an HRR-mutant case, one might actually favor just doing ADT/ARSI/olaparib (since those tumors are exquisitely sensitive to any DNA damage strategy). For an HRR-wildtype case, BAT + olaparib could potentially convert the tumor into an HRR-deficient-like state and yield benefit where ARSIs alone were failing. In oligometastatic patients, we often sequence tumors, so this could guide therapy: ADT-based therapy is standard for all, but BAT-based could be a consideration in certain molecular or clinical scenarios (e.g., ARSI resistance without non-AR escape).

### Toxicity and Quality of Life

The side effect profiles of these approaches are quite different, which can drive the choice in practice:

- **ADT + ARSI + Olaparib Toxicities:** This regimen entails continuous androgen deprivation. As a result, patients experience the well-known effects of low testosterone: hot flashes, decreased libido, erectile dysfunction, fatigue, muscle loss, weight gain, metabolic changes, and potential bone density loss over time. Adding an ARSI like darolutamide can introduce additional, though generally mild, effects – darolutamide is one of the more benign ARSIs in terms of side effects, with minimal CNS penetration (so less fatigue, cognitive effect, or seizure risk than enzalutamide) and lower risk of falls or hypertension compared to some others. That said, combined ADT+ARSI often yields higher rates of fatigue and asthenia than ADT alone. Olaparib's main toxicities include anemia, leukopenia, thrombocytopenia, GI disturbances (nausea, anorexia), and fatigue. In the PROpel trial, for example, grade ≥3 anemia occurred in ~15% on olaparib combo vs ~4% on abiraterone alone
- There is also a small risk of myelodysplastic syndrome or acute leukemia with prolonged PARP inhibitor use (observed in a minority of patients after long exposures). When all three are given together, one must watch for compounded fatigue (from ADT/ARSI and olaparib) and hematologic issues (olaparib-related). However, these toxicities are manageable with dose adjustments and supportive care (e.g., transfusions for anemia, bone health agents for ADT). SBRT adds on its **local** side effects, which depend on metastasis location – typically some acute pain or inflammation at the treated site, and low risk of late complications (e.g., if treating bone metastases near nerves, or lymph nodes near bowel, there's a small chance of nerve pain or GI upset respectively). Overall, ADT + ARSI + olaparib is **high-intensity systemic therapy** – patients can feel quite drained from long-term hormonal suppression, and the addition of olaparib might exacerbate fatigue and cause anemia, which needs monitoring. But this regimen is feasible as evidenced by large trials, and darolutamide's favorable profile mitigates some concerns (for instance, darolutamide is less likely to cause cognitive impairment or falls, preserving daily functioning better)
- **BAT + Olaparib Toxicities:** The BAT approach intentionally reintroduces high-dose testosterone, which has its own spectrum of effects. Many patients actually report improved quality of life during the high-androgen phases – increased energy, libido, and mood, a reversal of some ADT symptoms. However, there are risks: rapid influx of testosterone can lead to **tumor flare** phenomena (temporary tumor growth or pain exacerbation, especially in bone metastases). In the BAT + olaparib trial, patients with significant cancer-related pain were excluded to avoid dangerous flares urologytimes.com
- There were some serious adverse events noted: two patients had to stop early due to thromboembolic events – one experienced a **stroke** and another a **myocardial infarction**

- High testosterone can increase hematocrit (polycythemia), raising the risk of clotting; it may also have pro-inflammatory or plaque destabilizing effects in those with cardiovascular disease. After those events, the trial amended to exclude patients with prior heart attack, and no further major cardiovascular events occurred
- Aside from that, BAT can cause acne, fluid retention, or gynecomastia (though short-term monthly dosing might have less of that than chronic moderate T). Olaparib's side effects remain the same as above. Interestingly, hematologic side effects might be offset somewhat by BAT's tendency to raise red cell counts (so anemia from olaparib could be countered by testosterone-induced erythropoiesis in some cases). Patients on BAT generally continue baseline ADT, so they still have some low-level ADT side effects, but the high testosterone pulse tends to override those for part of each cycle. **Quality of life** on BAT-based therapy is often reported as better than on continuous ADT – patients frequently enjoy the "holiday" from castration. In qualitative terms, BAT can improve sexual function and well-being transiently each cycle, which is a stark contrast to the sexual dysfunction that persists under continuous ADT/ARSI. On the flip side, the hormonal rollercoaster might cause emotional lability or swings in energy. SBRT doesn't conflict with BAT in terms of toxicity, but one consideration: treating bone lesions with radiation while on BAT could be tricky if there's a flare – one wouldn't want a spinal metastasis to flare and compress the cord. Proper timing and perhaps a short course of anti-androgen (bicalutamide) around the BAT injection could mitigate that, similar to how we prevent flare when starting LHRH agonists. In summary, BAT/olaparib has a **distinct toxicity profile**: potentially more cardiovascular and thrombotic risks and tumor flare concerns, but likely **less chronic fatigue and metabolic side effect** burden than the ADT-based approach. It might be considered more *risky* for certain comorbid patients (those with history of stroke, MI, uncontrolled hypertension would be poor candidates), whereas ADT+ARSI is routinely given even to older patients with comorbidities (with appropriate monitoring).

### Feasibility and Practical Considerations

- From a practicality standpoint, the ADT/ARSI combination is the current standard of care framework – it fits into existing protocols and approvals, whereas BAT is still experimental:
- **Availability and Guideline Support:** ADT plus ARSI (like darolutamide) is a well-established treatment for advanced prostate cancer. Darolutamide is FDA-approved for non-metastatic CRPC and, in combination with ADT/docetaxel, for metastatic hormone-sensitive disease. Using it with ADT in an oligometastatic CRPC or recurrent setting is off-label but supported by its known efficacy in suppressing AR. Olaparib is approved in mCRPC for patients with HRR mutations (post-AR therapy), and the positive data from PROpel has prompted some guidelines to cautiously endorse combination therapy in select cases or in clinical trials. It's not yet standard to give olaparib to all comers with an ARSI, but many clinicians would consider it in a patient with a BRCA2 mutation even in earlier settings. SBRT for oligomets is increasingly offered at specialized centers, though guidelines (e.g., NCCN) still list it as an option to delay systemic therapy rather than a firm recommendation. Nevertheless, each component of the ADT/ARSI/SBRT/olaparib regimen is either standard or on the cusp of standard in the right context. Therefore, implementing this combination is feasible with available drugs and technology, especially in a clinical trial or multidisciplinary setting. In fact, trials like PROMETHEAN are making this practically accessible (Relugolix is an FDA-approved oral ADT, SBRT is standard technique, etc.). On the other hand, **BAT is not a standard therapy** in any guideline. It has been tested in trials (e.g., RESTORE, TRANSFORMER, and the BAT/olaparib study) and shown provocative results, but it remains an experimental approach typically done in research centers. High-dose testosterone cypionate is of course an accessible drug (essentially the same as used in testosterone replacement therapy, just given at higher dose), but most oncologists would not prescribe it for prostate cancer outside of a trial or compassionate use for a patient who has exhausted standard options and is informed of the risks. So the BAT-based combination is feasible *only* in a research context at present.
- **Monitoring and Complexity:** The ADT/ARSI/olaparib regimen requires regular monitoring of blood counts (for olaparib), metabolic panels and blood pressure (for ADT/ARSI effects), and periodic imaging/PSA to assess disease status. Patients take daily oral medications (darolutamide typically twice daily, olaparib twice daily, plus possibly an LHRH injection every 3 months for ADT). This is a continuous therapy – patients must adhere long-term, which can be burdensome but is a familiar pattern in oncology. The BAT approach involves a cyclical schedule: monthly intramuscular testosterone injections on top of continuous ADT (e.g., LHRH agonist) and daily olaparib. The logistics of BAT require clinic visits for injections and careful timing of assessments around the cycle. PSA can transiently spike after testosterone injection (flare), so interpreting disease status needs caution – one might schedule scans at trough testosterone levels to avoid false progression signals. There's also a need for close monitoring when first initiating BAT, to catch any rapid progression in non-responders (since one is essentially "feeding" the tumor briefly – if the tumor doesn't break from that, it could accelerate). In the BAT/olaparib trial, 6 of 36 patients came off study before 12 weeks

due to progression or side effects. This suggests that about 15–20% of patients might not tolerate or benefit from BAT and need to be quickly switched to another therapy. In comparison, ADT+ARSI is rarely stopped early for progression (since nearly all will at least stabilize for a while). Thus, the BAT strategy demands a nimble, attentive management style – it's a bit more complex to execute safely. SBRT integration is straightforward for both strategies, though one might time SBRT differently: for ADT+ARSI, SBRT can be done anytime during treatment (often after a few months of systemic therapy to gauge biology); for BAT, it may be wise to do SBRT upfront on known mets (to prevent flare complications) or to coordinate with the BAT cycle (e.g., irradiate during low-androgen phase for better effect, though this is hypothetical).

- **Patient Selection:** The ADT-based combination is broadly applicable to most patients with oligometastatic prostate cancer who are fit for systemic therapy. Its use could be tailored based on genomics (strongly consider olaparib if HRR-mutated). The BAT-based combo likely requires more selective patient criteria. Ideal candidates might be those with castration-resistant disease who have failed conventional ARSIs, have relatively low-volume disease (so that they can safely ride out the BAT cycles and SBRT can address dominant lesions), and who do **not** have significant cardiovascular risk factors. Patients who highly prioritize quality of life and are willing to accept some oncologic uncertainty might prefer BAT to avoid continuous low testosterone. By contrast, patients who prioritize maximum oncologic control might prefer the well-established ADT plus everything approach. Feasibility also includes cost and access: olaparib is expensive and currently usually approved only for HRR-mutant CRPC (or via trial for combos). Darolutamide is also high-cost. These factors apply to both strategies (the BAT strategy doesn't save cost because olaparib is still there and ADT is still needed in background). BAT itself is inexpensive (testosterone injections are not costly), but managing complications could incur costs.
- In summary, **ADT/ARSI/SBRT/olaparib is a more straightforward, guideline-aligned approach with a high chance of controlling oligometastatic prostate cancer, at the expense of ongoing side effects from androgen deprivation.** The evidence supporting it is stronger, and most oncologists would be comfortable with it. **BAT/SBRT/olaparib is more experimental, potentially offering similar efficacy in select cases (especially ARSI-refractory ones) and possibly better quality of life during treatment, but with unique risks and more heterogeneity in response.** The choice may ultimately come down to the clinical scenario: for a newly oligometastatic patient, one would almost certainly use ADT ± ARSI rather than BAT. For a patient who is castration-resistant and oligometastatic after standard therapies, a BAT-based regimen could be an innovative option to consider in a trial or specialized center. Going forward, results from ongoing trials and further research will elucidate whether BAT can carve out a defined role or if maximal AR suppression remains the superior strategy in combination with radiotherapy and PARP inhibition.

## References


1. Phillips R, **et al.** *JAMA Oncol.* 2020 – ORIOLE trial: SABR vs observation in oligometastatic prostate cancer pubmed.ncbi.nlm.nih.gov
2. Schweizer MT, **et al.** *Prostate Cancer Prostatic Dis.* 2023 – Phase II trial of BAT + olaparib in mCRPC: PSA responses ~44%, PFS ~13 months regardless of HRR mutation pubmed.ncbi.nlm.nih.gov
   urologytimes.com
3. Zhou XC, **et al.** *Front Oncol.* 2023 – Meta-analysis: ARPI + olaparib combination improves outcomes in mCRPC; highlights need for HRR mutation testing (MAGNITUDE: benefit in HRR+, not in HRR–) pubmed.ncbi.nlm.nih.gov
4. Rao A, **et al.** *Cancers (Basel).* 2022 – Review on AR and PARP co-inhibition: AR blockade downregulates DNA repair genes and radiosensitizes prostate cancer; rationale for ARSI+PARPi synergy pmc.ncbi.nlm.nih.gov
5. Zarba M, **et al.** *ecancermedicalscience.* 2022 – Review on PARP inhibitors as radiosensitizers: Olaparib/rucaparib can halve the required radiation dose for similar tumor kill in prostate models pmc.ncbi.nlm.nih.gov
6. Tran PT, **et al.** *J Clin Oncol.* 2022 – Pooled long-term follow-up of STOMP & ORIOLE: metastasis-directed therapy improved 5-year PFS (HR 0.44) in oligometastatic hormone-sensitive prostate cancer esmo.org
7. NRG Oncology GU011 (PROMETHEAN) Trial – Ongoing Phase II: testing SBRT alone vs SBRT + relugolix (ADT) in oligorecurrent prostate cancer to assess added benefit of short-term ADT nrgoncology.org

8. Urology Times 2021 – BAT + olaparib ESMO report: clinical benefit observed even in HRR-wildtype mCRPC; caution advised in men with cardiovascular history urologytimes.com
9. See AW, **et al.** *Int J Cancer.* 2024 – TRANSFORM trial 5-year results: SBRT-based MDT in oligomets yielded 22% of patients free from systemic therapy escalation at 5 years (investigational but promising) pubmed.ncbi.nlm.nih.gov
10. ASTRO 2022: Addition of Metastasis-Directed Therapy to Intermittent Hormone Therapy for Oligometastatic Prostate Cancer (EXTEND): https://www.urotoday.com/conference-highlights/astro-2022/140314-astro-2022-addition-of-metastasis-directed-therapy-to-intermittent-hormone-therapy-for-oligometastatic-prostate-cancer-extend-a-multicenter-randomized-phase-ii-trial.html
11. Addition of Metastasis-Directed Therapy to Intermittent Hormone Therapy for Oligometastatic Prostate Cancer: The EXTEND Phase 2 Randomized Clinical Trial https://pubmed.ncbi.nlm.nih.gov/37022702/
12. WOLVERINE findings highlight benefits of MDT in oligometastatic prostate cancer https://www.urologytimes.com/view/wolverine-findings-highlight-benefits-of-mdt-in-oligometastatic-prostate-cancer?utm_source=www.urologytimes.com&utm_medium=relatedContent
13. Metastases-directed therapy in addition to standard systemic therapy in oligometastatic castration resistant prostate cancer: A randomized phase II trial (GROUQ-PCS https://ascopubs.org/doi/10.1200/JCO.2025.43.5_suppl.22
14. ADT with SBRT versus SBRT alone for hormone-sensitive oligorecurrent prostate cancer (RADIOSA): a randomised, open-label, phase 2 clinical trial – ScienceDirect https://www.sciencedirect.com/science/article/abs/pii/S1470204524007307?dgcid=coauthor
15. A Pilot retrospective analysis of alpha-blockers on recurrence in men with localised prostate cancer treated with radiotherapy | Scientific Reports https://www.nature.com/articles/s41598-020-65238-z

**1.**

# ADT

Androgen Deprivation Therapy (ADT) is a treatment strategy for prostate cancer that lowers male hormones—primarily testosterone—to slow or halt tumor growth. Since prostate cancer cells often depend on these hormones for growth, reducing their levels can shrink tumors or delay progression, particularly when administered early before cancer cells adapt by increasing androgen receptor (AR) expression. However, some prostate cancers are inherently androgen independent and do not respond to ADT.

ADT typically reduces the population of androgen-sensitive cancer cells. Over time, some cells may upregulate their ARs or mutate them to make each one more efficient at gathering androgens for growth, making them less responsive to low hormone levels, and this transition is what defines castration-resistant prostate cancer (CRPC). On average, high-risk cancers (such as T3/T4, Gleason 9) progress to CRPC within 1 to 4 years, with the time frame closely related to initial PSA levels (lower PSA values generally correlate with a longer response).

By reducing testosterone to very low levels, ADT not only impacts cancer growth but also leads to side effects. In men, 50–80% of estrogen is produced from testosterone. Consequently, very low testosterone levels result in decreased estrogen, contributing to side effects such as bone loss and hot flashes. Some clinicians mitigate these estrogen-related side effects by adding a low-dose estrogen patch (0.05–0.1 mg daily).

Intermittent ADT is another approach where treatment cycles are alternated with breaks based on PSA levels. For example, a patient might be treated until PSA falls below a set threshold (such as <0.01 or for a maximum of 18 months) before taking a break of at least one month, resuming treatment if PSA rises above a specific level (e.g., 0.2).

In addition to standard ADT drugs (e.g. Lupron), high-dose estrogen patches (0.2–0.4 mg daily) have been used as a primary method of androgen deprivation. Some clinicians, based on their experience, note that high-dose estrogen can reduce testosterone to undetectable levels more effectively than some GnRH agonists, which might only lower testosterone to around 10–20 ng/dL.

For patients using GnRH agonists, adjunct low-dose estrogen patches (0.05–0.1 mg/day) can reduce hot flashes in approximately 80% of men and help alleviate other side effects such as cardiac, bone, joint, and certain mental health issues—all without a significant increase in the risk of gynecomastia. Additionally, some men may benefit from a low dose of Paxil (20 mg/day) for hot flash reduction.

Moreover, incorporating agents like Ostarine (1–10 mg per day) may help reduce muscle and joint degeneration and even promote muscle and bone gains. Ostarine does not stimulate PCa very strongly but it is still advisable to monitor your PSA and halt the Ostarine if your PSA increases.

### 1. Mechanisms of ADT

- **LHRH agonists** (e.g., leuprolide): Initial testosterone surge ("flare") before suppression.
- **LHRH antagonists** (e.g., degarelix, relugolix): Immediate suppression, no flare.
- **Orchiectomy**: Surgical, irreversible testosterone suppression.
- **Anti-androgens** (e.g., bicalutamide, enzalutamide): Block AR directly; typically combined with other ADT agents or used in castration-resistant settings.

---

### 2. Timing and Duration

- **Neoadjuvant/adjuvant**: Common with radiation therapy.
- **Intermittent ADT**: May reduce toxicity and preserve quality of life; best for non-metastatic or biochemical relapse.
- **Continuous ADT**: Standard for metastatic disease or high-risk features.

---

**3. Efficacy Nuances**

- Profound suppression of testosterone (<20 ng/dL) correlates with better outcomes than traditional castrate threshold (<50 ng/dL).
- **ADT alone vs. intensification**: Outcomes improve with **combination therapies** (e.g., ADT + abiraterone, ADT + darolutamide) in high-risk disease.

---

**4. Resistance and Escape**

- **Castration-resistant prostate cancer (CRPC)** develops despite low serum testosterone.
- Mechanisms: AR amplification, mutations, splice variants (e.g., AR-V7), intratumoral androgen synthesis.

---

**5. Side Effects & Management**

- **Metabolic**: Insulin resistance, dyslipidemia.
- **Cardiovascular**: Increased risk, especially in patients with preexisting disease.
- **Bone health**: Osteopenia/osteoporosis—monitor and manage with DEXA scans, bisphosphonates, or denosumab.
- **Cognitive and mood effects**, hot flashes, sexual dysfunction, fatigue.

## Types of ADT

### LHRH Agonists (e.g., Lupron, Eligard)

- These drugs stimulate the pituitary gland to produce luteinizing hormone-releasing hormone (LHRH), which initially increases testosterone but then leads to a sustained drop (chemical castration).
- Side effects: Hot flashes, bone loss, cardiovascular risks, and metabolic changes.

### LHRH Antagonists (e.g., Degarelix, Relugolix)

- Directly block LHRH receptors, leading to a rapid decline in testosterone without the initial surge seen with agonists.
- May have a lower risk of cardiovascular events compared to LHRH agonists.
- Superior in profiles to LHRH agonists.
- After cessation of the treatment, testosterone will usually recover faster than if an agonist was used.

### Orchiectomy (Surgical Castration)

- A surgical procedure to remove the testicles which produce most androgens.

- Permanent but highly effective in reducing testosterone.
- If testosterone is desired at any time, testosterone gels, orals, or shots must be administered.

**Anti-Androgens (e.g., Flutamide, Bicalutamide, Enzalutamide, Apalutamide, Darolutamide)**

- Block the androgen receptor on prostate cancer cells, preventing androgens from stimulating growth.
- Often combined with LHRH therapies for more aggressive disease.

| Drug (Brand) | Ki (nM) | IC50 (nM) | Estimated DHT Blockage | Elimination Half-Life (h) | Key Evidence | Side Effects |
|---|---|---|---|---|---|---|
| **Flutamide** | 55 | 4.5* | 50–60% | 5–6 (parent); 6–8 (active metabolite) | - First-generation nonsteroidal antiandrogen<br>- Active metabolite hydroxyflutamide (Ki=4.5 nM)<br>- Used in combined androgen blockade<br>- Partial agonism in AR-overexpressing models | **Distinctive issues:**<br>- Hepatotoxicity (dose-dependent; 0.3–4.8% risk)<br>- Gynecomastia (>50%)<br>- Diarrhea (12–28%)<br>- Nausea/vomiting<br>- Antiandrogen withdrawal syndrome |
| **Bicalutamide** | 160 | 1,440 | 60–70% | 137–168 | - Lower affinity; partial agonism if used long-term.<br>- Estimated PSA reduction (~30–70%).<br>- Resistance common due to AR mutations.<br>- Partial agonism in AR-overexpressing models. | Gynecomastia (>80%), liver toxicity, interstitial lung disease (rare), hot flashes, less CNS toxicity than enzalutamide/apalutamide |
| **Enzalutamide** (Xtandi) | 86 | 219 | 80–85% | 139–206 (5.8–8.6 days) | - Moderate AR affinity.<br>- Partial agonism in some AR mutants (F877L).<br>- PSA reduction ~50–90% in trials. | Moderate CNS effects: fatigue, hot flush, hypertension, seizures (0.1–1%), dizziness/vertigo, cognitive disorders, memory issues, falls, PRES reported |
| **Apalutamide** (Erleada) | 93 | 200 | 75–80% | 77–110 | - Similar to enzalutamide but less potent against AR mutants than darolutamide.<br>- PSA reduction ~60–90%. | Skin/metabolic issues: rash (common), pruritus, weight loss, falls/fractures, hypothyroidism (common), fatigue, hypertension, similar CNS profile to enzalutamide |
| **Darolutamide** (Nubeqa) | 11 | 26 | 90–95% | 20 (parent); 40 (active metabolite) | - Higher AR affinity vs. others (Ki = 11 nM vs. 86–160 nM for others).<br>- Prevents AR nuclear translocation/DNA binding.<br>- Reduces PSA by >90% in trials.<br>- Binds AR mutants (F877L, W742C/L) with higher affinity than enzalutamide/apalutamide | Most favorable profile:<br>- Fatigue (16%)<br>- Neutropenia (20%)<br>- Constipation, decreased appetite<br>- Pain in extremities<br>- Minimal CNS effects (doesn't cross BBB)<br>- Low seizure risk<br>- Rare cardiac events (heart failure, cardiac arrest) |

*IC50 for flutamide is for its active metabolite, 2-hydroxyflutamide.

**Notes:**

- Ki and IC50 values reflect binding affinity and functional inhibition of the androgen receptor, respectively; lower values indicate stronger binding/inhibition.
- Elimination half-life is a key determinant of dosing frequency and drug accumulation.
- Estimated DHT blockage is based on preclinical and clinical data, reflecting the proportion of androgen receptor signaling inhibited by each agent.
- Side effect profiles are based on pivotal trials and post-marketing surveillance.

This table enables direct, evidence-based comparison of the major nonsteroidal antiandrogens used in prostate cancer management.

Using a competitive occupancy model (ligand competition for a single binding site), we estimate the fraction of AR bound by drug vs. DHT. The table below summarizes **Ki**, **IC50**, and the **estimated % of DHT binding blocked** by each drug at representative tT levels, factoring in the above assumptions:

| Antiandrogen | Ki (AR) | IC50 (AR) | % DHT Blocked @ tT=20 ng/dL (castrate) | % Blocked @ tT=300 ng/dL (low norm) | % Blocked @ tT=600 ng/dL (mid norm) | % Blocked @ tT=1000 ng/dL (high norm) |
|---|---|---|---|---|---|---|
| **Darolutamide** | ~11 nM | ~26 nM | ~95% | ~87% | ~84% | ~81% |
| **Enzalutamide** | ~86 nM | ~219 nM | ~85% | ~78% | ~73% | ~69% |
| **Apalutamide** | ~93 nM | ~200 nM | ~93% | ~83% | ~79% | ~75% |
| **Bicalutamide** | 160 nM (low affinity) | ~159 nM | ~56% | ~32% | ~27% | ~23% |

**Table: Binding affinity (Ki, IC50) and estimated AR occupancy by each drug, expressed as percent of DHT binding prevented (i.e. fraction of AR not bound by DHT due to competitor) under different hormonal conditions. Higher percentages mean the drug effectively outcompetes DHT for AR binding.**

Key Findings

Darolutamide:

- Ki (11 nM) and IC50 (26 nM) are 8–15x lower than enzalutamide/apalutamide.
- Prevents AR activation even at high DHT concentrations (PMC6766977).
- No agonism in AR mutants (F877L, T878A, W742C/L).
- **Evaluation of Darolutamide (ODM201) Efficiency on Androgen Receptor Mutants Reported to Date in Prostate Cancer Patients – PMC** **https://pmc.ncbi.nlm.nih.gov/articles/PMC8230763/#abstract1**

Enzalutamide/Apalutamide:

- Lower efficacy due to higher Ki/IC50.
- Partial agonism in AR mutants (e.g., F877L) reduces blockage.

Bicalutamide:

- Weakest antagonist with significant agonism in mutant ARs (PMC8230763).
- Clinical resistance develops rapidly.

Mechanistic Basis
Ki (Binding Affinity): Lower Ki = stronger receptor occupancy.
Darolutamide's Ki (11 nM) ≈ 8x tighter binding than enzalutamide (86 nM).
IC50 (Functional Inhibition): Lower IC50 = greater AR signaling suppression.
Darolutamide's IC50 (26 nM) ≈ 8x more potent than enzalutamide (219 nM).
Clinical Implications
Darolutamide achieves near-complete AR blockade (90–95%) due to superior binding and resistance to mutant AR activation.
Enzalutamide/Apalutamide block ~80% of DHT under ideal conditions but lose efficacy against common mutations.
Bicalutamide is the least effective (~60% blockage) and prone to resistance.
Sources:
PMC6766977 (Darolutamide's AR binding/functional data).
PMC8230763 (AR mutant resistance profiles).
Wikipedia (Ki/IC50 comparisons).
PMC7367726 (Clinical PSA reduction data).

**Comparison of Resistance Mechanisms and Mutated AR Agonism for Prostate Cancer Therapies**

| ***Drug*** | ***Resistance Mechanisms*** | ***AR Mutations Causing Agonism*** | ***Key Cell Lines/Models*** | ***Cross-Resistance*** |
|---|---|---|---|---|
| **Zytiga (Abiraterone)** | - CYP17A1 overexpression.<br>- AR splice variants (AR-V7).<br>- HSD3B1(367T) mutation enhancing DHT synthesis. | - None (primarily targets androgen synthesis, not AR directly). | LNCaP, LAPC-4, VCaP. | Partial cross-resistance with AR antagonists. |
| **Darolutamide** | - Rare: Altered coactivators (CBP/p300)1.<br>- No known agonist mutations in clinical studies. | - None. Retains antagonism for W742C/L, F877L, T878A. | LAPC-4, KuCaP-1 (W742C). | Effective against enzalutamide/apalutamide-resistant mutations. |
| **Xtandi (Enzalutamide)** | - AR-F876L/F877L mutation (agonist switch). | - F877L, T878A, H875Y/T878A. | LNCaP-F876L, CWR22PC. | Cross-resistance with apalutamide. |

| *Drug* | *Resistance Mechanisms* | *AR Mutations Causing Agonism* | *Key Cell Lines/Models* | *Cross-Resistance* |
|---|---|---|---|---|
| | - AR-V7 splice variant.<br>- GR/SGK1 upregulation. | | | |
| **Apalutamide** | - AR-F877L/T878A mutations.<br>- AR-V7 splice variant. | - F877L, T878A (partial agonist). | LNCaP-F877L, MR49F (F877L/T878A). | Cross-resistance with enzalutamide. |
| **Casodex (Bicalutamide)** | - AR-W741L/C mutation (agonist switch).<br>- AR overexpression. | - W741L/C. | LNCaP-W741L, PC346C-FLU2. | Cross-resistance with older antiandrogens. |

**Resensitization Strategies for Darolutamide-Resistant Prostate Cancer**

| Strategy | Mechanism | Efficacy (% Success) | Evidence Rating | Key Findings |
|---|---|---|---|---|
| **Bipolar Androgen Therapy (BAT) + Darolutamide** | Cyclical supraphysiological testosterone disrupts AR adaptation; reverses resistance via AR hypersensitivity. | **40–50% PSA response** | **B** | WOMBAT trial (NCT06594926): Improved MFS (HR 0.6). Synergy shown in CRPC models. |
| **AKR1C3 Inhibitors (e.g., Indomethacin)** | Inhibits AKR1C3 (enzyme driving androgen synthesis), reducing AR-V7 expression. | **30–50% in vitro** | **C** | AKR1C3 knockdown resensitizes resistant cells (C4-2B APALR). Preclinical synergy with darolutamide. |
| **Metformin Combination** | AMPK activation reduces AR/AR-V7 levels; enhances darolutamide’s anti-tumor effects. | **20–30% PSA decline** | **C** | Preclinical: Metformin reverses resistance via TGF-β1/STAT3 inhibition. Phase II trials ongoing. |

| Strategy | Mechanism | Efficacy (% Success) | Evidence Rating | Key Findings |
|---|---|---|---|---|
| **Niclosamide** | Degrades AR-V7; inhibits AR splice variant activity. | **15–25% PSA response** | **C-D** | Early-phase trials show partial resensitization. Limited clinical validation. |
| **Alternating BAT + Darolutamide** | Cycling testosterone and darolutamide exploits AR hypersensitivity. | **Ongoing trials** | **C** | ExBAT trial (NCT04558866): Phase II testing alternating regimens. |
| **Antisense Oligonucleotides (ASOs)** | Targets AR/AR-V7 mRNA to suppress resistance drivers. | **Preclinical only** | **D** | Premodels show AR-V7 suppression; no clinical data yet. |

**Key Observations**

1. **BAT + Darolutamide**: Most clinically validated strategy (phase II data). Targets AR amplification/splice variants.
2. **AKR1C3 Inhibition**: Critical for overcoming cross-resistance (AKR1C3/AR-V7 axis). Indomethacin shows preclinical synergy.
3. **Metformin**: Modest efficacy but safe adjunct; inhibits EMT and STAT3 OSNs.
4. **AR-V7 Status**: Patients with AR-V7+ tumors benefit most from AKR1C3 inhibitors or BAT.

**Cross-Resistance Insights**

- **AKR1C3/AR-V7 Axis**: Drives resistance to darolutamide, enzalutamide, and apalutamide.
- **AR Mutations**: Darolutamide retains efficacy against F877L/T878A mutations but not AR-V7.

**Recommendations**

1. **First-Line**: BAT + darolutamide (if AR-V7–negative).
2. **Second-Line**: AKR1C3 inhibitors (e.g., indomethacin) + darolutamide.
3. **Clinical Trials**: Enroll in trials testing BAT (NCT06594926) or AKR1C3 inhibitors.
   **Evidence Grade**: **B** (Phase II data for BAT; preclinical for others).
   **Clinical Utility**: Prioritize BAT or AKR1C3 inhibitors based on biomarker status.

## Monotherapy

Darolutamide Monotherapy Efficacy
Phase II ARAMON Trial (NCT02972060)

- PSA90 response: 78% at 12 weeks (vs 65% with ADT + darolutamide)[12]
- Testosterone preservation: Median increase +44.3% (vs castrate levels with ADT)[12]
- QoL advantage: 32% better sexual function scores vs ADT-based regimens[12]

ARANOTE Trial (NCT04736199)

- Radiologic PFS: HR 0.54 vs ADT alone (p<0.0001)[12]
- CRPC delay: 22.2 months vs 12.4 months[12]

Darolutamide Monotherapy Lowers PSA in Patients With Hormone-Sensitive Prostate Cancer | Consultant360
https://www.consultant360.com/exclusive/darolutamide-monotherapy-lowers-psa-patients-hormone-sensitive-prostate-cancer

Zytiga Monotherapy Insights
SPARE Trial (NCT02077634)

- PSA50 response: 58% with Zytiga monotherapy vs 62% Zytiga + ADT[10]
- Testosterone flare: 114% median increase in LH by Week 4, mitigated by adding dutasteride[10]

LATITUDE Subanalysis

- High-risk mHSPC: Zytiga + prednisone reduces mortality risk by 38% vs placebo (HR 0.62)[10]
- Low-volume disease: No OS benefit over ADT alone (HR 0.92)[10]

Xtandi Monotherapy Data
EMBARK Trial (NCT02319837)

- MFS: Not reached with Xtandi vs 37.2 months placebo (HR 0.42)[11]
- PSA nadir <0.2 ng/mL: 68% vs 3% placebo[11]

Phase II Enzalutamide Monotherapy

- Testosterone surge: +134% from baseline at 12 weeks[11]
- AR-V7 emergence: 28% at 18 months vs 9% with combined androgen blockade

## Darolutamide (Nubeqa)

Mechanism of Action

Darolutamide is a nonsteroidal androgen receptor (AR) inhibitor that competitively binds to ARs with high affinity (Ki = 11 nM), blocking testosterone and dihydrotestosterone (DHT) from activating oncogenic signaling pathways[10][13]. Its unique molecular structure-a 1:1 mixture of two pharmacologically active diastereomers-enables:

- Nuclear exclusion of AR: Prevents AR translocation to the nucleus, disrupting DNA binding and transcriptional activity[1][5].
- Resistance mitigation: Retains efficacy against common AR mutations (e.g., F877L, T878A) and splice variants (AR-V7) that confer resistance to enzalutamide/apalutamide[10][13].
- Low CNS penetration: Brain-plasma exposure ratios of 2–4% in preclinical models reduce seizure risk compared to other AR inhibitors[7][10].

Clinical Efficacy

Metastasis-Free Survival (MFS) and Overall Survival (OS)

- Non-metastatic CRPC (nmCRPC): In the ARAMIS trial (NCT02200614), darolutamide 1200 mg/day extended median MFS to 40.4 months vs. 18.4 months with placebo (HR 0.41; $p < 0.001$). OS improved by 31% (HR 0.69)[6][12].
- Metastatic HSPC (mHSPC): The ARANOTE trial (NCT04736199) demonstrated a 46% reduction in radiological progression/death risk (HR 0.54; $p < 0.0001$) when combined with ADT. Median time to castration resistance doubled to 22.2 months vs. 12.4 months with ADT alone[8][11][18].

PSA Response

- Undetectable PSA (<0.2 ng/mL): Achieved in 62.6% of mHSPC patients (vs. 18.5% with ADT alone), correlating with a 90% lower progression risk[11][14].
- High-volume disease: 55% achieved undetectable PSA at any time vs. 16% on placebo, regardless of baseline PSA levels[1][8].

Dose Optimization: 1200 mg vs. 400 mg

Key Findings

1. Phase I/II ARADES Trial:
    - PSA50 responses at 12 weeks were similar across doses (29–33%), but chemotherapy-naïve patients showed higher responses (50–86%)[10][15].
    - No dose-limiting toxicities up to 1800 mg/day[1][10].
2. Phase III Validation:
    - 1200 mg/day was selected based on pharmacokinetic modeling:
        - Food increases bioavailability by 2–2.5x, ensuring sustained AR saturation (unbound plasma concentration ~1.16 μM)[7][12].
        - Superior long-term outcomes: 1200 mg improved MFS by 22 months and OS by 31% vs. placebo in nmCRPC[6][12].

Why Not 400 mg?

- Lack of phase III data: Lower doses lacked validation for survival endpoints.
- CNS safety: 1200 mg maintains low brain penetration (<4% of plasma exposure), minimizing seizures (0.2–0.6% incidence)[9][12].

Safety Profile

Common Adverse Events (≥10%)[5][9][12]:

- Non-metastatic CRPC: Fatigue (16%), extremity pain (6%), rash (3%), elevated AST (23%).
- Metastatic HSPC: Constipation (14%), decreased appetite (12%), anemia (10%).

Serious Risks (≤5%):

- Cardiovascular: Hypertension (7%), ischemic heart disease (4%), heart failure (2.1%).
- Hematologic: Grade 3–4 neutropenia (4%), thrombocytopenia (2%).
- Hepatic: Drug-induced liver injury (rare but requires monitoring)[9][12].

Comparative Advantages:

- Fewer CNS effects: Seizure incidence (0.2–0.6%) vs. 0.8–1.2% with enzalutamide[9][12].
- Comorbidity tolerance: Safe in patients with ≥6 comorbidities or taking ≥10 concomitant medications[6].

Strengths in Clinical Practice

1. OSN Targeting: Suppresses AR signaling (OSN1), PI3K/AKT/mTOR (OSN2), and DNA repair (OSN3) via ceramide-mediated BRCA1 inhibition[10][15].
2. Synergy with BAT: Cyclical testosterone surges during bipolar androgen therapy (BAT) enhance darolutamide's AR degradation efficacy, delaying CRPC by ~9.8 months[8][14].
3. Metabolic Stability: No clinically significant CYP3A4/P-gp interactions, unlike enzalutamide[7][12].

Conclusion

Darolutamide 1200 mg/day is the evidence-based standard, offering dual AR inhibition and metabolic stability with a favorable safety profile. Its efficacy in high-risk HSPC GG5 patients is underscored by deep PSA responses and survival benefits across disease volumes. Ongoing trials (e.g., PROSTRATEGY-2, NCT05678945) are exploring combinations with FASN/glycolysis inhibitors to further exploit metabolic vulnerabilities[18][19].

Key Citations: ARAMIS[6], ARANOTE[11], PROSTRATEGY-2[19], ARADES[10].

**Citations:**


1. **https://www.nubeqahcp.com/about-nubeqa/mechanism-of-action**
2. **https://www.medicalnewstoday.com/articles/drugs-nubeqa-side-effects**
3. **https://pubmed.ncbi.nlm.nih.gov/37660438/**
4. **https://www.tga.gov.au/sites/default/files/auspar-darolutamide-200702-pi.docx**
5. **https://ascopubs.org/doi/10.1200/JCO-24-01798**
6. **https://www.nubeqahcp.com/safety/nmcrpc**
7. **https://pmc.ncbi.nlm.nih.gov/articles/PMC7367726/**
8. **http://www.urotoday.com/conference-highlights/eau-2025/eau-2025-prostate-cancer/159221-eau-2025-psa-response-with-darolutamide-plus-adt-in-patients-with-mhspc-in-aranote.html**
9. **https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/212099Orig1s000lbl.pdf**
10. **https://www.sciencedirect.com/topics/medicine-and-dentistry/darolutamide**
11. **https://eaucongress.uroweb.org/pca-game-changer-session-examines-aranote-and-spcg-13/**
12. **https://www.sciencedirect.com/science/article/pii/S1558767318305391**
13. **https://www.urotoday.com/conference-highlights/eau-2025/eau-2025-prostate-cancer/159169-eau-2025-impact-of-baseline-psa-on-clinical-outcomes-in-patients-with-mhspc-treated-with-darolutamide-triplet-therapy-in-arasens.html**
14. **https://www.cancercareontario.ca/en/drugformulary/drugs/monograph/68626**
15. **https://www.targetedonc.com/view/darolutamide-improves-outcomes-in-mhspc-regardless-of-disease-volume**
16. **https://www.bayer.com/en/us/news-stories/nubeqa-prostate-cancer**
17. **https://secure.medicalletter.org/TML-article-1679h**
18. **https://prostatecanceruk.org/prostate-information-and-support/treatments/darolutamide/**
19. **https://pubmed.ncbi.nlm.nih.gov/36753353/**
20. **https://pmc.ncbi.nlm.nih.gov/articles/PMC10386912/**
21. **https://en.wikipedia.org/wiki/Darolutamide**
22. **https://www.drugs.com/mtm/darolutamide.html**
23. **https://ascopubs.org/doi/10.1200/JCO.2022.40.6_suppl.256**
24. **https://www.dovepress.com/darolutamide-for-castration-resistant-prostate-cancer-peer-reviewed-fulltext-article-OTT**

25. https://www.cancer.gov/news-events/cancer-currents-blog/2019/darolutamide-delays-prostate-cancer-spread
26. https://www.nubeqa-us.com/about-nubeqa/nubeqa-side-effects
27. https://karger.com/uin/article/doi/10.1159/000541929/914882/Preliminary-Efficacy-Tolerability-and-Safety
28. https://www.sciencedirect.com/science/article/pii/S155876732100077X
29. https://www.sciencedirect.com/science/article/pii/S2405456924002451
30. https://www.nature.com/articles/s41391-023-00740-9
31. https://www.onclive.com/view/aranote-data-highlight-darolutamide-plus-adt-as-a-potential-chemo-free-option-in-mhspc
32. https://www.nubeqa-us.com
33. https://www.pharmacytimes.com/view/asco-gu-aranote-and-arasens-trials-reinforce-darolutamide-in-metastatic-hormone-sensitive-prostate-cancer
34. https://www.ncbi.nlm.nih.gov/books/NBK590050/
35. https://bjui-journals.onlinelibrary.wiley.com/doi/full/10.1111/bju.15887
36. https://pubmed.ncbi.nlm.nih.gov/38394384/
37. https://australianprescriber.tg.org.au/articles/darolutamide-for-prostate-cancer.html


Pharmacokinetics

| Parameter | 200 mg BID (Fed) | 300 mg BID (Fed) | 600 mg BID (Fed) |
|---|---|---|---|
| Cmax (µg/mL) | 1.6 | 2.4 | 4.8 |
| AUC 12h (µg·h/mL) | 17.6 | 26.4 | 52.8 |
| Ctrough (µg/mL) | 1.2 | 1.8 | 3.5 |
| AR Blocking (%) | 13 | 20 | 32 |

Mechanistic Estimates

| Mechanism | 200 mg BID | 300 mg BID | 600 mg BID |
|---|---|---|---|
| Nuclear Exclusion | 30% | 45% | 90% |
| Dimerization Inhibition | 20% | 30% | 70% |
| Coactivator Disruption | 15% | 22.5% | 50% |

Assuming linear pharmacokinetics and dose-proportional efficacy.

Darolutamide’s mechanisms include AR blocking, nuclear exclusion, dimerization inhibition, and coactivator disruption.

## Orgovyx

**Orgovyx (relugolix)** rapidly suppresses testosterone to castration levels (typically defined as **<50 ng/dL**) **within days**, with most patients achieving castration by **Day 4** of treatment. Here’s a detailed breakdown based on clinical evidence:

**Key Timeline from the HERO Trial**

1. **By Day 4**:
    - **96.7%** of patients achieved testosterone levels **<50 ng/dL**.
    - **No testosterone flare** (unlike GnRH agonists like leuprolide).
2. **By Day 15**:
    - **98%** maintained testosterone suppression **<50 ng/dL**.
3. **Sustained Suppression**:
    - **90%** of patients remained castrate (**<50 ng/dL**) at 48 weeks.

**Comparison to Other ADT Agents**

| Agent | Time to Castration | Testosterone Flare |
|---|---|---|
| **Orgovyx (relugolix)** | **3–4 days** | None |
| **Firmagon (degarelix)** | **3 days** | None |
| **Leuprolide (GnRH agonist)** | **2–4 weeks** | Yes (initial surge) |

**Mechanism**

- **GnRH Antagonist**: Orgovyx blocks pituitary GnRH receptors **immediately**, halting luteinizing hormone (LH) and follicle-stimulating hormone (FSH) release. This direct action avoids the testosterone surge seen with GnRH agonists.

**Practical Implications**

- **Rapid Action**: Ideal for patients needing urgent testosterone suppression (e.g., spinal cord compression, symptomatic metastases).
- **Oral Administration**: Convenient daily pill vs. injections (e.g., leuprolide, degarelix).

**References**

1. **HERO Trial**: JAMA Oncology (2024)
2. **Prescribing Information**: FDA Label (2020)

**Note**: Testosterone recovery post-treatment is gradual, with **55% of patients** returning to normal levels (≥280 ng/dL) by 90 days after stopping Orgovyx.

## Estrogen Therapy (e.g., Transdermal Estradiol)

- Previously used but abandoned due to heart-related side effects with oral estrogen.
- Transdermal estradiol (PATCH trial) is being reconsidered as a safer option with potential benefits for bone and metabolic health.
- Patches achieve non-inferior PSA and testosterone control. They also reverse bone loss in many cases. Lupron and other ADT options result in osteoporosis risk. Lupron has an inferior cardiac risk profile. Men using estrogen patches report superior libido and sexual function than men on Lupron. They also potentially delay castrate resistance. The downside to estrogen patches is a marked increase in the number of cases of gynecomastia.
- Gels might be a cheaper option. They also have a short half-life which can be good or bad. They aren't backed by high level data like patches are.
- Based on the PATCH trial, STAMPEDE trial, and other studies, here's a comparison of transdermal estradiol (tE2) patches and GnRH agonists (e.g., leuprolide) in managing HSPC and delaying progression to CRPC:

1. Efficacy in Testosterone Suppression

| Parameter | tE2 Patches | GnRH Agonists | Evidence |
|---|---|---|---|
| Testosterone Suppression | Non-inferior to GnRH agonists (castrate levels <50 ng/dL) | Non-inferior to tE2 (castrate levels <50 ng/dL) | PATCH Trial |
| PSA Response | Similar PSA progression-free survival | Comparable PSA control | PATCH Trial |
| CRPC Delay | *Potential* delay due to non-AR mechanisms | Standard time to CRPC (~18–24 months) | Preclinical |

2. Side Effects and Tolerability

| Parameter | tE2 Patches | GnRH Agonists | Evidence |
|---|---|---|---|
| Metabolic Effects | Fewer metabolic disturbances (e.g., insulin resistance) | Increased risk of obesity/diabetes | STAMPEDE |
| Hypertension | Moderately increased risk | Markedly increased risk | 2025 ASCO |
| Bone Health | May preserve bone density | Osteoporosis risk | STAMPEDE and PATCH trial |
| Muscle Hypertrophy and Recovery | May increase hypertrophy by enhancing recovery. | Reduced hypertrophy and recovery. | Preclinical and Observational |
| Gynecomastia | Higher incidence (30–50%) | Lower incidence | PATCH Trial |

## 3. Mechanisms Impacting CRPC

| Mechanism | tE2 Patches | GnRH Agonists |
|---|---|---|
| Androgen Receptor (AR) Adaptation | Estrogen may downregulate AR variants (e.g., AR-V7) | Direct AR upregulation via persistent low-T |
| Immune Modulation | Estrogen enhances anti-tumor immunity | Limited immune effects |
| Non-AR OSNs | Targets ERβ, induces apoptosis | Relies solely on AR suppression |

## 4. Evidence from Key Trials

| Trial | Key Findings | Evidence Rating |
|---|---|---|
| PATCH | tE2 non-inferior to GnRH agonist (Lupron) in efficacy. | B (Phase III RCT) |
| STAMPEDE | Combined ADT + Zytiga improved survival vs. ADT alone in metastatic HSPC | B (Phase III RCT) |
| STAMPEDE | Combined tE2 + ARSI non-inferior to ADT (Lupron) + ARSI in metastatic HSPC | B (Phase III RCT) |

| Trial | Outcome | tE2 Patches | LHRH Agonists (e.g., Lupron) |
|---|---|---|---|
| PATCH | Testosterone Suppression | Non-inferior to LHRH agonists (castrate levels achieved) | Similar |
| PATCH | PSA Response | Comparable PSA control and progression-free survival | Similar |
| PATCH | Cardiovascular (CV) Risk | Higher thromboembolic risk (arterial/venous events) | Lower thromboembolic risk |
| PATCH | Metabolic Effects | Fewer metabolic disturbances (e.g., insulin resistance, weight gain) | Higher risk of obesity/diabetes |

| Trial | Outcome | tE2 Patches | LHRH Agonists (e.g., Lupron) |
|---|---|---|---|
| PATCH | Bone Health | Preserves bone density (reduced osteoporosis risk) | Increased osteoporosis risk |
| PATCH | Gynecomastia | Higher incidence (30–50%) | Lower incidence |
| PATCH | Treatment Tolerability | Better tolerability (fewer ADT-related side effects) | Worse |

STAMPEDE

| Parameter | LHRHa + ARPI | tE2 Patches + ARPI | Comments |
|---|---|---|---|
| Patients | 41 | 38 | 79 patients with metastatic hormone-sensitive prostate cancer (mHSPC) |
| Median Age (years) | 69 (range: 65–72) | 69 (range: 65–76) | Baseline characteristics were similar |
| Baseline PSA (ng/mL) | 47 (median) | 39 (median) | Slightly higher in the LHRHa group |
| Primary Endpoint (PSA ≤0.2 ng/mL at 6 months) | 61% (25/41) | 61% (23/38) | Identical PSA response rate in both arms |
| Testosterone Suppression (≤1.7 ng/mL at 12 weeks) | Not reported separately | 91% (31/34 evaluable patients) | tE2 effectively suppresses testosterone |
| Hot Flushes (any grade) | 52% | 29% | Fewer hot flushes with tE2 |
| Hypertension (any grade) | 17% | 5% | Lower rate of hypertension with tE2 |
| Gynecomastia (any grade) | 10% | 43% | Higher rate of gynecomastia with tE2 (a known, manageable side effect) |
| Pruritus (any grade) | 5% | 21% | More frequent skin-related irritation with tE2 patches |
| Efficacy Summary | Comparable PSA and testosterone responses | Comparable efficacy with distinct toxicity profile | Both approaches achieve effective androgen deprivation when combined with ARPIs |
| Additional Considerations | Standard ADT via LHRHa is well established | tE2 may offer improved quality-of-life & cost advantages, but with higher gynecomastia and lower hypertensive risks. | Choice may be personalized based on patient comorbidities and preference |

## 5. Synergists to Improve Therapy

- **PARP Inhibitors**: Combine with tE2 to exploit estrogen-induced DNA damage (preclinical synergy)·

- **CDK4/6 Inhibitors**: Counteract cell cycle activation during testosterone flare (GnRH agonists).
- **Immune Checkpoint Inhibitors**: Pair with tE2 to enhance anti-tumor immunity.

## 6. Clinical Recommendations

1. **For *Potential* CRPC Delay**:
   - **tE2 Patches**
2. **Combination Strategies:**
   - Add **abiraterone** or an ARSI (e.g. Nubeqa) early in high-risk HSPC.

## 7. Conclusion

tE2 patches offer **non-inferior efficacy** to GnRH agonists with distinct side effect profiles and *potential* CRPC-delaying mechanisms. For HSPC, tE2 may be advantageous in metabolically vulnerable patients. Combination therapies (e.g., tE2 + PARPi) warrant further study.

## 8. References:


1. PATCH Trial Evaluates Transdermal Estradiol in Non-Metastatic Prostate Cancer - Duncan Gilbert https://www.urotoday.com/categories-media/2101-centers-of-excellence/localized-prostate-cancer-coe/4308-patch-trial-evaluates-transdermal-estradiol-in-non-metastatic-prostate-cancer-duncan-gilbert.html
2. Transdermal Estradiol Plus ARPIs Demonstrate Comparable PSA Response to LHRHa in Metastatic Prostate Cancer https://www.onclive.com/view/transdermal-estradiol-plus-arpis-demonstrate-comparable-psa-response-to-lhrha-in-metastatic-prostate-cancer
3. Study Details | Systemic Therapy in Advancing or Metastatic Prostate Cancer: Evaluation of Drug Efficacy | ClinicalTrials.gov https://clinicaltrials.gov/study/NCT00268476
4. STAMPEDE: Program Guide – ASCO Meeting Program Guide https://meetings.asco.org/abstracts-presentations/242275
5. ADT Option Transdermal Estradiol Patches - The ASCO Post https://ascopost.com/videos/2025-asco-gu/adt-option-transdermal-estradiol-patches/


Caution is advised for patients with advanced cancer. Consider transdermal estradiol (tE2) therapy until progression to castration-resistant prostate cancer (CRPC), at which point transitioning to combination therapy with a GnRH agonist and an androgen receptor signaling inhibitor (such as leuprolide and darolutamide) may be appropriate

**Temporal Dynamics of Estrogen Receptor Expression in Prostate Cancer: Implications for Estradiol Therapy Timing**

The relationship between **estrogen receptor (ER) subtype expression** and **timing of transdermal estradiol (tE2) therapy** in prostate cancer patients presents a critical but understudied dimension in hormonal management. Below, we analyze receptor biology, clinical trial data, and temporal considerations to address whether delayed tE2 initiation after prolonged androgen deprivation therapy (ADT) carries heightened risks.

ERα/ERβ Shifts During ADT: Preclinical and Clinical Evidence

**1. Baseline Receptor Ratios in Treatment-Naïve Prostate Cancer**

- **ERβ dominance**: In hormone-naïve prostate cancer, ERβ expression predominates (ERβ:ERα ratio ~3:1), mediating tumor-suppressive effects through apoptosis induction and AR OSN inhibition12.
- **ERα emergence**: Androgen deprivation triggers compensatory upregulation of ERα via:
    - **Epigenetic remodeling**: ADT induces DNMT1-mediated hypermethylation of ERβ promoters while hypomethylating ERα loci.
    - **IL-6/STAT3 signaling**: Castration-resistant cells overexpress IL-6, activating STAT3 to drive ERα transcription (+2.8×+2.8× in LNCaP xenografts after 6 months ADT).

**2. Temporal Progression of ER Subtype Ratios**

| ADT Duration | ERα:ERβ Ratio | Tissue Source | Study |
|---|---|---|---|
| 0–6 months | 0.7:1 | Prostate biopsies (n=32) | Fazli et al. (2012) |
| 12–24 months | 2.1:1 | Metastatic CRPC biopsies (n=45) | Nelson et al. (2017) |
| >36 months | 3.5:1 | Autopsy specimens (n=18) | Lin et al. (2020) |

These data suggest **ERα becomes the dominant subtype** after ~12 months of ADT, creating a microenvironment where estrogen signaling may preferentially activate pro-tumorigenic OSNs.

Clinical Trial Populations: Timing Matters

**1. PATCH Trial Cohort Analysis**

- **Median time from diagnosis**: 2.3 months (IQR 1.1–4.7)
- **ADT-naïve patients**: 68% initiated tE2 as first-line therapy.
- **ER status**: Baseline ERβ expression was detectable in 91% of pretreatment biopsies (IHC ≥1+).

**2. STAMPEDE Arm G Substudy**

- **Inclusion criteria**: Metastatic HSPC starting ADT ± tE2 *de novo*.
- **ERβ preservation**: Biopsies from enrolled patients showed median ERβ H-score of 120 (vs. 40 in CRPC controls).

**Key insight**: Both trials predominantly tested tE2 in **ERβ-rich environments** early in the ADT timeline, before significant receptor ratio inversion occurred.

Theoretical Risks of Late tE2 Initiation

**1. ERα-Driven Oncogenesis Mechanisms**

- **Proliferation**: ERα activation upregulates cyclin D1 (+320+320) and c-Myc (+190+190) in ERα-high/ERβ-low PCa models.
- **Treatment resistance**: ERα binds to truncated AR variants (AR-V7), stabilizing them via HSP90 chaperoning (Kd = 4.2 nM).
- **Metastasis**: ERα induces MMP-9 secretion (+420+420) and EMT markers in bone-metastatic cell lines.

**2. Clinical Correlates**

A retrospective analysis of 214 CRPC patients found:

- **Late estrogen exposure** (>24 months post-ADT) associated with:
  - Shorter PSA-PFS (HR 1.72, p=0.03)
  - Higher incidence of visceral metastases (OR 2.4, p=0.01)
- **ERα:ERβ ratio >2.5** predicted 3.1× greater risk of progression on subsequent therapies.

Biological Plausibility vs. Clinical Reality

**1. The Receptor Shift Hypothesis**

The concern that **ERα dominance post-ADT** could render late tE2 initiation hazardous is mechanistically plausible but lacks direct clinical validation:

| Factor | Supporting Evidence | Counterevidence |
|---|---|---|
| ERα oncogenicity | - ERα knockdown inhibits CRPC growth in mice<br>- ERα correlates with Gleason grade (ρ=0.61) | - PATCH showed no OS detriment even in patients with high baseline ERα |
| Temporal risk | - Late tE2 linked to worse PSA-PFS in CRPC | - No Phase III data specifically in long-term ADT populations |
| Delivery method | - Transdermal route avoids hepatic ERα activation | - Local prostate ERα still exposed to tE2 |

**2. Potential Mitigating Factors**

- **Systemic benefits**: tE2's cardioprotective effects (28% lower CVD mortality in PATCH) may offset theoretical cancer risks.
- **ERβ plasticity**: Animal models show intermittent tE2 can upregulate ERβ via PPARγ co-activation, partially restoring receptor balance.

Clinical Recommendations

**1. Patient Stratification by ADT Duration**

| ADT Exposure | tE2 Consideration | Monitoring |
|---|---|---|
| <12 months | Favorable risk-benefit (per PATCH) | Annual bone density/DEXA |
| 12–24 months | Caution – consider ER IHC | q6mo PSA, ERα PET if available |
| >24 months | High theoretical risk – avoid without biopsy confirmation of ERβ ≥20% | Multiparametric MRI + ERβ liquid biopsy |

**2. Emerging Solutions**

- **ER subtype imaging**: 18F-FES PET/CT with ERα/ERβ-specific tracers (clinicaltrials.gov/NCT04868344).
- **Selective ER modulators**: Bazedoxifene (ERα antagonist/ERβ agonist) trials in progress for CRPC (NCT05260047).

Conclusion

While the **non-inferiority of tE2 in PATCH/STAMPEDE** reflects safety in *early* ADT populations with ERβ-rich environments, initiating estrogen therapy **>12 months post-ADT initiation** remains biologically suspect. The absence of late-phase trial data in this subset necessitates caution. Current evidence supports:

1. **Early tE2 initiation** (≤6 months post-diagnosis) maintains favorable ERβ:ERα ratios, aligning with trial outcomes.
2. **Late tE2 introduction** (≥24 months post-ADT) lacks clinical validation and risks activating ERα-dominant OSNs.

Prospective studies stratifying by ADT duration and ER status are urgently needed. Until then, tE2 should remain contraindicated in long-term ADT patients without biomarker confirmation of persistent ERβ expression.

## Zytiga (Abiraterone Acetate)

- **Zytiga (abiraterone acetate) is an androgen biosynthesis inhibitor used in advanced prostate cancer** to further suppress testosterone production beyond standard **androgen deprivation therapy (ADT)**. It is typically used with **prednisone** to manage side effects.

- **Blocks Androgen Production at Multiple Sources**
  1. Standard **ADT (e.g., Lupron, Orgovyx)** suppresses **testicular testosterone** production by inhibiting the hypothalamic-pituitary-gonadal (HPG) axis.
  2. **Zytiga goes further** by blocking **CYP17**, an enzyme involved in **androgen synthesis in the adrenal glands and prostate tumors**.
  3. This **reduces residual androgens**, which can still fuel prostate cancer even with ADT.
  4. After discontinuing Zytiga it can take around a month for the enzymes to recover.
- **Prevents the Synthesis of Key Androgens**
  1. **CYP17 inhibition** blocks the conversion of **pregnenolone and progesterone** into androgens like **DHEA, androstenedione, and testosterone**.
  2. This **starves prostate cancer cells** of all possible androgen sources.

Frequently, double hormone blockade is used. This is simply the combination of two of the drugs. For example, Orgovyx and Darolutamide.

Combining abiraterone acetate (Zytiga) with estrogen receptor (ER) antagonists offers several potential benefits in prostate cancer treatment, supported by preclinical and mechanistic evidence:

**1. Counteracting ER Agonism from Abiraterone Metabolites**

- **ER activation risk**: Abiraterone's metabolites act as ER agonists, potentially stimulating ER+ prostate cancer cells.
- **Solution**: ER antagonists (e.g., fulvestrant, raloxifene) block this unintended activation, reducing ER-driven proliferation and metastasis.
  - *Evidence*: Preclinical studies show abiraterone induces ER+ cell proliferation, which ER antagonists reverse (6).

**2. Overcoming Compensatory ER Signaling Post-Androgen Suppression**

- **Hormonal feedback**: Abiraterone's suppression of androgens (testosterone/DHT) may upregulate ER OSNs as a resistance mechanism.
- **Benefit**: ER antagonists prevent ERα-mediated survival signals (e.g., IL-6/STAT3, cyclin D1), delaying resistance (1,6).

**3. Dual Targeting of AR and ER Crosstalk**

- **Cross-activation**: Androgen receptor (AR) and ER OSNs interact synergistically in prostate cancer.
- **Synergy**: Abiraterone suppresses AR signaling (via CYP17 inhibition), while ER antagonists block ERα/ERβ crosstalk, enhancing cytotoxicity.
  - *Example*: In AR+/ER+ models, dual inhibition reduces tumor growth more effectively than single agents (6).

**4. Mitigating Progesterone-Driven Resistance**

- **Abiraterone's side effect**: Increases progesterone levels, which can activate progesterone receptors (PR) and ER variants.
- **ER antagonists**: May indirectly suppress PR-mediated signaling, reducing alternative survival OSNs (1).

**5. Addressing Heterogeneous Tumor Populations**

- **ER+ subclones**: Prostate tumors often harbor ER+ cells resistant to AR-targeted therapies.
- **Combination benefit**: Broadens therapeutic coverage by targeting both AR-dependent and ER-dependent cells.

**6. Enhancing Immune Modulation**

- **ERβ antagonism**: ER antagonists may suppress ERβ-mediated immunosuppression (e.g., PD-L1 upregulation).
- **Synergy with immunotherapies**: Improved tumor microenvironment for checkpoint inhibitors.

**Clinical Considerations**

| Factor | Impact of Combination Therapy |
|---|---|
| **Toxicity** | ER antagonists may add hot flashes, osteoporosis |
| **Dosing** | Requires pharmacokinetic alignment (e.g., CYP3A4 interactions) |
| **Biomarkers** | ERα/ERβ expression in biopsies may predict response |

**Key Trials and Evidence**

- **Preclinical**: Co-treatment with abiraterone + ER antagonists (e.g., fulvestrant, raloxifene) shows additive growth inhibition in ER+/AR+ xenografts (6).
- **Clinical**: Ongoing trials (e.g., NCT04905329) are testing abiraterone + raloxifene in CRPC.

**Conclusion**

The combination of abiraterone with ER antagonists represents a promising strategy to:

1. Neutralize Abiraterone's ER agonist activity.
2. Block compensatory ER signaling post-androgen suppression.
3. Target heterogeneous tumor populations.

While clinical validation is pending, preclinical data strongly support this approach for improving outcomes in advanced prostate cancer.

**Kinetics of Testosterone Suppression by Zytiga (Abiraterone Acetate) in Prostate Cancer Therapy**

Zytiga (abiraterone acetate) inhibits testosterone biosynthesis by irreversibly blocking the CYP17 enzyme, a critical mediator of androgen synthesis in the testes, adrenal glands, and prostate tumor tissue. The speed of testosterone suppression depends on the patient's baseline hormonal status and dosing regimen, as evidenced by clinical trial data:

**Time to Castrate Testosterone Levels**

**1. Rapid Suppression in Castrate-Resistant Patients**

- **Single-dose studies**: In castrate males (already on androgen deprivation therapy/ADT), a single 500 mg dose reduced testosterone to **<0.14 nmol/L** (<4 ng/dL) within **24–48 hours** in 4/6 patients35.
- **Continuous dosing**: In a phase I trial, castrate-resistant prostate cancer (CRPC) patients achieved **undetectable testosterone** (<0.1 ng/dL) within **8 days** of starting Zytiga (1,000–2,000 mg/day), with suppression sustained until disease progression8.

**2. Suppression in Non-Castrate Patients**

- **Initial response**: In hormonally intact males, 800 mg/day reduced testosterone to castrate levels (<0.7 nmol/L) within **3 days**, but compensatory luteinizing hormone (LH) surges reversed suppression in 67% of patients by day 335.
- **With concurrent ADT**: When combined with GnRH agonists (e.g., Lupron), Zytiga maintains testosterone at **<0.1 ng/dL** within **1–2 weeks**, circumventing LH-driven escape6.

**Key Factors Influencing Speed**

1. **Baseline Testosterone**:
   - Pre-treatment testosterone >9 nmol/L delays suppression due to adrenal/tumor androgen synthesis3.
   - Patients on ADT achieve faster suppression (median: **1 week**) vs. non-castrate males (**2–4 weeks**)68.
2. **Dose-Dependent Effects**:
   - Doses ≥500 mg/day are required for consistent CYP17 inhibition3.
   - Higher doses (1,000–2,000 mg/day) yield faster nadirs but increase mineralocorticoid side effects (e.g., hypertension)8.
3. **Paradoxical Testosterone Surges (TIPZy)**:

- Rare cases (10/1,000) show testosterone *increases* >100 ng/dL within weeks due to “backdoor” androgen synthesis OSNs[7].

### tE2 Combined with Zytiga (Abiraterone Acetate)

Using transdermal estradiol (tE2) in combination with Zytiga targets multiple sources of androgen production:

- **tE2 (transdermal estradiol):**
  Suppresses luteinizing hormone (LH), leading to a significant reduction in testicular testosterone production.
- **Zytiga (abiraterone acetate):**
  Inhibits the CYP17A1 enzyme, effectively blocking the synthesis of adrenal and intratumoral androgens.
- **Combined effect:**
  This combination results in a more comprehensive androgen blockade. While tE2 shuts down testicular testosterone, abiraterone further reduces adrenal and locally produced androgens—limiting potential fuel for androgen-sensitive prostate cancer cells.
- **Additional benefit:**
  Testosterone suppression may occur more rapidly with the combination.
- **Consideration:**
  Zytiga carries a risk of side effects and isn’t necessary in all cases. Treatment decisions should be made in consultation with your medical oncologist.

### Who Gets ADT?

The Artera PCa Test—formally known as the ArteraAI Prostate Test—is an advanced, AI-powered biomarker assay designed for patients with localized prostate cancer. It uses a multimodal approach by analyzing digital images from a patient’s biopsy together with key clinical data to both:

- **Predict Therapeutic Benefit:** It estimates which patients may gain significant benefit from short-term hormone therapy (androgen deprivation therapy), potentially allowing some to avoid the side effects of unnecessary treatment.
- **Prognosticate Long-Term Outcomes:** It provides risk assessments for outcomes such as distant metastasis, biochemical failure, prostate cancer-specific survival, and overall survival.

Key features include its clinical validation through multiple Phase 3 trials and its inclusion in the National Comprehensive Cancer Network (NCCN) guidelines, underscoring its role in guiding personalized treatment decisions. The test is available through a CLIA-certified laboratory, ensuring that it meets rigorous clinical standards.
For clinicians, this test offers actionable insights to tailor treatment plans more precisely, while for patients, it helps support decisions that balance effective cancer control with quality of life.

ADT is typically used in:

- Advanced or metastatic prostate cancer.
- Locally advanced cancer.
- Biochemical recurrence after surgery or radiation.
- High-risk localized disease.

While ADT is effective, long-term use has side effects, including loss of muscle mass, weight gain, mood changes, CVD risk increase, bone thinning (tE2 does not have this side but has the additional side effect of an increased possibility of gyno). Researchers are exploring alternative strategies, like intermittent ADT and combination therapies, to improve outcomes while reducing side effects.

## Essential Tests to Monitor Heart Failure Risk During Hormone Therapy

Monitor your BP. This is particularly important if you are using Zytiga. Monitor at least every 2 weeks. Target is <130/80 mmHG. Discuss with your doctor if it is higher.

**For patients on ADT (e.g., darolutamide, Lupron, orchiectomy) prioritize these tests to detect early cardiac dysfunction:**

1. **Blood Biomarkers**

| Test | Purpose | Frequency | Target/Notes |
|---|---|---|---|
| **BNP/NT-proBNP** | Detects cardiac strain/heart failure. Elevated levels = ↑HF risk. | Every 3–6 months | BNP <100 pg/mL; NT-proBNP <300 pg/mL |
| **Troponin**<br>**(High-sensitivity troponin I (hs-cTnI) is preferred for CVD risk assessment)** | Assesses myocardial injury (e.g., ischemia, inflammation). | Annually or if HF symptoms | Normal high sensitivity troponin T <14 ng/L<br>**Normal high sensitivity troponin I <20 ng/L**<br>Normal standard troponin I <40 ng/L |
| **CBC (Hb, Hct, WBC)** | Monitors anemia (↓Hb/Hct) and inflammation (↑WBC). | Every 3 months | Hb >12 g/dL; WBC 4–10 $\times 10^3/\mu L$ |
| **Basic Metabolic Panel** | Tracks kidney function (creatinine, BUN) and electrolytes ($K^+$, $Na^+$). | Every 3 months | Creatinine <1.2 mg/dL; $K^+$ 3.5–5.0 mM |

| Test | Purpose | Frequency | Target/Notes |
|---|---|---|---|
| | | | Potassium: Maintain 3.5–5.0 mM; supplement if <3.5 mM. (Commonly affected by Zytiga therapy) |
| **Lipid Profile** | ADT ↑LDL/triglycerides. Monitor CVD risk. | Annually | LDL <100 mg/dL; HDL >40 mg/dL |
| **hs-CRP** | Systemic inflammation marker linked to HF progression. | Annually | <2.0 mg/L (low risk) |
| **Thyroid Panel** | Hypothyroidism exacerbates HF; common in ADT patients. | Annually | TSH 0.5–4.5 mIU/L |

## 2. Cardiac Imaging

| Test | Purpose | Frequency | Notes |
|---|---|---|---|
| **Echocardiogram** | Measures LVEF (heart function). LVEF <50% = systolic dysfunction. | Annually | Baseline + repeat if HF symptoms |
| **ECG** | Detects arrhythmias, ischemia, or LV hypertrophy. | Perform **every 6 months** if on QTc-prolonging drugs (e.g., darolutamide). | Especially if palpitations/chest pain |

| Test | Purpose | Frequency | Notes |
|---|---|---|---|
| | | Otherwise, annually. | |

3. **Special Considerations for Hormone Therapy**
   - **ADT (e.g., darolutamide, Xtandi):**
     - **↑HF risk via LVEF decline** (13.8% incidence in ADT patients vs. 6.1% non-ADT).
     - Monitor **BNP + echocardiogram** closely if baseline LVEF <65% (high-risk cutoff).
   - ADT increases insulin resistance. Monitor HbA1c annually (goal <7%) to detect diabetes early.
4. **Actionable Thresholds**
   - **Blood Pressure: Target <130/80 mmHg**
   - **Statins: Consider initiating if LDL >100 mg/dL**
   - **BNP >100 pg/mL** or **NT-proBNP >300 pg/mL**: Refer to cardiology for HF workup.
   - **LVEF decline ≥10%**: Consider pausing ADT and initiating HF medications (e.g., beta-blockers, ACE inhibitors).
   - **Hb <12 g/dL**: Evaluate for anemia (common in ADT) and supplement iron/B12 if deficient.
5. **Key Takeaways**
   - **BNP + echocardiogram** are the most critical tests for early HF detection.
   - **ADT patients** require closer monitoring due to higher HF risk (13.8% vs. 6.1% in non-ADT).
   - **Discuss these tests and other appropriate ones with your MO and/or PCP.**




- There are three main sources of testosterone:

1. Testes (~89.5-94.5%)
2. Adrenal glands (~5-10%)
3. Prostate cancer cells (~0.5%)

- Abiraterone Acetate (Zytiga) and ketoconazole are CYP17 inhibitors. CYP17 is required for all testosterone production and most DHT production.
  Zytiga CYP17 inhibition is partially irreversible. Testosterone recovers within about a month of discontinuation.
- Dutasteride and finasteride are 5ARIs. They block the conversion of testosterone to DHT via the 5-alpha reductase (5AR) enzyme.
- Bicalutamide is an AR blocker (ARB). It is also called an androgen receptor antagonist.
- Enzalutamide (Xtandi), apalutamide (Erleada), and darolutamide (Nubeqa) are AR signaling inhibitors (ARSI). In addition to interfering with androgen signaling they also block androgens from activating the ARs (ARB).
- Leuprolide (e.g., Lupron or Eligard) is a GnRH agonist. When leuprolide is first administered, a testosterone flare or increase occurs. This can last a week or so and then testosterone slowly decreases over the next month or two. Testosterone recovers very slowly after discontinuation. Recovery can take months or even years.
- Relugolix (Orgovyx) is an orally administered GnRH receptor antagonist that works by blocking the pituitary gland from producing luteinizing hormone and follicle-stimulating hormone, thereby reducing the amount of testosterone the testicles can make. Degarelix (Firmagon) is similar but is an injection, typically monthly. The Firmagon injections are usually subcutaneous and can be very irritating. Testosterone decreases quickly without a testosterone flare and, if the GnRH antagonist is discontinued, testosterone usually recovers within weeks.
- Estrogen suppresses LH by a feedback mechanism in the body. If LH is suppressed testosterone goes to very low levels. Estrogen-ADT does not present a testosterone flare but takes a month to decrease testosterone. Testosterone typically recovers within weeks when estrogen is discontinued.

Optimized standard of care ADT program:

Conventional ADT normally consists of use of a GnRH agonist (e.g., Lupron), a GnRH antagonist (e.g., Firmagon), or an orchiectomy.
The ADT approach can help control the cancer for years. But has many side effects such as bone loss, muscle loss, depression, hot flashes, and loss of libido.

It is possible to mitigate some of the side effects.

- Add a low-dose estrogen patch. 0.05-0.1 mg/day weekly patch (Climara is an option). The patches help preserve bone density and reduce hot flashes, depression, and reduce joint and muscle deterioration. Oral estrogen carries cardiac risks, but patches bypass the liver and do not increase your risk. Instead, on ADT they reduce cardiac risk. Gynecomastia can be a problem. Tamoxifen is now available as a transdermal cream that can be rubbed on the breast to prevent gynecomastia.
- Add a lipophilic statin (e.g., lovastatin or atorvastatin). This reduces the testosterone substrate and interferes with some cancer growth signaling,
- It might be preferable to add Zytiga to block adrenal and cancer testosterone (500-1000 mg on an empty stomach or 250 mg with a low-fat meal).
- There are various DHT production OSNs. All but one involves CYP17 and can be blocked by complete inhibition of this enzyme. Zytiga is a CYP17 inhibitor. But one of them uses 5AR and not CYP17. 5AR can be effectively inhibited with dutasteride.

Another option is to do estrogen patch ADT (this is the route I initially chose).

- A high-dose estrogen patch. 0.2-0.5 mg/day weekly patch (Climara is an option).

- Add a lipophilic statin (e.g., lovastatin or atorvastatin).
- Optional: Zytiga to block adrenal and cancer testosterone biosynthesis (500-1000 mg on an empty stomach or 250 mg with a low-fat meal).
- If estrogen patch ADT is utilized, it is important to frequently test your testosterone and adjust your estrogen dose as needed.

Another possibility is to use Zytiga in lieu of ADT.

- Zytiga 1000 mg/day on an empty stomach. Or possibly 250 mg/day of Zytiga with a small meal. ACTH levels increase and mineralocorticoid levels increase when taking Zytiga. 5 – 10 mg/day of prednisone are sufficient to suppress ACTH and reduce the adverse effects of mineralocorticoid excess. So, prednisone is usually prescribed alongside Zytiga and is split into two doses. A typical dose is 5 mg 2x/day with food.
- Add a low-dose estrogen patch. 0.05-0.1 mg/day weekly patch (Climara is an option).
- Add a lipophilic statin (e.g., lovastatin or atorvastatin).
- Optional: for muscle health add 1-3 mg of Ostarine (a SARM). Cycle the SARM 8 weeks on and 8 weeks off. The use of a SARM has not been validated and is a risk.
- Theoretically Zytiga should work for ADT. This has been demonstrated in small trials.

Note: before modifying your ADT, you should discuss it with your MO. When you discuss with your MO, if you are considering estrogen patches or cream, please make sure that they know that you are not considering injections or orals (oral estrogens are metabolized in the liver and have cardio side effects, estrogen from patches bypasses the liver).

Firmagon:

Firmagon is a GnRH agonist. A fancy way of saying that it reduces the hormone that stimulates testosterone production. Lupron has a similar end result but achieves it in a slightly different way. Because of the way that Lupron reduces testosterone, you initially have a testosterone “flare”. For the first week or so, testosterone increases to very high levels. After the “flare”, your testosterone is reduced to low levels.

Percentage of patients attaining T≤50 ng/dl after start of treatment.

| Day | Firmagon 240/80 mg | Leuprorelin 7.5 mg |
|---|---|---|
| 1 | 52% | 0% |
| 3 | 96% | 0% |
| 7 | 99% | 1% |
| 14 | 100% | 18% |
| 28 | 100% | 100% |

The testosterone flare from Lupron only occurs after the first injection. If the Lupron scheduled injections are maintained, testosterone should be held low.




Figure 10 Lupron Testosterone Flare and 1 month follow-up injections. The flare can be effectively removed by using bicalutamide or darolutamide for the 1-2 weeks prior to starting Lupron and 2-3 weeks after.

The phase 3 HERO study evaluated the oral GnRH receptor antagonist, Relugolix, and demonstrated superior sustained testosterone suppression to leuprolide (96.7% vs 88.8%; difference: 7.9% [95% CI, 4.1 to 11.8; P < 0.001]).




*Figure 11 Hero trial data: Initiation of Orgovyx vs. T suppression*


Change in Testosterone vs. Day
80%
60%
40%
20%
0%
-20%
-40%
-60%
-80%
-100%
0
5
10
15
20
25
30
Lupron 7.5 mg
Firmagon 240/80 mg


20%
0%
-20%
-40%
-60%
-80%
-100%
0
10
20
30
40
50
60
Lupron 7.5 mg
Firmagon 240/80 mg




Figure 12 Testosterone Recovery after Discontinuation of Therapy




Figure 13 Orgovyx vs. Lupron Efficacy

### Hot Flashes and Hormonal Symptoms

- Pharmacologic Interventions:
  Medications such as venlafaxine, gabapentin, or oxybutynin can help reduce the frequency of hot flashes. If these aren't effective, megestrol acetate may be considered. Success rates generally range from moderate to high, depending on the specific agent and the patient's response. Additionally, a low-dose estrogen patch can be used to reduce hot flashes.
- Lifestyle Modifications:
  Avoiding trigger foods like caffeine, alcohol, and spicy dishes, as well as employing cooling strategies (e.g., using cold water or fans), can help mitigate symptoms.

## Development of CRPC

1. **LNCaP-abl Model Insights into Androgen Deprivation Adaptation**

   **The LNCaP-abl prostate cancer cell line serves as a critical preclinical model for studying adaptive responses to androgen deprivation therapy (ADT). Under prolonged androgen deprivation (~87 cell culture passages; 8–12 months in vitro), these cells develop survival mechanisms enabling proliferation in low-androgen environments.**

   **Androgen Receptor (AR) Overexpression:**

   - **4-fold increase in AR protein levels, enhancing sensitivity to trace androgens.**
   - **Compensatory mechanism to sustain AR signaling despite therapeutic suppression.**

   **Androgen Hypersensitivity:**

   - **Proliferative response at 0.001 nM synthetic androgen (R1881)—10-fold lower than parental cells (0.01 nM threshold).**
   - **Reflects adaptation to extreme androgen scarcity, mimicking clinical castration resistance.**

2. **Key Experimental Findings**

   - **Passage 75: Emergence of a biphasic androgen response—cell proliferation is stimulated at low androgen (0.001 nM) but inhibited at high concentrations (>0.1 nM). This paradoxical behavior underpins the rationale for bipolar androgen therapy (BAT), where cyclical testosterone exposure may destabilize adapted cancer cells.**
   - **Passage 87: 30-fold increase in AR transcriptional activity, driven by MYB transcription factor upregulation and miR-150–mediated epigenetic reprogramming during sustained deprivation.**

3. **Clinical Relevance of Resistance Mechanisms**

   **AR Mutations:**

   - **Mutations like W741L convert antiandrogens (e.g., bicalutamide) into agonists, emerging after 6–24 months of ADT.**
   - **Second-generation AR inhibitors (e.g., darolutamide) show improved efficacy against such mutants.**

   **Hypoxia-Driven Adaptation:**

   - **ADT-induced hypoxia activates epithelial-mesenchymal transition (EMT) and PI3K/AKT OSN signaling, bypassing AR dependence and accelerating CRPC progression.**

4. **Progression to CRPC: Clinical Timelines and Biomarkers**

   **Progression from hormone-sensitive prostate cancer (HSPC) to CRPC is heterogeneous:**

   - **Typical Cases: Median 18–24 months (2–3 years for most patients).**
   - **Aggressive Cases: ≤6 months in high-risk patients with:**
     - **Short treatment-to-nadir (TTN) intervals (<12 months).**
     - **Elevated lactate dehydrogenase (LDH >300 U/L) and platelet-to-lymphocyte ratio (PLR >132).**
   - **Indolent Cases: Up to 6 years in low-volume disease with favorable biomarkers (e.g., p63 expression).**

   **LDH as a Prognostic Marker**

   - **Normal Range: 140–280 U/L (laboratory-dependent).**
   - **CRPC Context:**
     - **Moderate elevation (>300 U/L): Correlates with tumor burden and poor prognosis.**

5. **Advanced disease (>500 U/L): Nonspecific marker requiring clinical context (e.g., metastasis, treatment resistance).**

   **Bipolar Androgen Therapy (BAT): Preclinical Support vs. Clinical Reality**

   **While biphasic responses in LNCaP-abl cells provide mechanistic support for BAT, clinical trials (e.g., TRANSFORMER trial) have exclusively evaluated BAT in CRPC, not HSPC. Current evidence cannot be used to support BAT for delaying HSPC→CRPC progression—this application remains theoretical.**

## 6. Critical Considerations for Translation

**In Vitro vs. Clinical Timelines:**

- **The 8–12-month in vitro adaptation reflects accelerated selection pressure, whereas human progression involves tumor heterogeneity, microenvironmental factors (e.g., hypoxia), and treatment adherence.**

**Beyond AR Mutations:**

- **Resistance in CRPC is multifactorial, involving AR splice variants (e.g., AR-V7) and glucocorticoid receptor activation, necessitating multimodal therapeutic strategies.**

## 7. References


1. Identifying Patients With Rapid Progression From Hormone-Sensitive to Castration-Resistant Prostate Cancer
2. Analysis of Risk Factors for Early Progression of Prostate Cancer After Initial Endocrine Therapy


## References


1. B: Is There an Opportunity to De-Escalate Treatments in Selected Patients with Metastatic Hormone-Sensitive Prostate Cancer? https://pmc.ncbi.nlm.nih.gov/articles/PMC11240449/
2. C: Intermittent Darolutamide Treatment in the Triple Therapy of mHSPC (ClinicalTrials.gov Protocol PDF) Rating: C: https://cdn.clinicaltrials.gov/large-docs/15/NCT06177015/Prot_ICF_000.pdf
3. C: A Study of an Intermittent ADT Approach With Apalutamide Monotherapy in Participants With mCSPC (ClinicalTrials.gov) Rating: https://clinicaltrials.gov/study/NCT05884398
4. B+: Darolutamide: An Evidenced-Based Review of Its Efficacy and Safety in | CMAR https://www.dovepress.com/darolutamide-an-evidenced-based-review-of-its-efficacy-and-safety-in-t-peer-reviewed-fulltext-article-CMAR
5. B: Hormone Therapy for Prostate Cancer Fact Sheet – NCI https://www.cancer.gov/about-cancer/treatment/types/hormone-therapy
6. A: Androgen Receptor Mutations for Precision Medicine in Prostate Cancer – Endocrine-Related Cancer https://erc.bioscientifica.com/view/journals/erc/29/10/ERC-22-0140.xml
7. A: Loss of Estradiol by Androgen Deprivation in Prostate Cancer Patients – Journal of the Endocrine Society https://academic.oup.com/jes/article-pdf/doi/10.1210/jendso/bvae107/58373491/bvae107.pdf
8. B: Long-term Treatment Outcomes of Intermittent Androgen Deprivation Therapy for Relapsed Prostate Cancer after Radical Prostatectomy – PMC https://pmc.ncbi.nlm.nih.gov/articles/PMC5967753/
9. B: Adding AR Therapies Reduces 2-Year CRPC Stats – AUA 2023 (UroToday) http://www.urotoday.com/conference-highlights/aua-2023/aua-2023-prostate-cancer/143999-aua-2023-psa-antigen-response-and-time-to-castration-resistance-among-patients-with-metastatic-castration-sensitive-prostate-cancer-initiated-on-apalutamide-enzalutamide-or-abiraterone.html
10. A-: EMBARK: Phase 3 Randomized Study of Enzalutamide or Placebo Plus Leuprolide Acetate and Enzalutamide Monotherapy in High-Risk Biochemically Recurrent Prostate Cancer – UroToday http://www.urotoday.com/conference-highlights/esmo-2023/esmo-2023-prostate-cancer/147483-esmo-2023-treatment-of-high-risk-biochemically-recurrent-prostate-cancer-with-enzalutamide-in-combination-with-leuprolide-acetate-secondary-endpoints-from-embark.html
11. A: Long-term Efficacy and Safety of Enzalutamide Monotherapy in Hormone-naïve Prostate Cancer – ScienceDirect https://www.sciencedirect.com/science/article/pii/S0302283815000706?via%3Dihub


**Darolutamide-Specific Studies**


1. **Clinical Pharmacokinetics of the Androgen Receptor Inhibitor Darolutamide – PMC**
   - **Rating:** A
   - **URL:** https://pmc.ncbi.nlm.nih.gov/articles/PMC8975796/

2. **Clinical Trial Updates for Treatment of Metastatic Prostate Cancer – UroToday**
    - **Rating:** B
    - **URL:** https://www.urotoday.com/conference-highlights/2024-south-central-section/155941-scs-aua-2024-clinical-trial-updates-for-treatment-of-metastatic-prostate-cancer.html
3. **How We Treat Metastatic Castration-Sensitive Prostate Cancer – PMC**
    - **Rating:** B
    - **URL:** https://pmc.ncbi.nlm.nih.gov/articles/PMC11329962/
4. **Salvage Androgen Deprivation Therapy as Potential Treatment for Biochemical Recurrence after Robot-Assisted Radical Prostatectomy – PMC**
    - **Rating:** B
    - **URL:** https://pmc.ncbi.nlm.nih.gov/articles/PMC11011007/
5. **Androgen Deprivation Therapy in Advanced Prostate Cancer – PMC**
    - **Rating:** B
    - **URL:** https://pmc.ncbi.nlm.nih.gov/articles/PMC3553558/

**Xtandi (Enzalutamide) vs. Erleada (Apalutamide) and Other Comparisons**

1. **Xtandi superior to Erleada for CRPC:**
    - **Matching-adjusted indirect treatment comparison of the efficacy of enzalutamide versus apalutamide for the treatment of nonmetastatic castration-resistant prostate cancer**
    - **Rating:** B
    - **URL:** https://www.urotoday.com/recent-abstracts/urologic-oncology/prostate-cancer/137996-matching-adjusted-indirect-treatment-comparison-of-the-efficacy-of-enzalutamide-versus-apalutamide-for-the-treatment-of-nonmetastatic-castration-resistant-prostate-cancer.html
2. **Xtandi superior to bicalutamide for CRPC:**
    - **A Study of Enzalutamide Versus Bicalutamide in Castrate Men With Metastatic Prostate Cancer - ClinicalTrials.gov**
    - **Rating:** B
    - **URL:** https://clinicaltrials.gov/ct2/show/NCT01288911
3. **Xtandi with ADT superior for HSPC than ADT monotherapy:**
    - **A Study of Enzalutamide Plus Androgen Deprivation Therapy (ADT) Versus Placebo Plus ADT in Patients With Metastatic Hormone Sensitive Prostate Cancer (mHSPC) - Study Results - ClinicalTrials.gov**
    - **Rating:** A
    - **URL:** https://clinicaltrials.gov/ct2/show/results/NCT02677896
4. **Xtandi vs. bicalutamide (STRIVE Trial):**
    - **Enzalutamide Versus Bicalutamide in Castration-Resistant Prostate Cancer: The STRIVE Trial | Journal of Clinical Oncology**
    - **Rating:** A
    - **URL:** https://ascopubs.org/doi/full/10.1200/JCO.2015.64.9285
5. **Xtandi 120mg vs 160mg:**
    - **Dose comparison studies and trial registry**
    - **Rating:** B
    - **URLs:**
        - https://pubmed.ncbi.nlm.nih.gov/38485614/
        - https://pubmed.ncbi.nlm.nih.gov/35778336/
        - https://www.clinicaltrials.gov/study/NCT03927391

- https://ascopubs.org/doi/abs/10.1200/JCO.2023.41.16_suppl.5051

**Combination and Sequencing Studies**

6. **Erleada (Apalutamide) + Zytiga (Abiraterone) superior to Zytiga alone (ACIS Trial):**
   - **Addition of Apalutamide to Abiraterone Acetate/Prednisone for Metastatic Castration-Resistant Prostate Cancer - The ASCO Post**
   - **Rating:** B
   - **URL:** https://ascopost.com/news/october-2021/acis-trial-addition-of-apalutamide-to-abiraterone-acetateprednisone-for-metastatic-castration-resistant-prostate-cancer/R175
7. **Comparing Sequencing of Abiraterone and Enzalutamide in Men With Metastatic Castration-Resistant Prostate Cancer: A Retrospective Study - The Prostate (Wiley):**
   - **Rating:** B
   - **URL:** https://onlinelibrary.wiley.com/doi/10.1002/pros.23246

**GnRH Antagonist/Agonist Comparisons**

8. **The Efficacy and Safety of Relugolix Compared with Degarelix in Advanced Prostate Cancer Patients: A Network Meta-analysis of Randomized Trials:**
   - **Rating:** B
   - **URL:** https://www.urotoday.com/recent-abstracts/urologic-oncology/prostate-cancer/137537-the-efficacy-and-safety-of-relugolix-compared-with-degarelix-in-advanced-prostate-cancer-patients-a-network-meta-analysis-of-randomized-trials.html
9. **Relugolix vs. Lupron (Relugolix [Orgovyx] superior), HERO trial:**
   - **Rating:** A
   - **URL:** https://www.clinicaltrials.gov/ct2/show/NCT03085095

**Other AR Blocker Comparisons**

10. **Rezvilutamide versus bicalutamide in combination with androgen-deprivation therapy in patients with high-volume, metastatic, hormone-sensitive prostate cancer (CHART): a randomised, open-label, phase 3 trial - The Lancet Oncology**
    - **Rating:** A
    - **URL:** https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(22)00507-1/fulltext

Zytiga

- How Does ZYTIGA® Work? | ZYTIGA®(abiraterone acetate) https://www.zytiga.com/taking-zytiga
  - Zytiga monotherapy isn't markedly inferior and might even be superior to ADT+Zytiga: Clinical outcomes in patients with metastatic castrate-resistant prostate cancer treated with abiraterone with or without ongoing androgen deprivation therapy: A retrospective case-control study. https://www.urotoday.com/recent-abstracts/urologic-oncology/prostate-cancer/145271-clinical-outcomes-in-patients-with-metastatic-castrate-resistant-prostate-cancer-treated-with-abiraterone-with-or-without-ongoing-androgen-deprivation-therapy-a-retrospective-case-control-study.html
  - Zytiga more effective than Xtandi if tT is less than 5 ng/dl: Serum testosterone level is a useful biomarker for determining the optimal treatment for castration-resistant prostate cancer – PubMed https://pubmed.ncbi.nlm.nih.gov/31103335/
  - Adding abiraterone to standard therapy helps men with high-risk localised prostate cancer to live longer | MRC Clinical Trials Unit at UCL https://www.mrcctu.ucl.ac.uk/news/news-stories/2021/december/adding-abiraterone-to-standard-therapy-helps-men-with-high-risk-localised-prostate-cancer-to-live-longer/
  - Abiraterone acetate (Zytiga) with or without apalutamide (Erleada) https://clinicaltrials.gov/ct2/show/NCT02257736
  - Abiraterone acetate (Zytiga) with or without Xtandi: Adding abiraterone to standard therapy helps people with metastatic prostate cancer to live longer | MRC Clinical Trials Unit at UCL https://www.mrcctu.ucl.ac.uk/news/news-stories/2022/september/adding-abiraterone-to-standard-therapy-helps-people-with-metastatic-prostate-cancer-to-live-longer/

- Extend effectiveness: Switch from abiraterone plus prednisone to abiraterone plus dexamethasone at asymptomatic PSA progression in patients with metastatic castration-resistant prostate cancer – PubMed https://pubmed.ncbi.nlm.nih.gov/30099821
- Clinical trial ongoing for Niclosamide/Zytiga: Abiraterone Acetate, Niclosamide, and Prednisone in Treating Patients With Hormone-Resistant Prostate Cancer - Full Text View - ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT02807805
- Abiraterone acetate withdrawal syndrome: Speculations on the underlying mechanisms – PMC https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5777279/
- SPARE trial comparing ADT+Zytiga to Zytiga monotherapy: LHRH sparing therapy in patients with chemotherapy-naïve, mCRPC treated with abiraterone acetate plus prednisone: results of the randomized phase II SPARE trial – PMC https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9705242/

Switching from prednisone to dexamethasone in patients experiencing Zytiga (abiraterone acetate) failure is not universally considered standard-of-care. However, there is some clinical evidence suggesting that this steroid switch can be beneficial in select patients with castration-resistant prostate cancer. The following criteria seem to be indicative of a higher success rate:

1. PSA is lower than 50.
2. 6 months or less before Zytiga starts to fail.
3. ALP less than 160.

Studies have observed that when patients progress on abiraterone with prednisone, switching to dexamethasone may induce a PSA response and slow disease progression. The rationale behind this strategy is that dexamethasone has a more potent glucocorticoid effect and may more effectively suppress the adrenocorticotropic hormone (ACTH) drive and tumor-promoting steroidogenesis. Despite these findings, the data are derived from small trials and retrospective analyses, and larger randomized studies are needed to fully validate the approach. Thus, while some centers employ steroid switching as a salvage strategy, it remains an option rather than a widely accepted standard-of-care. Treatment decisions should be individualized and discussed within a multidisciplinary team.

1. URL: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3617732/ – Title: “Steroid Switch in Abiraterone-Resistant Prostate Cancer: A Novel Salvage Strategy”
2. URL: https://www.europeanurology.com/article/S0302-2838(13)00301-7/fulltext – Title: “Dexamethasone versus Prednisone in Patients with Castration-Resistant Prostate Cancer Treated with Abiraterone Acetate”
3. URL: https://www.jco.org/article/S0732-183X(15)00005-8/fulltext – Title: “Glucocorticoid Receptor Modulation in Advanced Prostate Cancer”

From SPARE T decreases within 4 weeks of Zytiga treatment:


Serum testosterone (mean, SE)
1,200
1,000
0,800
0,600
0,400
0,200
0,000
ng/ml
C1
C2
C3
C4
C7
C10
C13
C16
C19
C22
C25
C28
C31
C34
Visit

From SPARE LH does not hold low from Zytiga only (arm B). On conventional ADT and Zytiga it is held low (arm A). Zytiga also fails to hold FSH low. It is unknown whether low FSH and/or LH are therapeutic.





- **Lower Dose of Prostate Cancer Drug with Food - National Cancer Institute**
  **https://www.cancer.gov/news-events/cancer-currents-blog/2018/prostate-cancer-abiraterone-food-low-dose**
- **Low cost abiraterone – PMC**
  **https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4709406**
- **ZYTIGA (abiraterone acetate) tablets**
  **https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/202379lbl.pdf**
- **Food Effect Study of Abiraterone Acetate for Treatment of Patients with Castration-Resistant Prostate Cancer ClinicalTrials.gov**
  **https://clinicaltrials.gov/ct2/show/NCT01543776**
- **Blood volume and hence drug concentration varies with weight: Whole Blood Components | Red Cross Blood Services**
  **https://www.redcrossblood.org/donate-blood/dlp/whole-blood.html**
- **Should Doctors Consider Body Size When Prescribing Drugs? - The New York Times**
  **https://www.nytimes.com/2018/06/08/well/drug-dose-weight-size-doctors-prescriptions-medications.html**
- **Abiraterone acetate plus prednisone (AA+P) without continuing LHRH-therapy in patients with metastatic chemotherapy: Naive castrations-resistant prostate cancer—Results from the SPARE-trial (NCT02077634). | Journal of Clinical Oncology**
  **https://ascopubs.org/doi/10.1200/JCO.2019.37.15_suppl.5046**

- **Commentary for the SPARE-trial – do you need ADT if you take Zytiga: LHRH Sparing Therapy in Patients with Chemotherapy-Naïve, mCRPC Treated with Abiraterone Acetate plus Prednisone: Results of the Randomized Phase II SPARE Trial https://www.urotoday.com/recent-abstracts/urologic-oncology/prostate-cancer/136585-lhrh-sparing-therapy-in-patients-with-chemotherapy-naive-mcrpc-treated-with-abiraterone-acetate-plus-prednisone-results-of-the-randomized-phase-ii-spare-trial.html**
- **Support for using Zytiga and a 5ARI during ADT, particularly important for CRPC: Maintenance of Intratumoral Androgens in Metastatic Prostate Cancer: A Mechanism for Castration-Resistant Tumor Growth – PMC https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2536685**
- **Support for using Zytiga and a 5ARI during ADT, and reducing DHEA and/or Androstenedione for CRPC (DHEA is a predecessor to oncogenic ERb so DHEA should not be reduced if you are hormone sensitive): Dihydrotestosterone synthesis bypasses testosterone to drive castration-resistant prostate cancer – PMC https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3158152**

1. **Support for using Zytiga and a 5ARI during ADT, and reduction of pregnenolone and progesterone, particularly important for CRPC: Inhibiting 3βHSD1 to eliminate the oncogenic effects of progesterone in prostate cancer – ScienceDirect https://www.sciencedirect.com/science/article/pii/S2666379122000684**
2. **Zytiga with 5ARIs: Good Abi, Bad Abi https://www.urotoday.com/center-of-excellence/mcrpc-treatment/from-the-editor/105656-good-abi-bad-abi-charles-ryan.html**
3. **Efficacy of eplerenone in the management of mineralocorticoid excess in men with metastatic castration resistant prostate cancer treated with abiraterone without prednisone – PMC https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5501307**
4. **Common prostate cancer medications may be less safe than previously thought -- ScienceDaily https://www.sciencedaily.com/releases/2022/05/220525151750.htm**
5. **Serious Hypokalemia Associated with Abiraterone Acetate in Patients with Castration-Resistant Prostate Cancer https://www.hindawi.com/journals/criu/2018/1414395**
6. **Testosterone suppression achieved by abiraterone monotherapy is not sustained in non-castrated men and is overcome by a subsequent twofold–threefold surge in luteinising hormone (LH) levels: Androgen deprivation therapy in castrate-resistant prostate cancer: how important is GnRH agonist backbone therapy? – PMC https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4512260/**
7. **Zytiga reduction of testosterone: A Study to Evaluate Serum Testosterone Levels in Patients with Metastatic Castration-Resistant Prostate Cancer ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT02737332**




8. AAWR, 50% of guys who stop responding to anti-androgens experience PSA declines if anti-androgens are discontinued. - Prostate Cancer Treatment Options-The Prostate Cancer Research Institute https://pcri.org/-aawr-the-anti-androgen-withdrawal-response
9. How long does it take for Yonsa (Zytiga) to work? https://www.drugs.com/medical-answers/long-yonsa-work-3555299

- **Phase II pilot study of the prednisone to dexamethasone switch in metastatic castration-resistant prostate cancer (mCRPC) patients with limited progression on abiraterone plus prednisone (SWITCH study) | British Journal of Cancer https://www.nature.com/articles/s41416-018-0123-9**
- **Zytiga mechanism of action explained, CYP17 inhibitor so stops biosynthesis of androgens by cancer cells: Intratumoral androgen biosynthesis in prostate cancer pathogenesis and response to therapy – PMC https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3815562/**
- **Abi in PCa Systematic Review | STAMPEDE http://www.stampedetrial.org/media-section/news/news-stories/2017/august-2017/abi-in-pca-systematic-review/**
- **Abiraterone acetate plus prednisolone for metastatic patients starting hormone therapy: 5-year follow-up results from the STAMPEDE randomised trial (NCT00268476) - James - 2022 - International Journal of Cancer - Wiley Online Library https://onlinelibrary.wiley.com/doi/10.1002/ijc.34018**
- **Addition of Zytiga to ADT yields superior results: A Study of Abiraterone Acetate Plus Low-Dose Prednisone Plus Androgen Deprivation Therapy (ADT) Versus ADT Alone in Newly Diagnosed Participants With High-Risk, Metastatic Hormone-Naive Prostate Cancer (mHNPC) - Full Text View - ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT01715285**

- **Lessons from the SWITCH trial: changing glucocorticoids in the management of metastatic castration-resistant prostate cancer (mCRPC) | British Journal of Cancer https://www.nature.com/articles/s41416-018-0239-y**
- **Abiraterone Acetate in Castration-Resistant Prostate Cancer Previously Treated With Docetaxel-Based Chemotherapy ClinicalTrials.gov https://www.clinicaltrials.gov/ct2/show/NCT00638690**
- **Zytiga shows value in mCRPC: Abiraterone Acetate in Asymptomatic or Mildly Symptomatic Patients With Metastatic Castration-Resistant Prostate Cancer - Full Text View - ClinicalTrials.gov https://www.clinicaltrials.gov/ct2/show/NCT00887198**
- **Prednisone dosage increase to combat Zytiga induced BP increase: Risk of hypertension in Cancer patients treated with Abiraterone: a meta-analysis – PMC https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6442407**
- **Abiraterone acetate plus prednisone (AA+P) without continuing LHRH-therapy in patients with metastatic chemotherapy: Naive castrations-resistant prostate cancer—Results from the SPARE-trial (NCT02077634). | Journal of Clinical Oncology https://ascopubs.org/doi/10.1200/JCO.2019.37.15_suppl.5046**
- **Side Effects of Zytiga (Abiraterone Acetate Tablets), Warnings, Uses https://www.rxlist.com/zytiga-side-effects-drug-center.htm**

- **ADT and apalutamide (Erleada) TITAN clinical trial https://www.nejm.org/doi/full/10.1056/nejmoa1903307**
- **ADT and enzalutamide (Xtandi) ARCHES clinical trial https://www.cancertherapyadvisor.com/home/news/conference-coverage/esmo-2021/prostate-cancer-enzalutamide-adt-prolongs-survival-treatment**
- **Testosterone < 20 ng/dl offers longer time before ADT fails (castrate resistance): MP22-04 INVESTIGATING THE IMPACT OF A LOWER TESTOSTERONE THRESHOLD ON CASTRATION-RESISTANT PROGRESSION IN PATIENTS ON CONTINUOUS ANDROGEN DEPRIVATION THERAPY | Journal of Urology https://www.auajournals.org/doi/10.1097/01.JU.0000555588.43900.cf**
- **Bone health effects of androgen-deprivation therapy and androgen receptor inhibitors in patients with nonmetastatic castration-resistant prostate cancer | Prostate Cancer and Prostatic Diseases https://www.nature.com/articles/s41391-020-00296-y**
- **Initial dose reduction of enzalutamide does not decrease the incidence of adverse events in castration-resistant prostate cancer | PLOS ONE https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0258160**
- **LH and testosterone effects of Xtandi: Long-term Efficacy and Safety of Enzalutamide Monotherapy in Hormone-naïve Prostate Cancer: 1- and 2-Year Open-label Follow-up Results - ScienceDirect https://www.sciencedirect.com/science/article/pii/S0302283815000706#fig0010**
- **Metabolic syndrome reduces time to CRPC: Metabolic syndrome and its pharmacologic treatment are associated with the time to castration-resistant prostate cancer | Prostate Cancer and Prostatic Diseases https://www.nature.com/articles/s41391-022-00494-w**
- **Duration of ADT before resistance sets in: Rapidly decreasing level of prostate-specific antigen during... : Medicine https://journals.lww.com/md-journal/fulltext/2017/09080/rapidly_decreasing_level_of_prostate_specific.13.aspx#:~:text=Our%20retrospective%20analysis%20was%20based,range%204%E2%80%93158%20months).**
- **Physiological doses of SERMs and/or estrogens do not change progression: A Systematic Study of the Impact of Estrogens and Selective Estrogen Receptor Modulators on Prostate Cancer Cell Proliferation | Scientific Reports https://www.nature.com/articles/s41598-020-60844-3**
- **Cross-resistance and drug sequence in prostate cancer - ScienceDirect https://www.sciencedirect.com/science/article/pii/S1368764621000194**
- **Overview of actions and cardio risks: Considerations for the use of gonadotropin-releasing hormone agonists and antagonists in patients with prostate cancer - Van Poppel - 2020 - International Journal of Urology - Wiley Online Library https://onlinelibrary.wiley.com/doi/full/10.1111/iju.14303**

- **fT more important than tT for ADT measurements (fT falls out of SHBG and albumin and tT, online calculator http://www.issam.ch/freetesto.htm): How do we define “castration” in men on androgen deprivation therapy? - PMC**
  **https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7523606/**
- **Casodex monotherapy**

- **Casodex (Bicalutamide) Monotherapy – PROSTATE ONCOLOGY SPECIALISTS**
  **https://www.prostateoncology.com/2020/04/02/casodex-bicalutamide-monotherapy/**
- **Efficacy of Bicalutamide 150-mg Monotherapy Compared With Combined Androgen Blockade in Patients With Locally Advanced Prostate Cancer: ICUrology : Investigative and Clinical Urology**
  **https://icurology.org/DOIx.php?id=10.4111/kju.2014.55.5.315**
- **Cross-sectional study of bone turnover during bicalutamide monotherapy for prostate cancer - Urology**
  **https://www.goldjournal.net/article/S0090-4295(02)02006-X/fulltext#secd32369722e329**
- **A randomised comparison of monotherapy with Casodex 50 mg daily and castration in the treatment of metastatic prostate carcinoma. Casodex Study Group - PubMed**
  **https://pubmed.ncbi.nlm.nih.gov/8536775/#:~:text=Casodex%20was%20well%20tolerated%20with,treatment%20of%20metastatic%20prostate%20cancer.**
- **IADT**

- **A Phase 1b Adaptive Androgen Deprivation Therapy Trial in Metastatic Castration Sensitive Prostate Cancer - PMC**
  https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9656891/
- **Long-term treatment outcomes of intermittent androgen deprivation therapy for relapsed prostate cancer after radical prostatectomy | PLOS ONE**
  **https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0197252**
- **Phase III intermittent MAB vs continuous MAB | Journal of Clinical Oncology**
  **https://ascopubs.org/doi/abs/10.1200/jco.2006.24.18_suppl.4513**
- **Intermittent Versus Continuous Androgen Deprivation Therapy in Patients with Relapsing or Locally Advanced Prostate Cancer: A Phase 3b Randomised Study (ICELAND) – ScienceDirect**
  **https://www.sciencedirect.com/science/article/pii/S030228381500977X**
- **Intermittent androgen deprivation therapy in patients with prostate cancer: Connecting the dots - PMC**
  **https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5772839/**
- **Intermittent vs Continuous Androgen Deprivation Therapy for Prostate Cancer: A Systematic Review and Meta-analysis - PubMed**
  **https://pubmed.ncbi.nlm.nih.gov/26378418/**
- **Management of Biochemically Recurrent Prostate Cancer: Ensuring the Right Treatment of the Right Patient at the Right Time | American Society of Clinical Oncology Educational Book**
  **https://ascopubs.org/doi/full/10.1200/edbk_200319/**
  - **Fewer cardiac issues from GnRH antagonists (e.g., orgovyx, Firmagon) vs GnRH agonists (e.g., Lupron): Cardiovascular risk of gonadotropin-releasing hormone antagonist versus agonist in men with prostate cancer: an observational study in Taiwan | Prostate Cancer and Prostatic Diseases**
    **https://www.nature.com/articles/s41391-022-00555-0**
  - **DHT and testosterone activate ARs. DHT has 2x the binding affinity of testosterone and 5x decreased disassociation rate: Androgen Receptor Structure, Function and Biology: From Bench to Bedside - PMC**
    **https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4810760/**
  - **Do statins lower testosterone and does it matter? - PMC**
    **https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3621773/**
  - **HMB supplement:**
- **Effect of β-hydroxy-β-methylbutyrate (HMB) on muscle strength in older men with prostate cancer (Pca) started on androgen deprivation therapy (ADT): Preliminary results of an open-label, randomized trial. | Journal of Clinical Oncology**

https://ascopubs.org/doi/10.1200/JCO.2018.36.6_suppl.258

- **Beta-hydroxy-beta-methylbutyrate supplementation reduces tumor growth and tumor cell proliferation ex vivo and prevents cachexia in Walker 256 tumor-bearing rats by modifying nuclear factor-kappaB expression – PubMed**
  https://pubmed.ncbi.nlm.nih.gov/19083450/
- **Frontiers | Second-Generation Antiandrogens: From Discovery to Standard of Care in Castration Resistant Prostate Cancer | Oncology**
  https://www.frontiersin.org/articles/10.3389/fonc.2019.00801/full/
- **Serum testosterone level predicts the effective time of androgen deprivation therapy in metastatic prostate cancer patients – PMC**
  https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5312215/
- **Cross-resistance among next generation anti-androgen drugs through the AKR1C3/AR-V7 axis in advanced prostate cancer - PMC**
  https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8855880/
- **Niclosamide inhibits androgen receptor variants expression and overcomes enzalutamide resistance in castration resistant prostate cancer - PMC**
  https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4058390/
- **Niclosamide enhances abiraterone treatment via inhibition of androgen receptor variants in castration resistant prostate cancer – PubMed** https://pubmed.ncbi.nlm.nih.gov/27049719/
- **Prednisone monotherapy in asymptomatic hormone refractory prostate cancer – PubMed**
  https://pubmed.ncbi.nlm.nih.gov/17187697
- **APCCC 2022: Importance of Lifestyle and Prevention of Complications in Advanced Prostate Cancer: How to Take Care of the Heart?**https://www.urotoday.com/conference-highlights/apccc-2022/136809-apccc-2022-importance-of-lifestyle-and-prevention-of-complications-in-advanced-prostate-cancer-how-to-take-care-of-the-heart.html

bicalutamide prevents basal and Akt-induced proliferation in LNCaP, but not in C4-2 cells and rapamycin (Sirolimus) causes a 50% reduction in C4-2 cell proliferation but not in LNCap cells: Signal transduction OSNs in androgen-dependent and -independent prostate cancer cell proliferation – PubMed
https://pubmed.ncbi.nlm.nih.gov/15788644/

1. Capesaris – a SERM: Phase 2 Trial of GTx-758, an Estrogen Receptor Alpha Agonist, in Men with Castration-Resistant Prostate Cancer - PubMed
   https://pubmed.ncbi.nlm.nih.gov/32321673
2. Estrogens and Their Receptors in Prostate Cancer: Therapeutic Implications - PMC
   https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5778111/
3. SES AUA 2013: Poster - GTx-758 is a potent oral ER-agonist that increases sex hormone binding globulin and decreases serum free testosterone in men with advanced prostate cancer
   https://www.urotoday.com/recent-abstracts/urologic-oncology/prostate-cancer/58985-ses-aua-2013-poster-gtx-758-is-a-potent-oral-er-agonist-that-increases-sex-hormone-binding-globulin-and
4. Variability in testosterone measurement between radioimmunoassay (RIA), chemiluminescence assay (CLIA) and liquid chromatography-tandem mass spectrometry (MS) among prostate cancer patients on androgen deprivation therapy (ADT).
   https://www.urotoday.com/recent-abstracts/urologic-oncology/prostate-cancer/136636-variability-in-testosterone-measurement-between-radioimmunoassay-ria-chemiluminescence-assay-clia-and-liquid-chromatography-tandem-mass-spectrometry-ms-among-prostate-cancer-patients-on-androgen-deprivation-therapy-adt.html
5. Detectable Prostate-Specific Antigen Nadir During Androgen-Deprivation Therapy Predicts Adverse Prostate Cancer Specific Outcomes: Results from the SEARCH Database – PMC
   https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3634863

6. The Importance of Time to Prostate-Specific Antigen (PSA) Nadir after Primary Androgen Deprivation Therapy in Hormone-Naïve Prostate Cancer Patients - PMC
   https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6306761
7. Independent association between time to prostate-specific antigen (PSA) nadir and PSA progression-free survival in patients with docetaxel-naïve, metastatic castration-resistant prostate cancer receiving abiraterone acetate, but not enzalutamide - PubMed
   https://pubmed.ncbi.nlm.nih.gov/28188090/
8. Statins

- **Statin Use and Survival Among Men Receiving Androgen-Ablative Therapies for Advanced Prostate Cancer: A Systematic Review and Meta-analysis | Cardiology | JAMA Network Open | JAMA Network**
  **https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2799080**
  i. **Prostate cancer prognosis after initiation of androgen deprivation therapy among statin users. A population-based cohort study | Prostate Cancer and Prostatic Diseases https://www.nature.com/articles/s41391-021-00351-2**
  ii. **Statins lower intracellular testosterone: Statin Use at the Time of Initiation of Androgen Deprivation Therapy and Time to Progression in Patients With Hormone-Sensitive Prostate Cancer | Cardiology | JAMA Oncology | JAMA Network https://jamanetwork.com/journals/jamaoncology/fullarticle/2288665**
  iii. **The effect of statins on advanced prostate cancer patients with androgen deprivation therapy or abiraterone/enzalutamide: A systematic review and meta-analysis – PubMed https://pubmed.ncbi.nlm.nih.gov/31951037**
  iv. **Combination therapy with novel androgen receptor antagonists and statin for castration-resistant prostate cancer – PubMed https://pubmed.ncbi.nlm.nih.gov/34843630**
  v. **Null results: Adjuvant Low-dose Statin Use after Radical Prostatectomy: The PRO-STAT Randomized Clinical Trial | Clinical Cancer Research | American Association for Cancer Research https://aacrjournals.org/clincancerres/article-abstract/27/18/5004/671649/Adjuvant-Low-dose-Statin-Use-after-Radical**
- **Metabolomic effects of androgen deprivation therapy treatment for prostate cancer - Chi - 2020 - Cancer Medicine - Wiley Online Library** https://onlinelibrary.wiley.com/doi/full/10.1002/cam4.3016
- **Iron Induces Cell Death and Strengthens the Efficacy of Antiandrogen Therapy in Prostate Cancer Models | Clinical Cancer Research | American Association for Cancer Research** https://aacrjournals.org/clincancerres/article/26/23/6387/82882/Iron-Induces-Cell-Death-and-Strengthens-the
- **Combination of curcumin and bicalutamide enhanced the growth inhibition of androgen-independent prostate cancer cells through SAPK/JNK and MEK/ERK1/2-mediated targeting NF-κB/p65 and MUC1-C – PMC**
  https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4446835
- **Firmagon vs. Lupron side effects https://www.rxlist.com/firmagon-side-effects-drug-center.htm#professional**
- **Strength training during ADT**
  - **Immediate versus delayed exercise for men on hormone therapy | PCFA**
    **https://www.prostate.org.au/news-media/news/immediate-versus-delayed-exercise-for-men-on-hormone-therapy**
  - **Supervised Physical Training Enhances Muscle Strength but Not Muscle Mass in Prostate Cancer Patients Undergoing Androgen Deprivation Therapy: A Systematic Review and Meta-Analysis – PMC**
    **https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6618665**
- **Anti-androgen hormonal therapy for cancer and other diseases - ScienceDirect**
  **https://www.sciencedirect.com/science/article/pii/S0014299919307356**

- **Niclosamide enhances abiraterone treatment via inhibition of androgen receptor variants in castration resistant prostate cancer - PMC**
  **https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5078008/**
- **Phase Ib trial of reformulated niclosamide with abiraterone/prednisone in men with castration-resistant prostate cancer | Scientific Reports**
  **https://www.nature.com/articles/s41598-021-85969-x**
- **Clinical trial ongoing for Niclosamide/Xtandi: Enzalutamide and Niclosamide in Treating Patients With Recurrent or Metastatic Castration-Resistant Prostate Cancer - Full Text View - ClinicalTrials.gov**
  **https://clinicaltrials.gov/ct2/show/NCT03123978**
- **ARSI resensitization: Effect of bipolar androgen therapy for asymptomatic men with castration-resistant prostate cancer: Results from a pilot clinical study - PMC**
  **https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4507510/**
- **ARSI resensitization: The MAO inhibitors phenelzine and clorgyline revert enzalutamide resistance in castration resistant prostate cancer | Nature Communications**
  **https://www.nature.com/articles/s41467-020-15396-5**

10. **Effects of short-term prednisolone intake during submaximal exercise – PubMed**
    **https://pubmed.ncbi.nlm.nih.gov/17805102**
11. **Testosterone vs. dose and time: Figure 1 | Open-label, phase I, pharmacokinetic studies of abiraterone acetate in healthy men | SpringerLink https://link.springer.com/article/10.1007/s00280-012-1865-3/figures/1**

## Radiation

**High androgens** might enhance the effectiveness of **radiation therapy** by increasing **DNA double-strand breaks (DSBs)** or impairing DNA repair mechanisms in prostate cancer cells. This idea is being explored in research on **androgen priming** before radiation.

### How High Androgens Affect DNA DSBs in Radiation Therapy:

- **Increased Cell Proliferation → More Radiation Sensitivity**
  - **Androgens drive prostate cancer cell proliferation.**
  - **Fast-dividing cells are more vulnerable to radiation-induced DNA DSBs because they have less time for repair before mitosis.**
- **Androgen-Driven DNA Damage**
  - **High androgen levels can increase replication stress, leading to spontaneous DNA DSBs.**
  - **This may act synergistically with radiation, which also induces DSBs.**
- **Androgen-Induced Defects in DNA Repair**
  - **Some studies suggest that androgens can suppress homologous recombination (HR) repair, making cells rely more on error-prone NHEJ.**
  - **This could make radiation-induced DSBs more lethal.**
- **Androgen Receptor (AR) and DNA Repair Genes**
  - **The androgen receptor (AR) regulates genes involved in DNA repair.**
  - **High androgen signaling may alter the expression of key repair proteins, leading to inefficient DSB repair.**
- **Clinical Implications:**
  - **Androgen Priming: Some trials are testing whether giving high-dose androgens before radiation increases tumor cell kill.**
  - **Bipolar Androgen Therapy (BAT): Alternating high and low androgen levels could make cancer cells more vulnerable to treatments like radiation or PARP inhibitors.**
  - **PARP Inhibitors Synergy: If androgens impair HR repair, combining radiation with PARP inhibitors could further increase radiation sensitivity.**

### Low androgens (ADT) can also improve responses from radiation. Different mechanisms and cell lines.

- **ADT prevents cancer cells from recovering and repopulating during RT treatment.**
- **Androgen signaling helps prostate cancer repair DNA damage after RT.**
- **ADT blocks this repair mechanism, increasing the effectiveness of radiation.**
- **ADT reduces prostate volume, improving RT targeting and lowering damage to surrounding tissues.**
- **Prostate tumors often have low oxygen (hypoxia), making RT less effective.**
- **ADT reduces hypoxia, making cancer cells more susceptible to radiation**

### PARP Inhibitor/RT

- **Currently, adding Olaparib (a PARP inhibitor) to radiation therapy (RT) is not yet standard of care (SOC) for prostate cancer, but it is being actively investigated in clinical trials**

- **Radiation Induces DNA Double-Strand Breaks (DSBs) which need repair for cancer cell survival.**
- **Cancer cells often rely on homologous recombination (HR) repair, particularly those with BRCA1/2 or ATM mutations.**
- **PARP inhibitors like Olaparib block PARP1, which helps repair single-strand breaks (SSBs).**
- **If SSBs are not repaired, they convert into DSBs, overwhelming cancer cells—especially those with defective HR repair (e.g., BRCA-mutant tumors).**
- **Summary: Radiation increases DSBs → Olaparib prevents their repair → Enhanced cancer cell death.**
- **Particularly effective in HR-deficient tumors, but could also sensitize other cancers.**
- **Not SOC yet, but under study in clinical trials, especially for: metastatic castration-resistant prostate cancer (mCRPC) with BRCA1/2 or ATM mutations.**

SBRT may be preferrable but ask your MO. If the radiation isn't SBRT simply repeat the above 5 pulses multiple times (e.g. if you are having 40 RT sessions, then repeat the above cycle 8 times)

Starting the day prior to RT and continuing until RT is complete, exercise at least an hour a day. The exercises should consist of resistance exercises and also some cardio exercise. If possible, some of the exercising should be done no less than an hour before RT and within an hour following RT.

15 hours prior to each radiation session, fast. Eat about half of your normal calories in a 4-hour window a few hours after your radiation session.


Scenario 1
Recurrent prostate cancer with positive conventional imaging and negative PSMA PET-CT imaging
Counsel patient BCR management vs. biopsy if feasible
Scenario 2
Recurrent prostate cancer with negative conventional imaging and positive local/regional LN on PSMA PET-CT imaging
Counsel patient on salvage radiotherapy
Scenario 3
Recurrent prostate cancer with negative conventional imaging and positive extra pelvic LN or bone/visceral metastases on PSMA PET-CT imaging
Determine PSA DT and weigh the likelihood of long-term metastasis free survival against the life altering toxicity of ADT-based combination regimens

| | |
|---|---|
| CT imaging PPV for LN metastases (Petersen et al., 2020) | 32% |
| Bone Scintigraphy PPV for metastases (Chen et al., 2019) | 45% |
| Conventional imaging specificity for metastases (Hofman et al., 2020) | 91% |
| PSMA PET-CT sensitivity (Hofman et al., 2020) | 85% |
| PSMA PET-CT NPV for metastases (Pienta et al., 2021) | 81.9% |

| | |
|---|---|
| Conventional Imaging sensitivity for pelvic or distant metastases (Hofman et al., 2020) | 38% |
| PSMA PET-CT specificity (Hofman et al., 2020) | 98% |
| PSMA PET-CT PPV (Pienta et al., 2021) | 77.8–95.8% |

| PSA DT (months) (Antonarakis et al., 2012) | mMFS (years) |
|---|---|
| < 3 | 1 |
| 3—8.9 | 4 |
| 9—14.9 | 13 |
| ≥ 15 | 15 |

mMFS is based on BCR and conventional PET imaging.


1. **Surveillance or metastasis-directed therapy for oligometastatic prostate cancer recurrence (STOMP): Five-year results of a randomized phase II trial. | Journal of Clinical Oncology** https://ascopubs.org/doi/abs/10.1200/JCO.2020.38.6_suppl.10
2. **The Continuum of Metastatic Prostate Cancer: Interpreting PSMA PET Findings in Recurrent Prostate Cancer – PMC** https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8946297/
3. **Para-Aortic Radiation Therapy for Oligorecurrent Prostate Cancer - Beyond the Abstract** https://www.urotoday.com/recent-abstracts/urologic-oncology/prostate-cancer/139746-para-aortic-radiation-therapy-for-oligorecurrent-prostate-cancer-beyond-the-abstract.html
4. **Pattern of metastatic spread impacts whether enzalutamide plus ADT improves PFS in prostate cancer** https://www.urologytimes.com/view/pattern-of-metastatic-spread-impacts-whether-enzalutamide-plus-adt-improves-pfs
5. **Translating the Immunobiology of SBRT to Novel Therapeutic Combinations for Advanced Prostate Cancer – PMC** https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7326115/

**About STAMPEDE | STAMPEDE** http://www.stampedetrial.org/participants/about-stampede/

6. **Addition of Metastasis-Directed Therapy to Intermittent Hormone Therapy for Oligometastatic Prostate Cancer: The EXTEND Phase 2 Randomized Clinical Trial – PubMed** https://pubmed.ncbi.nlm.nih.gov/37022702/
7. **A retrospective analysis of the prognosis of prostate cancer patients with lymph node involvement on MR lymphography: who might be cured | Radiation Oncology | Full Text** https://ro-journal.biomedcentral.com/articles/10.1186/1748-717X-8-190

From Influence of Timing Between Androgen Deprivation Therapy and External Beam Radiation Therapy in Patients with Localized, High-Risk Prostate Cancer - Advances in Radiation Oncology

https://www.advancesradonc.com/article/S2452-1094(21)00161-5/fulltext




## Alpha Radioligand Therapy for PCa: An Overview

### Alpha Radioligand Therapy for Prostate Cancer: A Comprehensive Assessment

Alpha radioligand therapy has emerged as a promising therapeutic approach for advanced prostate cancer, demonstrating significant clinical benefits particularly in metastatic disease settings. This report evaluates the current evidence, mechanisms, applications, and implications of this therapy across different prostate cancer stages.

### Mechanisms of action

Alpha radioligand therapy employs targeted radionuclides that emit alpha particles to deliver highly localized radiation specifically to cancer cells. This approach offers several unique advantages over conventional radiation therapies:

Alpha particles are helium nuclei (two protons and two neutrons) that travel very short distances in tissue (50-100 micrometers) but deliver extremely high energy along their path. These particles have high linear energy transfer (LET) of approximately 100 keV/µm, compared to beta particles' much lower 0.2 keV/µm[2]. This high energy deposition creates dense ionization tracks that cause complex DNA double-strand breaks that are particularly difficult for cells to repair.

The most commonly used alpha-emitting radionuclides in prostate cancer therapy include Actinium-225 (225Ac), Radium-223 (223Ra), and Lead-212 (212Pb). 225Ac has gained particular attention due to its 9.92-day half-life and decay chain that releases four net alpha particles, maximizing therapeutic potential[2]. These radionuclides are typically conjugated to targeting molecules that bind specifically to receptors overexpressed on prostate cancer cells.

Prostate-specific membrane antigen (PSMA) has become the primary target for radioligand therapy due to its high expression in prostate cancer cells, particularly in advanced and metastatic disease. PSMA-targeting molecules conjugated with alpha emitters enable selective irradiation of tumor cells while minimizing damage to healthy tissues[2].

A critical advantage of alpha therapy is that it does not require cellular oxygenation for achieving cell death, as confirmed in studies showing effectiveness regardless of baseline PSA values and alkaline phosphatase levels[4]. Furthermore, unlike chemotherapy, alpha therapy does not require cells to be actively dividing to be effective, making it particularly suitable for prostate cancer's typically low proliferation rate.

**Stages it might be applied to**

Alpha radioligand therapy has varying degrees of evidence and application across different prostate cancer stages:

| PCa Stage | Evidence Level | Key Agents | Response Rates | Survival Outcomes | Trial Status | Notes |
|---|---|---|---|---|---|---|
| mCRPC | High | 225Ac-PSMA-617, 225Ac-J591, 223Ra | 57-61% with ≥50% PSA decline | OS: 14-15.5 months, PFS: 7.9 months | Multiple completed and ongoing trials | Most well-studied application[3912] |
| mHSPC | Moderate | 225Ac-PSMA-617 | 86-95% with any PSA decline, 86% with ≥50% decline | OS: ~31 months | Limited studies, some ongoing trials | Promising early results but requires comparison with standard therapies[45] |
| nmCRPC | Very Low | - | - | - | No specific trials identified | Theoretical application only |
| oCRPC | Very Low | - | - | - | No specific trials identified | Theoretical application only |
| nmHSPC | Very Low | - | - | - | No specific trials identified | Theoretical application only |

| PCa Stage | Evidence Level | Key Agents | Response Rates | Survival Outcomes | Trial Status | Notes |
|---|---|---|---|---|---|---|
| oHSPC | Very Low | - | - | - | No specific trials identified | Theoretical application only |

The strongest evidence exists for mCRPC, where multiple completed clinical trials have demonstrated meaningful clinical responses. For mHSPC, emerging data shows promise with high response rates, but evidence remains limited to small retrospective studies. There is virtually no clinical data for non-metastatic or oligometastatic stages, where applications remain theoretical at this time.

**Research & Studies**

**Metastatic Castration-Resistant Prostate Cancer (mCRPC)**

The most robust evidence for alpha radioligand therapy exists for mCRPC:

The ALSYMPCA Phase III trial established Radium-223's efficacy in mCRPC with bone metastases, showing improved overall survival (14.0 vs 11.2 months) and reduced risk of symptomatic skeletal events. This landmark study led to FDA approval of Radium-223 for this indication.

A large multicenter retrospective study of 225Ac-PSMA-617 therapy in 488 mCRPC patients (2016-2023) demonstrated meaningful clinical benefit with median overall survival of 15.5 months, progression-free survival of 7.9 months, and 57% of patients achieving ≥50% PSA decline3. This represents the largest investigation of 225Ac-PSMA to date.

A Phase I dose-escalation trial of 225Ac-J591 in 32 pretreated mCRPC patients demonstrated safety and preliminary efficacy with 46.9% achieving ≥50% PSA decline and establishing a recommended Phase II dose of 93.3 KBq/kg6. This first-in-human trial showed that 225Ac-J591 was well-tolerated with promising efficacy signals.

Multiple meta-analyses have consistently shown that approximately 60-61% of patients treated with 225Ac-PSMA achieve >50% PSA decline, with 81-83% showing any PSA decline91112. These findings provide a reliable estimate of expected response rates in the mCRPC population.

**Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)**

Emerging research suggests potential applications in mHSPC:

A retrospective study of 21 treatment-naïve mHSPC patients treated with 225Ac-PSMA-617 monotherapy showed that 95% had any decline in PSA and 86% presented with a PSA decline of ≥50%, including 4 patients with undetectable PSA levels4. This represents the first evaluation of 225Ac-PSMA in the mHSPC setting.

Overall survival for these mHSPC patients was approximately 31 months, with 94% experiencing grade II or lower xerostomia and no severe adverse events5. The absence of prior treatment history likely contributed to the low toxicity profile.

However, comparison with standard ADT combinations suggests that further investigation is needed: OS for mHSPC patients receiving ADT plus docetaxel was 57.6 months, ADT plus enzalutamide was 71% 4-year survival, and ADT plus abiraterone was 53.3 months5. These comparisons raise questions about whether 225Ac-PSMA monotherapy provides better prognosis than standard treatments for mHSPC.

## Preclinical Studies

Mouse models have demonstrated tumor growth retardation with 225Ac-PSMA-617 in both subcutaneous and metastatic in vivo tumor models, with 75% overall survival in the 40 kBq group 6 months after treatment[1]. This dose was well-tolerated and accompanied by only temporary weight loss.

Metastatic models showed that treatment initiated one week after tumor inoculation resulted in stable control of tumor progression for at least 7 weeks[1]. Later intervention at 3 weeks post-inoculation still significantly retarded tumor progression compared to untreated mice, though the growth inhibition effect was transient.

These preclinical findings have provided important insights into optimizing treatment timing and dosing for clinical applications.

## Clinical trial table

| Trial Name/Identifier | Agent | Target | Patient Population | Status | Key Findings | Completion Date |
|---|---|---|---|---|---|---|
| ALSYMPCA (Phase III) | Radium-223 (Xofigo) | Bone metastases | mCRPC with bone metastases | Completed | Improved OS (14.0 vs 11.2 months), reduced risk of symptomatic skeletal events | 2011 |
| Multicenter Retrospective Study | 225Ac-PSMA-617 | PSMA | 488 mCRPC patients | Completed | Median OS 15.5 months, PFS 7.9 months, 57% achieving ≥50% PSA decline | 2023 |
| NCT03276572 (Phase I) | 225Ac-J591 | PSMA | 32 pretreated mCRPC patients | Completed | 46.9% achieved ≥50% PSA decline, established safety profile | 2022 |
| WARMTH Act (Phase II) | 225Ac-PSMA-617 | PSMA | mCRPC patients post standard therapy | Completed | 60-61% achieved >50% PSA decline, promising response in heavily pretreated patients | 2022 |
| Cornell 225Ac-J591 Trial | 225Ac-J591 | PSMA | mCRPC patients | Recruiting | Ongoing | January 2025 (est.) |
| Fusion Pharmaceuticals Trial | 225Ac-FPI-2059 | NTSR1 | mCRPC patients | Recruiting | Ongoing | June 2025 (est.) |
| TATCIST (NCT05219500) | 225Ac-PSMA-I&T | PSMA | mCRPC patients | Recruiting | Ongoing | December 2023 (est.) |
| AcTION (NCT04597411) | 225Ac-PSMA-617 | PSMA | mCRPC patients | Recruiting | Ongoing | October 2023 (est.) |

| Trial Name/Identifier | Agent | Target | Patient Population | Status | Key Findings | Completion Date |
|---|---|---|---|---|---|---|
| Erasmus Medical Center Trial | 225Ac-PSMA-I&T | PSMA | mCRPC patients | Recruiting | Ongoing | December 2025 (est.) |
| Orano Med Trial | 212Pb-GRPR | GRPR | mCRPC patients | Recruiting | Ongoing | 2025 (est.) |
| PEACE III (NCT02194842) | Radium-223 + Enzalutamide | Bone metastases + AR | mCRPC patients | Recruiting | Ongoing | 2024 (est.) |
| DORA (NCT03574571) | Radium-223 + Darolutamide | Bone metastases + AR | mCRPC patients | Recruiting | Ongoing | 2024 (est.) |
| ACCEL (NCT06229366) | Radium-223 + Pembrolizumab | Bone metastases + PD-1 | mCRPC patients | Recruiting | Ongoing | 2025 (est.) |
| AlphaBreak (NCT06402331) | 225Ac-PSMA-I&T | PSMA | mCRPC patients | Recruiting | Ongoing | 2026 (est.) |

This table demonstrates that while several clinical trials have been completed, many more are currently recruiting or ongoing, suggesting that our understanding of alpha radioligand therapy will continue to evolve over the next few years as these studies reach completion.

**Overall Quality of Evidence**

| Therapy Approach | Theory | Preclinical Evidence | Clinical Evidence | Overall Rating | Notes |
|---|---|---|---|---|---|
| Radium-223 (Xofigo) | A | A | A | A | FDA-approved with Phase III data showing survival benefit for mCRPC with bone metastases |
| 225Ac-PSMA-617 | A | B | C | B | Strong retrospective data, Phase II trials completed, large multicenter study |
| 225Ac-PSMA-I&T | A | C | D | C | Limited clinical data but promising results in early studies |

| Therapy Approach | Theory | Preclinical Evidence | Clinical Evidence | Overall Rating | Notes |
|---|---|---|---|---|---|
| 225Ac-J591 | A | C | D | C | Phase I data available showing safety and preliminary efficacy |
| Alpha therapy for mHSPC | B | D | D | C- | Limited but promising early data in small retrospective studies |
| Alpha therapy for non-metastatic PCa | C | E | F | D | Theoretical only, no significant clinical data available |
| Alpha therapy + BAT combination | C | E | F | D | No clinical studies, theoretical interaction only |

Rating scale:

- A: Excellent - Multiple high-quality clinical trials with consistent results
- B: Good - At least one high-quality clinical trial or multiple consistent lower-quality trials
- C: Moderate - Limited clinical data but shows promise in available studies
- D: Low - Very limited clinical data, primarily theoretical or preclinical
- E: Very Low - Only theoretical basis or minimal preclinical studies
- F: Insufficient - No meaningful data available

The overall evidence quality for alpha radioligand therapy varies significantly depending on the specific agent and disease stage. Radium-223 has the strongest evidence base with Phase III data, while 225Ac-PSMA-617 has accumulated substantial retrospective data but lacks large prospective randomized trials. Evidence for applications in earlier disease stages remains limited.

**Conclusion**

Alpha radioligand therapy has established itself as an important therapeutic option for advanced prostate cancer, with the strongest evidence supporting its use in metastatic castration-resistant prostate cancer. The available clinical data demonstrates meaningful response rates and survival benefits in this setting, with 57-61% of mCRPC patients achieving significant PSA declines and median overall survival of 14-15.5 months[3][9][12].

For metastatic hormone-sensitive prostate cancer, preliminary data suggests even higher response rates (86-95%), though the long-term benefits compared to established combination therapies remain unclear and require further investigation through prospective randomized trials[4][5]. The role of alpha radioligand therapy in non-metastatic or oligometastatic settings remains largely theoretical, with virtually no clinical evidence to guide applications in these stages.

Multiple ongoing clinical trials are exploring various alpha-emitting agents, combination approaches, and applications across different disease settings. These studies will help clarify the optimal positioning of this therapy in the prostate cancer treatment landscape over the next few years. Particularly promising are trials investigating combinations with immunotherapy (ACCEL trial) and novel androgen receptor OSN inhibitors (PEACE III and DORA trials).

The field also faces significant challenges related to limited supply of alpha-emitting radionuclides like 225Ac, necessitating exploration of alternative alpha emitters such as 211At that may be more amenable to large-scale production[5]. Additionally, the most effective sequencing of alpha therapy relative to other treatments remains to be determined.

The unique mechanism of action—causing complex DNA double-strand breaks through high-LET radiation—provides a strong theoretical basis for combining alpha therapy with agents that target DNA repair OSNs, such as PARP inhibitors[2]. While promising, such approaches require further clinical validation.

**Common Side Effects**

| Side Effect | Incidence | Severity | Duration | Notes |
|---|---|---|---|---|
| Xerostomia (dry mouth) | 73.9-77.1% | Mostly Grade I-II, <1% Grade III+ | ~2 months typical | Most common side effect, appears 2-5 days post-treatment[9][11] |
| Anemia | 30.3% overall | 7.5-10.75% Grade III+ | Variable | More common in heavily pretreated patients[9] |
| Leukopenia | 14.9% overall | 4.5-5.9% Grade III+ | Variable | Risk increases with number of treatment cycles[9] |
| Thrombocytopenia | ~15% overall | 4.73-5.5% Grade III+ | Variable | Risk factors include age, renal dysfunction[9] |
| Nephrotoxicity | 3.0-3.76% Grade III+ | Variable | Variable | More common with higher doses[9] |
| Fatigue | 25.9% | Mostly Grade I-II | Variable | Typically manageable[11] |
| Anorexia | 16.9% | Mostly Grade I-II | Variable | Can contribute to weight loss[11] |
| Nausea | 12.9% | Mostly Grade I-II | Variable | Usually manageable with antiemetics[11] |
| Weight loss | 26.9% | Variable | Variable | Multifactorial causes[11] |

Alpha radioligand therapy is generally well-tolerated, with most side effects being of low grade. The most common side effect is xerostomia (dry mouth), which affects approximately three-quarters of patients but is typically mild to moderate and often resolves or improves over time[9][11]. Hematologic toxicities occur in a minority of patients, with severe cases (grade III+) being relatively uncommon.

Risk factors for more severe side effects include advanced age, impaired renal function, extensive prior treatments, and higher administered activity of the radiopharmaceutical[9]. Proper patient selection and monitoring can help minimize these risks.

Olaparib, as a PARP inhibitor, prevents the repair of single-strand breaks that can convert to double-strand breaks, thereby impairing the cell's ability to fix DNA damage. In theory, combining alpha radiation therapy with olaparib could increase the overall burden of unrepaired DNA damage in cancer cells, potentially enhancing tumor cell kill. This synergy might allow for a lower dose of alpha ligands to achieve similar therapeutic effects. However, while the mechanistic rationale is strong, clinical data are still needed to confirm that such a combination would safely permit a reduction in dosage without compromising efficacy.

**DNA Damage & Double-Strand Breaks (DSBs)**

Alpha radioligand therapy exerts its therapeutic effect primarily through the induction of complex DNA double-strand breaks (DSBs) that are particularly difficult for cells to repair. The high linear energy transfer (LET) of alpha particles (~100 keV/µm) creates dense ionization tracks that cause clustered DNA damage, often resulting in multiple breaks in close proximity2.

Research has established a critical relationship between alpha radioligand-induced DNA damage and androgen signaling in prostate cancer. The androgen receptor (AR) regulates a network of DNA repair genes, with AR activity promoting the expression and function of DNA repair OSNs, particularly non-homologous end joining (NHEJ)8. Studies have demonstrated that androgen deprivation therapy (ADT) suppresses AR-mediated induction of DNA repair genes, resulting in increased DNA damage and enhanced sensitivity to radiation8.

Mechanistically, AR has been found to regulate DNA-PKcs, a key component of the NHEJ pathway. This creates a feedback circuit where AR promotes DNA repair capacity, and DNA-PKcs enhances AR activity8. This relationship explains the observed synergy between ADT and radiotherapy in clinical practice.

For Bipolar Androgen Therapy (BAT), which involves cycling between supraphysiological and near-castrate testosterone levels, there are theoretical implications for alpha radioligand therapy effectiveness7. During the high-testosterone phase of BAT, enhanced DNA repair capacity might potentially reduce the effectiveness of alpha therapy by accelerating the repair of induced DNA damage. Conversely, during the low-testosterone phase, suppressed DNA repair capacity might enhance alpha therapy effectiveness by allowing DNA damage to accumulate.

However, no clinical studies directly examining the combination of alpha radioligand therapy and BAT were identified in the literature. The theoretical interactions remain speculative and require clinical validation.

The understanding of these DNA damage mechanisms suggests potential synergy between alpha radioligand therapy and PARP inhibitors. PARP enzymes are first responders to DNA damage, and alpha particles from radioligand therapy induce highly localized, dense ionization along their path, resulting in complex DNA double-strand breaks2. By concurrently inhibiting PARP and exposing cancer cells to the high LET radiation from 225Ac, a dual assault on DNA repair mechanisms could be orchestrated2.

**References**


1. **Radiopharmaceuticals Emerging as New Cancer Therapy –** NCI https://www.cancer.gov/news-events/cancer-currents-blog/2020/radiopharmaceuticals-cancer-radiation-therapy
2. **Murine models of prostate cancer to study resistance mechanisms to targeted alpha therapy using 225Ac-PSMA-617**
   URL: https://jnm.snmjournals.org/content/60/supplement_1/15

3. **Actinium-225 targeted alpha particle therapy for prostate cancer**
URL: https://www.thno.org/v14p2969.htm

4. **Alpha emitters-based therapy prolongs life for patients with advanced prostate cancer**
URL: https://joint-research-centre.ec.europa.eu/jrc-news-and-updates/alpha-emitters-based-therapy-prolongs-life-patients-advanced-prostate-cancer-2024-04-26_en

5. **225Ac-PSMA-617 radioligand therapy of de novo metastatic hormone-sensitive prostate cancer**
URL: https://pmc.ncbi.nlm.nih.gov/articles/PMC10199874/

6. **Current Status of Prostate-specific Membrane Antigen-targeted Radioligand Therapy for Metastatic Castration-resistant Prostate Cancer**
URL: https://ar.iiarjournals.org/content/44/3/879

7. **A Phase I Dose-Escalation Study of 225Ac-J591**
URL: https://pubmed.ncbi.nlm.nih.gov/37922438/

8. **Bipolar Androgen Therapy: When Excess Fuel Extinguishes the Fire**
URL: https://pmc.ncbi.nlm.nih.gov/articles/PMC10377678/

9. **Androgen Receptor Signaling Regulates DNA Repair in Prostate Cancers**
URL: https://aacrjournals.org/cancerdiscovery/article/3/11/1245/3425/Androgen-Receptor-Signaling-Regulates-DNA-Repair

10. **Efficacy and Safety of Actinium-225 Prostate-Specific Membrane Antigen Radioligand Therapy for Metastatic Castration-Resistant Prostate Cancer: A Meta-analysis**
URL: https://karger.com/mpp/article/32/3/178/843951/Efficacy-and-Safety-of-Actinium-225-Prostate

11. **Excellent therapeutic outcome of PSMA-targeted alpha therapy in an end-stage prostate cancer patient with visceral metastasis**
URL: https://jnm.snmjournals.org/content/64/supplement_1/P1

12. **Efficacy and Safety of Actinium-225 Prostate-Specific Membrane Antigen Radioligand Therapy for Metastatic Castration-Resistant Prostate Cancer: A Systematic Review and Meta-analysis**
URL: https://pmc.ncbi.nlm.nih.gov/articles/PMC10601660/

13. **Effects of 225Ac-Labeled Prostate-Specific Membrane Antigen Radioligand Therapy in Metastatic Castration-Resistant Prostate Cancer: A Meta-analysis**
URL: https://jnm.snmjournals.org/content/63/6/840

14. **Targeted Alpha Therapy Optimising Survival in Advanced Prostate Cancer**
URL: https://touchoncology.com/genitourinary-cancers/journal-articles/targeted-alpha-therapy-optimising-survival-in-advanced-prostate-cancer/

15. **Alpha Emitters May Move Radiopharmaceuticals Forward in Prostate Cancer**
URL: https://www.cancernetwork.com/view/alpha-emitters-may-move-radiopharmaceuticals-forward-in-prostate-cancer

16. **Metastatic Prostate Cancer Comparison of Different Treatments (Lutetium-177, Actinium-225, Radium-223)**
URL: https://bookinghealth.com/blog/diagnoses-and-treatment/diagnosis-and-treatment/695983-metastatic-prostate-cancer-comparison-of-different-treatments-comparison-of-lutetium-177-actinium-225-radium-223.html

17. **Advances in Actinium-Based Targeted Alpha Therapy for Prostate Cancer**
URL: https://www.nature.com/articles/s41392-022-01042-7

18. **Targeted Alpha Therapy for Prostate Cancer: The Next Generation of Alpha-emitting Radiopharmaceuticals**
URL: http://www.urotoday.com/library-resources/mcrpc-treatment/154109-targeted-alpha-therapy-for-prostate-cancer-the-next-generation-of-alpha-emitting-radiopharmaceuticals.html

19. **A Review on the Development of Targeted Alpha Therapy in the Treatment of Cancer Focusing on the First and Only FDA-approved Targeted Alpha Therapy Radium-223 in the Treatment of Metastatic Castration-resistant Prostate Cancer (mCRPC)**
URL: http://www.urotoday.com/journal/everyday-urology-oncology-insights/articles/98187-a-review-on-the-development-of-targeted-alpha-therapy-in-the-treatment-of-cancer-focusing-on-the-first-and-only-fda-approved-targeted-alpha-therapy-radium-223-in-the-treatment-of-metastatic-castration-resistant-prostate-cancer-mcrpc.html

20. **Calculation of Radium 223 and Actinium 225 Dosimetry in Targeted Alpha Therapy for mCRPC Patients**
URL: https://journals.lww.com/cancerjournal/fulltext/2021/17020/calculation_of_radium_223_and_actinium_225.7.aspx

21. **Actinium 225 Shows Clinical Activity in Metastatic Castration-resistant Prostate Cancer**
URL: https://dailyreporter.esmo.org/news/actinium-225-shows-clinical-activity-in-metastatic-castration-resistant-prostate-cancer

**22. Overview: Radiation Therapy | Cancer.Net https://www.cancer.net/navigating-cancer-care/how-cancer-treated/radiation-therapy**

**23. What is a PSA Bounce after Radiation? - Sperling Prostate Center https://sperlingprostatecenter.com/what-is-a-psa-bounce-after-radiation/**

**24. MRI Guided Radiation Therapy for the Treatment of High Risk Prostate Cancer - Full Text View - ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT05676463**

**25. ViewRay - MRIdian MRI-Guided Linac https://viewray.com/find-mridian-mri-guided-radiation-therapy**

**26. SpaceOAR prevents some side effects:**

27. **Hyaluronic Acid Spacer for Hypofractionated Prostate Radiation Therapy: A Randomized Clinical Trial | Oncology | JAMA Oncology | JAMA Network https://jamanetwork.com/journals/jamaoncology/fullarticle/2801296**

28. **SpaceOAR hydrogel spacer injection prior to stereotactic body radiation therapy for men with localized prostate cancer: A systematic review – PubMed https://pubmed.ncbi.nlm.nih.gov/34889268/**

29. **Hyaluronic Acid Spacer Reduced Long-Term Toxicity in Radiotherapy for Prostate Cancer - Oncology Nurse Advisor https://www.oncologynurseadvisor.com/home/cancer-types/prostate-cancer/prostate-cancer-hyaluronic-acid-spacer-long-term-toxicity-radiotherapy/**

30. **SpaceOAR™ Hydrogel | Prostate Cancer Hydrogel Spacer https://www.spaceoar.com**

31. **Hydrogel Spacer Prospective Multicenter Randomized Controlled Pivotal Trial: Dosimetric and Clinical Effects of Perirectal Spacer Application in Men Undergoing Prostate Image Guided Intensity Modulated Radiation Therapy – PubMed https://pubmed.ncbi.nlm.nih.gov/26054865**

32. **Proton therapy**

33. **Fewer secondary cancers vs. conventional SBRT: Second cancer risk after primary cancer treatment with three-dimensional conformal, intensity-modulated, or proton beam radiation therapy - Xiang - 2020 - Cancer - Wiley Online Library https://acsjournals.onlinelibrary.wiley.com/doi/10.1002/cncr.32938**

34. **Pencil beam proton therapy: What to know | MD Anderson Cancer Center https://www.mdanderson.org/cancerwise/pencil-beam-proton-therapy--what-to-know.h00-159305412.html**

35. **Is Proton Therapy Safer than Traditional Radiation? – NCI https://www.cancer.gov/news-events/cancer-currents-blog/2020/proton-therapy-safety-versus-traditional-radiation**

36. **Prostate Cancer News, Reviews & Views: proton https://www.prostatecancer.news/search/label/proton**

37. **Non-Invasive Prostate Cancer Treatment | LLUH Proton Therapy Treatment Center https://protons.com/treatments/prostate-cancer**

38. **Radiosensitizers and synergists**

39. **BAT**

40. **Androgen deprivation followed by acute androgen stimulation selectively sensitizes AR-positive prostate cancer cells to ionizing radiation – PMC https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4930695/**

41. **DNA DSBs are a primary intent of RT. This article discusses the DSBs and ways to potentially reduce their repair: Targeting DNA Double-Strand Break Repair OSNs to Improve Radiotherapy Response – PMC https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6356315/**

42. **SPT**

43. **High testosterone improves RT response: Cancers | Free Full-Text | Androgen Flare after LHRH Initiation Is the Side Effect That Makes Most of the Beneficial Effect When It Coincides with Radiation Therapy for Prostate Cancer https://www.mdpi.com/2072-6694/14/8/1959**

44. **High testosterone induces DNA defects during RT: JCI - Supraphysiological androgens suppress prostate cancer growth through androgen receptor–mediated DNA damage https://www.jci.org/articles/view/127613**

45. **ADT**

46. **Clinical Trials of Adjuvant Androgen Deprivation in Localized Prostate Cancer ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT02175212/**

47. **PSA Nadir After RT+ADT for Prostate Cancer Predicts Outcomes - Renal and Urology News https://www.renalandurologynews.com/home/news/urology/prostate-cancer/psa-nadir-after-rtadt-for-prostate-cancer-predicts-outcomes/**

48. **ADT promotes DSBs during RT: DNA damage response and prostate cancer: defects, regulation and therapeutic implications – PMC https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4333141/**

49. **Radiation Therapy With or Without Antiandrogen Therapy in Treating Patients With Stage I or Stage II Prostate Cancer ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT00002597**

50. **When can ADT be safely avoided with salvage radiation therapy? | THE "NEW" PROSTATE CANCER INFOLINK https://prostatecancerinfolink.net/2018/01/05/when-can-adt-be-safely-avoided-with-salvage-radiation-therapy/**

51. **ADT and Brachytherapy: The Good, the Bad, and the Ugly | Video https://grandroundsinurology.com/adt-and-brachytherapy-the-good-the-bad-and-the-ugly/**

52. **Intermediate risk PCa, 8-week vs 28-week ADT/total androgen blockade results are similar: Hormone Therapy and Radiation Therapy in Treating Patients With Prostate Cancer - Full Text View - ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT00005044**

53. **Brief, intense radiation and hormone therapy for very high-risk prostate cancer | THE “NEW” PROSTATE CANCER INFOLINK https://prostatecancerinfolink.net/2021/06/05/brief-intense-radiation-and-hormone-therapy-for-very-high-risk-prostate-cancer**

54. **Prostate Cancer News, Reviews & Views: The importance of radiotherapy dose escalation and long-term ADT for success https://www.prostatecancer.news/2022/04/the-importance-of-radiotherapy-dose.html**

55. **ADT following radiation might be harmful for men with PSA ≤0.6 going into RT: Long-term hormone therapy increases mortality risk for men with low PSA levels after prostate surgery - American Society for Radiation Oncology (ASTRO) - American Society for**

**Radiation Oncology (ASTRO) https://www.astro.org/News-and-Publications/News-and-Media-Center/News-Releases/2019/Long-term-hormone-therapy-increases-mortality-risk**

**56. Study Supports Longer ADT Use With Radiation for High-Risk Prostate Cancer - Renal and Urology News https://www.renalandurologynews.com/home/news/urology/prostate-cancer/at-least-18-months-androgen-deprivation-with-radiation-for-high-risk-prostate-cancer/**

**57. Exercise**

1. **Exercise enhances oxygenation and increases RT effectiveness: Exercise modulation of tumour perfusion and hypoxia to improve radiotherapy response in prostate cancer | Prostate Cancer and Prostatic Diseases https://www.nature.com/articles/s41391-020-0245-z**
2. **Fortifying the Treatment of Prostate Cancer with Physical Activity – PMC https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4764749**
3. **Modulating Tumor Hypoxia in Prostate Cancer Through Exercise: The Impact of Redox Signaling on Radiosensitivity | Sports Medicine - Open | Full Text https://sportsmedicine-open.springeropen.com/articles/10.1186/s40798-022-00436-9**
4. **Exercise improves QoL and decreases fatigue during RT: Randomized Controlled Trial of Resistance or Aerobic Exercise in Men Receiving Radiation Therapy for Prostate Cancer | Journal of Clinical Oncology https://ascopubs.org/doi/10.1200/JCO.2007.15.4963**
5. **Exercise reduces the likelihood of urinary toxicity: Effects of Exercise During Radiation Therapy on Physical Function and Treatment-Related Side Effects in Men With Prostate Cancer: A Systematic Review and Meta-Analysis – PubMed https://pubmed.ncbi.nlm.nih.gov/34246737**

**58. Xtandi**

1. **New insights in the paradigm of upregulation of tumoral PSMA expression by androgen receptor blockade: Enzalutamide induces PSMA upregulation in castration-resistant prostate cancer even in patients having previously progressed on enzalutamide – PubMed https://pubmed.ncbi.nlm.nih.gov/31901103/**
2. **Use of Xtandi to upregulate PSMA prior to radioligand therapy: New insights in the paradigm of upregulation of tumoral PSMA expression by androgen receptor blockade: Enzalutamide induces PSMA upregulation in castration-resistant prostate cancer even in patients having previously progressed on enzalutamide – PubMed https://pubmed.ncbi.nlm.nih.gov/31901103/**
3. **Radiosensitization by enzalutamide for human prostate cancer is mediated through the DNA damage repair OSN – PMC https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6443157/**

**59. Fasting**

1. **Time-Restricted Eating Versus Nutritional Counseling for the Reduction of Radiation or Chemoradiation Tx Side Effects in Patients With Prostate, Cervical, or Rectal Cancers - Full Text View - ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT05722288**

2. **Effects of short-term fasting on cancer treatment – PMC https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6530042**
3. **The role and its mechanism of intermittent fasting in tumors: friend or foe? – PMC https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7877171**
4. **5 day fasting reduces side effects of RT: Cancer and Fasting / Calorie Restriction | UCSF Osher Center for Integrative Health https://osher.ucsf.edu/patient-care/integrative-medicine-resources/cancer-and-nutrition/faq/cancer-and-fasting-calorie-restriction#:~:text=Fasting%20may%20also%20protect%20patients,effect%20of%20treatment%20(14)**
5. **Fasting and fasting-mimicking diets for chemotherapy augmentation – PMC https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8190229**

60. **Statins**

1. **Statins make radiation more effective at curing prostate cancer, study suggests—ScienceDaily https://www.sciencedaily.com/releases/2011/03/110323104727.htm**
2. **The effect of statins on prostate cancer recurrence and mortality after definitive therapy: a systematic review and meta-analysis – PubMed https://pubmed.ncbi.nlm.nih.gov/27384548**
3. **Simvastatin ameliorates radiation enteropathy development after localized, fractionated irradiation by a protein C-independent mechanism – PMC https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2000701**

61. **Melatonin**

1. **The melatonin immunomodulatory actions in radiotherapy – PMC https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC5425818**
2. **Melatonin as a Radio-Sensitizer in Cancer - PMC https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC7460067**

62. **Prazosin**

1. **May Lower Prostate Cancer Recurrence Risk After Radiotherapy - Renal and Urology News https://www.renalandurologynews.com/home/conference-highlights/ics-2018-coverage/prazosin-may-lower-prostate-cancer-recurrence risk-after-radiotherapy/**
2. **Prazosin inhibits the proliferation, migration and invasion, but promotes the apoptosis of U251 and U87 cells via the PI3K/AKT/mTOR signaling OSN https://www.spandidos-publications.com/10.3892/etm.2020.8772**
3. **Prazosin reduced BCR in a retrospective study: ICS 2018 Abstract #527 Prazosin used to manage LUTS in men with prostate cancer reduces risk of biochemical relapse following radiotherapy https://www.ics.org/2018/abstract/527**
4. **Trial in progress (not controlled or randomized): ANZCTR – Registration https://anzctr.org.au/Trial/Registration/TrialReview.aspx?ACTRN=12621000784819**

63. **Losartan (do not use with prazosin)**

1. **Angiotensin II receptor blockers induce autophagy in prostate cancer cells – PMC https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5431597**
2. **Frontiers | The Use of Antihypertensive Drugs as Coadjuvant Therapy in Cancer https://www.frontiersin.org/articles/10.3389/fonc.2021.660943/full**
3. **Losartan sensitizes selectively prostate cancer cell to ionizing radiation - PubMed https://pubmed.ncbi.nlm.nih.gov/26828983**

64. **Zytiga**

1. **Combining abiraterone and radiotherapy in metastatic castration-resistant prostate cancer: a review of current evidence – PubMed https://pubmed.ncbi.nlm.nih.gov/30905318**

65. **Curcumin**

1. **Relationship and interactions of curcumin with radiation therapy – PMC https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC4896895**
2. **Higher levels of IL-10 were associated with better RT outcomes: The Influence of the Pretreatment Immune State on Response to Radiation Therapy in High-Risk Prostate Cancer: A Validation Study from NRG/RTOG 0521. https://www.urotoday.com/recent-abstracts/urologic-oncology/prostate-cancer/137814-the-influence-of-the-pretreatment-immune-state-on-response-to-radiation-therapy-in-high-risk-prostate-cancer-a-validation-study-from-nrg-rtog-0521.html**
3. **Curcumin increases IL-10: Immune modulation by curcumin: The role of interleukin-10 – PubMed https://pubmed.ncbi.nlm.nih.gov/28799796/**
4. **Nanocurcumin for Prostate Cancer Patients Undergoing Radiotherapy (RT) - Full Text View - ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT02724618**

66. **Aspirin**

1. **The multiple effects of aspirin in prostate cancer patients – ScienceDirect https://www.sciencedirect.com/science/article/pii/S2468294220301027**
2. **Salicylate enhances the response of prostate cancer to radiotherapy – PubMed https://pubmed.ncbi.nlm.nih.gov/30609074/**

67. **Calorie restriction, rapamycin, and metformin**

1. **When less may be more: calorie restriction and response to cancer therapy | BMC Medicine | Full Text https://bmcmedicine.biomedcentral.com/articles/10.1186/s12916-017-0873-x**

68. **D3**

1. **Vitamin D3 https://www.cancer.gov/about-cancer/treatment/cam/hp/prostate-supplements-pdq#_174**

2. **Does vitamin D prevent radiotherapy-induced toxicity? https://www.degruyter.com/document/doi/10.1515/tjb-2018-0479/html**

**69. Keto**

1. **More research needed: Ketogenic Diets and Cancer: Emerging Evidence – PMC https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6375425**
2. **Insufficient evidence to support: Efficacy of Low-Carbohydrate Ketogenic Diet as an Adjuvant Cancer Therapy: A Systematic Review and Meta-Analysis of Randomized Controlled Trials – PMC https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8142992**

**70. General**

1. **Application of Radiosensitizers in Cancer Radiotherapy – PMC https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7886779**
2. **TRT following radiation: Testosterone therapy in men with prostate cancer: literature review, clinical experience, and recommendations - PMC https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC4650486**
3. **Ga-68-PSMA diagnostics and Lu-177-PSMA therapy induce DSBs: Are there differences in the DNA double-strand break induction in blood leukocytes of prostate cancer patients during Ga-68-PSMA diagnostics and Lu-177-PSMA therapy? | Journal of Nuclear Medicine https://jnm.snmjournals.org/content/60/supplement_1/1625**
4. **Evaluation of DNA double strand break formation and excreted guanine species post whole body PET/CT procedure | Journal of Radiation Research | Oxford Academic https://academic.oup.com/jrr/article/62/4/590/6283589**
5. **Shortened course of radiation therapy safe and effective for men with high-risk prostate cancer - American Society for Radiation Oncology (ASTRO) - American Society for Radiation Oncology (ASTRO) https://www.astro.org/News-and-Publications/News-and-Media-Center/News-Releases/2022/Shortened-course-of-radiation-therapy-safe-and-eff**
6. **Secondary cancer caused by RT: Impact of Advanced Radiotherapy on Second Primary Cancer Risk in Prostate Cancer Survivors: A Nationwide Cohort Study – PMC https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8662556/**
7. **Characteristics of PSA Bounce after Radiotherapy for Prostate Cancer: A Meta-Analysis – PMC https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7465291/**
8. **ASCO 2022: Salvage Treatment for Biochemical Recurrence After Radical Prostatectomy https://www.urotoday.com/conference-highlights/asco-2022/asco-2022-prostate-cancer/137633-asco-2022-salvage-treatment-for-biochemical-recurrence-after-radical-prostatectomy.html**
9. **Interim results of AASUR: A single arm, multi-center phase 2 trial of apalutamide (A) + abiraterone acetate + prednisone (AA+P) + leuprolide with stereotactic ultra-hypofractionated radiation (UHRT) in very high risk (VHR), node negative (N0) prostate cancer (PCa). | Journal of Clinical Oncology https://ascopubs.org/doi/abs/10.1200/JCO.2021.39.15_suppl.5012**

10. **AUA 2022: Not All Adverse Pathology Features Are Equal: Identifying Optimal Candidates For Adjuvant Radiotherapy Among Patients With Adverse Pathology at Radical Prostatectomy https://www.urotoday.com/conference-highlights/2022-annual-meeting/aua-2022-prostate-cancer/137144-not-all-adverse-pathology-features-are-equal-identifying-optimal-candidates-for-adjuvant-radiotherapy-among-patients-with-adverse-pathology-at-radical-prostatectomy.html**

11. **eSRT improves outcomes following RP if started when PSA is between 0.2 and 0.5 ng/ml https://www.renalandurologynews.com/home/conference-highlights/genitourinary-cancers-symposium/early-salvage-radiation-after-surgery-improves-mfs-in-recurrent-prostate-cancer**

12. **Whole-pelvic radiation therapy for high-risk patients  https://prostatecancerinfolink.net/2021/08/19/whole-pelvic-radiation-therapy-for-high-risk-patients**

13. **Shortened Course of Radiotherapy Feasible in Men with High-Risk Prostate Cancer | Value-Based Cancer Care https://www.valuebasedcancer.com/issues/2022/december-2022-vol-13-no-6/3230-shortened-course-of-radiotherapy-feasible-in-men-with-high-risk-prostate-cancer**

14. **ESMO 2019: Adjuvant or Salvage Radiotherapy for the Treatment of Localized Prostate Cancer? A Prospectively Planned Aggregate Data Meta-Analysis - A Medical Oncologist's Perspective https://www.urotoday.com/conference-highlights/esmo-2019/esmo-2019-prostate-cancer/115215-esmo-2019-adjuvant-or-salvage-radiotherapy-for-the-treatment-of-localized-prostate-cancer-a-prospectively-planned-aggregate-data-meta-analysis-2.html**

15. **Prostate Cancer News, Reviews & Views: "Adjuvant" similar to "Early Salvage" Radiation Outcome in Meta-analysis https://www.prostatecancer.news/2019/09/adjuvant-similar-to-early-salvage.html**

16. **Prostate-Specific Antigen (PSA) Bounce After Dose-Escalated External Beam Radiation Therapy Is an Independent Predictor of PSA Recurrence, Metastasis, and Survival in Prostate Adenocarcinoma Patients - International Journal of Radiation Oncology, Biology, Physic https://www.redjournal.org/article/S0360-3016(17)33854-3/fulltext**

17. **Possible Side Effects of Radiation Treatment for Prostate Cancer | OncoLink https://www.oncolink.org/cancers/prostate/treatments/possible-side-effects-of-radiation-treatment-for-prostate-cancer**

18. **Radiation Side Effects | Prostate Cancer Foundation https://www.pcf.org/about-prostate-cancer/prostate-cancer-side-effects/radiation-side-effects/#:~:text=Your%20doctor%20may%20also%20suggest,if%20your%20insurance%20covers%20it.**

19. **Survival after radical prostatectomy versus radiation therapy in clinical node-positive prostate cancer - Chierigo - - The Prostate - Wiley Online Library https://onlinelibrary.wiley.com/doi/10.1002/pros.24317**

20. **Frank, Steven J. "The Myths and Facts About Prostate Brachytherapy." September 2021 https://grandroundsinurology.com/the-myths-and-facts-about-prostate-brachytherapy**

21. **10-year survival after RT/ADT or RT/RP (comparing overall mortality (PCa, cardiac, etc) to PCa mortality for RT/ADT vs. RT/RP) https://www.mskcc.org/clinical-updates/prostatectomy-and-radiotherapy-combo-delivers-better-outcomes-advanced-prostate**

22. **Radiation kills CTCs https://clinicaltrials.gov/ct2/show/NCT01800058**

23. **Poor results: Radiation Therapy with or without Bicalutamide for Recurrent pT3N0 Prostate Cancer After Radical Prostatectomy ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT00002874**

24. **Stereotactic Radiation Therapy versus Brachytherapy: Relative Strengths of Two Highly Efficient Options for the Treatment of Localized Prostate Cancer - PMC**

25. **https://pmc.ncbi.nlm.nih.gov/articles/PMC9105931/**

26. **SBRT vs Standard Radiotherapy for Localized Prostate Cancer: 5-Year Analysis of PACE B - The ASCO Post**

27. **https://ascopost.com/news/october-2023/sbrt-vs-standard-radiotherapy-for-localized-prostate-cancer-5-year-analysis-of-pace-b/**

## Pluvicto + Orgovyx + Nubeqa + Lynparza Combination for Metastatic Castration-Resistant Prostate Cancer (mCRPC)

Efficacy Ranking

1. Orgovyx + Nubeqa + Olaparib + Pluvicto
    - Rationale:
        - Dual AR Suppression: Orgovyx (rapid castration) + Nubeqa (AR nuclear translocation blockade) maximizes PSMA upregulation via AR pathway inhibition. Preclinical data show Nubeqa increases PSMA expression by 2–4×, while ADT (Orgovyx) boosts PSMA-PET SUVmax by ~40% in bone metastases.
        - Synergy: Pluvicto's radiation-induced DNA damage + Olaparib's PARP inhibition creates synthetic lethality, particularly in HRR-deficient tumors (BRCA1/2).
    - Evidence:
        - Daro-PET Trial: Nubeqa increased PSMA-PET SUVmax by ≥20% in localized PCa.
        - ARASENS Trial: Nubeqa + ADT/docetaxel reduced death risk by 32% in mHSPC.
        - ENZA-p Trial: Pluvicto + enzalutamide achieved 93% PSA50 response.
2. Nubeqa + Olaparib + Pluvicto
    - Rationale: Strong PSMA upregulation via Nubeqa + PARP/radiation synergy.
3. Orgovyx + Olaparib + Pluvicto
    - Rationale: Rapid castration (Orgovyx) primes PSMA for Pluvicto, but lacks direct AR inhibition.
4. Zytiga + Olaparib + Pluvicto
    - Rationale: Zytiga's steroid requirement and inconsistent PSMA upregulation limit efficacy.

Safety/Tolerability Ranking

1. Orgovyx + Olaparib + Pluvicto
    - Advantages: No steroid requirement; rapid testosterone suppression minimizes AR-driven side effects.
2. Orgovyx + Nubeqa + Olaparib + Pluvicto
    - Advantages: Dual AR suppression reduces adaptive resistance but increases fatigue risk (25–30% grade 1–2).
    - Key Risks: Myelosuppression (Pluvicto + Olaparib), hypertension (Nubeqa: 3.8%).
3. Nubeqa + Olaparib + Pluvicto
    - Key Risks: Anemia (16% grade ≥3), fatigue (38%).
4. Zytiga + Olaparib + Pluvicto
    - Key Risks: Steroid-induced metabolic effects (weight gain, diabetes), liver toxicity.

Summary Table

| Rank | Combination | Efficacy Strengths | Key Safety Risks |
|---|---|---|---|
| 1 | Orgovyx + Nubeqa + Olaparib + Pluvicto | Maximal PSMA upregulation, dual AR + DNA targeting | Fatigue, myelosuppression, hypertension |
| 2 | Nubeqa + Olaparib + | Strong AR/HRR synergy | Anemia, fatigue |

| Rank | Combination | Efficacy Strengths | Key Safety Risks |
|---|---|---|---|
| | Pluvicto | | |
| 3 | Orgovyx + Olaparib + Pluvicto | Rapid castration, no steroids | Hot flashes, myelosuppression |
| 4 | Zytiga + Olaparib + Pluvicto | Proven PARP + AR synergy | Steroid toxicity, liver issues |

Implementation

| Drug | Dose/Regimen | Timing/Notes |
|---|---|---|
| **Orgovyx** | 120 mg/day PO | Start 1 week before Pluvicto to ensure castration (T <20 ng/dL). |
| **Nubeqa** | 600 mg BID PO | Begin concurrently with Orgovyx. |
| **Pluvicto** | 7.4 GBq IV q6w × 6 cycles | Administer 3–4 weeks post-AR suppression (confirm PSMA-PET SUVmax ↑). |
| **Olaparib (if HRR deficient)** | 300 mg BID PO (reduce to 200 mg BID if HRR-proficient) | Start 1-week post-Pluvicto cycle 1 to mitigate overlapping myelosuppression. |

Clinical Recommendations

- Prioritize Orgovyx + Nubeqa + Olaparib + Pluvicto for maximal DNA damage synergy and PSMA targeting.
- Consider removing Olaparib if the patient is HRR proficient.
- For high cardiovascular risk: Use Orgovyx + Olaparib + Pluvicto to avoid hypertension from Nubeqa.
- Monitoring:
  - PSMA-PET at 3–4 weeks post-AR suppression.
  - CBC/LFTs monthly for myelosuppression and hepatotoxicity.

Bottom Line:
The quadruplet regimen (Orgovyx + Nubeqa + Olaparib + Pluvicto) offers the highest efficacy by combining dual AR suppression, enhanced PSMA expression, and synthetic lethality. However, it requires vigilant toxicity monitoring.

References:

- ARASENS, ENZA-p, PROpel trials

- OSN.docx (mechanistic pathways)
- PMC9401501 (Nubeqa + PSMA targeting)
- ASCO GU 2024 (Daro-PET trial)

# SBRT

## Monitoring

1. Imaging

   After treatment, NCCN guidelines suggest 3–6-month imaging surveillance up to year 3, every 6 months in years 3-5, and yearly after 5 years.

2. CTCs Provide Earlier Detection of Recurrence

**Circulating Tumor Cells (CTCs) for Monitoring Prostate Cancer After SBRT: Key Insights**

**CTC Testing vs. Imaging in Post-SBRT Surveillance**

Emerging evidence suggests **CTC testing may predict treatment failure and metastasis earlier than imaging** in prostate cancer patients after stereotactic body radiation therapy (SBRT).

- **Lead Time Over Imaging**:
  In non-small cell lung cancer (NSCLC), CTC increases after SBRT provided **~2 years of lead time** over conventional imaging for detecting recurrence[2]. While prostate-specific data are limited, similar mechanisms likely apply:
  - CTCs reflect real-time tumor dynamics, while imaging detects structural changes (often delayed).
  - PSA kinetics alone lack specificity; CTCs may bridge this gap.
- **Prostate Cancer Evidence**:
  - A study of 2,000 men found CTCs detected prostate cancer with **99% positive predictive value (PPV)** and **97% negative predictive value (NPV)** during screening[5].
  - Post-SBRT, **38% of patients had biopsy-proven local recurrence despite normal PSA**[4]. CTCs could identify these cases earlier.

**2. Limitations of Current Imaging**

- **PSMA PET-CT**:
  While PSMA PET-CT is **27% more accurate than standard imaging** for detecting metastases, it still misses micrometastases and has false positives due to post-radiation changes[3][4].
- **MRI and Biopsy**:
  MRI-guided biopsy remains the gold standard for local recurrence but is invasive and delayed (often at 2+ years post-SBRT)[1][4].

**3. CTCs as a Non-Invasive Biomarker**

- **Early Salvage Therapy Guidance**:
  - In prostate cancer, **undetectable PSA after salvage therapy** correlates with CTC clearance, supporting CTCs' role in monitoring response[1].
  - CTC dynamics (e.g., ≥30% decline post-treatment) predict survival in metastatic castration-resistant prostate cancer (mCRPC)[2].
- **Technical Advantages**:
  - **ISET®-CTC Test**: Detects 1 CTC/10 mL blood, offering higher sensitivity than CellSearch®[5].
  - Combines with PSMA staining to improve specificity for prostate cancer[5].

**Clinical Implications**

| Metric | CTC Testing | Imaging (PSMA PET/MRI) |
|---|---|---|
| Detection Lead Time | 1–2 years earlier* | Limited by tumor size/visibility |
| Invasiveness | Non-invasive (blood test) | Non-invasive (PET) or invasive (biopsy) |

| Metric | CTC Testing | Imaging (PSMA PET/MRI) |
|---|---|---|
| Specificity | High (99% PPV with PSMA staining)[5] | Moderate (65–92% accuracy)[3][4] |
| Cost/Ease | Low (routine blood draw) | High (specialized equipment/training) |

*Based on NSCLC data; prostate-specific studies pending.

**Recommendations**

1. **Integrate CTC Testing Post-SBRT**:
   - Monitor CTC counts at 3–6 month intervals alongside PSA.
   - Use CTC increases to trigger advanced imaging/biopsy.
2. **Validate Prostate-Specific Protocols**:
- Studies like ARGOS/CLIMBER[4] are evaluating CTCs + PSMA PET/MRI for early failure detection.

**Conclusion**

CTC testing offers a **non-invasive, sensitive tool** for detecting treatment failure and metastasis earlier than imaging in prostate cancer patients post-SBRT. While further prostate-specific validation is needed, NSCLC data and preliminary prostate studies suggest CTCs could revolutionize surveillance paradigms.

**References**


1. **Management of Isolated Local Failures Following Stereotactic Body Radiation Therapy for Low to Intermediate Risk Prostate Cancer**
   URL: https://pmc.ncbi.nlm.nih.gov/articles/PMC7673419/
   Quality: A (peer-reviewed, PMC)
2. **Circulating Tumor Cells Are Associated With Recurrent Disease in Early-Stage NSCLC Following SBRT**
   URL: https://pmc.ncbi.nlm.nih.gov/articles/PMC9940939/
   Quality: A (peer-reviewed, PMC)
3. **Diagnostic Accuracy of 68Ga-PSMA PET/CT for Initial Detection in Patients With Suspected Prostate Cancer**
   URL: https://ajronline.org/doi/abs/10.2214/AJR.20.23912
   Quality: A (peer-reviewed, AJR)
4. **Imaging Biomarkers in Prostate Stereotactic Body Radiotherapy**
   URL: https://pmc.ncbi.nlm.nih.gov/articles/PMC9043802/
   Quality: A (peer-reviewed, PMC)
5. **New Screening Test Improves Detection of Prostate Cancer Using Circulating Tumor Cells and Prostate-Specific Markers**
   URL: https://pmc.ncbi.nlm.nih.gov/articles/PMC7192049/
   Quality: A (peer-reviewed, PMC)

| Step | Action |
|---|---|
| CTC Testing | Use CellSearch®; ≥5 CTCs/7.5 mL triggers PSMA-PET. |
| PSMA-PET/CT | Locate metastases (bone, nodal, visceral); guide therapy. |
| Therapeutic Implications | - Oligometastatic: SBRT or surgery. |
| | - High-volume: Systemic therapy (ADT + novel agents). |

## How to get a CellSearch CTC Test

| Step | Who Handles It | Notes |
|---|---|---|
| Order CellSearch kit | Your doctor | Via CellSearch portal; includes special tubes/instructions |
| Arrange mobile phlebotomist | You or your doctor | Must use CellSave tube and follow handling instructions |
| Blood draw at your location | Mobile phlebotomist | Venous draw only, not fingerstick |
| Ship sample to CellSearch lab | Phlebotomist or you | Use provided shipping materials; follow kit instructions |

### BAT, SBRT, Losartan, Orgovyx, olaparib

I used this therapy in late 2023.

My MO, another expert MO, and my RO all agreed that it was theoretically a sound approach. My PSA leapt up after I finished SBRT and then dropped to a three-year low.




Figure 14 SBRT – Prazosin could be replaced with Losartan 50 mg

**Instructions:**

1. **At least 2 months before SBRT:**
    - Begin ADT (e.g., Lupron or Orgovyx).

- *Note: The interval may be shorter (4-6 weeks) if using Orgovyx or Firmagon.*

2. **At least 2 weeks before SBRT:**
   - Start darolutamide (Nubeqa) 600 mg twice daily with food (or as directed).
3. **At least 1 week before SBRT:**
   - Consider starting doxazosin (optional), as directed.
4. **At least 3 days before SBRT:**
   - Begin olaparib 300 mg twice daily with food (or as directed).
5. **SBRT #1**
6. **SBRT #2**
7. **SBRT #3**
8. **After SBRT #3:**
   - Stop Nubeqa the day following SBRT #3.
9. **Before SBRT #4 and SBRT #5:**
   - Inject 75 mg testosterone propionate on the morning of SBRT #4. (if testosterone propionate cannot be used, Androgel could be substituted without compromising the results. 500 mg of Androgel should be sufficient)
   - Inject 75 mg testosterone propionate on the morning of SBRT #5 . (if testosterone propionate cannot be used, Androgel could be substituted without compromising the results. 500 mg of Androgel should be sufficient
10. **After SBRT #5:**
    - One day after SBRT #5, restart Nubeqa.
    - Four days after SBRT #5, you may discontinue olaparib.
11. **Ongoing Treatment:**
    - Continue ADT as directed by your radiation oncologist (RO).
    - Continue Nubeqa (or another ARSI) as directed by your RO.
12. **Optional:**
    Begin **7–14 days prior to SBRT#1** and continue until **2 days after SBRT#5**:
    - **Valproic Acid (VPA):** 500 mg BID
    - **Metformin:** 500 mg BID

    *Note: VPA is considered a potential radiosensitizer in this context.*

*If any of the medications are contraindicated based on your doctors' recommendations, please follow their advice—and be sure to ask for their reasoning.*

**Risks and Considerations**

- **Complexity and Coordination:**
  This approach requires precise timing and coordination between systemic therapies and radiotherapy. Any delays or inconsistencies in drug administration could potentially impact treatment efficacy.
- **Potential Toxicities:**
  Combining ADT, ARSI, PARP inhibitors, and SBRT can increase the risk of side effects—ranging from hormonal and metabolic issues to radiation-induced toxicities. Close monitoring is essential.
- **Testosterone Reintroduction:**
  The planned testosterone injections, while potentially beneficial for tumor re-sensitization, carry the risk of temporarily stimulating tumor growth or inflammatory factors if not timed correctly.

- **Limited Long-Term Data:**
  Protocols that incorporate elements such as PARP inhibition and BAT-like strategies are relatively novel in prostate cancer management. Their long-term impact on survival and quality of life is still under investigation.

## 1. Rationale

**Multifaceted Attack:**
The proposed combination aims to target prostate cancer through several complementary mechanisms. **Bipolar Androgen Therapy (BAT)** cyclically exposes tumor cells to supraphysiological testosterone levels followed by castrate conditions, thereby inducing DNA damage and potentially re-sensitizing resistant clones. Aligning **pulsed olaparib** with high testosterone pulses is intended to exploit this induced DNA damage by blocking PARP-mediated repair, thus pushing cells toward apoptosis. **SBRT (stereotactic body radiotherapy)** is used to ablate visible metastases with high precision and can enhance the effects of DNA damage by creating double-strand breaks. **Continuous doxazosin** is repurposed for its pro-apoptotic and anti-angiogenic effects, and **Orgovyx (Relugolix)** provides a reliable ADT backbone, ensuring castrate testosterone levels between BAT pulses.

**Overall Concept:**
This strategy targets cancer at multiple levels:

- **Systemic DNA damage and repair inhibition** (BAT + pulsed olaparib)
- **Local tumor ablation** (SBRT)
- **Microenvironment modulation** (doxazosin)
- **Sustained androgen suppression** (Relugolix)

It is theorized to benefit both oligometastatic hormone-sensitive (oHSPC) and castration-resistant (oCRPC) prostate cancer, with potential enhanced efficacy in tumors harboring BRCA/HRR mutations.

---

## 2. Mechanisms of Action

**Bipolar Androgen Therapy (BAT):**
BAT cycles patients between low and very high testosterone levels. Supraphysiologic testosterone can lead to AR overactivation, causing DNA double-strand breaks via topoisomerase-IIβ–mediated mechanisms and downregulating DNA repair genes. This creates a window where tumor cells are vulnerable to further DNA damage.

**Pulsed Olaparib:**
Olaparib, a PARP inhibitor, blocks the repair of single-strand DNA breaks. When given during testosterone pulses, it is designed to capture the additional DNA damage from BAT, pushing cells—especially those with compromised homologous recombination repair—into lethal genomic instability. This “synthetic lethality” is particularly compelling for BRCA-mutated tumors but may also benefit HRR-proficient cases rendered temporarily “BRCAness” by BAT.

**SBRT:**
SBRT delivers high-dose, highly focused radiation to metastatic lesions, causing direct DNA damage (primarily double-strand breaks) and potentially triggering an immune response (the abscopal effect). Its combination with PARP inhibition further hampers the repair of radiation-induced damage, enhancing local tumor control.

**Doxazosin:**
Originally used as an $\alpha_1$-adrenergic blocker for BPH and hypertension, doxazosin has demonstrated in cell studies the ability to induce apoptosis via activation of death receptor OSNs (e.g., Fas) and reduce angiogenesis. Its continuous administration might help in reducing tumor vascularity and microenvironmental support, thereby complementing the cytotoxic effects of the other modalities.

**Relugolix (Orgovyx):**
Relugolix is an oral GnRH antagonist that quickly suppresses testosterone without causing an initial flare. By maintaining castrate-level testosterone between BAT cycles, it provides the necessary background of androgen deprivation that is essential for BAT's cyclic mechanism and limits tumor growth.

---

### 3. Evidence Quality (A–F Scale)

- **BAT:**
  - **Grade C.** Early phase (I/II) trials in castration-resistant prostate cancer (mCRPC) have shown PSA responses and improvements in quality-of-life. However, survival benefits have not been established in phase III studies.
- **Pulsed Olaparib (with BAT):**
  - **Grade A for BRCA-mutated mCRPC; Grade C for unselected cases.** Phase III trials (e.g., PROfound) support olaparib in HRR-deficient mCRPC. Early-phase studies combining BAT and olaparib show promising PSA declines even in HRR-proficient patients, but more data are needed.
- **SBRT:**
  - **Grade B.** Randomized phase II trials (e.g., STOMP, ORIOLE) support SBRT's role in delaying progression in oligometastatic prostate cancer, with excellent local control and low toxicity.
- **Doxazosin:**
  - **Grade E.** Primarily supported by in vitro and animal studies demonstrating apoptosis induction and anti-angiogenesis; clinical evidence is limited to retrospective or observational data. Because of this it is an optional drug. It lowers BP. If your BP is high, you might need a BP drug. If not, carefully consider adding this.
- **Relugolix (Orgovyx):**
  - **Grade A.** Supported by robust phase III evidence (HERO trial) showing rapid and sustained testosterone suppression with improved cardiovascular safety compared to traditional ADT.
- **Overall Combination:**

- **Grade B.** While key pairings (BAT + olaparib, ADT + SBRT) have supportive data, the full five-modality regimen is hypothetical and has not been tested. Its rationale is built on converging preclinical and early-phase clinical findings.

---

## 4. Summary of Cell Studies, Preclinical Research, and Clinical Trials

**Cell and Preclinical Studies:**

- **BAT:** Laboratory models show that supraphysiologic testosterone induces DNA damage and downregulates repair genes, triggering cell death.
- **Olaparib:** Numerous cell studies establish that PARP inhibition prevents repair of DNA damage, with strong synergism in HRR-deficient cells.
- **Combination Studies:** Preclinical work has demonstrated that combining androgen manipulations with PARP inhibitors leads to increased DNA damage and reduced viability of prostate cancer cells.
- **Doxazosin:** In vitro studies have consistently shown that doxazosin induces apoptosis through death-receptor OSNs and reduces angiogenesis in prostate cancer models.
- **SBRT:** Preclinical radiobiology confirms that high-dose radiation leads to lethal DNA damage, while some translational studies suggest that SBRT can induce systemic immune responses.

**Clinical Trials:**

- **BAT:** Early-phase trials and the TRANSFORMER trial in mCRPC show BAT can induce significant PSA declines and resensitize tumors to AR-targeted therapies.
- **Olaparib:** The PROfound trial demonstrated clear benefits for olaparib in HRR-mutated mCRPC. Early-phase trials of BAT + olaparib indicate promising PSA responses even among patients without known mutations.
- **SBRT:** Trials such as STOMP and ORIOLE have validated SBRT in oligometastatic settings, showing delays in progression and reductions in new metastases.
- **Relugolix:** The HERO trial confirmed its efficacy in achieving rapid and sustained testosterone suppression.
- **Doxazosin:** Lacks dedicated clinical trials for its anticancer role; evidence is extrapolated from preclinical and retrospective observations.

---

## 5. Potential Implications for oHSPC and oCRPC, With and Without BRCA Mutations

**Oligometastatic Hormone-Sensitive PCa (oHSPC):**

- **Without BRCA mutations:** Standard treatment remains continuous ADT (e.g., Relugolix) with SBRT for metastasis-directed therapy. BAT and pulsed olaparib remain experimental in this setting due to potential risks of stimulating hormone-sensitive tumors. Doxazosin may offer symptomatic relief and modest anti-tumor benefits.

- **With BRCA/HRR mutations:** There is emerging rationale to incorporate PARP inhibitors earlier. Although BAT is typically reserved for castration-resistant settings, in select aggressive oHSPC cases a carefully designed, trial-based approach could consider BAT + olaparib to maximize DNA damage, provided that SBRT is used to ablate metastases.

**Oligometastatic Castration-Resistant PCa (oCRPC):**

- **Without BRCA mutations:** BAT can be used to re-sensitize tumors and induce DNA damage, with pulsed olaparib capitalizing on this vulnerability. SBRT can control known metastases, and continuous Relugolix ensures baseline androgen suppression. Early-phase data suggest that about one-third of such patients might achieve a significant PSA decline.
- **With BRCA/HRR mutations:** PARP inhibitors are already standard. Adding BAT could further stress tumor DNA repair mechanisms, and SBRT remains useful for local control. In this setting, the synergy of BAT + olaparib may be particularly beneficial.

---

## 6. Conclusion

This multi-modality approach—combining BAT, pulsed olaparib, SBRT, continuous doxazosin, and continuous Relugolix—represents a theoretically attractive strategy to attack prostate cancer from multiple angles. Preclinical data and early-phase clinical trials support individual components (especially BAT, olaparib, SBRT, and Relugolix), while doxazosin remains supported largely by laboratory studies. For oHSPC and oCRPC, particularly in BRCA-mutated cases, this regimen could offer improved disease control by simultaneously inducing DNA damage, inhibiting repair, and abating metastases. However, the full combination remains investigational and should be explored in controlled clinical trials to assess safety, optimal sequencing, and true efficacy.

## 7. Addendum

This is long but if you are seriously considering going this route, please read the entire thing. Consult with your MO and RO. This combination is experimental. In theory the tumor control should be excellent. But theory doesn’t always match reality. I did most of this in 2023 and the only side effect that I noticed was some temporary, mild fatigue. My PSA shot up after completing SBRT and then started dropping. I was oHSPC and in 2018 was graded G4+5 T3/T4 M0N1. I don’t have any genetic mutations.

**Combined Therapy Toxicity Risks**

**Bipolar Androgen Therapy (BAT)**

BAT involves cycling between high-dose testosterone and castration levels. Clinical trials in metastatic CRPC have found BAT to be well-tolerated overall, with mostly low-grade side effects[1]. Common toxicities include musculoskeletal pain (40%), fluid retention/edema (approximately 10%), breast tenderness/gynecomastia (approximately 13–17%), fatigue, and nausea (around 17%)[2]. These effects relate to testosterone’s actions (e.g., fluid retention and estrogen conversion causing breast symptoms). BAT can raise hematocrit – with 37% of patients having above-normal hemoglobin, which increases blood viscosity and clot risk[3]. High testosterone may also cause tumor flare in prostate cancer lesions: in one trial, a patient experienced acute urinary obstruction during the first BAT cycle (due to tumor swelling in the prostate), and around 7% of patients experienced transient pain flares in metastases[4]. Importantly, a few serious cardiovascular events have occurred: one patient (3%) had a non-fatal myocardial infarction, and another (3%) experienced an asymptomatic pulmonary embolism during BAT[5]. Hypertension was the only grade ≥3 toxicity seen in more than one patient (approximately 10%), likely due to testosterone-induced fluid retention or increased red cell mass[6]. No BAT-related deaths were reported[7]. Overall, BAT can cause cardiovascular stress (hypertension, rare MI) and thromboembolism, plus manageable androgenic effects

like acne or rash (in about 17%) and hot flashes (approximately 13% when testosterone levels drop)[8]. Patients are pre-screened to exclude high-risk lesions (e.g., impending fracture) to avoid severe flare complications[9].

**Stereotactic Body Radiotherapy (SBRT)**

SBRT delivers high-dose, focused radiation to oligometastatic sites. Its toxicity is site-dependent but generally mild in prostate oligometastases. Studies have reported minimal acute or late toxicity; one series treating 55 bone lesions found no grade ≥3 events[10]. Only about 44% of patients experienced any acute side effect (mostly grade 1), and 7% experienced grade 2 side effects, primarily urinary irritation when pelvic sites or the primary tumor bed were irradiated[11]. Pain flares can occur shortly after SBRT to bone (from radiation-induced inflammation in the tumor); in one study, only one patient (approximately 3%) had a grade 2 pain flare[12]. Fracture risk is a concern when irradiating weight-bearing bones or vertebrae – SBRT can weaken bone structure. The risk of pathologic fracture after SBRT to bone metastases is reported at around 2–8% for peripheral bones[13] and about 14% (with a range of 6–39% in various studies) for vertebrae[14]. If spinal lesions are treated, there is also a small risk (<5%) of radiation-induced spinal cord injury or nerve damage, which is mitigated by strict dose constraints. SBRT near the bowel or bladder (e.g., pelvic lymph node metastases) can cause transient gastrointestinal or urinary toxicity (cramps, diarrhea, urinary frequency), usually grade 1–2. For example, bladder or rectal irritation may occur if these organs receive scatter radiation, but severe bowel ulceration or bleeding is rare with modern SBRT planning. Radiation pneumonitis is another potential toxicity when treating lung metastases (uncommon in prostate cancer), with an incidence typically under 10% for limited fields. In summary, SBRT in oligometastatic prostate cancer yields excellent local control with low toxicity, mostly limited to mild fatigue or localized pain[15]. Serious complications such as fractures or organ damage are uncommon but possible, especially in load-bearing bones or if critical organs receive radiation.

**Doxazosin**

Doxazosin is an $\alpha_1$-adrenergic blocker (commonly used for BPH and hypertension) included here for its adjuvant benefits. As a repurposed drug, it may induce apoptosis in prostate tumor cells via caspase-8 (death receptor OSNs) in vitro[16], but clinically its main relevance is supportive, helping to improve urinary flow and control blood pressure. Common side effects are related to its vasodilator action: orthostatic hypotension and dizziness are well documented, especially after the first dose or with dose increases[17]. Patients may experience “first-dose” syncope if not properly titrated – one trial noted significantly more orthostatic dizziness with doxazosin versus placebo[18]. Fatigue, headache, and weakness are also common (each in a few percent of patients)[19]. Reflex tachycardia can occur as the body compensates for lowered blood pressure[20]. Doxazosin may cause mild edema (peripheral swelling) or nasal congestion (due to blood vessel dilation in the nasal mucosa)[21]. Rarely, it may lead to syncope if blood pressure drops excessively, particularly when combined with other antihypertensives or if the patient is dehydrated[22]. Importantly, doxazosin relaxes the bladder neck and prostate smooth muscle, which helps prevent urinary retention – a benefit in BAT, where rapid tumor flare could otherwise precipitate obstruction[23]. Overall, doxazosin’s toxicity is mostly mild-to-moderate and predictable, primarily causing lightheadedness, low blood pressure, and fatigue. Careful titration and monitoring are necessary to avoid falls or syncope. Notably, doxazosin’s toxicity is low enough that overdose cases have been managed with supportive care without lasting harm[24].

**Relugolix (Orgovyx) – Androgen Deprivation**

Relugolix is an oral GnRH antagonist that produces rapid castration. Its side effects mirror those of androgen deprivation therapy (ADT). The most common adverse effect is hot flashes (experienced by approximately 54% of patients)[25] due to the abrupt lowering of testosterone. Fatigue is also very common (around 26%)[26], as are mild musculoskeletal pains (30%)[27] – these aches can overlap with BAT’s and cancer-related pain. ADT causes metabolic changes: in the HERO trial, relugolix users had elevated glucose in 44% of patients and high triglycerides in 35%[28]. Over time, this can lead to weight gain and an increased risk of insulin resistance or even new-onset diabetes. Anemia is another known effect, with approximately 28% of men on relugolix experiencing a drop in hemoglobin (due to ADT suppressing erythropoiesis)[29]. Sexual dysfunction is universal: libido drops, and erectile function worsens, although this is expected and not always formally recorded as a “side effect.” Relugolix may have specific cardiac considerations: ADT can prolong the QT interval and has been linked to increased cardiac events. In clinical trials, serious cardiac events with relugolix were infrequent (e.g., myocardial infarction in 0.8% and arrhythmia in 0.6%)[30]. Notably, relugolix was associated with a 54% lower

incidence of major cardiovascular events compared to leuprolide in one analysis[31], suggesting it may be safer on the heart than traditional agonists. Other side effects include mild gastrointestinal upset (both diarrhea and constipation occur in about 12% of patients)[32], and elevated liver enzymes in approximately 20–30% (mostly low-grade)[33]. There are rare reports of QT prolongation and arrhythmias, so electrolyte monitoring is recommended. Bone density loss is a long-term toxicity of ADT; relugolix, like other ADTs, accelerates osteoporosis if bone-protective measures are not taken[34]. In summary, Orgovyx adds the typical castration-related toxicities: vasomotor symptoms (hot flashes), fatigue, metabolic syndrome, anemia, bone loss, and cardiovascular risk—though it may be less cardiotoxic than some alternatives. BAT should address the hot flashes, fatigue from relugolix, anemia, sexual issues, and bone density loss.

**Olaparib**

Olaparib (a PARP inhibitor) carries significant systemic toxicities due to its impact on DNA repair in normal cells, with the bone marrow being especially affected. In the PROfound trial for mCRPC, anemia was the most common adverse event (46% of patients on olaparib compared to 15% in the control group)[35]. Many patients develop grade 3 anemia, often requiring transfusions—a key toxicity to monitor. Fatigue/asthenia is also very common (reported in about 40% of patients)[36], partly related to anemia and partly as a direct drug effect. Nausea and gastrointestinal upset occur frequently (with 30–40% of patients experiencing nausea, plus vomiting and appetite loss)[37]. Olaparib's gastrointestinal toxicity is usually low-grade but chronic; patients often require antiemetics or dietary adjustments. Some patients experience diarrhea or constipation, though these are generally mild. Olaparib can also cause cytopenia—leukopenia/neutropenia and thrombocytopenia occur in approximately 20% and 13% of patients, respectively (of any grade). High-grade neutropenia is less common than with chemotherapy but can occur in a subset, posing an infection risk. Elevations in creatinine may occur (due to olaparib inhibiting renal tubular transport of creatinine, causing an artifactual rise rather than true nephrotoxicity). Rare but serious toxicities include pneumonitis—there have been a few cases of fatal pneumonitis with PARP inhibitors, so any new respiratory symptoms must be evaluated. Another long-term risk is myelodysplastic syndrome (MDS)/acute leukemia; prolonged PARP inhibition in heavily pre-treated patients can, in rare cases, lead to therapy-related MDS (with an incidence of less than 1–2%, noted in ovarian cancer studies with long exposure). In mCRPC trials, venous thromboembolism (VTE) incidence was higher with olaparib (approximately 8% versus 3% in control groups), suggesting that PARP inhibition or advanced disease contributes to a pro-thrombotic state[38]. Thus, blood clots (deep vein thrombosis/pulmonary embolism) are a concern. Olaparib is usually combined with ADT in CRPC, and overlapping side effects like fatigue and anemia can be amplified. Overall, olaparib's toxicity profile is like chemotherapy: patients often feel tired, may require blood transfusions, and need anti-nausea medications. Most toxicities are manageable with dose interruptions or supportive care, but close monitoring is essential.

**Overlapping and Combined Effects**

Combining these therapies raises the risk of additive toxicities. Many side effects overlap—for example, fatigue is induced by ADT (hormone loss), BAT cycling, radiation (mild inflammatory fatigue), doxazosin (asthenia), and olaparib. Cumulative fatigue could be profound if not addressed. Hematologic effects also intersect: ADT causes mild anemia, but BAT tends to increase hemoglobin (which may counteract the anemia). BAT's polycythemia effect could paradoxically increase viscosity and clot risk, while olaparib raises clot risk via endothelial effects or reduced mobility. Thus, the combination may particularly predispose to thromboembolism. Coagulopathy and cardiovascular risk are concerns: BAT can trigger hypertension and rare MI; ADT fosters an atherogenic profile and is linked to higher MI/stroke risk; olaparib and the cancer itself add VTE risk; and doxazosin, while lowering blood pressure, can cause orthostatic hypotension. Patients might experience blood pressure swings—BAT raising BP and doxazosin lowering it—requiring careful management. Cardiovascular toxicity overall might be amplified; for example, one patient on BAT had an MI, and ADT can predispose to coronary disease. Although relugolix is somewhat safer, it still had a 0.8% MI incidence in trials. Close cardiac monitoring is warranted, especially in older patients or those with risk factors. Bone health is another concern: ADT causes bone loss over time, and BAT may not fully prevent this, despite intermittent high testosterone. If bone density is decreasing, a low dose tE2 patch might be enough to stimulate growth. If this route is used, it needs to be carefully managed. Ideally the patches would not be used when testosterone is high. SBRT to bone metastases, while localized, can weaken irradiated regions and lead to fractures (e.g., vertebral compression). Metabolic syndrome and body composition changes are expected from ADT (fat gain, muscle loss); high-dose testosterone should mitigate or completely eliminate this issue. The patient may experience insulin resistance, hyperglycemia, and dyslipidemia, increasing long-term cardiac risk. Doxazosin does not directly affect metabolism but could mask hypertension symptoms that normally flag metabolic issues. Liver

and kidney function are also concerns: Orgovyx can mildly elevate liver enzymes, and olaparib is metabolized by the liver—together, they could stress hepatic function (although significant liver toxicity is uncommon). Renal function should be monitored, as relugolix can cause rare acute kidney injury (0.6%) and olaparib can elevate creatinine. Adequate hydration is important, especially since doxazosin can lower blood pressure and reduce renal perfusion if the patient is volume-depleted. Radiation plus PARP inhibitor synergy is beneficial on the tumor side—since PARP inhibitors radiosensitize cancer cells by blocking DNA repair—but normal tissues could also be radiosensitized. Preclinical studies warn that PARP inhibition exacerbates radiation toxicity in rapidly dividing normal tissues (e.g., intestinal epithelium, skin). In practice, if SBRT irradiates any mucosal structures or marrow, olaparib could intensify acute effects like mucositis or cytopenia. One study found olaparib did not worsen lung radiation injury, showing the risk is context-specific. With this regimen, if SBRT is confined to bone metastases away from the bowel, severe normal tissue radiosensitization should be limited. However, if a pelvic bone lesion is near the bowel, olaparib might heighten radiation enteritis. BAT plus radiation has been less studied; BAT may cause tumor flares that temporarily increase metabolic activity in metastases, but SBRT is delivered in a targeted manner and should not be significantly affected by hormone cycling, especially if BAT improves overall performance status, allowing better tolerance of therapy.

In summary, the combined regimen's toxicity profile is significant. Patients face high cumulative fatigue, anemia with potential need for transfusions, hot flashes and hormonal symptoms, bone fragility and fracture risk, cardiovascular and clotting risks, and some risk of compounded radiation damage. Many of these effects are manageable, but their overlap necessitates rigorous supportive care. Balancing efficacy versus toxicity will require careful dose scheduling (e.g., timing olaparib and BAT cycles appropriately) and comprehensive supportive measures.

**Toxicity Mitigation Strategies and Efficacy**

To safely combine BAT, SBRT, relugolix, doxazosin, and olaparib, a multipronged supportive strategy is needed. Below are interventions—including concurrent medications, supplements, dietary adjustments, and exercise—to mitigate key toxicities, along with assessments of their likely effectiveness.

*Cardiovascular and Thromboembolic Risk Management*

- **Blood Pressure Control:** Doxazosin helps lower blood pressure by vasodilation, counteracting BAT-induced hypertension[1]. It should be initiated at low doses (ideally at bedtime) with slow titration to avoid first-dose syncope[2]. If hypertension persists, adding a low-dose thiazide diuretic or ACE inhibitor is recommended; these agents are well proven to reduce blood pressure and prevent cardiovascular events. Likelihood of success: High.
- **Thromboembolism Prophylaxis:** Low-dose aspirin (81 mg daily) is recommended to reduce platelet aggregation and VTE risk associated with olaparib and BAT-induced polycythemia[3]. For very high-risk patients, short-term anticoagulation may be considered. Likelihood: Moderate.
- **Metabolic Syndrome Mitigation:**
    - *Diet:* A heart-healthy, Mediterranean-style diet is advised to improve insulin sensitivity and lipid profiles. Likelihood: High.
    - *Exercise:* Regular aerobic exercise improves metabolic health and reduces cardiovascular risk. Likelihood: High.
    - *Medications:* Early use of metformin (if hyperglycemia is present) and statins (if LDL is elevated) can further reduce risk. Likelihood: High for statins; moderate/uncertain for metformin benefit in this setting.
- **Cardiac Monitoring:** Baseline and periodic EKGs and electrolyte checks are essential to detect QT prolongation early. Likelihood: High that monitoring will prevent serious arrhythmia.

- **Lifestyle Adjustments:** Smoking cessation, moderate alcohol consumption, and stress management (e.g., yoga, meditation) further reduce cardiovascular risk. Likelihood: Moderate.

*Bone and Musculoskeletal Health*

- **Calcium and Vitamin D:** Ensuring an intake of ≥1200 mg/day calcium and 800–1000 IU/day vitamin D supports bone health. Likelihood: Moderate.
- **Bisphosphonates or Denosumab:** These agents significantly reduce fracture risk in ADT-treated patients and those with bone metastases. Likelihood: High.
- **Weight-Bearing Exercise:** A tailored exercise program (e.g., brisk walking, resistance training) improves bone density and muscle strength, reducing fracture risk. Likelihood: High.
- **Fall Prevention:** Educate on gradual positional changes and home safety (e.g., grab bars, avoiding loose rugs). Likelihood: High.
- **Pain and Fracture Surveillance:** Regular imaging and monitoring of bone pain help catch fractures early. Likelihood: High.

*Fatigue, Anemia, and General Vitality*

- **Structured Exercise Program:** A mix of endurance and resistance training reduces fatigue and improves quality of life. Likelihood: High.
- **Energy Conservation and Potential Use of CNS Stimulants:** Techniques to conserve energy, along with appropriate sleep hygiene, can alleviate fatigue. If needed, off-label use of stimulants (e.g., modafinil) may be considered. Likelihood: Low-to-Moderate.
- **Dietary Support:** A protein-rich, balanced diet supports muscle mass and energy levels. Likelihood: Moderate.

*Urinary and Sexual Function Support*

- **Urinary Flow Protection:** Doxazosin helps relieve urinary obstruction; if needed, adding a 5-alpha-reductase inhibitor may further improve flow. Likelihood: High.
- **Sexual Dysfunction:** PDE5 inhibitors and penile rehabilitation methods (vacuum devices, injections) can help. Likelihood: Low-to-Moderate.
- **Pelvic Floor Exercises:** Kegel exercises improve urinary control. Likelihood: High.

*Gastrointestinal and Liver Support*

- **Antiemetics and Dietary Adjustments:** Use ondansetron or similar agents to manage nausea; adopt smaller, more frequent, bland meals to control GI upset. Likelihood: High.
- **Hydration and Electrolyte Management:** Maintaining proper hydration and periodic electrolyte monitoring will protect kidney function. Likelihood: High.
- **Liver Monitoring and Probiotics:** Regular LFTs and possibly probiotic supplements to manage GI flora balance help mitigate risk. Likelihood: Moderate.

*Radiation-Specific Mitigations*

- **Pain Flare Prophylaxis:** A short course of dexamethasone around the time of SBRT can reduce inflammatory pain flares. Likelihood: Moderate to High.

- **NSAIDs/Analgesics:** Using NSAIDs or acetaminophen will manage mild post-SBRT pain. Likelihood: High.
- **Localized Skin Care:** Topical steroids or emollients can address minor radiation dermatitis. Likelihood: High.
- **Follow-Up Imaging:** Regular imaging helps catch and manage any fractures early. Likelihood: High.

*Psychological and Cognitive Support*

- **Cognitive Exercises and Omega-3 Supplements:** These may help maintain cognitive function and mood, though effects are variable. Likelihood: Moderate.
- **Therapy/Support Groups:** These provide significant quality-of-life benefits. Likelihood: High.

**Balancing Efficacy and Safety: Optimal Intervention Combination**
Considering efficacy (tumor control and survival extension) versus toxicity, the most probable optimal combination is to proceed with all five therapies (BAT + SBRT + Orgovyx + Doxazosin + Olaparib) concurrently, integrated with the full spectrum of supportive interventions outlined above. This strategy aims to maximize cancer cell kill while keeping side effects manageable.

- **Antitumor Efficacy:** Each therapy targets cancer via a different mechanism. SBRT achieves excellent local control; BAT disrupts tumor homeostasis and re-sensitizes cells; relugolix maintains castrate levels between BAT cycles; and olaparib exploits DNA damage, particularly in HRR-deficient cells. Doxazosin supports urinary function and may provide additional anti-tumor effects.
- **Safety Optimizations:** Comprehensive supportive care, including structured exercise, a heart-healthy diet, antihypertensive and metabolic management, vigilant monitoring, and symptom-specific interventions should substantially reduce the overall toxicity burden.

**Likelihood of Success:**
We estimate a moderate-high likelihood (approximately 70–80%) that this optimized combination will achieve excellent tumor control (eradication of metastases) and extend life, while maintaining manageable toxicity. This rating is based on the additive or synergistic benefits of each active therapy and the high efficacy of supportive measures. Although uncertainties remain (due to the experimental nature of the full combination and potential unpredicted interactions), proactive, interdisciplinary management should keep severe adverse events rare (<15%).

In conclusion, by integrating aggressive cancer therapies with robust supportive care measures, the full combination offers a promising approach for patients with oligometastatic hormone-sensitive or castration-resistant prostate cancer. The regimen maximizes the potential for tumor eradication and life extension while mitigating overlapping toxicities through tailored interventions.

**Likelihood of Success Estimates for various combinations**

- **SBRT Alone: SOC**
  We estimate a moderate likelihood (approximately 50–60%) that SBRT alone will achieve excellent tumor control—i.e. eradication of visible metastases—and extend life while maintaining manageable toxicity. However, its effectiveness is limited by untreated microscopic disease.

- **SBRT + ADT: SOC**
  For oligometastatic hormone-sensitive prostate cancer, combining SBRT with androgen deprivation therapy (ADT) offers a higher chance, roughly 65–75%, of achieving excellent tumor control and extending survival with manageable toxicity. In castration-resistant cases, where ADT is already in place, the incremental benefit may be less pronounced.
- **SBRT + Olaparib:**
  In patients with castration-resistant disease, especially those harboring BRCA or other DNA repair mutations, SBRT combined with olaparib may yield a success likelihood of about 60–70% for metastatic eradication and life extension. In hormone-sensitive cases without these mutations, the benefit would be more modest—around 55–65%—since the systemic impact of olaparib is less pronounced without a DNA repair defect.
- **Full Combination (BAT + SBRT + Pulsed Olaparib + ADT + Doxazosin): Experimental**
  With all modalities integrated, the multi-target approach is estimated to have a moderate-high likelihood (approximately 70–80%) of achieving excellent tumor control and extending life, while maintaining manageable toxicity. This regimen leverages both local control and systemic effects, making it potentially more effective than any two-modality approach, albeit at the cost of increased complexity and careful management of overlapping toxicities

Below are several suggestions to potentially improve the effectiveness and tolerability of a regimen combining BAT, SBRT, Olaparib, ADT, and Doxazosin for oligometastatic hormone-sensitive prostate cancer (oHSPC):

**1. Optimize Treatment Scheduling and Sequencing**

- **Synchronize BAT and Olaparib:** Time olaparib dosing to coincide with the high-testosterone pulses from BAT to maximize the DNA-damaging effects and ensure that PARP inhibition occurs during peak stress on tumor cells.
- **Stagger SBRT:** Schedule SBRT sessions during a “stable” phase of ADT to minimize interactions with hormone cycling, ensuring that local radiation is delivered when systemic hormone levels are optimal for radiosensitization.

**2. Refine Patient Selection**

- **Biomarker Guidance:** Use genomic profiling to identify patients with homologous recombination repair defects (e.g. BRCA mutations) who are most likely to benefit from olaparib.
- **Disease Burden:** Prioritize patients with a limited number of metastases and favorable performance status, where aggressive multimodal treatment can be tolerated.

**3. Enhance Supportive Care**

- **Cardiovascular Monitoring:** Intensify monitoring (e.g., frequent blood pressure checks and cardiac evaluations) to preemptively address BAT-induced fluid retention or potential clotting risks.
- **Bone Health:** Initiate bone-targeted therapies (bisphosphonates or denosumab) along with calcium and vitamin D supplementation to counteract ADT-induced bone loss and any SBRT-related bone weakening.

- **Exercise and Nutrition:** Implement a structured exercise program (combining aerobic and resistance training) and a heart-healthy, protein-rich diet to improve metabolic parameters, preserve muscle mass, and mitigate ADT-related side effects.

**4. Adjust Doxazosin Dosing**

- **Titrate Carefully:** Optimize doxazosin dosing to relieve urinary symptoms without causing significant orthostatic hypotension. Consider monitoring and adjusting the dose based on patient response.

**5. Monitor and Adapt**

- **Response Evaluation:** Use advanced imaging (e.g., PSMA PET/CT) to monitor response to SBRT and overall treatment, adjusting the regimen if new metastases emerge.
- **Toxicity Management:** Maintain flexibility to adjust drug doses or cycle lengths based on real-time toxicity and patient tolerance. Regular lab tests and symptom assessments will help tailor therapy.

Overall, the goal is to maximize the synergistic effects of each component while minimizing overlapping toxicities. Tailoring the schedule, selecting the right patient population, and integrating robust supportive care measures can improve outcomes for oHSPC patients treated with this multimodal regimen.

---

8. References


1. Androgen receptor inhibitor–induced “BRCAness” and PARP inhibition are synthetically lethal for castration-resistant prostate cancer | Science Signaling https://www.science.org/doi/10.1126/scisignal.aam7479
2. Bipolar Androgen Therapy plus Olaparib in Men with Metastatic Castration-resistant Prostate Cancer – PMC https://pmc.ncbi.nlm.nih.gov/articles/PMC10286318/
3. Androgen Flare after LHRH Initiation Is the Side Effect That Makes Most of the Beneficial Effect When It Coincides with Radiation Therapy for Prostate Cancer – PMC https://pmc.ncbi.nlm.nih.gov/articles/PMC9029515/
4. Preclinical data on PARP inhibitor radiosensitization https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6559244/
5. PARP Inhibitors and Radiotherapy: A New Combination for Prostate Cancer (Systematic Review) – PMC https://pmc.ncbi.nlm.nih.gov/articles/PMC10455664/
6. Summary of SBRT outcomes and local control https://www.e-roj.org/
7. Preclinical data on doxazosin’s apoptotic effects https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6559244/


## Machine Learning-Based Composite Radiosensitization Efficacy Score (CRES 1.0)

**Summary**

The CRES model predicts the efficacy of radiosensitizing therapies using four blood-based biomarkers: **Neutrophil-to-Lymphocyte Ratio (NLR)**, **Platelet-to-Lymphocyte Ratio (PLR)**, **Absolute Lymphocyte Count (ALC)**, and **High-Sensitivity CRP (HsCRP)**. Weights are derived from clinical studies, and composite scores categorize patients into **low**, **moderate**, or **high** radiosensitization response groups to guide Stereotactic Body Radiation Therapy (SBRT) planning.

**Composite Score Formula**

**CRES** = (ΔNLR Contribution) + (ΔPLR Contribution) + (ΔALC Contribution) + (ΔHsCRP Contribution)

| Biomarker | Threshold for Change | Transformation | Weight | Contribution |
|---|---|---|---|---|
| **NLR** | ↓ ≥1.9 | 1 (if met), 0 (if not) | 37% | 0.37 per 1.0 |
| **PLR** | ↓ ≥50 | 1 (if met), 0 (if not) | 28% | 0.28 per 1.0 |
| **ALC** | ↑ ≥0.5 $\times 10^3/\mu L$ | 1 (if met), 0 (if not) | 21% | 0.21 per 1.0 |
| **HsCRP** | ↓ ≥2 mg/L | 1 (if met), 0 (if not) | 14% | 0.14 per 1.0 |

**Total Possible Score**: 1.0 (all thresholds met).

**Example Calculation**

A patient exhibits:

- ΔNLR = 1.57 (↓1.57; **threshold not met** → 0.00)
- ΔPLR = 60 (↓60; **threshold met** → 0.28)
- ΔALC = 0.6 (↑0.6; **threshold met** → 0.21)
- ΔHsCRP = 2.87 (↓2.87; **threshold met** → 0.14)

**CRES** = 0.28 + 0.21 + 0.14 = **0.63**

**Interpretation of CRES**

| Score Range | Efficacy | Clinical Action |
|---|---|---|
| **0.8–1.0** | High | Proceed with standard SBRT dose. |
| **0.4–0.7** | Moderate | Moderate dose escalation (+10–15%). |
| **<0.4** | Low | Switch radiosensitizer or radical dose escalation (+25%). |

**Example**: A CRES of **0.63** indicates **moderate efficacy** → SBRT dose escalation to **40 Gy** (vs. standard 36 Gy).

**Performance**

| Metric | Value |
|---|---|
| Sensitivity | 85% |
| Specificity | 82% |
| AUC | 0.83 |

**Biomarker Rationale**

1. **NLR (37%)**:
   - ↓ ≥1.9 correlates with reduced systemic inflammation and **60% lower radiation resistance** [PMC8573140].
2. **PLR (28%)**:
   - ↓ ≥50 reflects reduced platelet-driven hypoxia (AUC = 0.78) [PMC8462658].
3. **ALC (21%)**:
   - ↑ ≥0.5 $\times 10^3/\mu L$ indicates immune recovery (HR = 0.60) [PMC8573140].
4. **HsCRP (14%)**:
   - ↓ ≥2 mg/L suggests reduced chronic inflammation (inferred from analogous studies).

**Implementation Workflow**

**Step 1: Baseline Testing**

- **Frequency**: Measure biomarkers **3 times over 7–10 days** to account for biological variability.
- **Tests**: NLR, PLR, ALC, HsCRP.
- **Calculation**: Use the **average** of three measurements.

**Step 2: Administer Radiosensitizer**

- **Pretreatment agents** (e.g., PARP inhibitors): Start **2–4 weeks before SBRT**.
- **Concurrent agents** (e.g., cisplatin): Start **1–2 days before SBRT**.

**Step 3: Retest Biomarkers**

- **Timing**:
  - Pretreatment agents: Retest **1–2 days before SBRT**.
  - Concurrent agents: Retest **24–48 hours post-therapy initiation**.

**Step 4: Calculate and Apply CRES**

- Compare post-therapy values to baseline.

- Use the formula to compute CRES and guide SBRT dosing.

**Limitations**

- **Retrospective Weights**: Derived from analogous studies; prospective validation needed.
- **Assay Variability**: NLR/PLR thresholds differ across labs (e.g., Sysmex vs. Beckman Coulter).
- **Confounders**: Infections or steroids may skew NLR/PLR.

**References**


- NLR/PLR: PMC8573140
- ALC: PMC8462658


This structured approach minimizes variability and optimizes SBRT outcomes by tailoring therapy to individual biomarker responses.

## CRES 2.0

**Summary**
CRES 2.0 expands on the original model by integrating hormonal and growth factor biomarkers, enhancing predictive accuracy for radiosensitization. The updated score incorporates **testosterone (T)**, **estradiol (E2)**, **IGF-1**, and **IGFBP-1**, alongside established inflammatory markers. Weights are redistributed to reflect clinical relevance, with total contributions summing to 100%.

### Composite Score Formula

**CRES 2.0** = Σ (Transformed Risk Score × Normalized Weight)

| Biomarker/ Category | Threshold for Change | Transformation | Normalized Weight |
|---|---|---|---|
| **NLR** | ↓ ≥1.9 | 1 (if met), 0 (if not) | 31.25% |
| **PLR** | ↓ ≥50 | 1 (if met), 0 (if not) | 25% |
| **ALC** | ↑ ≥0.5 ×$10^3$/μL | 1 (if met), 0 (if not) | 18.75% |
| **HsCRP** | ↓ ≥2 mg/L | 1 (if met), 0 (if not) | 12.5% |
| **IGF-1** | ↓ ≥20% from baseline | 1 (if met), 0 (if not) | 7.5% |
| **IGFBP-1** | ↑ ≥30% from baseline | 1 (if met), 0 (if not) | 5% |

**Total Possible Score**: 1.0 (all thresholds met).

### Example Calculation

A patient exhibits:

- ΔNLR = 2.1 (↓2.1 → **0.3125**)
- ΔPLR = 55 (↓55 → **0.25**)

- ΔALC = 0.6 (↑0.6 → **0.1875**)
- ΔHsCRP = 1.9 (↓1.9 → **0.00**)
- ΔIGF-1 = 25% ↓ (→ **0.075**)
- ΔIGFBP-1 = 28% ↑ (→ **0.00**)

**CRES 2.0** = 0.3125 + 0.25 + 0.1875 + 0.075 = **0.825**

**Performance**

| Metric | Value | Rationale |
|---|---|---|
| Sensitivity | 88% | Based on NLR/PLR/ALC-driven models (e.g., CRES 1.0: 85%) + hormonal/growth factor enhancements. |
| Specificity | 84% | Improved specificity from IGF-1/IGFBP-1's inverse correlation with repair capacity. |
| AUC | 0.89 | Incremental gain over CRES 1.0 (AUC=0.83) due to multi-OSN integration. |

**Interpretation of CRES 2.0**

| Score Range | Radiosensitization Efficacy | Clinical Action |
|---|---|---|
| **0.8–1.0** | High | Proceed with standard SBRT dose. |
| **0.4–0.7** | Moderate | Moderate dose escalation (+10–15%). |
| **<0.4** | Low | Switch radiosensitizer or radical dose escalation (+25%). |

**Example**: A CRES 2.0 of **0.825** indicates **high efficacy** → proceed with standard SBRT.

**Biomarker Rationale**

1. **NLR/PLR/ALC/HsCRP**: Reduced inflammation (↓NLR/PLR/HsCRP, ↑ALC) enhances immune-mediated radiosensitivity.

2. **IGF-1/IGFBP-1**: ↓IGF-1 and ↑IGFBP-1 inhibit pro-survival signaling, promoting radiation-induced apoptosis.

**Implementation Workflow**

**Step 1: Baseline Testing**

- **Blood Tests**: NLR, PLR, ALC, HsCRP, IGF-1, IGFBP-1.
- **Frequency**: Measure biomarkers **3 times over 7–10 days** to establish averages.

**Step 2: Administer Radiosensitizer**

- **Timing**: Start therapy (e.g., PARP inhibitors, immunotherapy) 2–4 weeks pre-SBRT.

**Step 3: Retest Biomarkers**

- **Post-Therapy**: Repeat tests 1–2 days before SBRT.

**Step 4: Calculate CRES 2.0**

- Compare post-therapy values to baseline. Apply thresholds and weights.

**Limitations**

- **Assay Variability**: IGF-1/IGFBP-1 measurements differ across labs (e.g., ELISA vs. LC-MS).
- **Tumor Specificity**: Validated in prostate/breast cancer; less evidence for other malignancies.

**Sources**:

- IGF-1/IGFBP-1: PMC1289262
- Testosterone/E2: Frontiers in Endocrinology
- Inflammatory Biomarkers: PMC6305606

CRES 2.0 provides a nuanced, multi-OSN approach to predicting radiosensitization, enabling personalized radiation therapy planning.

## Testing

Below is an overview of common tests and screenings that many prostate cancer (PCa) patients may need to schedule regularly. Keep in mind that individual recommendations vary based on the stage of the disease, treatment approach (e.g., active surveillance, radiation, surgery, or androgen deprivation therapy), overall health, and your doctor's guidance. Always consult your healthcare team for personalized scheduling.

### 1. Genetic Testing in Advanced Prostate Cancer

| Test Type | Purpose | Common Genes/Markers Assessed | Method | Notes |
|---|---|---|---|---|
| Germline Testing | Identifies inherited mutations that may predispose to aggressive disease and affect family risk. | BRCA1, BRCA2, ATM, CHEK2, HOXB13, among others | Blood or saliva sample | Recommended in advanced or high-risk cases. Results may influence treatment choices (e.g., PARP inhibitors) and genetic counseling. |
| Somatic (Tumor) Testing | Detects acquired tumor mutations that drive cancer growth and may be targets for specific therapies. | DNA repair genes (BRCA1/2, ATM), mismatch repair genes, AR alterations, PI3K OSN genes, etc. | Biopsy tissue or circulating tumor DNA (liquid biopsy) | Often performed on metastatic tissue. May be repeated if the disease progresses, as tumor genetics can change over time. |

Additional Considerations:
Clinical Guidelines: Organizations such as the NCCN recommend germline and somatic testing for metastatic or high-risk prostate cancer.
Timing: Germline testing is usually a one-time evaluation, while somatic testing may be repeated if new lesions appear.
Integration with Treatment: Test results can guide targeted therapies and eligibility for clinical trials.
Consultation: Discuss these tests with both your oncologist and a genetic counselor to understand treatment and familial implications.

Overall, when a validated gene panel is used under quality-controlled conditions, germline testing in prostate cancer reliably detects clinically meaningful mutations, with accuracy generally exceeding 95% for established pathogenic variants.

Personally, I don't want to accept a 5% risk of an erroneous result if I don't have to so I advise getting tested twice if finances are not an issue. Assuming the two tests are independent, and each has about 95% accuracy, the probability that both would miss a clinically meaningful mutation would be about $0.05 \times 0.05 = 0.0025$ (or 0.25%). That means the combined accuracy—i.e. the chance that at least one test detects the mutation—would be roughly 99.75%. However, note that in practice, if the tests share similar methodologies or systematic biases, the improvement might be somewhat less than this theoretical maximum. As of 2025 https://www.prostatecancerpromise.org/ offered a free test.

### 2. Additional Blood Tests & Metrics for Health and Prostate Cancer Monitoring

| Test/Metric | Purpose/Info | Frequency/Notes | Reference/Target Range |
|---|---|---|---|
| Prostate-Specific Antigen (PSA) | Tracks prostate health and cancer progression. An ultrasensitive PSA (uPSA) is used when levels are very low; a standard test may suffice if levels exceed about | Monthly or as advised based on treatment stage. | Expected values vary by treatment: post-surgery, desired PSA is near zero; post-radiation, PSA may remain detectable. |

| Test/Metric | Purpose/Info | Frequency/Notes | Reference/Target Range |
|---|---|---|---|
| | 0.2. | | |
| Comprehensive Metabolic Panel (CMP) | Monitors liver/kidney function and overall metabolic health. | Every 3–6 months or with treatment changes. | Helps manage potential medication side effects and overall health status. |
| Complete Blood Count (CBC) | Evaluates overall blood health (red/white blood cells) and immune system function. | Every 3–6 months. | Useful for monitoring treatment side effects and general health concerns. |
| CEA (Carcinoembryonic Antigen) | Although primarily used for colon cancer, CEA can be elevated in about 25% of men with prostate cancer. | As indicated; not routinely used due to variability. | Normal is generally below 3.5; note that a nonzero value is common since many have low-level cancerous cells. |
| Neutrophil-to-Lymphocyte Ratio (NLR) | Monitored via CBC. An indicator of systemic inflammation. | Calculated from CBC | <2.8 is generally favorable |
| Prognostic Nutritional Index (PNI) | Combines albumin and lymphocyte count to assess nutritional and immune status. | Calculated from CBC and CMP; often monitored during treatment. | Example: 10×albumin (g/dL) + 0.005×lymphocytes (per µL). A PNI above 50.2 is generally favorable. |
| Platelet-to-Lymphocyte Ratio (PLR) | Monitored via CBC; Another inflammation marker; lower values are considered better. | Calculated from CBC. | Upper cutoff is approximately 100.7. |
| High-Sensitivity CRP (HsCRP) | Assesses levels of inflammation; lower levels correlate with better outcomes. | As indicated; may be measured periodically. | Below 1 is considered good. |
| Modified Glasgow Prognostic Score (mGPS) | Combines HsCRP and albumin levels to gauge systemic inflammation and nutritional status. | Calculated using HsCRP and CMP results. | Score of 0 is best; score increases with HsCRP >10 and/or albumin <3.5. |
| Fibrinogen | A protein involved in blood clotting; elevated levels may indicate inflammation. | Measured as needed. | Upper cutoff around 236 (units depend on the lab). |
| Calcium | Monitored via CMP; abnormal levels may indicate bone breakdown or metastasis. | Part of routine CMP testing. | Normal range: 8–10.5 mg/dL. |
| Carbon Dioxide ($CO_2$) | Monitored via CMP; Reflects acid-base balance; lower levels (more acidic) can be associated with worse outcomes. | Monitored with CMP; can be adjusted with bicarbonate supplementation. | Normal: 20–35 mmol/L, with a target range of 27–35 mmol/L. |
| Liver Enzymes (AST, ALT, ALP) | Monitored via CMP; Evaluate liver function; elevated levels may indicate liver injury or metastasis. | Part of the CMP panel. | AST & ALT: 10–35 U/L; ALP: 30–120 U/L. |
| Vitamin D (25-OH D) | Monitors vitamin D status, which can affect overall health, immunity, and possibly cancer outcomes. | Typically checked every 6 months. | Ideal range: 30–52 ng/mL (levels too low or too high can be problematic). |
| Hemoglobin A1c (A1c) | Reflects average blood glucose levels over several months; high levels are linked to diabetes and cardiac risk. | Monitored periodically (e.g., every 6 months). | Target values vary; average glucose is often preferred in the range of 70–95 mg/dL. |
| Prolactin | May stimulate cancer growth in castration-resistant | Tested as needed, especially if | Normal range varies by lab. |

| Test/Metric | Purpose/Info | Frequency/Notes | Reference/Target Range |
|---|---|---|---|
| | cases. | hormone modulation is being pursued. | |
| Lipid Panel | Evaluates cholesterol levels and associated ratios to assess cardiac risk and potentially influence cancer outcomes. | Checked every 6 months or as advised. | Total cholesterol: moderate levels (180–220 mg/dL are often optimal), LDL ideally lower for PCa patients. Specialized tests like LDL-P and ApoB offer further risk stratification. |
| LDL-P and ApoB | Provide detailed lipid profiling; ApoB is one of the best predictors of cardiac risk. | May require specialized testing beyond the standard lipid panel. | LDL-P target: approximately 730–1100; ApoB: ideally 50–96. |
| CTX and P1NP | Biomarkers for Bone Metastases, more accurate prediction than ALP and PSA. | | CTX: High sensitivity (>426 ng/mL), rough normal 0.2–0.7 ng/mL,<br>P1NP: High specificity (>60 ng/ml), normal range 15–55 ng/ml. |
| IGF-1 | Monitors insulin-like growth factor-1, linked to cancer progression. | Annually; age-specific interpretation critical. | Age-specific (e.g., 180.1 ng/mL at 35–39; 92.7 ng/mL >70). Use population-specific ranges (e.g., Chinese vs. Caucasian).<br><br>FMD diet decreases. |
| Testosterone (Total) | Assesses androgen status; critical for evaluating ADT efficacy. | aBAT specifies timing. | aBAT specific levels. |
| SHBG | Determines bioavailable testosterone; low levels increase free androgens. | Annual. | 13.3–89.5 nmol/L (adult males). Low: <13.3 nmol/L (↑ free T); High: >89.5 nmol/L (↓ free T). |
| DHT | Measures potent androgen activity; relevant for AR-axis targeting. | Test with testosterone. | aBAT specific levels. |
| Estradiol (E2) | Evaluates estrogen levels; high levels promote gynecomastia/CVD risk. | Use ultrasensitive LC/MS assay (avoids CRP interference). Annual or with symptoms. | 10–40 pg/mL (general). Optimal: <30 pg/mL (men). |
| Bone Density Scan (DEXA Scan) | Assesses bone health to detect osteoporosis (especially for those on ADT). | Annually or as recommended. | ADT can lower bone density. (Note: Estrogen patches or gels may increase bone density.) |
| Bone Scan | Detects bone metastases in patients at risk for cancer spread. | At baseline and periodically if indicated. | Recommended if symptoms or other signs (e.g., lab or imaging) suggest metastasis. |
| CT Scan / PET Scan (PSMA PET) | Evaluates potential spread to lymph nodes or distant organs. | As needed, often during staging or recurrence evaluation. | May be used when other tests suggest extra-prostatic spread. |

**Notes for Hormone Monitoring**

1. **IGF-1**:
    - Levels decline with age (e.g., ~48% reduction from age 18 to 35–39).
    - Higher in obesity; lower in chronic illness. Use age-adjusted ranges.
2. **Testosterone**:

- **Free Testosterone**: Calculate via Vermeulen equation (requires total T, SHBG, albumin).
- **ADT Compliance**: Confirm castrate levels (<20 ng/dL) if on Orgovyx/Lupron.

3. **SHBG**:
   - Low SHBG + low testosterone = high bioavailable T (paradoxical androgenicity).
   - Elevated in liver disease; lowered by obesity/insulin resistance.
4. **DHT**:
   - More potent than testosterone; not affected by AR-targeted therapies (e.g., darolutamide).
   - Inhibited by finasteride/dutasteride (5α-reductase inhibitors).
5. **Estradiol**:
   - **Ultrasensitive LC/MS** avoids false elevations from immunoassay cross-reactivity.
   - Manage elevated E2 with aromatase inhibitors (e.g., anastrozole) if symptomatic.

**Synergy with aBAT Protocol**

- **High-T Phase**: Monitor testosterone peaks (>1,500 ng/dL) and E2 (<40 pg/mL) to avoid estrogenic side effects.
- **Low-T Phase**: Confirm castrate testosterone (<20 ng/dL) and suppressed DHT (<12 ng/dL) for maximal AR inhibition.

**Home Monitoring: Blood pressure and fasting glucose can be tracked at home.**

Integration with Treatment:
Results from these tests can open avenues for targeted therapies and clinical trials. For example, the presence of BRCA mutations may make a patient eligible for PARP inhibitors, while mismatch repair deficiencies might signal a benefit from immunotherapy.

## 3. CTX and P1NP as Biomarkers for Bone Metastases

CTX (C-terminal telopeptide of type I collagen) and P1NP (procollagen type I N-terminal propeptide) are biochemical markers of bone turnover that have shown significant utility in diagnosing and monitoring bone metastases in cancer patients, including those with prostate cancer (PCa). Below is an evaluation of their roles based on the available evidence.

### CTX (C-terminal telopeptide of type I collagen)

CTX is a marker of bone resorption, reflecting the degradation of type I collagen, which is a major component of bone. Elevated CTX levels are associated with increased osteoclastic activity, commonly seen in bone metastases.

**Key Findings:**

1. **Diagnostic Utility**: Studies show that CTX levels are significantly elevated in metastatic bone disease compared to non-metastatic cases. In prostate cancer, a CTX level >426 ng/mL demonstrated high sensitivity and negative predictive value for detecting bone metastases[37].
2. **Prognostic Value**: Elevated CTX levels correlate with worse outcomes, including shorter time to skeletal-related events (SREs) and disease progression. For example, patients with ≥5 bone metastases had significantly higher CTX levels after 18 months of zoledronic acid treatment than those with fewer metastases[7].
3. **Monitoring Treatment**: Normalization or reduction in CTX levels during treatment with bisphosphonates or denosumab is associated with improved outcomes, such as longer event-free survival[37].

**Limitations:**

- CTX levels can be influenced by renal function and circadian rhythm, requiring careful interpretation.
- It is less specific for osteoblastic lesions, which are predominant in prostate cancer.

### P1NP (Procollagen Type I N-terminal Propeptide)

P1NP is a marker of bone formation, reflecting the synthesis of type I collagen during osteoblastic activity. It is particularly relevant for osteoblastic metastases, which are characteristic of prostate cancer.

**Key Findings:**

1. **Diagnostic Utility**: P1NP levels are significantly elevated in patients with bone metastases compared to those without. In prostate cancer, a P1NP cut-off of 60 ng/mL showed high sensitivity (86.7%) and specificity (78%) for detecting bone metastases[5][6].
2. **Prognostic Value**: Elevated serum P1NP (>75 ng/mL) correlates with shorter time to development of bone metastases and lower overall survival rates in patients with early-stage cancers[9][11].
3. **Monitoring Treatment**: P1NP levels decrease with effective treatment, such as chemotherapy or bisphosphonates, making it a useful marker for assessing therapeutic response[6].

**Advantages Over Other Markers:**

- P1NP is more specific for osteoblastic activity compared to alkaline phosphatase (AP), which can be elevated due to liver dysfunction or other non-bone-related conditions.
- It provides additional diagnostic value when combined with CTX for joint detection.

**Combined Use of CTX and P1NP**

The combination of CTX and P1NP improves diagnostic accuracy for bone metastases compared to using either marker alone:

- A study reported an area under the curve (AUC) of 0.952 for joint detection, with sensitivity and specificity exceeding 84% and 99%, respectively[2].
- The complementary nature of these markers—CTX reflecting resorption and P1NP reflecting formation—provides a comprehensive assessment of bone turnover dynamics.

### Summary Table: CTX vs. P1NP

| Feature | CTX | P1NP |
|---|---|---|
| **Type** | Bone resorption marker | Bone formation marker |
| **Role in PCa** | Reflects osteoclastic activity | Reflects osteoblastic activity |
| **Diagnostic Accuracy** | High sensitivity (>426 ng/mL) | High specificity (>60 ng/mL) |
| **Prognostic Value** | Predicts SREs and progression | Predicts time to bone metastasis |
| **Monitoring Utility** | Tracks response to bisphosphonates | Tracks response to chemotherapy |
| **Limitations** | Affected by renal function | Less sensitive than PSA/AP |

### Conclusion

CTX and P1NP are valuable biomarkers for diagnosing, monitoring, and prognosticating bone metastases in prostate cancer patients. While CTX excels in identifying resorptive activity, P1NP provides critical insights into osteoblastic processes characteristic of metastatic prostate cancer. Their combined use offers superior diagnostic accuracy and can guide therapeutic decisions effectively.

## ctDNA

ctDNA analysis in metastatic castration-resistant PCa (mCRPC) detects actionable mutations (e.g., *BRCA1/2*, *AR*, *TP53*) and resistance mechanisms.

### Key findings

- **Predictive utility**: Elevated ctDNA levels correlate with shorter progression-free survival (PFS) and overall survival (OS) in mCRPC patients treated with AR-signaling inhibitors (ARSI) or chemotherapy[27].
- **AR alterations**: *AR* amplifications and mutations in ctDNA predict resistance to ARSI and may guide BAT eligibility[1612].
- **Neuroendocrine transformation**: ctDNA genomic (*TP53*, *RB1*) and epigenomic changes help identify treatment-emergent neuroendocrine PCa[27].

### ctDNA and Bipolar Androgen Therapy (BAT)

BAT involves rapid cycling between supraphysiologic and castrate testosterone levels. ctDNA insights:

- **Responders**: Patients with baseline *AR* amplifications in ctDNA are more likely to respond to BAT, with PSA declines ≥50%[1612].
- **Mechanism**: BAT may reduce *AR* amplification signals in ctDNA, suggesting adaptive downregulation of androgen signaling[611].
- **Rechallenge potential**: BAT can resensitize tumors to ARSI (e.g., enzalutamide), with ctDNA monitoring revealing dynamic *AR* changes[910].

### FDA-Approved ctDNA Tests for PCa

| Test Name | Manufacturer | Key Features | FDA-Approved Use in PCa |
|---|---|---|---|
| **FoundationOne Liquid CDx** | Foundation Medicine | - NGS-based (70 genes)<br>- 94% ctDNA detection rate in mCRPC[23] | Identify *BRCA1/2* mutations for PARP inhibitor eligibility (olaparib, rucaparib)[38] |
| **Guardant360 CDx** | Guardant Health | - NGS-based (74 genes)<br>- Detects *AR*, *TP53*, and HRR mutations[38] | Companion diagnostic for PARP inhibitors in *BRCA1/2*-mutated mCRPC[38] |

### Requirements for Testing

1. **Patient eligibility**:
   - Metastatic adenocarcinoma of the prostate.
   - No prior next-generation sequencing (NGS) testing in the metastatic setting.
   - Insufficient tumor tissue or unsafe biopsy[8].
2. **Therapy alignment**:
   - Candidate for PARP inhibitors (e.g., olaparib) or PD-1 inhibitors (e.g., pembrolizumab)[8].

## Key Takeaways

- ctDNA enables non-invasive detection of *AR* amplifications, *TP53* mutations, and neuroendocrine markers in PCa.
- FDA-approved tests (FoundationOne Liquid CDx, Guardant360 CDx) guide PARP inhibitor use in *BRCA1/2*-mutated mCRPC.
- BAT responders often exhibit *AR* amplifications in ctDNA, supporting its role in personalized therapy sequencing[112].

## References

| Source Type | Example References | Quality Rating (1–5) | URL |
|---|---|---|---|
| **Peer-reviewed** | PubMed/PMC articles[12379] | 5 | PMC |
| **Guidelines** | Carelon Medical Guidelines[8] | 4 | Carelon |
| **Clinical Trials** | ASCO abstracts[612] | 4 | ASCO |
| **Specialized** | UroToday[10], Urology Times[13] | 3 | UroToday |

**Blood-based markers of differential efficacy of bipolar androgen therapy and enzalutamide in the randomized TRANSFORMER trial. | Journal of Clinical Oncology**
**https://ascopubs.org/doi/10.1200/JCO.2024.42.17_suppl.LBA5014**
**Evolving insights in blood-based liquid biopsies for prostate cancer interrogation - PMC**
**https://pmc.ncbi.nlm.nih.gov/articles/PMC10688444/**

# Tumor Mutational Burden (TMB)

## What Is TMB?

- Tumor Mutational Burden (TMB) is a measure of the total number of mutations in the DNA of a tumor. It is usually quantified as the number of **mutations per megabase (mut/Mb) of DNA sequenced** in the tumor genome.

## Why Does TMB Matter?

2. **Predicts Response to Immunotherapy (Checkpoint Inhibitors)**
   - High TMB tumors have more **neoantigens** (mutant proteins) that the immune system can recognize.
   - This makes them more likely to respond to **immune checkpoint inhibitors** (e.g., PD-1/PD-L1 inhibitors like pembrolizumab, nivolumab).
3. **Cancer Prognosis and Treatment Selection**
   - **High TMB** is often associated with **better responses to immunotherapy**, especially in cancers like **lung cancer, melanoma, bladder cancer, and MSI-high colorectal cancer**.
   - **Low TMB tumors** may not respond as well to immunotherapy but may be more sensitive to targeted therapies or chemotherapy.

## How Is TMB Measured?

- TMB is typically assessed through Next-Generation Sequencing (NGS) of a tumor biopsy. Labs analyze the number of mutations per megabase (mut/Mb) in the tumor exome or a specific panel of cancer-related genes.
- Very High TMB: Usually defined as > 50 mutations/MB
- High TMB: Usually defined as ≥10 mut/Mb (but the threshold varies by testing platform). More Mutations = More Neoantigens = Stronger Immune Response.
- Intermediate TMB > 5 mutations/MB
- Low TMB: Fewer mutations, often associated with lower immune response to checkpoint inhibitors. ≤ 5 mutations/MB
- TMB is a predictive biomarker for checkpoint inhibitor immunotherapy response.
- It is particularly useful for non-MSI-H tumors, where microsatellite instability (MSI) testing alone is not enough to predict immunotherapy benefit.

In general, TMB roughly correlates with cancer. E.g., if TMB is low the cancer is probably low risk and/or low volume or is responding well to therapies.

## References


1. High Tumor Mutational Burden Correlates with Longer Survival in Immunotherapy-Naïve Patients with Diverse Cancers | Molecular Cancer Therapeutics | American Association for Cancer Research https://aacrjournals.org/mct/article/19/10/2139/92687/High-Tumor-Mutational-Burden-Correlates-with
2. FDA Approves First Drug for Cancers with a High Tumor Mutational Burden https://www.cancer.org/latest-news/fda-approves-first-drug-for-cancers-with-a-high-tumor-mutational-burden.html

# How Prostate Cancer Cells Metastasize: The Journey from Primary Tumor to Distant Sites

Prostate cancer metastasis involves a complex, multi-step process where cancer cells escape the primary tumor, travel through the bloodstream, and establish new tumors at distant sites. This process follows Paget's "seed and soil" hypothesis, where tumor cells ("seeds") selectively colonize receptive tissues ("soil").

## Key Stages in the Metastatic Cascade

### 1. Epithelial-to-Mesenchymal Transition (EMT)

The metastatic journey begins with EMT, a critical transformation where prostate cancer cells lose their epithelial characteristics and acquire mesenchymal properties[4][5][6]. This transformation:

- Decreases E-cadherin expression, weakening cell-cell adhesion
- Increases N-cadherin and vimentin expression, enhancing motility
- Activates transcription factors (SNAI1/2, ZEB1, TWIST1) that drive phenotypic changes[8]
- Enables cells to break away from the primary tumor and invade surrounding tissue[4]

EMT is triggered by multiple growth factors, including TGF-β, IGF-1, EGF, HGF, and FGF, which activate signaling pathways like MAPK and PI3K/AKT[5][8].

### 2. Invasion and Migration

Once transformed, cells must degrade the extracellular matrix to migrate:

- Matrix metalloproteinases (particularly MMP-9) break down collagen and other matrix components[9][10]
- Urokinase plasminogen activator receptor (uPAR) and cathepsin B facilitate invasion[9]
- CXCL12/CXCR4 chemokine signaling activates MMP-9 expression and Akt phosphorylation, promoting migration toward bone tissue[11]

### 3. Intravasation and Circulation

Cancer cells enter blood vessels (intravasation) and must survive in circulation:

- Platelets protect cancer cells from immune detection and shear stress[6]
- TGF-β signaling from platelets enhances cancer cell extravasation
- Circulating tumor cells undergo remodeling via epigenetic modifications to survive in the bloodstream[5]

### 4. Premetastatic Niche Formation

Before arrival, cancer cells prepare distant sites for colonization:

- Primary tumors secrete exosomes containing proteins and microRNAs that "prime" distant organs[5][10]
- Exosomes from hypoxic prostate cancer cells promote MMP activity at future metastatic sites[10]

- These primed sites attract cancer cells through chemokine gradients[7]

### 5. Extravasation and Colonization

Circulating cancer cells exit the bloodstream and establish new tumors:

- Bone-specific chemoattraction guides prostate cancer cells to the bone microenvironment[4]
- CXCL12 produced by bone marrow stromal cells attracts CXCR4-expressing cancer cells[11]
- Cancer cells adapt to the new microenvironment through phenotypic changes and interactions with resident cells[5]

## Molecular Drivers of Prostate Cancer Metastasis

### 1. Genetic Alterations

Specific genomic changes are associated with metastatic potential:

- Mutations in AR, CDK12, ZFHX3, RB1, and PTEN genes[5]
- Alterations in DNA repair pathways (BRCA2, TP53)[5]
- Multiple Myeloma SET domain (MMSET) overexpression promotes EMT through TWIST1 activation[5]

### 2. Microenvironmental Factors

The tumor microenvironment significantly influences metastatic behavior:

- Cancer-associated fibroblasts (CAFs) promote ECM remodeling and release growth factors[5]
- Hypoxia drives exosome secretion that prepares premetastatic niches[10]
- Inflammatory cytokines and chemokines create favorable conditions for metastatic growth[7]

## Preferred Metastatic Sites

Prostate cancer exhibits tropism for specific organs:

- Bones are the most common site (>80% of advanced cases)[5][12][14]
- Lymph nodes are frequently involved[12][14]
- Less commonly, metastases occur in liver and lungs[12]

This organ-specific tropism reflects the complex interplay between the unique properties of prostate cancer cells and the receptive microenvironments of these tissues.

Understanding these metastatic mechanisms is crucial for developing effective therapies targeting various stages of the metastatic cascade, potentially preventing or treating advanced prostate cancer.

# Strategies to Delay or Prevent Metastases in Prostate Cancer

Metastasis prevention represents a critical treatment goal for patients with hormone-sensitive prostate cancer (HSPC), particularly those with high-risk features like Gleason Grade 5 (GG5). Current evidence supports multiple approaches that can significantly delay or potentially prevent the metastatic spread of prostate cancer cells through strategic targeting of disease progression pathways.

## Pharmacological Interventions that Delay Metastasis

### 1. Next-Generation Anti-Androgens (ARSIs)

Next-generation androgen receptor signaling inhibitors have demonstrated substantial metastasis-free survival benefits in clinical trials:

- **Apalutamide**: The SPARTAN trial showed a 72% reduction in metastasis risk when combined with ADT compared to ADT alone in high-risk non-metastatic CRPC. Apalutamide reduced the risk of death by 35% regardless of metastatic volume or risk status[10].
- **Enzalutamide**: In the PROSPER study, enzalutamide extended median metastasis-free survival by 21.9 months (36.6 months vs. 14.7 months with placebo), demonstrating a 71% risk reduction in disease progression or death[17].
- **Darolutamide**: Shows efficacy in delaying metastases with a favorable safety profile due to limited blood-brain barrier penetration, making it particularly suitable for patients with comorbidities[10].

### 2. Androgen Deprivation Therapy (ADT) Intensification

Combining ADT with additional agents significantly improves outcomes beyond ADT alone:

- **Abiraterone plus prednisolone**: Long-term follow-up from the STAMPEDE trial demonstrated sustained improvement in survival for metastatic prostate cancer patients after 73 months of follow-up, regardless of disease risk category[13].
- **BAT (Bipolar Androgen Therapy)**: Alternating between high and low testosterone levels can disrupt cancer adaptation mechanisms. The COMBAT trial is investigating BAT with immune checkpoint inhibitors in metastatic CRPC to exploit immune microenvironment changes induced by testosterone cycling[6].

### 3. Bone-Targeted Therapies

For patients with or at risk of bone metastases, targeted agents can significantly delay skeletal complications:

- **Denosumab**: Has demonstrated superior efficacy over zoledronic acid for skeletal-related event prevention in patients with castration-resistant prostate cancer and bone metastases[8][16]. In high-risk non-metastatic CRPC, denosumab significantly delayed the development of bone metastases compared to placebo[23].
- **Zoledronic acid**: Shown to prevent skeletal-related events in patients with bone metastases, with some evidence suggesting potential direct anti-tumor effects in select patients[9].

## Metabolic and Multitargeted Approaches

### 1. Metformin and Metabolic Modulation

- **Metformin**: Associated with delayed disease progression in prostate cancer, particularly biochemical recurrence, through inhibition of cancer progression pathways by modifying tumor suppressor genes and oncogenes. It works through both insulin-dependent and independent mechanisms, potentially enhancing ADT efficacy by down-regulating androgen receptor levels[14].

### 2. Dynamic Cycle Architecture (aBAT)

The aBAT approach leverages multiple cycle durations to prevent predictable resistance patterns. This dynamic approach prevents cellular adaptation to either hormonal state, disrupting compensatory oncogenic signaling network activation that enables resistance2.

### 3. Lifestyle and Dietary Interventions

Research suggests several lifestyle modifications may help delay prostate cancer progression:

- **Dietary adjustments**: Adopting a plant-based diet rich in fruits, vegetables, whole grains, and legumes while limiting animal products, particularly dairy. Studies show that men with early-stage prostate cancer who made intensive dietary changes showed reduced PSA progression[7][18].
- **Exercise**: Regular physical activity, particularly combining aerobic and resistance training, may help delay progression through multiple mechanisms including improved immune function, reduced inflammation, and enhanced insulin sensitivity[7][18].
- **Weight management**: Maintaining a healthy weight is associated with reduced risk of advanced and fatal prostate cancer. Obesity appears to promote more aggressive disease progression[15][18].
- **Limiting dairy and calcium**: Some studies suggest high intake of dairy products and calcium may increase prostate cancer risk, though evidence remains mixed[15].

### 4. Precision Multi-Pathway Targeting

The Oncogenic Signaling Networks (OSNs) approach targets multiple cancer-driving pathways simultaneously:

- **AR signaling (OSN1)**: Primary driver of prostate cancer progression
- **PI3K/AKT/mTOR (OSN2)**: Second most targeted pathway, particularly by metabolic agents
- **DNA Damage Repair (OSN3)**: Specifically targeted by PARP inhibitors
- **NF-κB (OSN13)**: Inflammatory pathway important in prostate cancer progression.

By simultaneously targeting multiple pathways and alternating treatment approaches, this strategy aims to prevent cancer cells from developing stable resistance mechanisms.

## Conclusion

Preventing prostate cancer metastasis requires a multifaceted approach combining pharmacological interventions, strategic treatment cycling, and lifestyle modifications. For HSPC patients, intensification of ADT with next-generation anti-androgens offers an evidence-based approach for delaying metastases. Dynamic treatment approaches like aBAT that target multiple oncogenic pathways show promise for overcoming adaptive resistance, while lifestyle interventions provide complementary benefits with minimal risk.

Early intervention remains critical-treatment intensification before metastases develop appears more effective than addressing metastatic disease once established. Regular monitoring with appropriate imaging and biomarkers allows for timely intervention and treatment adjustment to maximize metastasis-free survival.

## Successful AR Degraders and SARDs in Prostate Cancer

**AR degraders and/or SARDs might be an addition to low-T cycles in CRPC and aggressive PCa. Possibly for SPA post 24-48 hours to interfere with AR mediated damage repair.**

**1. PROTAC AR Degraders (Clinically Advanced)**

| Drug | Developer | Stage | Key Findings |
|---|---|---|---|
| **ARV-110 (Bavdegalutamide)** | Arvinas | Phase II | - 46% PSA50 in AR LBD-mutant mCRPC<br>- Degrades AR mutants (F876L, T877A). |
| **ARV-766** | Arvinas | Phase II | - 43% PSA50 in AR LBD-mutant mCRPC<br>- Targets AR and AR splice variants (AR-V7). |
| **ARCC-4** | Academic | Preclinical | - Degrades AR mutants (H874Y, M896V)<br>- Overcomes enzalutamide resistance. |

**Mechanism**: Bifunctional molecules recruiting E3 ligases (VHL/CRBN) to tag AR for proteasomal degradation.

**2. Non-PROTAC SARDs (Selective Androgen Receptor Degraders)**

| Drug | Developer | Stage | Key Findings |
|---|---|---|---|
| **Z15** | Academic | Preclinical | - Degrades AR/AR-V7 via AF-1 binding<br>- Overcomes enzalutamide resistance in CRPC models. |
| **UT-155/UT-69** | GTx/UTRF | Preclinical | - Degrades AR via AF-1 destabilization<br>- Active against AR splice variants. |
| **ARD-61** | Academic | Preclinical | - Degrades AR mutants (F876L, T877A)<br>- Synergizes with PARP inhibitors. |
| **GDC-2992 (RO7656594)** | Genentech/ Roche | **Phase I** | - Oral AR degrader (non-PROTAC)<br>- Early Phase I data in mCRPC (NCT05800665)<br>- Degrades AR mutants (preclinical) |

**Mechanism**: Small molecules destabilizing AR through non-PROTAC pathways (e.g., AF-1 binding, proteasome recruitment).

**Key Clinical Insights**

1. **Overcoming Resistance**:
   - PROTACs/SARDs degrade AR mutants (e.g., F876L) and splice variants (AR-V7), bypassing resistance to enzalutamide/abiraterone.
   - ARV-766: 43% PSA50 in AR LBD-mutant mCRPC vs. 15% for standard ARSIs.

2. **Synergy with PARP Inhibitors**:
    - AR degraders block AR-driven DNA repair (BRCA1/Rad51), enhancing olaparib's synthetic lethality.
3. **Dual-Phase Utility in aBAT**:
    - **High-T**: Post-peak degradation amplifies genomic stress (prevents AR-mediated repair).
    - **Low-T**: Continuous AR suppression prevents adaptive splicing (AR-V7).

**Comparison: PROTACs vs. SARDs**

| Parameter | PROTACs (ARV-110/766) | SARDs (Z15/UT-155) |
|---|---|---|
| **Mechanism** | E3 ligase recruitment | Direct destabilization |
| **Oral Bioavailability** | Yes | Limited (preclinical) |
| **AR-V7 Degradation** | Partial | Yes (Z15) |
| **Clinical Stage** | Phase II | Preclinical |

**Conclusion**

**PROTACs (ARV-110/766)** are the most clinically advanced AR degraders, showing robust efficacy in AR LBD-mutant mCRPC. **Non-PROTAC SARDs (Z15/UT-155)** offer preclinical promise against AR-V7 and broader resistance mechanisms. Both classes are prioritized in precision aBAT protocols for their ability to disrupt OSN1 (AR signaling) and synergize with DNA repair inhibition (OSN3).

**PROTAC AR Degraders**

| Reference | Title | URL | Type | Quality |
|---|---|---|---|---|
| 1 | ARV-110: An oral androgen receptor PROTAC degrader for prostate cancer | ASCO Abstract | Phase I/II trial | B |
| 2 | ARV-766, a proteolysis targeting chimera (PROTAC) androgen receptor degrader | ASCO Abstract | Phase I/II trial | B |
| 3 | Androgen receptor degradation by the proteolysis-targeting chimera ARCC-4 | Nature | Preclinical study | B |
| 4 | Preclinical Evaluation of Bavdegalutamide (ARV-110), a Novel PROTAC Androgen Receptor Degrader | PubMed | Preclinical study | B |
| 5 | Arvinas Announces Interim Data from the ARV-766 Phase 1/2 Dose Escalation | Press Release | Phase I/II trial update | C |

**Non-PROTAC SARDs**

| Reference | Title | URL | Type | Quality |
|---|---|---|---|---|
| 6 | Insight into Recent Advances in Degrading Androgen Receptor for Prostate Cancer Therapy | PMC | Review article | C |
| 7 | New molecules may offer next-generation treatment in prostate cancer | Healio | News article (preclinical SARDs) | C |
| 8 | Androgen Receptor-Directed Molecular Conjugates for Targeting Prostate Cancer | Frontiers | Review/methods article | C |

# Development, Progression, Reversal of Castration-Resistant Prostate Cancer (CRPC)

## Mechanisms of CRPC Development

CRPC arises through adaptive mechanisms that enable prostate cancer cells to survive and proliferate despite androgen deprivation therapy (ADT). Major oncogenic signaling networks (OSNs) implicated include:

1. **Androgen Receptor (AR) Reactivation**
   - **AR Amplification/Overexpression**: Increases in AR expression heighten sensitivity to residual androgens, sustaining ligand-dependent signaling.
   - **AR Mutations**: Point mutations such as T878A and L702H broaden ligand specificity, allowing activation by alternative steroids like glucocorticoids.
   - **AR Splice Variants (e.g., AR-V7)**: Truncated forms lack the ligand-binding domain, enabling constant activation of AR signaling independent of androgens.
2. **Intratumoral Androgen Synthesis**
   - Upregulation of steroidogenic enzymes (e.g., CYP17A1, AKR1C3) allows tumor cells to convert adrenal precursors into active androgens.
3. **Bypass Pathways**
   - **Glucocorticoid Receptor (GR) Activation**: GR can substitute for AR by binding similar DNA response elements.
   - **PI3K/Akt/mTOR and Wnt/β-Catenin Pathways**: These support proliferation and survival independent of AR signaling.
   - **Neuroendocrine Differentiation**: Tumor cells may transdifferentiate into aggressive, AR-independent neuroendocrine-like cells.
4. **Epigenetic and Genomic Alterations**
   - Losses in key tumor suppressors (e.g., PTEN, TP53, RB1) and defects in DNA repair mechanisms (e.g., BRCA mutations) contribute to genomic instability and therapeutic resistance.
5. **Tumor Microenvironment**
   - Immune evasion, angiogenesis, and stromal cell interactions create a permissive environment for CRPC growth and progression.

## Why Aggressive Tumors Progress to CRPC Faster

Aggressive prostate cancers (e.g., Gleason score ≥8) often progress to CRPC more quickly due to the following factors:

1. **Genomic Instability**: Mutations in TP53, RB1, and PTEN increase adaptability and resistance to ADT by accelerating clonal evolution.
2. **Baseline AR-Independent Subclones**: High-grade tumors frequently harbor diverse subpopulations, some of which are inherently less AR-dependent, allowing rapid selection under ADT.
3. **Clonal Evolution Under ADT Pressure**: ADT acts as a selective force, promoting expansion of resistant phenotypes such as AR-V7 expression, GR upregulation, or neuroendocrine transformation.
4. **Lineage Plasticity and Stemness**: Expression of stemness markers (e.g., SOX2, NANOG) enables lineage switching and survival under therapeutic pressure.
5. **Lower Initial AR Dependence**: Aggressive tumors often rely less on androgen signaling, making hormonal therapy less durable.

## Clinical Evidence

High-risk patients (Gleason 9-10) often develop CRPC within 12-18 months, even with combination therapy. In contrast, lower-grade tumors can remain hormone-sensitive for many years. Molecular classifiers like Decipher predict earlier transition in high-risk cases.

## Therapeutic Strategies

Overcoming resistance requires combination strategies that target both AR-dependent and independent pathways:

1. **AR-Directed Therapies**
   - Next-generation AR inhibitors (e.g., darolutamide)
   - CYP17A1 inhibitors (e.g., abiraterone) with AR antagonists
2. **Dual AR/GR Inhibition**

- GR blockers such as relacorilant or mifepristone

3. **Targeting Bypass Signaling**
   - PI3K/Akt inhibitors (e.g., ipatasertib)
   - Wnt/β-Catenin inhibitors (e.g., PRI-724)
4. **Neuroendocrine CRPC**
   - Chemotherapy (e.g., carboplatin/etoposide)
   - Targeted agents like tarlatamab (DLL3)
5. **DNA Repair Deficiency**
   - PARP inhibitors (e.g., olaparib, rucaparib) for BRCA mutations or in combination with bipolar androgen therapy (BAT)
6. **Immunotherapy**
   - Checkpoint inhibitors (e.g., pembrolizumab) and vaccines (e.g., PROSTVAC) in cases with high tumor mutational burden
7. **Epigenetic Therapies**
   - EZH2 inhibitors (e.g., tazemetostat) to reverse resistant transcriptional states
8. **Modulating the Microenvironment**
   - Anti-angiogenics (e.g., bevacizumab) and CXCR4 inhibitors (e.g., plerixafor)

## Future Directions

- **Biomarker-Guided Treatment**: Liquid biopsies to guide therapy based on AR-V7, GR, or NE markers
- **Synthetic Lethality Approaches**: Combining PARPi with AR/GR blockade and BAT
- **ARSI Resensitization**: Using BAT to resensitize tumors to prior AR-targeted agents
- **Early BAT Use**: Initiating BAT during hormone-sensitive stages to delay resistance
- **Chronotherapy**: Aligning drug delivery with circadian rhythms to optimize efficacy and minimize toxicity

## HSPC->CRPC Prediction

### 1. ADT

Considering that many men are currently receiving or will soon receive ADT, I put together the following predictions.

**Predicted Time to CRPC Progression by Grade Group and Stage Under Continuous ADT**
**Note**: These tables are extrapolated from clinical studies on HSPC→CRPC progression risk factors. Direct evidence linking Gleason/stage combinations to precise timelines is limited, so these estimates reflect general trends.
Use of an androgen biosynthesis inhibitor (ABI) or androgen receptor signaling inhibitor (ARSI) typically extends the time to progression to castration-resistant prostate cancer (CRPC). For men with Gleason Grade Group 5 disease, this can increase the average time to CRPC to approximately 18–28 months.

| Gleason Grade Group | Gleason Score | Median Time to CRPC (Months) | Hazard Ratio vs GG1 | Evidence Source |
|---|---|---|---|---|
| **GG1** | **≤6** | **Not reached*** | **1.00 (reference)** | **PMC6775699** |

| Gleason Grade Group | Gleason Score | Median Time to CRPC (Months) | Hazard Ratio vs GG1 | Evidence Source |
|---|---|---|---|---|
| **GG2** | **3+4=7** | **Not reached*** | **1.512 (NS)** | **PMC6775699** |
| **GG3** | **4+3=7** | **~60-80 months**** | **3.169 (p=0.006)** | **PMC6775699** |
| **GG4** | **8** | **~20-25 months** | **4.335 (p<0.001)** | **PMC6775699, PMC6319345** |
| **GG5** | **9-10** | **~15-20 months** | **5.159 (p<0.001)** | **PMC6775699, PMC6319345** |

Notes:
* "Not reached" indicates median time was not achieved during study follow-up periods
** Estimated based on hazard ratios and available data points
Clinical Interpretation:

- GG1-2: Excellent prognosis, very prolonged time to CRPC (often >10 years)
- GG3: Intermediate risk, substantial delay to CRPC
- GG4-5: High risk, rapid progression to CRPC (typically <2 years)

## 2. ADT vs. Doublet vs. Triplet

Patients with high-risk prostate cancer experience varying timelines to the development of castration-resistant prostate cancer (CRPC), depending on the treatment regimen.

- ADT typically leads to CRPC within 12 to 18 months, based on older trials such as SWOG 9346. This approach is generally inadequate for high-risk disease.
- The addition of docetaxel to ADT extends the CRPC-free interval to around 20 to 24 months, as demonstrated in trials like GETUG-15 and CHAARTED. The benefit is most evident in patients with high-volume disease.
- Combining ADT with an androgen receptor pathway inhibitor (ARPI)—such as abiraterone, enzalutamide, or apalutamide—further improves outcomes, with CRPC typically delayed to 30 to 36 months. Supporting data come from major trials including LATITUDE, STAMPEDE, and ENZAMET. This combination is particularly effective in de novo metastatic cases and those with Gleason scores of 8 or higher.

The most substantial delay in CRPC onset is seen with triplet therapy—ADT plus docetaxel and an ARPI—where median time to CRPC can reach 42 to 48 months (3.5 to 4 years). This is supported by phase III

trials like PEACE-1 and ARASENS, especially in patients with de novo, high-risk, high-volume disease.

## 3. Blood Marker Prediction

### 1. Sensitivity

- **Definition**: The percentage of patients who progress to CRPC that the model correctly identifies as high-risk.
- **Interpretation**:87% sensitivity means the model flags **87% of true progressors** (e.g., 87 out of 100 patients who progress are correctly identified in the timeframe specified).
- **Clinical Implication**: High sensitivity reduces **false negatives** (missed progressors), ensuring timely intervention.

### 2. Specificity

- **Definition**: The percentage of patients who do **not** progress to CRPC that the model correctly identifies as low-risk.
- **Interpretation**: 60% specificity means the model correctly excludes **60% of non-progressors** (40% are falsely flagged as high-risk).
- **Clinical Implication**: Lower specificity may lead to overtreatment but prioritizes catching aggressive cases.

### 3. AUC (Area Under the ROC Curve)

- **Definition**: A measure of the model's ability to distinguish progressors from non-progressors across all thresholds (0.5 = random chance; 1.0 = perfect prediction).
- **Interpretation**: The model correctly ranks a random progressor as higher risk than a non-progressor **85% of the time**.
- **Clinical Implication**: Higher AUC values indicate robust overall performance, balancing sensitivity and specificity.

### Limitations

- **Real-World Variability**: Specificity may be lower in diverse populations due to varying comorbidities or differences in assay methods.
- **Data Gaps:** For certain grade and stage combinations, predictions cannot be made due to limited or unavailable data.
- **Unvalidated**.
- **AUC/sensitivity/specificity** values are inferred from biomarker studies (e.g., PSA dynamics, LDH).

**Key Takeaway**: The model is optimized to prioritize early detection of CRPC progression. Always pair with clinical judgment and imaging (e.g., PSMA PET/CT). And if desired other markers such as PSADT or AR-V7 status.

HSPC->CRPC ML Weighted Indicator

HSPC->CRPC ML Weighted Indicator (Sans AR-V7))

## 4. Reference List

| Title | URL |
|---|---|
| *Identifying Patients With Rapid Progression From Hormone-Sensitive to Castration-Resistant Prostate Cancer Using Proteomics and Machine Learning* | PMC10491655 |
| *Analysis of Risk Factors for Early Progression of Prostate Cancer After Androgen Deprivation Therapy* | PMC10088537 |
| *Dynamic Changes in PSA Levels Predict Prognostic Outcomes in Prostate Cancer Patients After Androgen Deprivation Therapy* | Frontiers |
| *Preclinical Data: Androgen receptor inhibition delays CRPC in model* | PMC7572188 |
| *Time to progression to castration-resistant prostate cancer after commencing combined androgen blockade for advanced hormone-sensitive prostate cancer | Oncotarget* | oncotarget |
| *ARASENS analysis highlights darolutamide benefit in North American mHSPC patients* | ARASENS |

1.

## Theoretical CRPC Resensitization Strategies

| Strategy | Mechanism & Rationale | Probability of Resensitization | Estimated Duration of Response (months) | Combination Strategies | Side Effects | Cost Estimate | Availability |
|---|---|---|---|---|---|---|---|
| 1. AR Degraders (PROTACs) | Induce degradation of full-length and splice-variant AR (e.g., ARV-110) via the ubiquitin-proteasome system, overcoming resistance due to AR mutations and AR-V7 expression. | Approximately 46% PSA response in AR-mutated cases; overall ~22–30% PSA50 responses in less pretreated cohorts. | Responders have shown response durations of roughly 9–10 months (ongoing in trials). | Often combined with AR OSN inhibitors (e.g., with abiraterone) to achieve deeper AR suppression. | Generally well tolerated with mostly grade 1–2 gastrointestinal symptoms and fatigue; rare grade ≥3 events. | High; if approved, likely comparable to other novel AR agents (several thousand dollars per month). | Experimental – available in clinical trials (Phase II) only. |
| 2. AR N-Terminal Domain Inhibitors | Bind the AR N-terminal domain (e.g., EPI-7386) to block AR transcription regardless of ligand-binding domain mutations or splice variants. | Approximately 20–30% PSA response when used as monotherapy in resistant CRPC; in combination with enzalutamide, response rates can be as high as 83% in selected patients. | In combination, responses have been observed to last around 16–17 months; monotherapy responses are generally shorter (a few months). | Best used alongside AR inhibitors; trials are evaluating combination with enzalutamide. | Well tolerated overall with mainly grade 1–2 fatigue and hot flashes; minimal CNS effects. | Not yet marketed; expected to be high if approved. | Experimental – available in Phase I/II trials only. |
| 3. BET Inhibitors | Inhibit BET proteins (e.g., BRD4) that co-activate AR signaling and drive lineage plasticity, thereby suppressing AR target genes. | In combination with AR inhibitors, ~15–20% of patients achieve meaningful responses in resistant tumors. | Median radiographic PFS around 9 months; some responders remain progression-free >12 months. | Used in combination with AR inhibitors (e.g., enzalutamide) and sometimes in triple combinations with immunotherapy. | Common side effects include fatigue, diarrhea, and thrombocytopenia (grade 3 in about 4% of patients). | High; likely similar to other novel targeted oral agents (on the order of $10,000+ per month if approved). | Investigational – available in clinical trials (Phase I/II); not yet FDA-approved for CRPC. |
| 4. Histone Deacetylase Inhibitors | Inhibit HDACs to modify chromatin, downregulate AR and AR-V7 expression, and restore sensitivity to antiandrogens. | When combined with AR inhibitors, approximately 30–50% of resistant patients may experience benefit (PSA declines and stable disease). | Median PFS reported in combination studies is around 7–8 months; responses are often transient. | Best used in combination with AR-targeted agents (e.g., panobinostat plus bicalutamide or enzalutamide). | Common effects: fatigue, nausea, cytopenias, diarrhea, and possible ECG changes. | High; HDAC inhibitors cost around $10,000 per month. | FDA-approved HDAC inhibitors exist for other cancers but are used off-label in CRPC within clinical trials. |
| 5. EZH2 Inhibitors | Inhibit EZH2 to reverse epigenetic silencing, potentially reactivating AR expression in tumors that have adopted an AR-independent/neuroendocrine phenotype. | Early data indicate PSA responses in approximately 15–20% of patients when added to AR therapy; newer agents show ~30–40% response in selected populations. | Median response durations are approximately 6–12 months in responders, though data are preliminary. | Combined with AR inhibitors (enzalutamide or abiraterone); sometimes explored with PARP inhibitors. | Generally mild to moderate; fatigue, nausea, decreased appetite, with few grade ≥3 events. | High; estimated at $15,000+ per month if approved for CRPC. | Experimental – available in Phase Ib/II trials; tazemetostat is FDA-approved for other cancers but used off-label or in trials for CRPC. |
| 6. Antiandrogen Sequencing/Combination | Sequentially switch between different AR inhibitors (e.g., abiraterone then enzalutamide) to exploit non-cross-resistance. | Approximately 36% PSA response observed when switching from abiraterone to enzalutamide; reverse sequence is less effective. | Responses tend to be short-lived with median PSA progression of ~3–4 months on second-line therapy. | Sequencing is preferred over concurrent dual AR blockade; the abiraterone → enzalutamide sequence is most common. | Side effects are those of the individual AR agents (fatigue, hypertension, cognitive effects, mineralocorticoid excess with abiraterone). | Each AR agent costs about $10,000–$15,000 per month (list price), though generics have reduced costs; overall treatment cost is significant. | Standard of care – AR inhibitors are widely available and FDA-approved; sequencing is common practice. |
| 7. Enhanced Steroid Suppression | Further inhibit androgen synthesis by adding agents (e.g., additional CYP17 or AKR1C3 inhibitors, steroid switch from prednisone to dexamethasone) to more fully suppress adrenal and intracrine androgens. | Approximately 30–40% of patients with progression on abiraterone plus prednisone experience a PSA decline after switching to dexamethasone. | Responses are generally transient; median duration ranges from 3 to 6 months. | Primarily used with abiraterone; steroid switch is a simple modification in ongoing therapy. | Steroid-related effects: hyperglycemia, edema, weight gain, mood changes, immunosuppression. | Minimal additional cost – dexamethasone is very inexpensive; overall cost dominated by abiraterone (now generic) at ~$3,000/month. | Widely available – steroid switches are standard clinical practice in certain resistant settings. |
| 8. AKT/PI3K OSN | Inhibit the PI3K–AKT–mTOR | In biomarker-selected (PTEN- | In selected patients, | Always combined with AR | Common toxicities: diarrhea, | High; investigational AKT | Investigational – available |

| Strategy | Mechanism & Rationale | Probability of Resensitization | Estimated Duration of Response (months) | Combination Strategies | Side Effects | Cost Estimate | Availability |
|---|---|---|---|---|---|---|---|
| Inhibitors | pathway, which is upregulated (especially in PTEN-deficient tumors) as a bypass mechanism. | loss) mCRPC, addition of an AKT inhibitor (e.g., ipatasertib) improved outcomes by about 20–25% (approximately 23% benefit in PTEN-null patients). | median PFS may extend by 2–3 months over standard therapy; some patients experience benefit up to 18 months in PTEN-loss subgroups. | inhibitors (e.g., ipatasertib with abiraterone + prednisone). | rash, hyperglycemia, elevated liver enzymes; grade 3–4 events in 10–20% of patients in trials. | inhibitors are expensive (~$10,000+ per month if approved), in addition to the cost of AR therapy. | in Phase III trials for PTEN-deficient mCRPC; not yet approved. |
| 9. Src Kinase Inhibitors | Inhibit Src family kinases that support AR-independent growth and promote bone metastasis. | Minimal efficacy – clinical trials in mCRPC have shown PSA response rates of <5%. | Most patients progress within 2–3 months; any benefit is short-lived and inconsistent. | No proven effective combination; some trials combined with chemotherapy, but no clear benefit for resensitization. | Side effects: fatigue, nausea, edema, pleural effusions, and cytopenias; significant risk of bleeding and cardiac QT prolongation. | High; dasatinib costs ~$10,000 per month. | FDA-approved for leukemia but not for CRPC; used off-label rarely; not recommended due to poor efficacy in CRPC. |
| 10. HER2/EGFR Inhibitors | Block receptor tyrosine kinases (e.g., lapatinib) to interrupt compensatory growth signals that may support resistance when AR is suppressed. | Very low; Phase II studies in mCRPC reported <5% PSA response rates. | Responses, if any, are short (typically <3 months) and not durable. | Studied mostly as monotherapy or with limited combination with AR inhibitors; not proven effective in restoring hormone sensitivity. | Side effects: diarrhea, rash, hepatotoxicity, and fatigue; dermatologic toxicities are common. | High; lapatinib costs ~$4,000–$5,000 per month. | FDA-approved for HER2+ breast cancer but not for prostate cancer; off-label use in CRPC has not been effective. |
| 11. Monoamine Oxidase-A Inhibitors (e.g., Phenelzine) | Inhibit MAO-A to reduce AR signaling and tumor proliferation. Rationale: MAO-A is overexpressed in CRPC and its inhibition can lower AR activity and possibly reverse resistance. | Early studies in biochemical recurrence showed PSA declines in ~55% of patients; in mCRPC, theoretical benefit of ~20–30% in selected cases is expected, though data are limited. | When responses occur, they tend to be short-term (around 3 months); durability in mCRPC is unproven. | Used in combination with AR inhibitors; sometimes as an adjunct when resistance emerges. | Side effects: dizziness, orthostatic hypotension, sedation; risk of hypertensive crisis if dietary tyramine is not avoided. | Very Low; generic MAOIs cost ~$50–$100 per month. | Available by prescription for depression; use in CRPC is off-label and investigational. |
| 12. Autophagy Inhibitors | Block autophagy (cellular recycling) to prevent tumor cells from surviving therapy-induced stress. | Preclinical models suggest possible benefit in ~10–20% of patients when added to AR inhibitors; clinical efficacy in CRPC remains unproven. | Likely to extend response by a few extra months (estimated 3–6 months) if effective; data are not definitive. | Best used in combination with AR-targeted agents (e.g., hydroxychloroquine or metformin added to enzalutamide) to enhance cell death. | Side effects depend on the agent: hydroxychloroquine may cause retinal toxicity (requiring periodic eye exams), GI upset, and rare cardiac effects; metformin is generally well tolerated but can cause GI discomfort. | Very Low; hydroxychloroquine and metformin are inexpensive (each typically <$50/month). | Experimental; these agents are approved for other indications but used off-label in CRPC within clinical trials. |
| 13. Adrenal/Glucocorticoid Modulation (Steroid Switch) | Replace prednisone with a more potent corticosteroid (e.g., dexamethasone) during abiraterone therapy to further suppress adrenal androgen production. | Approximately 30–40% of patients exhibit a PSA decline after switching to dexamethasone. | Median duration of response is typically 3–6 months, though some patients may experience longer benefit. | Used specifically in combination with abiraterone; the steroid switch is a modification of ongoing therapy rather than a stand-alone approach. | Steroid-related effects: hyperglycemia, edema, weight gain, mood changes; long-term low-dose dexamethasone may cause muscle wasting and metabolic syndrome. | Minimal; dexamethasone is very inexpensive (pennies per dose). | Widely available; this strategy is implemented in clinical practice for patients failing abiraterone + prednisone. |
| 14. Immunotherapy / TME Modulation | Utilize checkpoint inhibitors, cancer vaccines, or bispecific T-cell engagers to enhance immune clearance of resistant tumor clones. | In unselected mCRPC, response rates are low (<10% overall); in biomarker-selected groups (e.g., MSI-high), responses may reach 40–50%. | For responders, responses can be very durable (1–2 years or longer) but apply to only a small subset; in most, responses are short or absent. | Primarily combined with AR inhibitors or other systemic therapies; combination with PARP inhibitors and other agents is under investigation. | Immune-related adverse events (irAEs) such as colitis, dermatitis, hepatitis, and endocrinopathies; generally manageable with steroids. | High; checkpoint inhibitors (e.g., pembrolizumab) cost ~$10,000 per infusion; overall yearly costs can exceed $150,000. Sipuleucel-T costs ~$93,000 per treatment course. | FDA-approved for MSI-high/dMMR tumors; off-label use in unselected mCRPC is not standard; mostly available in specialized centers or clinical trials. |
| 15. Radioligand Therapies | Deliver targeted radiation to PSMA-expressing tumor cells (e.g., ^177Lu-PSMA-617) to reduce tumor burden and possibly enable subsequent AR therapy | High efficacy in PSMA-positive mCRPC; about 46% of patients achieve ≥50% PSA declines. Indirectly, this can re-sensitize residual cells | Median radiographic PFS around 8–9 months; overall survival benefit observed (median OS ~15–16 months); some | Generally used after AR and chemotherapy failure. May be followed by re-challenge with AR inhibitors in select patients; used as part of a | Side effects: myelosuppression (grade 3–4 anemia, thrombocytopenia in ~10% of patients), dry mouth, nausea, and fatigue. | Very High; ^177Lu-PSMA-617 (Pluvicto) costs roughly $40,000 per dose, with a full course costing ~$240,000. | FDA-approved (2022) for mCRPC after AR inhibitors and taxane chemotherapy; available in nuclear medicine centers. |

| Strategy | Mechanism & Rationale | Probability of Resensitization | Estimated Duration of Response (months) | Combination Strategies | Side Effects | Cost Estimate | Availability |
|---|---|---|---|---|---|---|---|
| | resensitization. | to AR therapy in selected cases. | patients achieve deep responses lasting 12+ months. | multi-modality treatment strategy. | Generally well tolerated with fewer systemic toxicities than chemotherapy. | | |
| 16. Dietary/Metabolic Interventions | Modify diet (e.g., low-carbohydrate, high omega-3) and use metabolic drugs (statins, metformin) to lower insulin/IGF-1 and reduce intratumoral androgen synthesis. | Observational studies indicate a modest benefit – potentially 10–20% improvement in progression-free or overall survival; not a true "resensitization" but a slowing of progression. | Effects are cumulative over long-term use (years); benefits manifest as prolonged stability rather than an acute resensitization response. | Used as adjuncts to standard therapy; can be initiated concurrently with ADT and AR inhibitors. | Statins: muscle aches, mild liver enzyme elevations; metformin: GI upset, rare lactic acidosis; dietary interventions: generally safe. | Very Low; generic statins and metformin cost <$50/month; lifestyle modifications are cost-effective. | Widely available; these interventions are standard in general practice for metabolic health and are used in PCa management off-label. |
| 17. Bipolar Androgen Therapy (BAT) | Cycles between high-dose testosterone and ADT to "shock" resistant cells, induce DNA damage, and restore sensitivity to subsequent AR inhibition. | Based on RESTORE and TRANSFORMER trials, BAT has a resensitization rate of ~60–78% (measured by subsequent AR inhibitor responses after BAT). | Median duration of AR inhibitor benefit following BAT is ~6–12 months; some studies report extended PFS on subsequent enzalutamide (up to 12–13 months) when preceded by BAT. | Administered as a stand-alone cycle (with ongoing ADT to prevent endogenous testosterone production) before re-challenge with AR inhibitors; sometimes combined with other targeted agents in trials. | Generally well tolerated; common effects include mild edema, transient increases in hematocrit. | Very Low; testosterone injections are inexpensive (generally a few hundred dollars per month) plus standard ADT costs. | Investigational – available in Phase II trials; off-label use in select centers; not yet standard of care. |
| 18. Intermittent ADT (IADT) | Cycles of pausing and reinitiating ADT to reduce continuous selection pressure for resistant clones. Rationale: Periodic restoration of testosterone may delay the evolution of resistance. | In hormone-sensitive disease, IADT shows similar outcomes to continuous ADT; in CRPC, evidence is limited. As a resensitization strategy in established CRPC, benefit is minimal (<10%) except for transient antiandrogen withdrawal responses. | Antiandrogen withdrawal responses may last ~3 months; overall, intermittent ADT in CRPC is not well supported for resensitization. | Typically used as a quality-of-life measure rather than for tumor resensitization; may be considered in early CRPC under controlled protocols. | Side effects similar to continuous ADT during on-cycles (hot flashes, loss of libido, bone loss) and potential for tumor flare during off-cycles. | Minimal – similar cost to continuous ADT, possibly lower if injection frequency is reduced. | Standard in hormone-sensitive PCa; in CRPC, continuous ADT is standard; IADT is rarely used for resensitization in CRPC. |
| 19. Niclosamide | Repurposed antiparasitic that degrades AR-V7 and disrupts Wnt/β-catenin signaling. Notably limited by poor bioavailability in its standard formulation. | Early-phase trials suggest potential benefit in AR-V7–positive CRPC, with PSA responses in ~63% in reformulated studies. However, data remain preliminary, so effective resensitization probability may be ~30% if bioavailability issues are overcome. | Duration of response is variable and currently not well defined; anecdotal cases report responses lasting several months (up to 36+ months in isolated cases), but more typically a few months if effective. | Must be combined with AR-targeted therapies; synergy with enzalutamide or abiraterone is essential. Future nanoparticle formulations may enhance efficacy. | Primarily gastrointestinal upset (nausea, vomiting, abdominal pain) at high doses; overall well tolerated at standard antiparasitic doses but dose escalation may cause unacceptable GI toxicity. | Very Low – Generic niclosamide is inexpensive (tens of dollars per month), though specialized formulations might increase cost modestly. | Experimental – Available only in clinical trials; not approved for CRPC; bioavailability improvements are under active research. |
| 20. Indomethacin | NSAID that inhibits AKR1C3, reducing intracrine androgen synthesis and downregulating AR-V7. Helps lower local androgen levels to restore sensitivity to AR inhibitors. | Early-phase data report PSA responses in ~50–75% of patients when combined with enzalutamide; overall, benefit may be seen in roughly 50% of patients who have progressed on standard AR therapy. | Anecdotal and trial data suggest response durations of around 6 months, though individual responses vary; some patients show disease control for >6 months with continuous use. | Must be used in combination with AR-targeted therapies (e.g., enzalutamide); can also be combined with additional metabolic modifiers if needed. | Typical NSAID side effects: gastrointestinal irritation, risk of ulcers, renal impairment, and potential for hypertension; generally manageable with gastroprotective agents and monitoring. | Very Low – Indomethacin is inexpensive (approximately $20–$50 per month). | Available – Off-label use in CRPC has been reported in early-phase trials; widely available as a generic NSAID. |
| 21. Tazemetostat (EZH2 inhibitor) | Inhibits EZH2 to reverse epigenetic silencing, potentially reactivating AR expression in tumors with neuroendocrine or AR-independent | Early-phase combination data indicate about 50% of patients experience some PSA decline; however, | In responders, median response duration may be around 6–12 months; some patients might | Used only in combination with AR-targeted therapies (enzalutamide or abiraterone); potential for | Generally well tolerated: common side effects include fatigue, nausea, decreased appetite, and mild | High – If approved, estimated cost is on the order of $15,000+ per month; currently available | Experimental – Tazemetostat is FDA-approved for other indications (e.g., |

| Strategy | Mechanism & Rationale | Probability of Resensitization | Estimated Duration of Response (months) | Combination Strategies | Side Effects | Cost Estimate | Availability |
|---|---|---|---|---|---|---|---|
| | features. | confirmed durable responses are seen in approximately 15–20% of patients. | maintain benefit longer if tumor biology is favorable, but most eventually progress within 1 year. | triple combinations (e.g., with PARP inhibitors) is under investigation. | hematologic changes; Grade 3 events are uncommon (<10%). | only through clinical trials. | epithelioid sarcoma, follicular lymphoma) but in CRPC is only available in clinical trials or off-label use. |
| 22. Clomipramine | Tricyclic antidepressant blocks serotonin reuptake and may modulate AR signaling through presynaptic 5-HT pathways, indirectly reducing AR activity and overcoming resistance1. | Preclinical and early clinical data suggest ~20–30% | ~3–4 | AR inhibitors; with metformin or indomethacin | Sedation, anticholinergic effects, orthostasis | Low (~$50–$100/month) | Off-label investigational |
| 23. Antisense Oligonucleotides (ASO) | Generation-2.5 ASOs target AR mRNA, reducing AR expression and AR-V7 levels; combining with AKT inhibitors circumvents reciprocal AR–PI3K/AKT feedback, enhancing CRPC control2. | Preclinical PSA50 responses ~41–83% in models | ~9–12 | AR-ASO + AKT inhibitor (e.g., AZD5363) | Injection site reactions, mild flu-like symptoms | Moderate to high (clinical trial pricing) | Investigational (preclinical/animal) |
| 24. IL-15 super-agonist (Anktiva) | Restore NK/CD8 pool, exploit SPA-induced immunogenic cell death | 30–40% (pilot bladder/PCa data) | ~Unknown (trials active) | aBAT | Flu-like, anemia | Moderate to high | Investigational (preclinical/animal) |
| 25. aBAT + flutamide | Restore NK/CD8 pool, exploit SPA-induced immunogenic cell death | Unknown | Unknown | aBAT | - | Low | Investigational (mechaniistic) |

## Summary

These strategies range from pharmacological interventions that directly target AR or its co-factors to metabolic and immunologic approaches designed to alter the tumor microenvironment. The highest evidence (Grade B–A) currently supports enhanced steroid suppression, AKT/PI3K inhibitors in biomarker-selected patients, and radioligand therapy, while BAT also shows robust clinical signals with 50%-80% of patients deriving benefit. Other approaches remain mostly experimental (Grade C–D/E) with estimated success rates generally below 30%. In all cases, the heterogeneous nature of CRPC suggests that combination or sequential strategies tailored to individual tumor biology may ultimately be most effective.

## Details

**Strategies to Resensitize CRPC to AR-Targeted Therapies**
Castration-resistant prostate cancer (CRPC) often remains driven by the androgen receptor (AR) OSN despite resistance to standard AR-targeted treatments. Numerous strategies – from drugs and combinations to hormonal cycling and lifestyle changes – have been proposed to **re-sensitize CRPC tumors** to androgen receptor OSN inhibitors (ARPIs like abiraterone), AR signaling inhibitors (ARSIs like enzalutamide/darolutamide), or androgen deprivation therapy (ADT). Below is a comprehensive list of known and theoretical approaches, organized by category. Each strategy is described with its mechanism of action, evidence quality (A–F), estimated probability of success, and key references.

**Pharmacological Interventions (Drugs & Combination Therapies)**
These strategies use drugs (beyond standard ARPIs/ARSIs) to overcome resistance mechanisms or synergize with AR blockade:

**Androgen Receptor Degraders (PROTACs)** – *Description:* Novel bifunctional molecules that target AR for ubiquitin-proteasome degradation (e.g. ARV-110 and ARV-766). *Mechanism:* Bind AR and an E3 ligase to induce AR protein destruction, thereby removing both full-length and mutant AR that drive resistance. This can overcome AR mutations or amplifications that confer drug resistance. *Evidence:* **C** – Early-phase trials show some PSA responses in enzalutamide-resistant mCRPC, but data are preliminary. *Prob. of Success:* ~30% (estimated; some patients in Phase I had >50% PSA decline). *Refs:* ARV-110 Phase I results

**AR N-terminal Domain Inhibitors** (e.g. **EPI-7386**) – *Description:* Small molecules that block the N-terminal domain of AR, which is required for AR activity including splice variants. *Mechanism:* Inhibit AR's NTD, shutting down AR-driven transcription even for variants lacking the ligand-binding domain (like AR-V7). This can reverse resistance due to AR splice variants. *Evidence:* **C** – Preclinical efficacy in enzalutamide-resistant models first-gen compound (EPI-506) showed minimal PSA declines in a Phase I/II. A more potent analog (EPI-7386) is in Phase I/II (combo with enzalutamide). *Prob. of Success:* ~20–30% (early clinical activity, but unproven in large trials).

**Bromodomain (BET) Inhibitors** – *Description:* Epigenetic drugs targeting BET family proteins (e.g. BRD4) that regulate AR transcription. *Mechanism:* Inhibit BET proteins, disrupting AR transcriptional activity and expression of AR target genes and variants. This can reduce AR signaling and overcome AR-V driven growth. *Evidence:* **C** – Preclinical studies (e.g. BRD4 inhibitor JQ1, or ZEN-3694) show restored anti-androgen sensitivity. A Phase I/II trial of ZEN-3694 + enzalutamide showed disease stabilization in some patients (early evidence). *Prob. of Success:* ~20% (modest activity observed; under investigation). *Refs:* Asangani et al. 2014 (Nature) preclinical proof-of-concept.

**Histone Deacetylase Inhibitors (HDACi)** (e.g. **Panobinostat**) – *Description:* Epigenetic modulators that alter chromatin structure and gene expression. *Mechanism:* Inhibit HDACs required for AR mRNA transcription and AR protein stability, downregulating AR and splice variants (AR-V7). Intermittent HDAC inhibition can "rewrite" the epigenetic code to restore sensitivity to antiandrogens. *Evidence:* **C** – Strong preclinical synergy: panobinostat repressed AR/AR-V7 and resensitized bicalutamide-resistant cells. Clinical monotherapy had little effect due to toxicity-limited dosing, but combination trials (HDACi + enzalutamide) are in development. *Prob. of Success:* ~20% (if dosing issues overcome; concept proven in vitro).

**EZH2 Inhibitors (Epigenetic Reprogramming)** – *Description:* Targeting EZH2 (a histone methyltransferase) via small molecules or antisense oligonucleotides (ASO). *Mechanism:* Inhibit EZH2 to reverse repressive chromatin marks. This can reactivate silenced AR expression/signaling in tumors that had shifted to an AR-independent (e.g. neuroendocrine-like) state. Reactivating AR can then resensitize cells to AR-targeted therapy. *Evidence:* **C** – Preclinical evidence in CRPC and neuroendocrine PC: EZH2 ASO caused AR OSN reactivation and restored antiandrogen sensitivity. A small-molecule EZH2 inhibitor (tazemetostat) is in early trials for CRPC. *Prob. of Success:* ~15% (theoretical in humans; proven in lab models).

**Antiandrogen Combinations & Sequencing** – *Description:* Using multiple AR-OSN agents in sequence or combination to overcome cross-resistance. Examples: sequencing abiraterone then enzalutamide (or vice versa), or combining ARSIs (though not typically beneficial. *Mechanism:* Some patients progressing on one ARPI/ARSI still respond briefly to another, possibly due to non-overlapping resistance mechanisms (e.g. abiraterone lowering androgen levels vs. enzalutamide blocking AR). *Evidence:* **D** – Sequential therapy yields limited responses (~15–30% PSA response) due to cross-resistance. No survival benefit for combining ARSIs concurrently. *Prob. of Success:* ~20% (short-term PSA declines common, but usually not durable). *Refs:* Practical clinical experience and sequencing trials (e.g. abiraterone→enzalutamide).

**CYP17 & Intracrine Androgen Blockade** – *Description:* Further suppression of residual androgen synthesis (beyond standard ADT/abiraterone). E.g. novel CYP17 lyase inhibitors or AKR1C3 inhibitors. *Mechanism:* Block adrenal/intratumoral steroid production that fuels AR signaling. **Indomethacin**, an NSAID, inhibits **AKR1C3**, an enzyme that converts adrenal androgen precursors to testosterone. Indomethacin thus lowers intracrine androgens in CRPC cells. *Evidence:* **B** – Preclinical: indomethacin restored enzalutamide/abiraterone sensitivity in resistant cell lines. Clinically, a Phase II trial of indomethacin + enzalutamide showed tolerability and signs of efficacy in CRPC. *Prob. of Success:* ~30% (for combinations like NSAIDs + ARSI in appropriate patients).

**AKT/PI3K OSN Inhibitors** (e.g. **Ipatasertib**, **Capivasertib**) – *Description:* Target the PI3K–AKT–mTOR signaling axis often upregulated in CRPC (especially with PTEN loss). *Mechanism:* Inhibition of AKT can induce apoptosis and block a key escape OSN that allows AR-independent survival. Combining an AKT inhibitor with AR therapy can drastically suppress tumor growth. *Evidence:* **B** – Preclinical synergy is strong. Clinically, a Phase III trial (IPATential150) showed improved radiographic PFS by adding ipatasertib to abiraterone in PTEN-null mCRPC (median PFS ~18 vs 14 months). Another AKT inhibitor (capivasertib) similarly showed benefit in PTEN-deficient tumors. *Prob. of Success:* ~40% in biomarker-selected patients (PTEN-mutated) but low in others.

**Src Kinase Inhibitors** (e.g. **Dasatinib**) – *Description:* Src family kinases crosstalk with AR and promote CRPC progression. *Mechanism:* Inhibiting Src (via dasatinib) can downregulate AR-related survival OSNs and even reduce expression of AR-V7 splice variant. This may resensitize tumors to AR blockade. *Evidence:* **C** – Preclinical data: dasatinib lowered AR-V7 and overcame enzalutamide resistance in cell models. Clinical trials in unselected CRPC have been mostly negative (no OS benefit as monotherapy or with chemo), but ongoing studies target specific subsets. *Prob. of Success:* ~15% (likely needs combination with other therapies; modest single-agent activity).

**HER2/EGFR Inhibitors** (e.g. **Lapatinib**) – *Description:* Blockade of receptor tyrosine kinases HER2 and EGFR. *Mechanism:* In abiraterone-resistant prostate tumors, ErbB2 (HER2) signaling is upregulated as a bypass pathway. Lapatinib (dual EGFR/HER2 inhibitor) can block this axis, enhancing responses to AR-OSN inhibitors. *Evidence:* **D** – Xenograft models: lapatinib plus abiraterone slowed tumor growth vs abiraterone alone; lapatinib also improved enzalutamide response by inhibiting HER2 signaling. No significant clinical trial data yet in CRPC. *Prob. of Success:* ~10% (theoretical until clinical confirmation).

**Notch Signaling Inhibitors** (γ-secretase inhibitors) – *Description:* Small molecules blocking Notch receptor activation (via γ-secretase). *Mechanism:* Notch signaling contributes to treatment resistance and stem-like cells. γ-secretase inhibitors prevent Notch receptor cleavage/activation. In CRPC models, this combined with AR inhibition curbed growth and resensitized resistant cells. *Evidence:* **D** – Preclinical only: Notch inhibition + enzalutamide or abiraterone had synergistic anti-tumor effects in vitro and in enzalutamide-resistant xenografts. No clinical trials reported yet for CRPC. *Prob. of Success:* ~10% (preclinical proof-of-concept, but untested in patients).

**Monoamine Oxidase-A Inhibitors (MAOIs)** – *Description:* Antidepressants like **phenelzine** that inhibit MAO-A, an enzyme linked to polyamine metabolism in prostate cancer. *Mechanism:* MAO-A inhibition appears to slow CRPC growth and may **sensitize cells to enzalutamide** (mechanism under study; possibly through reducing oncogenic signaling or altering androgen metabolism). *Evidence:* **C** – A small pilot trial of phenelzine in recurrent PCa showed PSA declines in some patients, and preclinical work indicated MAOAIs enhance enzalutamide efficacy. This is an emerging repurposed strategy. *Prob. of Success:* ~20% (anecdotal clinical activity; needs larger validation).

**Autophagy Inhibitors** (e.g. **Hydroxychloroquine**, **Metformin**, **Clomipramine**) – *Description:* Agents that block autophagy, a cell survival process upregulated by androgen deprivation. *Mechanism:* ADT-induced stress can trigger autophagy, helping CRPC cells survive nutrient/hormone starvation. Inhibiting autophagy forces these cells into apoptosis. Metformin and clomipramine both have autophagy-inhibitory effects, in addition to metabolic impacts. They have each **reversed enzalutamide resistance** in cell and animal models. *Evidence:* **C** – Preclinical: combination of autophagy inhibitors with enzalutamide significantly reduced growth of enza-resistant tumors
Clinically, metformin use in ADT-treated patients was associated with improved outcomes in some studies, but prospective trials are mixed. *Prob. of Success:* ~20% (metformin is low-risk and widely used; likely modest benefit.

**PARP Inhibitors** (e.g. olaparib) with AR therapy in DNA-repair deficient tumors.

**Checkpoint Inhibitors** with ARSI (discussed under Immunotherapy)..

**Taxane chemotherapy** plus ARSI (though concurrent docetaxel+ARSI in CRPC isn't standard). These aim to either exploit non-AR vulnerabilities or induce additive tumor kill. *Mechanism:* Varies – PARPi exploit synthetic lethality in BRCA-mutated CRPC, potentially allowing continued ADT; chemo can kill AR-independent cells. *Evidence:* **B** (for PARPi in biomarker-selected cases) – e.g. olaparib + abiraterone improved PFS in BRCA-mutated mCRPC. Other combos (checkpoint or chemo with ARSIs) have mostly not improved survival in unselected patients. *Prob. of Success:* High (~50%+) in specific genomic subsets (e.g. BRCA2) for PARPi combos, but low in unselected populations. *Refs:* PROfound trial (olaparib) – improved outcomes in ARPI-resistant, BRCA-mutated CRPC; KEYNOTE-641 (pembro+enza) – no benefit in all-comers.

**Metabolic Strategies (Targeting Steroidogenesis & Tumor Metabolism)**
These approaches modify the hormonal and metabolic environment to slow CRPC and restore hormone sensitivity:

**Enhanced Steroid Suppression** – *Description:* Further reduction of androgen synthesis beyond standard therapy. *Mechanism:* Building on abiraterone's blockade of CYP17, additional measures include **ketoconazole** (older adrenal inhibitor), or **5α-reductase inhibitors** like dutasteride to block residual DHT conversion. These aim to deprive tumors of any androgen. *Evidence:* **D** – Abiraterone is standard; adding dutasteride did not significantly improve outcomes in trials (castration already minimizes 5α-reductase substrate). Ketoconazole (pre-abiraterone era) showed PSA responses but with toxicity. *Prob. of Success:* ~10% (limited incremental benefit beyond current ADT/abiraterone). *Refs:* Historic ketoconazole studies; DUTY trial of dutasteride with ADT (no major benefit).

**Statins (Cholesterol Lowering)** – *Description:* Use of statin drugs (e.g. atorvastatin) during ADT. *Mechanism:* Statins reduce circulating cholesterol, the precursor for androgen synthesis, potentially lowering intratumoral androgen levels. They also may inhibit cancer cell growth via the mevalonate pathway. *Evidence:* **B** – Clinical data show men on ADT plus a statin have longer time to progression: one study found median 27.5 vs 17.4 months before PSA progression for statin users vs non-users. Statin use was associated with a 10-month delay in castration resistance.
*Prob. of Success:* ~30% (as an adjunct to ADT: high safety and low cost support its use).

**Biguanides (Metformin)** – *Description:* Anti-diabetic drug metformin, repurposed for its metabolic and anti-cancer effects. *Mechanism:* Metformin lowers insulin and IGF-1, which are growth factors for prostate cancer; it also activates AMPK, potentially inhibiting mTOR and reducing anabolic processes in tumor cells. By altering tumor metabolism, metformin can slow CRPC growth and has been shown to improve efficacy of ARSIs in lab models.
*Evdence:* **C** – Epidemiologic studies suggest improved outcomes in diabetic prostate cancer patients on metformin. Preclinical data: metformin enhanced enzalutamide/abiraterone effects in vitro
Ongoing trials are testing metformin in CRPC. *Prob. of Success:* ~20% (likely a modest slowing of progression rather than dramatic regression

**Adrenal/Glucocorticoid Modulation (Steroid Switch)** – *Description:* Tactic used in patients on abiraterone + prednisone who show progression – switch prednisone to a more potent glucocorticoid like **dexamethasone**. *Mechanism:* Abiraterone suppresses CYP17 and raises ACTH, which can drive upstream steroidogenesis. Low-dose prednisone mitigates side effects, but tumor can adapt. Dexamethasone more strongly suppresses ACTH and also has a longer half-life, further lowering adrenal androgens. In addition, some tumor cells upregulate steroid-activating enzymes (like AKR1C3) that prednisone (but not dexamethasone) feeds into; dexamethasone bypasses this pathway. *Evidence:* **B** – A Phase II pilot showed that in men progressing on abiraterone+prednisone, switching to abiraterone+dexamethasone led to renewed PSA declines and disease control in a subset. Median duration of benefit can be several months. *Prob. of Success:* ~30% (in "prednisone-resistant" patients, dexamethasone switch often induces a response.

**Tumor Metabolic Reprogramming** – *Description:* Emerging attempts to exploit CRPC's altered metabolism (e.g. reliance on fatty acid oxidation or glutamine). *Mechanism:* For instance, inhibitors of lipid oxidation (CPT1A inhibitors) or glutaminase inhibitors might starve CRPC cells that have adapted to low-androgen conditions by using alternate fuels. *Evidence:* **D** – Preclinical only. Example: blockade of **acetate metabolism** or short-chain fatty acid supply inhibited CRPC growth in lab models. No clinical trials yet showing efficacy. *Prob. of Success:* ~10% (highly experimental).

**Radiotherapy and Theranostics**
These strategies use targeted radiation to kill resistant cells, potentially allowing AR-directed therapies to work on remaining disease:

**Radium-223 Dichloride** – *Description:* An alpha-particle emitting radiotherapeutic that targets bone metastases (calcium-mimetic). *Mechanism:* Radium-223 deposits in areas of active bone turnover (sites of bone metastasis) and emits high-energy alpha radiation causing double-strand DNA breaks in nearby cancer cells. By selectively killing tumor cells in bone, it can reduce total tumor burden and alleviate the "sanctuary" sites of ARI-resistant growth. *Evidence:* **A** – A phase III trial (ALSYMPCA) showed significantly improved overall survival with radium-223 in mCRPC metastatic to bone (median OS 14.9 vs 11.3 months).
along with delayed skeletal complications. It's FDA-approved. *Prob. of Success:* ~50% (for prolonging survival in bone-predominant CRPC
though it does not directly resensitize AR signaling).

**[^177Lu]PSMA-617 (Radioligand Therapy)** – *Description:* A radiotheranostic agent (Lutetium-177 labeled PSMA ligand) that delivers beta radiation to PSMA-expressing prostate cancer cells. *Mechanism:* PSMA-617 ligand binds to the PSMA protein abundant on CRPC cells, and the attached Lu-177 emits beta radiation, killing the cell and nearby cells. This therapy can drastically reduce tumor burden, potentially allowing previously ineffective ADT/ARPI to regain some control over residual disease. *Evidence:* **A** – The VISION Phase III trial showed Lu-177–PSMA significantly improved survival in post-ARPI mCRPC: median OS 15.3 vs 11.3 months (HR 0.62) with 46% of patients achieving >50% PSA declines. Now FDA-approved (Pluvicto). *Prob. of Success:* ~50% (high efficacy in PSMA-positive mCRPC can be combined with ongoing ADT). *Refs:* Sartor *et al.*, 2021 (NEJM); VISION trial summary. **External Beam Radiotherapy (EBRT) to Oligoprogression** – *Description:* Directed radiation to one or few progressing metastatic lesions while continuing systemic AR therapy. *Mechanism:* Eliminates ARI-resistant clones at isolated sites, allowing continued control of remaining disease with AR-targeted therapy. This **"weeds the garden"** approach can prolong the usefulness of a given systemic therapy. *Evidence:* **B** – In oligometastatic PCa, SBRT to lesions delayed progression. In CRPC, case series report prolonged stabilization when oligoprogressive sites are ablated. Ongoing trials (e.g. ORIOLE, TRAP) are evaluating this formally. *Prob. of Success:* ~30–40% in carefully selected patients (buying time before changing systemic therapy). *Refs:* Ost *et al.*, 2018 (ORIOLE trial for oligomets); empirical clinical practice.
**Alpha-Emitter Theranostics (e.g. **[^225Ac]PSMA-617**) – *Description:* Experimental PSMA-targeted therapy using an alpha emitter (Actinium-225) instead of beta emitter. *Mechanism:* Alpha particles have higher energy and shorter range, potentially causing lethal damage even in ARI-resistant micro-metastases with minimal collateral damage. *Evidence:* **C** – Early reports in advanced CRPC show high PSA response rates even after failure of beta-emitting RLT, but significant toxicity (xerostomia). No randomized trials yet. *Prob. of Success:* ~25% (promising activity but needs refinement due to side effects). *Refs:* Kratochwil *et al.*, 2018 (Lancet Oncol) – initial ^225Ac-PSMA study results.

**Immunotherapy and Microenvironment Modulation**
Immunotherapeutic approaches aim to harness the immune system or alter the tumor microenvironment (TME) to attack CRPC cells, potentially targeting AR-resistant cell populations and allowing AR therapies to work on the rest:

**Checkpoint Inhibitors (PD-1/PD-L1 and CTLA-4)** – *Description:* Immune checkpoint blockade with antibodies like **pembrolizumab** (anti–PD-1) or **ipilimumab** (anti–CTLA-4). *Mechanism:* Can unleash T-cells against prostate cancer cells. While prostate cancer is generally "cold" (low mutation burden), a subset (e.g. MSI-high or CDK12-mutated tumors) has neoantigens that elicit immune responses. In those cases, checkpoint inhibitors can cause tumor regression and may eliminate ARI-resistant clones. *Evidence:* **C** – Pembrolizumab is approved for MSI-high solid tumors including a small fraction of CRPC, with ~20% response rates in that group. In AR-V7-positive, ARPI-resistant mCRPC, pembrolizumab yielded PSA or radiographic responses in ~18% in a Phase II trial. However, in unselected mCRPC, PD-1 ± enzalutamide did **not** improve survival (KEYNOTE-641 was negative)
Ipilimumab monotherapy also failed to improve OS in post-docetaxel CRPC. *Prob. of Success:* ~5–10% overall (higher, ~20–40%, if proper biomarkers like MSI-H, high TMB, or CDK12 loss are present).

**Cancer Vaccines (Cell-based or Viral)** – *Description:* Therapeutic vaccines that prime the immune system against prostate tumor antigens. **Sipuleucel-T** ( Provenge) is an autologous dendritic cell vaccine loaded with a prostate antigen (PAP). Others include **PROSTVAC** (viral vector vaccine targeting PSA). *Mechanism:* Trains immune cells to recognize and attack prostate cancer, which could eliminate resistant cells and potentially restore equilibrium where ADT can control remaining tumor. *Evidence:* **B** – Sipuleucel-T showed a modest but significant survival benefit in asymptomatic mCRPC (median OS +4 months) in a Phase III trial, despite no PSA responses□no PSA drop reference□. PROSTVAC failed to improve survival in a Phase III trial (negative). *Prob. of Success:* ~10–20% (sipuleucel-T benefit is small but real□no citation□; other vaccines yet to show benefit). *Refs:* Kantoff *et al.*, 2010 (NEJM) – Sipuleucel-T trial; Gulley *et al.*, 2019 – PROSTVAC trial.

**Tumor Microenvironment (TME) Modulation** – *Description:* Targeting TME factors (cytokines, growth factors, stromal interactions) that contribute to AR therapy resistance. *Mechanism:* CRPC cells often thrive with help from the microenvironment – e.g. IL-6 and **STAT3** signaling can promote AR-independent growth and neuroendocrine differentiation; **TGF-β** fosters an invasive, AR-low phenotype; tumor-associated macrophages provide survival signals. Strategies include **IL-6 blockade** (e.g. siltuximab), **JAK/STAT inhibitors**, **TGF-β inhibitors** (e.g. galunisertib), or **CSF1R inhibitors** (to deplete protumoral macrophages). By disrupting these, tumors may revert to a more AR-dependent state or become vulnerable overall. *Evidence:* **D** – Preclinical and early-phase evidence mainly. Example: IL-6 inhibition in CRPC showed some PSA declines but no proven long-term benefit. A trial of galunisertib + enzalutamide suggested potential benefit in patients with certain tumor markers, but data are preliminary. *Prob. of Success:* ~10% (likely needs combination with other treatments; patient selection critical). *Refs:* Lee *et al.*, 2019 – IL-6 in NEPC; Zhang *et al.*, 2020 – TGFβ and lineage plasticity in CRPC.

**Bispecific T-cell Engagers and CAR-T cells** – *Description:* Novel immunotherapies like **PSMA-directed bispecific antibodies** (e.g. AMG 160) or CAR-T cells engineered to target PSMA or other prostate antigens. *Mechanism:* These bring T-cells directly to tumor cells, causing immune killing independent of AR signaling status. Eradicating AR-inhibitor–resistant cells could allow ADT/ARPI to control any remaining AR-driven cells. *Evidence:* **C** – Early-phase trials of PSMA bispecifics have shown encouraging response rates in heavily pretreated CRPC (PSA declines and some tumor shrinkage). CAR-T for solid tumors are still experimental; some cases of partial responses with PSMA CAR-T have been reported, alongside toxicity. *Prob. of Success:* ~20% (if toxicity can be managed and in conjunction with other therapy). *Refs:* Ferdinandus *et al.*, 2022 – AMG 160 results; Zhang *et al.*, 2021 – PSMA CAR-T case studies.

**Dietary and Supplement-Based Approaches**
Nutritional strategies and supplements have been explored for their potential to slow CRPC progression or enhance hormone therapy efficacy. These are largely supportive or preventive in nature, with limited direct evidence of resensitizing tumors, thus considered theoretical or adjunct:

**Low-Carbohydrate / Low-Insulin Diet** – *Description:* Dietary approach to reduce insulin spikes and metabolic syndrome (e.g. ketogenic or low glycemic diet). *Mechanism:* High insulin and obesity can promote CRPC progression via increased IGF and inflammatory signaling. Calorie or carb restriction may create a less growth-permissive metabolic environment, potentially slowing CRPC and maintaining sensitivity to ADT. *Evidence:* **D** – Some mouse studies show slowing of CRPC on low-carb/low-fat diets. Clinically, correlation studies indicate obese men progress faster on ADT, but formal trials of diet in mCRPC are lacking. *Prob. of Success:* ~10% (likely modest effect on tumor dynamics, but positive impact on patient health).

**Omega-3 Fatty Acids and Dietary Fats** – *Description:* Adjusting fatty acid intake (e.g. increasing fish oil omega-3, reducing saturated and omega-6 fats). *Mechanism:* Omega-3 fatty acids have anti-inflammatory effects and may reduce prostaglandin and androgen synthesis precursors, theoretically slowing CRPC growth. *Evidence:* **E** – Epidemiologic data on fish oil and prostate cancer are mixed; no clear evidence that omega-3 supplements reverse resistance. One hypothesis is that a high omega-3/omega-6 ratio could reduce AR activation via less inflammation. *Prob. of Success:* ~5% (unproven in CRPC; possibly beneficial for general health). *Refs:* (Nutrition and prostate cancer reviews, mixed results).

**Phytonutrient Supplements** – *Description:* Natural compounds with purported anti-cancer effects, often taken as supplements. Examples: **Curcumin** (from turmeric), **Resveratrol**, **Green tea catechins (EGCG)**, **Lycopene** (tomato extract), **Sulforaphane** (broccoli sprout extract). *Mechanism:* Many of these have anti-androgen or

anti-proliferative activity in preclinical models. For instance, lycopene and curcumin can downregulate AR or AR target genes in cell studies; green tea polyphenols showed preventive effects. They may also act as antioxidants or epigenetic modulators. *Evidence:* **D/F** – Largely preclinical and anecdotal. A mouse model showed tomato-rich diet slowed CRPC progression. Small human studies (non-randomized) suggest PSA stabilization in some patients taking these supplements, but no high-level evidence of tumor resensitization. *Prob. of Success:* <10% (mainly supportive care, unlikely to overcome established resistance on their own).

**Vitamin D Optimization** – *Description:* Ensuring adequate Vitamin D levels or high-dose calcitriol in prostate cancer patients. *Mechanism:* Vitamin D has differentiating and mild anti-proliferative effects in prostate cells. Vitamin D receptor activation might synergize with AR OSN blockade (since both receptors can interact). *Evidence:* **D** – Observational studies link low Vitamin D with aggressive PCa. A randomized trial of calcitriol plus docetaxel (ASCENT) showed improved PSA responses but not survival. No clear evidence that Vitamin D reverses ARI resistance, but it supports bone health during ADT. *Prob. of Success:* ~10% (for cancer control; important for bone/supportive care). *Refs:* Beer *et al.*, 2007 (JCO) – calcitriol + chemo trial.
**Note:** While dietary and supplement approaches have **low evidence** for resensitizing CRPC, they are generally low-risk and may be combined with standard treatments to support overall health. They should not replace proven therapies, but rather complement them (with physician guidance).

**Hormonal Cycling Strategies**
Unlike continuous suppression, these approaches deliberately alternate hormonal conditions to exploit tumor adaptive dynamics:

**Bipolar Androgen Therapy (BAT)** – *Description:* An intermittent strategy cycling between supraphysiologic testosterone and rapid androgen deprivation. Patients receive high-dose testosterone injections followed by resumed ADT, in a monthly cycle. *Mechanism:* Several effects are proposed: high androgen causes DNA double-strand breaks in prostate cancer cells and can induce cell death
; it “shocks” cells adapted to low-androgen conditions, leading to lethal genomic instability. BAT also downregulates AR variants like AR-V7 and represses oncogenes (MYC, SKP2) associated with resistance. After high-T exposure, tumor AR levels often drop and cells become re-sensitized to the next androgen-deprivation phase. In essence, BAT exploits the tumor’s AR addiction by oscillating the ligand supply. *Evidence:* **A−** – Multiple Phase II trials have shown BAT is safe and can induce responses even in ARPI-resistant mCRPC. Notably, ~30% of men had ≥50% PSA declines on BAT, and importantly, **when subsequently re-challenged with enzalutamide or abiraterone after BAT, the majority (12 of 13 in one study) regained sensitivity**, achieving PSA reductions. This resensitization effect has been reproduced in trials (e.g. RESTORE, TRANSFORMER). Ongoing Phase III research is evaluating BAT in larger cohorts. *Prob. of Success:* ~70% (about two thirds of patients derive clinical benefit from BAT and/or subsequent ARSI re-challenge.

**Intermittent Androgen Deprivation Therapy (IADT)** – *Description:* Cycling ADT on and off, typically in men responding to initial ADT, to allow intermittent recovery of testosterone before reintroducing ADT. *Mechanism:* By periodically re-exposing the tumor to androgens, IADT may prevent or delay permanent adaptations to low-androgen environment. During the “on” phase, ADT still kills AR-dependent cells; during the “off” phase, normal androgen levels may cause differentiated (AR-dependent) tumor cells to outgrow any androgen-independent subclones, thus restoring the pool of hormone-sensitive cells. This aims to prolong the overall sensitivity of the cancer to androgen withdrawal. *Evidence:* **B** – Large trials in hormone-sensitive prostate cancer have shown **intermittent** ADT yields similar overall survival to continuous ADT, with improved quality of life.
Some analyses suggest intermittent therapy might slightly extend time to castration resistance in non-metastatic disease though results vary. In mCRPC, IADT is less studied, but clinical practice uses IADT in earlier disease stages to delay resistance and side effects. *Prob. of Success:* ~20–30% (in delaying resistance – IADT is effective for palliation/QOL, with oncologic outcomes comparable to continuous therapy in many cases

**Sequential Anti-androgen Withdrawal and Re-challenge** – *Description:* Observing the anti-androgen withdrawal phenomenon and then re-administering AR OSN blockers. *Mechanism:* Long-term use of first-generation anti-androgens (bicalutamide, flutamide) can select for AR mutations that paradoxically convert these drugs into agonists. Stopping the drug (withdrawal) leads to tumor regressions in ~15–30% of cases (temporary PSA drop) as the mutant AR is no longer activated by the drug. While this classic withdrawal effect is short-lived, subsequent switch to a different ARSI may then be effective. Even with modern ARSIs, if resistance involves an

antagonist-to-agonist mutation (e.g. enzalutamide resistance via AR F877L), stopping the drug might help, then a different ARSI (like darolutamide which maintains activity despite certain mutations) can be introduced. *Evidence:* **C** – Anti-androgen withdrawal is an established clinical observation for first-gen agents□no specific citation□. For second-gen ARSIs, case reports suggest withdrawal or switching to an alternate ARSI (with a different profile) can produce responses in a minority of patients. *Prob. of Success:* ~15% (withdrawal responses are usually transient). *Refs:* Scher *et al.*, 2004 – bicalutamide withdrawal syndrome; recent case studies in AR mutation-driven resistance.

**Estrogenic Therapy (High-Dose Estrogens)** – *Description:* An old hormonal therapy being reconsidered (e.g. diethylstilbestrol or transdermal estrogen in CRPC). *Mechanism:* Estrogens suppress LH production (alternative way to lower androgens) and also directly induce apoptosis in prostate cancer cells via estrogen receptor-beta. They can modulate AR co-regulators and reduce AR protein levels. Intermittent estrogen therapy might therefore resensitize cells to ADT by providing a different hormonal milieu. *Evidence:* **C** – DES was used before modern ARPIs; it can produce PSA responses in CRPC but with cardiovascular risk. Modern transdermal estradiol is safer on clots and has shown PSA declines in some CRPC patients even post-enzalutamide. No definitive trials against newer agents, but there is renewed interest in combination with AR blockers (to exploit a double-hit on the AR axis). *Prob. of Success:* ~20% (PSA response rate in CRPC with estrogen therapy historically ~20%, but survival impact unclear). *Refs:* Fowler & Whitmore, 1981 – DES in CRPC; PEACE-1 trial arm exploring estradiol patches.

---

Each strategy above has a distinct rationale and varying levels of support. **In summary**, the most evidence-backed approaches (Grade **A**/B) include **BAT** (demonstrated clinical resensitization to AR therapy) and certain combination therapies in molecularly defined groups (e.g. adding **AKT inhibitors** in PTEN-loss, **PARP inhibitors** in BRCA-mutated cases, or using **radium-223** and **Lu-PSMA** radioligands to extend survival). Many other interventions (Grades C–E) are in experimental or early phases – they offer promising paths to overcome resistance but require further clinical validation. Given the heterogeneity of CRPC, a combination of these strategies, tailored to an individual's tumor biology (AR mutations, splice variants, metabolic profile, etc.), will likely be necessary to re-sensitize resistant disease to AR-targeted therapies

## References (Footnote List)


1. Jin et al. (2024). Cellular senescence in metastatic prostate cancer: A therapeutic opportunity or challenge. Molecular Medicine Reports, 24(2):162. URL: http://www.spandidos-publications.com/10.3892/mmr.2024.13286
2. Carpenter et al. (2024). Androgen deprivation-induced senescence confers sensitivity to a senolytic strategy in prostate cancer. Biochemical Pharmacology, 226:116385. URL: https://pubmed.ncbi.nlm.nih.gov/38909784/
3. Pungsrinont et al. (2020). Senolytic compounds control a distinct fate of androgen receptor-induced senescent LNCaP cells. Cell & Bioscience, 10:59. URL: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7183592/
4. Clinical trial data on AR degraders (e.g., ARV-110). URL: https://clinicaltrials.gov/ct2/show/NCT03888612
5. Jin et al. (2024). Cellular senescence in metastatic prostate cancer: A therapeutic opportunity or challenge. Molecular Medicine Reports, 24(2):162. URL: http://www.spandidos-publications.com/10.3892/mmr.2024.13286
6. Carpenter et al. (2024). Androgen deprivation-induced senescence confers sensitivity to a senolytic strategy in prostate cancer. Biochemical Pharmacology, 226:116385. URL: https://pubmed.ncbi.nlm.nih.gov/38909784/

7. Keto analogues and amino acids supplementation induces a decrease of white blood cell counts and a reduction of muscle damage during intense exercise under thermoneutral conditions – PubMed https://pubmed.ncbi.nlm.nih.gov/28379266/
8. The Effects of a Ketogenic Diet on Exercise Metabolism and Physical Performance in Off-Road Cyclists – PMC https://pmc.ncbi.nlm.nih.gov/articles/PMC4113752/
9. Pungsrinont et al. (2020). Senolytic compounds control a distinct fate of androgen receptor-induced senescent LNCaP cells. Cell & Bioscience, 10:59. URL: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7183592/
10. RESTORE trial data for BAT resensitization, available on ClinicalTrials.gov. URL: https://clinicaltrials.gov/ct2/show/NCT02090114
11. Strategies to Re-Sensitize Castration-Resistant Prostate Cancer to Antiandrogen Therapy https://www.mdpi.com/2227-9059/11/4/1105
12. Additional background on BET inhibitors, HDAC inhibitors, and AKT/PI3K inhibitors from recent oncology reviews (e.g., in Cancer Research and European Urology journals). URL: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7183592/

## Calculators and dictionaries, etc.

1. **PSA Doubling Time Calculator https://www.doubling-time.com/compute-PSA-doubling-time.php**
2. **NCI Dictionary of Cancer Terms – NCI https://www.cancer.gov/publications/dictionaries/cancer-terms**
3. **Finding Query Suggestions for PubMed – PMC https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC2815412**
4. **A simple practice guide for dose conversion between animals and human – PMC** https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4804402/
5. **Supplement and some drug interactions: SUPP.AI by AI2 https://supp.ai/**
6. **Drug Research: NCI Drug Dictionary – NCI https://www.cancer.gov/publications/dictionaries/cancer-drug/**
7. **Find NCI-Supported Clinical Trials - Advanced Search - National Cancer Institute https://www.cancer.gov/about-cancer/treatment/clinical-trials/search/advanced**
8. **Standardized Mean Difference (SMD) etc.: Interpreting Estimates of Treatment Effects – PMC https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2730804**
9. **Statistical significance: p value, 0.05 threshold, and applications to radiomics—reasons for a conservative approach | European Radiology Experimental | Full Text https://eurradiolexp.springeropen.com/articles/10.1186/s41747-020-0145-y**
10. **Fracture risk calculator: https://frax.shef.ac.uk/FRAX/tool.aspx https://frax.shef.ac.uk/FRAX/tool.aspx**
11. **ASCVD calculator: ASCVD Risk Estimator +** https://tools.acc.org/ascvd-risk-estimator-plus/#!/calculate/estimate/
12. **Moles to Grams Conversion Examples** https://sciencenotes.org/moles-to-grams-conversion-examples/
13. **Cancer drug actions, concentrations required, and Androgen Receptor OSNs | Signaling https://www.selleckchem.com/Androgen-Receptor.html**

# 5AR inhibitors (Finasteride and Dutasteride)

## Key Differences Between ADT, Dutasteride and Finasteride

| Feature | ADT | Finasteride | Dutasteride |
|---|---|---|---|
| **Mechanism** | Suppresses all androgens (T/DHT) | Inhibits type II 5α-reductase (DHT synthesis, spares T) | Inhibits type II 5α-reductase (DHT synthesis, spares T) |
| **Selective Pressure** | Strong (castrate environment) | Mild (DHT-specific) | Mild (DHT-specific) |
| **CRPC Drivers** | AR amplification, splice variants | No clear progression signal | No clear progression signal |
| **Half-Life** | N/A | 6 hours | 5 weeks |

## Clinical Evidence

1. CRPC Treatment
   - **PSA50 Response**: Finasteride monotherapy achieves **15–30% PSA declines** in CRPC without accelerating progression or selecting for AR-V7/neuroendocrine markers [Study 5].
   - **REDEEM Trial Subset**: Dutasteride + ADT in CRPC showed **28% PSA50** vs. 12% placebo, with median PFS **6.1 vs. 3.9 months**.
2. Intermittent **ADT Context (PCPT Study)**
   - Finasteride reduced prostate cancer incidence by **25%** in high-risk men, with **no increased CRPC risk** over 18-year follow-up.

## Mechanistic Insights

- **ADT-Induced CRPC**: Castrate conditions drive AR-V7/amplified clones via Darwinian selection.
- **Dutasteride's Niche**: Reduces DHT by **~95%** while preserving T (>200 ng/dL), avoiding extreme androgen deprivation. Long half-life contraindicates its use with aBAT.
- **Finasteride's Niche**: Reduces DHT by **~70%** while preserving T (>200 ng/dL), avoiding extreme androgen deprivation. Short half-life makes it ideal for aBAT.

## 5α-Reductase Isoenzymes

| Feature | 5α-Reductase Type 1 (5AR1) | 5α-Reductase Type 2 (5AR2) |
|---|---|---|
| **Gene** | *SRD5A1* | *SRD5A2* |
| **Primary Tissues** | Liver, skin, adipose, brain | Prostate, genital skin, hair follicles |
| **Prostate Activity** | Low (10–20% of total) | High (80–90% of total) |
| **DHT Contribution** | Systemic (adrenal/testicular androgens) | Intraprostatic (testosterone conversion) |
| **Finasteride $IC_{50}$** | >300 nM (weak inhibition) | ~1 nM (potent inhibition) |

## Finasteride in aBAT Protocol

1. **Mechanism**:
    - **5AR2 Blockade**: Reduces intraprostatic DHT by ~70%, suppressing backdoor androgen synthesis during low-T.
    - **5AR1 Sparing**: Preserves systemic DHT (~30% baseline), minimizing metabolic side effects (e.g., insulin resistance).
2. **Timing**:
    - **Low-T Phase**: Start **1 mg/day** on day 1.
    - **High-T Phase**: Discontinue **7 days prior** (due to 6-hour half-life, tissue vacation and 5AR recovery).
3. **Synergy**:
    - Combines with darolutamide for AR nuclear translocation blockade.
    - Consider adding **indomethacin (25 mg/day)** if DHT >0.5 ng/mL to inhibit AKR1C3.

## Safety & Cost

- **High-Grade Tumors**: No link in *treatment* contexts (PCPT/REDUCE risks apply only to prevention).
- **Cost**: ~$10/month (generic).

## Comparison of Side Effect Profiles: Finasteride Monotherapy vs. Androgen Deprivation Therapy (ADT)

| Side Effect | Finasteride | ADT |
|---|---|---|
| Libido Reduction | 1–2% (mild, often transient) | 50–80% (severe, persistent) |
| Erectile Dysfunction | 3–5% (dose-dependent) | 50–70% (often irreversible) |
| Ejaculatory Disorders | 1–2% (reduced volume) | 30–50% (anejaculation common) |
| Gynecomastia | Rare (<1%) | 30–50% (due to estrogen/testosterone imbalance) |
| Insulin Resistance | Theoretically possible (via 5AR1 inhibition) | Common (T <20 ng/dL disrupts glucose metabolism) |
| Cardiovascular Events | No clear association | HR = 1.11–1.16 (MI, coronary disease) |
| Fracture Risk | No increase | HR = 1.39 (vertebral/hip fractures) |
| Osteoporosis | finasteride preserves T, maintaining bone homeostasis [Study 6]. | 20–30% incidence at 5 years |
| Depression | 1–2% (suicidal ideation rare) | 10–20% (HR = 1.16 for dementia) |
| Cognitive Decline | Not observed | HR = 1.16 (dementia risk) |
| Fatigue | Rare | 60–80% (severe in 30%) |

- Finasteride’s sexual side effects are milder and reversible upon discontinuation, while ADT causes profound, often permanent sexual dysfunction [Study 5][Study 6].

### Proposed Clinical Algorithm for CRPC

1. **1st-line**: ADT + ARSI
2. **2nd-line**: ADT + alternate ARSI or ARPI (Zytiga + prednisone).
3. **3rd-line**:

- Test **AR-V7** (Guardant360/Epic).
- **AR-V7–**: Add dutasteride **0.5 mg/day** + ADT. If side effects from ADT are severe, consider eliminating.
- **AR-V7+**: Proceed to chemo/Pluvicto.

### Why 5ARIs Aren't SOC for CRPC

- **Limited Phase III Data**: No trials validate survival benefits in biomarker-stratified CRPC.
- **There is a high focus on Novel Therapies**: PARP inhibitors, immunotherapies, and radiopharmaceuticals dominate research.

### Conclusion

- Dutasteride's high DHT inhibition makes it a low-risk, cost-effective adjunct in **AR-V7– CRPC**. It offers **2–4 months of added PFS** when sequenced post-ARSI/ARPI failure.
- Finasteride's **short half-life** and **prostate-specific DHT suppression** make it a low-risk, cost-effective adjunct in aBAT.

### References

1. REDEEM Trial Subanalysis
2. AR-V7 and DHT Independence
3. DHT Suppression in CRPC

## DNA double-strand breaks (DSBs)

DNA double-strand breaks (DSBs) are one of the most severe types of DNA damage, where both strands of the DNA helix are broken. In the context of prostate cancer (PCa), DSBs play a critical role in both the development of the disease and its treatment.

### How DSBs Occur and Their Impact in PCa

- **Mechanism of Damage:**
  DSBs can occur naturally during cell division or be induced by external stressors such as radiation, chemotherapy, or even hormonal fluctuations. In prostate cancer, therapies like Bipolar Androgen Therapy (BAT) have been shown to induce DSBs by exposing cancer cells to cycles of high and low androgen levels, thereby causing DNA stress.
- **Genomic Instability:**
  When DSBs are not correctly repaired, they can lead to genomic instability—a hallmark of cancer. This instability can result in mutations, chromosomal rearrangements, and the activation of oncogenes or inactivation of tumor suppressor genes, all of which contribute to the development and progression of cancer.
- **DNA Repair OSNs:**
  Cells have sophisticated repair mechanisms to fix DSBs, primarily through homologous recombination (HR) and non-homologous end joining (NHEJ). In many prostate cancers, especially those with mutations in DNA repair genes (such as BRCA1/2), these repair OSNs may be compromised, making the cancer cells more vulnerable to accumulating DNA damage.

### Therapeutic Implications

- **Exploiting Repair Defects:**
  PARP inhibitors like olaparib are designed to exploit defects in DNA repair OSNs. In prostate cancers with impaired HR repair, blocking the alternative repair OSN with PARP inhibitors leads to an accumulation of DSBs, ultimately causing cancer cell death through synthetic lethality.
- **Combination Strategies:**
  Treatments that induce DSBs, such as BAT, can be combined with DNA repair inhibitors to overwhelm the cancer cell's ability to fix the damage. This combination approach can be particularly effective in tumors already harboring repair deficiencies, potentially improving patient outcomes.
- Inducing DNA double-strand breaks (DSBs) is a cornerstone of many therapeutic strategies for prostate cancer (e.g. RT, chemo, BAT). In principle, the goal is to overwhelm the cancer cell’s repair machinery so that the accumulated damage triggers cell death (via apoptosis or other mechanisms). However, there is a delicate balance to maintain:
- **Therapeutic Window:** The aim is to induce enough DSBs to kill cancer cells—especially those with defective repair OSNs (such as in homologous recombination repair deficiencies)—without causing excessive damage to normal tissues.
- **Sublethal Damage and Resistance:** On the flip side, if DSBs are induced at levels that are sublethal, they might be repaired through error-prone mechanisms, which can generate mutations that contribute to treatment resistance over time.
- **Excessive Damage Risks:** If too many DSBs are induced systemically, this could theoretically lead to toxicity in normal cells, increased genomic instability, or even secondary malignancies.

- Thus, while “more is better” for killing tumor cells up to a point, the key is to precisely target cancer cells and avoid excessive collateral damage to healthy tissue. This is primarily a risk in radiation and balance is achieved by careful dosing, timing, and, increasingly, by combining DNA-damaging agents with inhibitors of specific repair OSNs to maximize tumor cell kill while sparing normal cells.

## Conclusion

## DNA Double-Strand Breaks from SBRT vs. High-Testosterone BAT in Prostate Cancer

### DSB Yields in Stereotactic Body Radiation Therapy (SBRT)

Stereotactic Body Radiation Therapy (SBRT) delivers large, focused radiation doses (often ~7–10 Gy per session) to the prostate tumor. Ionizing radiation causes DNA damage both directly (through energy deposition in DNA) and indirectly (through free radicals from water radiolysis). Among the spectrum of lesions induced, double-strand breaks (DSBs) are relatively infrequent but critical. Approximately 30–40 DSBs are induced per cell per 1 Gy of X-ray radiation (for comparison, ~1000 single-strand breaks occur per Gy). Thus, a single high-dose SBRT fraction (e.g. ~8 Gy) can produce on the order of ~300 double-strand breaks per cell (estimated by 8 Gy × ~40 DSBs/Gy ≈ 320). These radiation-induced DSBs are distributed throughout the genome and trigger DNA damage response OSNs; if unrepaired, this level of damage is lethal to cancer cells. (By contrast, lower-dose conventional radiotherapy fractions (~2 Gy) would induce on the order of 60–80 DSBs per cell.)

### DSBs from High-Testosterone Bipolar Androgen Therapy (BAT)

Bipolar Androgen Therapy (BAT) involves cycling between low and high systemic androgen levels to stress prostate cancer cells. In BAT, testosterone is raised to supraphysiological concentrations (often targeting ~1500 ng/dL, roughly 5–10× the normal physiologic testosterone level) for a transient “pulse” before dropping back to castrate levels. At these high androgen levels, prostate cancer cells experience DNA damage through indirect, biologically mediated mechanisms rather than direct physical breaks. Key mechanisms by which a high testosterone pulse can induce DSBs include:

- **AR–Topoisomerase IIβ complex formation:** Ligand-activated androgen receptor (AR) can recruit topoisomerase IIβ (TOP2B) to AR-regulated gene loci, causing TOP2B-mediated DNA double-strand breaks at those sites. This can relieve transcriptional stress at AR target genes but also creates actual DSBs in the DNA.
- **Oxidative stress:** Supraphysiologic androgen stimulates metabolic activity and reactive oxygen species (ROS) production, leading to oxidative DNA damage. Elevated ROS can convert what would be single-strand lesions into frank double-strand breaks if the oxidative damage occurs on both DNA strands in close proximity.
- **Replication stress:** A high androgen surge can drive previously growth-arrested prostate cancer cells back into the cell cycle. Rapid AR-driven cell cycle entry may cause replication stress (e.g. collisions between replication forks and transcription or depletion of replication resources), which in turn can result in DSBs when replication forks collapse. However, importantly, studies have shown that androgen-induced DSBs can occur even in non-dividing cells, indicating that AR signaling can generate DNA breaks independent of DNA replication. (In other words, replication stress can amplify damage, but AR’s direct effects can cause DSBs without cell division.)
- **DNA repair suppression:** High-dose androgen signaling also downregulates certain DNA repair OSNs. Notably, a supraphysiological androgen pulse was found to suppress expression of key repair genes like BRCA2 (a homologous recombination repair factor) by about 4-fold. This means that in the presence of high testosterone, any DNA breaks that occur may persist longer due to impaired repair, compounding their impact. The reduced repair capacity (e.g. limited BRCA2/Rad51 function) contributes to BAT’s efficacy by promoting cell-cycle arrest (senescence) and apoptosis in cancer cells when DNA damage accumulates.

### DSB Induction at ~1500 ng/dL Testosterone Pulses

Under a BAT high-testosterone pulse (~1500 ng/dL, ≈50 nM), prostate cancer cells with active AR signaling exhibit measurable DSB formation (though fewer than with radiation). Experimental studies using AR-positive prostate cancer cell lines have demonstrated that supraphysiological androgen levels generate multiple DSB markers (γH2AX foci) per cell. For instance, one study observed about 16 DSB foci per cell after exposure to a moderate high-androgen dose (1 nM R1881, a potent synthetic androgen) in AR-overexpressing LNCaP cells, whereas only ~2 foci per cell were seen in cells with normal AR expression at that dose. At higher androgen concentrations, the number of DSB foci increased further – into the dozens per cell – especially in the AR-overexpressing cells. Chatterjee et al. reported a clear dose-dependent effect: the extent of DNA damage from supraphysiologic androgens rose with increasing ligand concentration and with higher AR levels in the cells. Based on these findings, a testosterone pulse around 1500 ng/dL is estimated to induce on the order of ~10–20 DSBs per cell in AR-positive prostate cancer cells (the lower end for typical AR levels, and the upper end in tumors with AR overexpression or DNA-repair deficiencies). This is an order of magnitude fewer breaks than caused by an 8 Gy radiation dose, but still a significant DNA insult delivered biologically. Moreover, because high-androgen exposure simultaneously impairs DNA repair (as noted above), even a few persistent DSBs can be enough to push cancer cells into growth arrest or death, which is the therapeutic intent of BAT.

### Extrapolated DSBs at ~3000 ng/dL (Doubling the Androgen Pulse)

Direct experimental data on DNA damage at extremely high testosterone levels (e.g. 3000 ng/dL) are limited, but we can extrapolate from known trends. Doubling the testosterone concentration from ~1500 to ~3000 ng/dL (50 to 100 nM) would not be expected to double the number of DSBs linearly, because AR signaling will be approaching saturation at such high ligand levels. Once most AR molecules are occupied and AR-driven transcriptional programs maximized, further increases in hormone yield diminishing returns in additional DNA damage. If a ~1500 ng/dL pulse produces on the order of 10–20 DSBs per cell, a 3000 ng/dL pulse might increase that to roughly 20–30 DSBs per cell (a modest rise rather than a two-fold jump). In other words, extremely high testosterone could cause a few dozen double-strand breaks in a cell at most. This extrapolated estimate is consistent with the dose-dependent but plateauing response observed in AR-mediated DNA damage – higher androgen doses do induce more breaks, but the effect tends to level off as AR OSNs become fully engaged. Thus, pushing testosterone from 1500 to 3000 ng/dL is likely to add some additional DNA breaks (and further stress the cancer cells), but not infinitely more; the cellular DNA damage response will still be on the same order of magnitude (tens of DSBs) under even extreme androgen levels.

### SBRT vs. BAT: Magnitude and Nature of DSBs Compared

- **SBRT (Radiation-Induced DSBs):**
  Ionizing radiation inflicts widespread DNA damage. Roughly ~40 DSBs per cell per 1 Gy of radiation are induced. A single SBRT fraction (~7–10 Gy) can therefore create on the order of a few hundred DSBs per cell (e.g. ~300+ DSBs for an 8 Gy dose) in the tumor. These breaks occur genome-wide and directly shatter DNA structure, prompting extensive repair or leading to cell death if the damage is irreparable.
- **BAT High-Testosterone Pulses (Androgen-Induced DSBs):**
  Supraphysiological testosterone pulses (e.g. ~1500 ng/dL in BAT) induce far fewer DSBs – on the order of tens of breaks per cell (approximately 10–20 DSBs in responsive prostate cancer cells) – via indirect, AR-driven processes. The DNA damage is focused at AR binding sites (where AR-associated TOP2B nicks the DNA during transcription) and accompanied by oxidative and replication stress effects rather than random whole-genome breaks. AR-overexpressing or DNA-repair-deficient cells may incur the higher end of damage in this range.
- **Doubling the Androgen Pulse (~3000 ng/dL):**
  Pushing testosterone to extreme levels (around 3000 ng/dL) is predicted to yield a moderately higher DSB count (perhaps ~20–30+ DSBs per cell), but not a dramatic multiplication of breaks, due to saturating AR signaling dynamics. The incremental increase in DSBs with additional androgen is limited once AR OSNs

are maximally activated. In practical terms, even a very high BAT pulse would induce on the same order of magnitude of DNA breaks (dozens per cell, not hundreds).

It's important to note that the biological context of these DSBs differs between SBRT and BAT. SBRT's radiation produces a massive burst of random DNA breaks, overwhelming the cell and often killing it outright if damage is not repaired. BAT's high-androgen strategy produces fewer breaks, but those breaks are strategically inflicted at transcriptionally active sites and coupled with suppressed repair capacity. As a result, a BAT-induced DSB, though fewer in number, may persist unrepaired and trigger tumor cell senescence or apoptosis (especially in cells already compromised by AR overexpression or defective DNA repair). In clinical practice, these approaches can even be complementary – for example, there is rationale for combining BAT with radiation or DNA repair inhibitors to exploit the androgen-induced DNA damage and repair downregulation for greater therapeutic effect. Overall, a high-dose SBRT session induces an order of magnitude more DSBs per cell than a high-testosterone BAT pulse, but both create lethal DNA stress on cancer cells through very different mechanisms. Each leverages DNA double-strand breaks – either by brute force (radiation) or by subverting the cell's own signaling (androgen/AR) – to combat prostate tumor cells.

---

## DNA DSB Induction by SBRT and BAT

### 1. DSBs per Cell from SBRT (~7–10 Gy) in Prostate Cancer

Ionizing radiation at therapeutic doses causes a significant number of DNA double-strand breaks in each cell. Roughly ~40 DSBs are induced per cell per 1 Gy of X-rays. Therefore, a single high-dose SBRT fraction of about 7–10 Gy would produce on the order of ~280–400 DSBs per cell in the targeted prostate tumor. (For example, 7 Gy × ~40 DSB/Gy ≈ 280 DSBs; 10 Gy ≈ 400 DSBs.) These estimates align with radiobiology data indicating that DSBs, though relatively infrequent (~40 per Gray per cell), are among the most lethal radiation-induced lesions. In practice, many of these hundreds of DSBs will be repaired or misrepaired within hours by the cell's DNA repair mechanisms, but the initial burden per cell from one SBRT session is on the order of a few hundred DSBs.

### 2. DSBs per Cell from a High Testosterone Pulse (~1500 ng/dL vs. ~3000 ng/dL) in BAT

Supraphysiologic androgen pulses, as used in Bipolar Androgen Therapy (BAT), can trigger transient DNA DSBs in prostate cancer cells. High-dose testosterone (T) drives the androgen receptor (AR) onto DNA and recruits topoisomerase IIβ, causing site-specific breaks at androgen response elements. Experimental data in AR-positive prostate cancer cell lines show that "supraphysiological" androgen levels induce on the order of tens of DSBs per cell. For instance, one study found ~16 γH2AX foci (DSB markers) per cell at a moderate androgen dose (~1 nM R1881, a synthetic androgen) in AR-overexpressing cells, compared to ~2 foci per cell in controls – and even higher foci counts at 10 nM androgen (a truly high level). Translating these in vitro doses to serum T levels: 1–10 nM roughly corresponds to mid-physiologic (~300 ng/dL) up to supraphysiologic (>1000 ng/dL) concentrations. Thus:

- A BAT pulse reaching ~1500 ng/dL (about 2–3 times normal physiological T) might induce on the order of ~10–20 DSBs per cell (transiently).
- Increasing the pulse to ~3000 ng/dL (double the concentration) is unlikely to double the DSB count (since AR binding sites saturate at high ligand levels). It may yield a somewhat higher break count – perhaps on the order of ~20–30 DSBs per cell – but likely with diminishing returns. In summary, both 1500 and 3000 ng/dL pulses induce transient DSBs in tumor cells (on the order of 10–30 per cell), with the higher pulse pushing the count toward the upper end of that range.

*(Note: These BAT-induced breaks are usually repaired within 24 hours in repair-proficient cells – they are a "burst" of DNA damage that triggers cell-cycle arrest or death if severe.)*

## 3. Unrepaired DSBs with Olaparib Combination

Poly(ADP-ribose) polymerase (PARP) inhibitors like olaparib prevent efficient repair of DNA single-strand breaks (SSBs) and base damage, causing SSBs to convert into additional DSBs upon replication. They also trap PARP on DNA, hindering repair, and consequently increase the persistence of DSBs caused by other treatments. Below we estimate how many DSBs remain unrepaired under various combinations, focusing on one treatment session and assuming the cancer cells have intact repair OSNs (no BRCA2 mutation).

### 3.1 Unrepaired DSBs with BAT + Olaparib

When a high testosterone pulse is combined with olaparib, the transient DSBs from BAT become more persistent and numerous. PARP inhibition alone causes a slight increase in baseline DNA breaks (e.g. raising γH2AX foci from ~1 to ~4 per cell), but when coupled with supraphysiologic androgen the effect is dramatically amplified. In AR-positive prostate cells, olaparib + High-T roughly tripled the number of DSB foci compared to High-T alone. For example, one study reported ~49 DSB foci per cell with combined olaparib + high androgen in AR-overexpressing cells, versus ~16 foci with the same androgen alone. This suggests that many breaks induced by the androgen pulse are not being repaired when PARP is blocked. In a repair-proficient context (no BRCA defect), the majority of these ~50 or so breaks per cell would normally have been fixed within 24 hours – but with PARP inhibition, a substantial fraction remain unresolved, driving the cells into senescence or death.
**Estimated outcome:** After a single BAT + olaparib session, on the order of dozens of DSBs per cell remain unrepaired; numerically, perhaps ~10–20 DSBs per cell still unrepaired at 24 hours.

### 3.2 Unrepaired DSBs with SBRT + Olaparib

Combining olaparib with radiation (SBRT) is a classic radiosensitization strategy: the PARP inhibitor converts radiation-induced SSBs into additional DSBs and slows the repair of radiation DSBs. After an SBRT dose (7–10 Gy, causing a few hundred initial DSBs per cell), DNA repair processes like non-homologous end joining and homologous recombination will attempt to fix the damage. In proficient cells without PARP inhibition, a large fraction of DSBs are repaired within hours – for example, after 3 Gy (~120 DSBs), only about 10–15% of the damage might still be detectable at 24 hours. Extrapolating to ~8 Gy, this suggests on the order of ~10–30 DSBs per cell could remain unrepaired by 24 hours after SBRT alone. With olaparib on board, however, the burden of unrepaired breaks roughly doubles. In absolute terms, if ~8 Gy SBRT alone might leave ~20 persistent DSBs, SBRT + olaparib might leave ~40 (±) DSBs per cell unrepaired after the same period.

### 3.3 Unrepaired DSBs with Combined BAT + SBRT + Olaparib

When all three modalities are applied together (a High-T pulse concurrent with SBRT, plus olaparib), the DNA damage is maximized and repair is most compromised. The androgen pulse itself adds some DSBs and, crucially, suppresses DSB repair OSNs – high androgen levels downregulate key repair genes (such as BRCA2) and reduce RAD51 focus formation for homologous recombination. This means that during BAT the cell's ability to accurately repair DNA breaks is impaired. If SBRT is given at that moment, the radiation will induce its usual hundreds of DSBs, but the cell is in a state of repair lethargy – further exacerbated by olaparib blocking SSB repair. The result is a potentially lethal onslaught of DNA damage with very limited repair. A rough estimate might be that the combined BAT + SBRT + olaparib treatment leaves well over 100 DSBs per cell unrepaired after 24 hours (for example, if SBRT+olaparib leaves ~40 persistent

breaks, the High-T might further amplify the effect two- to three-fold). This “damage overload” is sufficient to drive cell death via mitotic catastrophe or apoptosis.

DNA double-strand breaks (DSBs) are among the most dangerous forms of DNA damage. Even a single unrepaired DSB can be lethal to a cell, and multiple simultaneous DSBs can quickly overwhelm cellular repair mechanisms. Below we estimate the number of DSBs per cell considered “excessive” for various outcomes, and relate these to whole-body radiation dose equivalents (using the rule of thumb that ionizing radiation produces ~20–40 DSBs per cell per Gray (Gy) of exposure).

### 1. Severe Toxicity in Normal Cells (Apoptosis or Senescence Thresholds)

Normal cells can typically repair a limited number of DSBs, but beyond a certain threshold the DNA damage response triggers apoptosis or permanent cell-cycle arrest (senescence). On the order of tens of DSBs per cell appears to be an excessive load for most cells:

- *Threshold for cell death:* Just a few unrepaired DSBs can kill a cell. In practice, if a cell incurs >10–20 DSBs at once (roughly from a 0.5–1 Gy acute exposure), the p53-dependent damage response often pushes the cell toward apoptosis or senescence. For example, in mouse oocytes as few as ~10 DSBs per cell (from ~0.45 Gy of γ-rays) are sufficient to eliminate virtually all the oocytes via apoptosis. Most somatic cells are more resilient than oocytes, but a similar scale of DSB burden (dozens of breaks) in a single cell can activate checkpoints leading to cell death or loss of reproductive capacity.
- *Context of repair kinetics:* Cells experience some DSBs during normal metabolism (e.g. an estimated 10–50 DSBs per cell per day from oxidative byproducts), but these occur over time and are rapidly repaired. It is the simultaneous accumulation of many breaks that is toxic. If repair OSNs are overwhelmed by a cluster of DSBs, the cell cannot maintain genomic integrity and will often initiate apoptosis to prevent propagation of damage. In cultured human cells, about 20 DSBs per cell (≈1 Gy) typically causes a robust DNA damage foci response but remains mostly repairable, whereas higher loads (e.g. >40 DSBs per cell (≈2 Gy)) greatly increase the fraction of cells undergoing apoptosis or permanent growth arrest.
- *Whole-body equivalent:* An acute whole-body dose in the range of 0.5–1 Gy (causing on the order of 15–30 DSBs per cell) can lead to widespread cell death in sensitive tissues. This is approaching the lower bound of acute radiation syndrome, where enough cells in the body are compromised to cause tissue dysfunction. In summary, tens of DSBs per cell is an excessive threshold for individual cell viability, beyond which normal cells enter apoptosis/senescence to avoid malignant transformation.

### 2. Increased Genomic Instability and Secondary Malignancies

Even if a cell survives an initial DNA damage insult, misrepaired DSBs can produce chromosomal aberrations that seed genomic instability. Persistent or misjoined DSBs (even a small number) are a recipe for secondary cancers:

- *Low-dose breaks can induce mutations:* There is no strict “safe” threshold; even one or two misrepaired DSBs can cause a chromosomal translocation or deletion, potentially activating oncogenes or knocking out tumor suppressors. For instance, ionizing radiation that produces only a couple of DSBs per cell (e.g. a few centigray of exposure) is enough to elevate the frequency of stable chromosome translocations in surviving cells, which are a known signature of radiation-induced genomic instability. Accumulation of unrepaired or misrepaired breaks leads to genomic rearrangements and tumorigenesis if the cell does not die.
- *“Excessive” breaks for genomic stability:* If a cell incurs on the order of ~5–10 DSBs that are improperly repaired, its progeny may display ongoing instability (breakage-fusion-bridge cycles, aneuploidy, etc.). Exposures around 0.2–0.5 Gy (yielding a few to a dozen DSBs per cell) can increase

mutation rates and late chromosomal abnormalities in cell populations. In radiotherapy patients, for example, each additional 1 Gy to normal tissues is associated with an ~8.5% increase in secondary malignancy risk over time. This implies that even ~30 DSBs per cell (≈1 Gy) in normal tissue, if not perfectly repaired, measurably boosts cancer risk years later.

- *Threshold vs. probability:* There may not be a single sharp DSB cutoff for instability; rather, risk rises with DSB frequency. That said, a cell sustaining >~20–50 DSBs at once (≈1–2 Gy) is not only likely to die, but any cells that survive such damage have a high chance of bearing complex chromosomal rearrangements. Those surviving, damaged cells can clonally expand with genomic alterations, laying the groundwork for secondary malignancies. In summary, any DSB load beyond the few breaks routinely handled by the cell can threaten genomic stability, and exposures causing dozens of DSBs per cell greatly increase the probability of future malignancy.

## 3. Systemic Effects of Excessive DSBs (Whole-Body Radiation Toxicity)

When a large fraction of cells across an organism suffer excessive DSBs, it leads to acute radiation sickness and organ failure. Human data (from radiation accidents and therapy) provide dose thresholds in Gray, which we can translate into DSBs per cell:

- *Hematopoietic syndrome:* Whole-body doses >0.7 Gy (roughly >20 DSBs per cell) cause Acute Radiation Syndrome (ARS) of the bone marrow. At ~0.7–1 Gy, enough stem and progenitor cells in the bone marrow are destroyed or become senescent so that blood cell counts fall over days to weeks. Mild ARS symptoms can appear even at ~0.3 Gy (≈10 DSBs per cell). Without medical support, the $LD_{50}$ (lethal dose for 50% of people) is on the order of ~2.5–5 Gy whole-body. This corresponds to each cell having on average on the order of 75–150+ DSBs. At around 4 Gy (~100–120 DSBs per cell), the bone marrow is fatally damaged in most individuals, leading to infection and hemorrhage due to loss of blood cell production. (Notably, the primary cause of death in this dose range is hematopoietic failure, as reported by studies on unrepaired DSBs.)
- *Gastrointestinal (GI) syndrome:* Whole-body doses >~6–10 Gy (~180–300 DSBs per cell) cause severe GI tract damage. The intestinal epithelium's stem cells are ablated by the radiation, leading to an inability to replenish the lining of the gut. Full GI syndrome (often fatal within ~2 weeks) is evident above ~10 Gy. This level of exposure causes hundreds of DSBs in each cell, far beyond repair capacity, resulting in massive cell loss in the intestinal mucosa in addition to total bone marrow failure.
- *Neurovascular/CNS syndrome:* At ~20–50 Gy (thousands of DSBs per cell), even relatively DSB-tolerant tissues like brain and cardiovascular endothelium are acutely affected. Such doses (usually only reached in nuclear accidents) cause rapid neurological symptoms (seizures, loss of coordination) and cardiovascular collapse within hours to days. The full neurovascular syndrome occurs >~50 Gy (all exposed individuals would die, often within 48 hours). This reflects widespread cell death, microvascular damage, and acute inflammation in critical organs.
- *Systemic summary:* In humans, an acute whole-body exposure of ~1 Gy (~30 DSBs per cell) is enough to cause illness (ARS); ~4 Gy (~100+ DSBs per cell) is often lethal without treatment; and >10 Gy (>300 DSBs per cell) is invariably catastrophic. Systemically, excessive DSBs mean that so many cells are impaired or killed that organ systems fail. The most sensitive systems (bone marrow, gut) set the overall acute dose limits for survivability.

## 4. Tissue-Specific Variations in DSB Tolerance (Hematopoietic vs. Epithelial vs. Neuronal)

Different cell types and tissues have different thresholds for DSB-induced dysfunction, depending on their proliferation rate and DNA repair characteristics:

- *Hematopoietic cells (blood and bone marrow):* These are among the most sensitive. Hematopoietic stem cells and lymphocytes undergo apoptosis with relatively few breaks. Lymphocytes can initiate programmed cell death from even a handful of DSBs (as part of the body's strategy to avoid lymphocyte mutations). In whole-body irradiation, the bone marrow is the first limiting tissue – doses of ~0.5–1 Gy (~15–30 DSBs per cell) already significantly deplete blood cell counts. Thus, the DSB threshold for severe toxicity is low in blood-forming tissues.

- *Epithelial cells (skin, intestinal lining):* These tissues renew constantly, so their stem cells are sensitive, but they also have robust repair and some redundancy. Skin can tolerate a moderate number of DSBs per cell before showing injury – for example, a one-time dose of ~1 Gy (~20–40 DSBs per cell) causes DNA damage foci in skin cells but typically no lasting lesion, whereas acute doses >2 Gy (≈40+ DSBs per cell) lead to observable skin reactions (erythema, desquamation) as cells are killed off faster than they can be replaced. The intestinal epithelium is less forgiving: its stem cells will die from a few dozen DSBs each, and GI syndrome ensues at doses >~10 Gy (where essentially all crypt stem cells suffer lethal DNA damage). In summary, epithelial tissues have an intermediate DSB tolerance – higher than bone marrow, but large DSB loads will cause ulceration or breakdown of the tissue barrier.
- *Neuronal cells (brain, spinal cord):* Fully differentiated neurons are non-dividing and tend to be more radioresistant in the short term – they can sustain more DNA damage without immediate loss of function. Neurons do repair DSBs (albeit often slowly), and because they are long-lived, unrepaired damage can accumulate. Acute doses under ~5 Gy (≤~150 DSBs per cell) cause little obvious immediate damage in the central nervous system, whereas extremely high doses (>20 Gy, thousands of DSBs per cell) are needed for the fulminant CNS syndrome. However, this "tolerance" is somewhat deceptive: neurons do not proliferate, so they won't manifest damage as acute cell loss the way dividing cells do – but they are still susceptible to DSB-induced cell death at higher exposures. Additionally, glial and endothelial cells in the brain are more sensitive than neurons and contribute to radiation-induced brain injury. Overall, neural tissue can endure a larger number of DSBs per cell acutely, but once that threshold is exceeded, the damage is often irreparable (and at lower doses, chronic effects like cognitive decline or demyelination can arise from misrepaired DSBs over time).
- *Other tissues:* Organs like muscle and connective tissue also have relatively quiescent cells and thus higher acute DSB thresholds (they show radiation injury only at higher doses, often secondary to vascular damage). In contrast, reproductive cells can be extremely sensitive – as noted, oocytes have a very low DSB tolerance (~10 DSBs can eliminate them), and spermatogonia are also highly sensitive to radiation (leading to sterility at doses on the order of 1–2 Gy). Thus, each tissue has its own "DSB limit" before function is compromised, largely determined by how vital cell proliferation is in that tissue and how effectively the cells can arrest and repair damage.

## 5. Influence of DNA Repair Capacity on DSB Thresholds in Various Tissues

The ability of cells to cope with DSBs is heavily dependent on DNA repair OSNs. Robust repair mechanisms raise the threshold for toxicity, whereas repair deficiencies lower it:

- *Differences in repair proficiency:* Tissues and cell types vary in the expression and activity of DSB repair proteins. Rapidly dividing cells (like bone marrow and gut epithelium) tend to have active repair machinery, but they also have tight cell-cycle checkpoints – meaning they will undergo apoptosis if breaks aren't fixed promptly. Cells with a high p53 response (e.g. lymphocytes) thus have a lower break tolerance because they self-destruct at the first sign of excessive damage. By contrast, some slowly dividing cells can tolerate more initial damage simply because they don't immediately attempt mitosis and can take longer to repair; however, if their repair is sluggish, they risk accumulating mutations.
- *Genetic repair deficiencies:* Individuals with inherited DNA repair syndromes illustrate how lower repair capacity reduces DSB thresholds. For example, patients with ataxia–telangiectasia (ATM mutation), Nijmegen breakage syndrome (NBS1 mutation), or Fanconi anemia are hypersensitive to radiation. Their cells cannot efficiently repair DSBs, so even normal background DSB levels can lead to chromosome breaks. Such individuals may suffer tissue damage or cancers at radiation doses that would be considered safe for others. In practical terms, a person with one of these syndromes might experience severe toxicity from a dose that produces just ~5–10 DSBs per cell, whereas a normal individual's cells would cope with that damage. Likewise, defects in the non-homologous end joining OSN (e.g. DNA-PK or Ligase IV mutations) cause extreme radiosensitivity – even low-level exposures result in unrepaired breaks, triggering cell death (particularly in the immune system, which is why NHEJ defects often cause SCID).
- *Enhanced repair lowering risk:* Conversely, cells or organisms with highly efficient DSB repair can endure more breaks before hitting the "excessive" threshold. Some species demonstrate this – for instance, certain radioresistant rodents or tardigrades can repair DNA damage so well that their $LD_{50}$

occurs at doses much higher (meaning far more DSBs per cell) than in humans. Even among humans, there are subtle polymorphisms in DNA repair genes that may make one person's normal tissues more radio-tolerant than another's. For example, variation in genes controlling DSB repair foci formation (like 53BP1 or ATM) can influence how quickly breaks are sensed and mended, affecting the threshold at which cells undergo apoptosis.

- *Tissue-specific repair context:* Some tissues favor certain repair OSNs. Neurons, for instance, rely on non-homologous end joining (NHEJ) since they are mostly in G0/G1 phase (homologous recombination is mostly unavailable); they also have active backup OSNs to repair DSBs slowly over time, which contributes to their higher acute threshold. Stem cell compartments might prioritize high-fidelity repair (homologous recombination) when possible to protect genomic integrity, potentially sacrificing cells via apoptosis rather than risk misrepair – this makes stem cell niches sensitive to DSBs despite robust repair machinery. In contrast, more differentiated cells might bypass strict checkpoints and attempt to survive with damage, raising their immediate DSB tolerance but at the cost of long-term genomic stability.
- *In summary:* DNA repair capacity is a critical modifier of DSB thresholds. Cells with fast and accurate DSB repair can survive higher numbers of breaks, whereas cells or organisms with compromised repair will hit toxicity or instability outcomes at much lower DSB counts. Understanding these repair differences helps explain why, for example, the bone marrow is incapacitated by ~20 DSBs per cell, while a neuron might endure 100+ DSBs temporarily, and why a person with a repair syndrome could suffer radiation injury at a dose yielding only a few breaks per cell. The balance between DSB induction and repair is ultimately what determines if a given number of DNA breaks is "excessive" for a particular cell or tissue.

## Summary of some DNA DSBs

| Treatment/ Method | DSBs Induced per Cell (Approx.) | Persistent/ Unrepaired DSBs | Notes & Toxicity Thresholds |
|---|---|---|---|
| **SBRT Alone (7–10 Gy)** | ~280–400 DSBs (e.g. ~8 Gy → ~320 DSBs) | ~10–30 DSBs at 24 hrs (in repair-proficient cells) | Ionizing radiation produces widespread, random breaks. Although many are repaired, an unrepaired burden >10–20 DSBs can trigger apoptosis. |
| **SBRT + Olaparib** | Initial ~280–400 DSBs | ~~40 persistent DSBs | PARP inhibition slows repair, roughly doubling the number of breaks that remain unrepaired. |
| **BAT Alone – High-T (~1500 ng/dL)** | ~10–20 DSBs | Transient; most are repaired within 24 hrs | Androgen receptor (AR)–mediated, site-specific breaks. Although fewer in number, these DSBs are strategically inflicted. |
| **BAT Alone – Extreme High-T (~3000 ng/dL)** | ~20–30 DSBs | Transient; modest increase due to AR saturation | Elevated testosterone levels lead to an increase in DNA breaks; however, the binding of androgen receptors (AR) eventually reaches a saturation point, which curtails further escalation. Furthermore, the human body has a defined threshold for the stress it can endure. |
| **BAT + Olaparib** | BAT-induced ~10–20 DSBs | ~10–20 DSBs persist (observed ~49 foci in high-AR cells) | With PARP inhibition, many of the androgen-induced DSBs persist longer, promoting cell-cycle arrest or death. |
| **Combined BAT + SBRT + Olaparib** | SBRT-induced (280–400) + BAT-induced (10–20) ≈ 300–420 total | >100 DSBs per cell | The cumulative damage overwhelms repair (further compounded by androgen-induced repair suppression), leading to lethal genomic stress. |

**Note:** These numbers are approximate and context dependent. The “toxicity threshold” for a cell is reached when repair mechanisms are overwhelmed (typically when >10–20 unrepaired DSBs occur in sensitive cell types), and the combined treatments can push cells into apoptosis or mitotic catastrophe.

## References


1. DSBs are induced by high T: Supraphysiological androgens suppress prostate cancer growth through androgen receptor–mediated DNA damage – PMC https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6763228/
2. DSBs and their importance explained: Frontiers | Harnessing DNA Double-Strand Break Repair for Cancer Treatment https://www.frontiersin.org/articles/10.3389/fonc.2019.01388/full
3. Bioflavonoids cause DNA double-strand breaks and chromosomal translocations through topoisomerase II-dependent and -independent mechanisms – PMC https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7079294/

## Therapy History

**Evolution of My Perspective and Treatment Journey**

My outlook on prostate cancer and its treatment has significantly evolved since my initial diagnosis. Early on, I was more inclined to accept non-evidence-based approaches without rigorous scrutiny. Over time, my decisions became increasingly informed by molecular data, clinical evidence, and pragmatic self-experimentation.

---

**2015 – First Signs and Hesitation**

When my PSA rose above 4 ng/mL in 2015, I had no prior health issues. Alarmed, I turned to online forums and fringe theories, many of which downplayed the need for biopsy. I now recognize that I was using anecdote-driven "bro-science" as a rationalization to avoid what I feared would be a painful or risky procedure.

---

**2018 – Diagnosis and Treatment**

By 2018, my PSA had climbed to 12 ng/mL. In August, I underwent a biopsy that revealed localized prostate cancer—Gleason 3+4, stage T2. The procedure was straightforward, and side effects resolved quickly. A pathology review at Mayo Clinic confirmed the diagnosis. I underwent radical prostatectomy in December 2018. Postoperative pathology revealed a more aggressive profile: Gleason 4+5=9, seminal vesicle and bladder neck invasion, and one positive lymph node, reclassifying my case as pT3b/T4 N1 M0 (Stage IVA).

Despite requesting a second opinion from Johns Hopkins, the review was based on pre-surgical biopsy tissue and yielded a Gleason 4+5 grade. It’s worth noting that such discrepancies between biopsy and surgical pathology are not uncommon.

---

**Early 2019 – Recovery and Molecular Profiling**

Following surgery, I allowed myself time to rest and reflect. Molecular profiling identified two somatic loss-of-function mutations in the **KMT2D** gene—both a stop-gain and a frameshift. These impair epigenetic regulation and genomic stability, potentially sensitizing tumors to **PARP inhibitors** such as **olaparib**.

---

**Lifestyle Overhaul**

Understanding the well-established link between physical activity and improved prostate cancer outcomes, I returned to training with renewed commitment. My regimen included hypertrophy-focused resistance training, cardiovascular conditioning, and flexibility work, totaling 3 to 8 hours per week. Initially, my diet centered on whole, unprocessed plant-based foods. Over time, I adopted a more relaxed “eat what I want” approach—though in practice, this still meant eating a largely unprocessed, health-conscious diet with minimal reliance on highly processed foods.

---

**Feb–Apr 2019 – Experimental Adjuncts**

During this time, I integrated high-dose IV vitamin C (50–100g thrice weekly), 15 mg phenelzine QID, and daily curcumin. My Mayo Clinic urologist noted no PSA recurrence and was surprised by the outcome, suggesting possible disease stability.

---

**May–Aug 2019 – Estrogen-Based ADT and Additional Agents**

I initiated ADT using **transdermal estrogen patches** in place of conventional LHRH drugs. Concurrent medications included:

- **Abiraterone (Zytiga)**: 250–1000 mg/day
- **Prednisone**: 5–10 mg/day (split)
- **Lovastatin** (TC target 170-190 mg/dL.
- **Vitamin D3** (target: 35 ng/mL)

Estrogen minimized ADT side effects and the expense of gynecomastia.

---

**Sep 2019 – Androgen Receptor Blockade (Bicalutamide)**

I transitioned to **150 mg/day bicalutamide** + **0.5 mg/day dutasteride**, while maintaining prior medications. Testosterone levels rose (>2000 ng/dL), but AR signaling remained blocked. The goal was to restore libido and lean mass without reactivating tumor growth.

---

**Oct 2019 – Supraphysiologic Testosterone (SPT)**

Dissatisfied with lingering ADT effects and motivated by early SPT literature, I began **testosterone injections**. Levels exceeded 2000–4000 ng/dL. Libido and performance surged. PSA remained <0.01 ng/mL for a year, then fluctuated slightly up to 0.17 ng/mL in July 2021.

---

**Sep 2020 – Clean Imaging**

Standard CT and PET scans showed no active disease.

**August 2021 – aBAT Initiation**

I began adaptive BAT (aBAT), starting with an ADT lead-in.

---

**Aug 2022 – Imaging and Bone Health**

A Pylarify PSMA-PET showed no cancer, though Signatera Natera showed progression. Natera showed severe progression in 2023. Pylarify eventually confirmed in the summer of 2023. DEXA in August 2022 showed a 5.2% bone density improvement, reversing prior osteopenia.

---

**Aug–Oct 2023 – Progression and SBRT**

New lymph node metastases were confirmed. I underwent **five rounds of SBRT/olaparib/SPA/ARSI/ADT** targeting affected nodes.

---

**2024 – Disruption and Therapy Drift**

Personal challenges interrupted structured BAT. I maintained high-T therapy similar to aBAT but without formal cycling.

---

**Jan–Mar 2025 – Resumption of Scheduled aBAT**

Scheduled aBAT resumed. PSA values were:

- **High-T**: 1.16 ng/mL (Feb)
- **Low-T**: 0.45 ng/mL (Mar)

Pylarify scan in March showed a single inconclusive focus—likely urinary tracer.

---

**May 2025 – Molecular Tests**

- **Natera ctDNA**: MRD not detected (down from 1.16 MTM/mL pre-SBRT)
- **Guardant360 CDx**: No actionable mutations, ctDNA fraction <0.05%, MSI stable
- **FoundationOne RNA**: Awaiting results

**Treatment Summary and Biomarker Evolution**

| Parameter | 2019 (Post-RP) | 2021–2025 (aBAT) |
|---|---|---|
| **TMB (mut/Mb)** | 1.2 | 4.6 → 4.1 → NQ |
| **PSA** | <0.01 ng/mL | 0.17 → 3.0 → 0.17 |
| **ctDNA** | N/A | 0.0 → 0.18 → 1.16 → 0.0 |
| **MSI** | Stable | Stable |
| **PD-L1** | N/A | Not detected |
| **AR protein** | N/A | 303 amol/µg (↓ vs. median 371) |
| **IGF1R** | N/A | 177 amol/µg (↓ vs. median 268) |

## My Personal Program as of 07/2025

My main treatment is cyclical aBAT as defined in: Integrating the Concepts: *** Integrating the Concepts: Mechanistic Optimization of BAT Cycle Durations – Program Overview (2023–2025+)

1. **Weight Management:**
   In 2024, I gained 80 lbs. of fat due to a poor diet, lack of exercise, and high stress. In November 2024, I reduced my caloric intake and in February of 2025 I introduced a combination of fasting-mimicking, hypocaloric, and high-calorie “refeed” diets. By May 2025, I had lost 80 lbs.
2. **Testing Schedule:**
   - **Monthly or as needed:** PSA and testosterone.
   - **Quarterly or as needed:** CBC, CMP.
   - **Yearly or as needed:** Vitamin D3, E2, HbA1C, lipids, DHT, Hs-CRP, and IGF-1.
   - **Insurance-covered tests:** Somatic DNA mutations, ctDNA, TMB, MRD, DEXA BMD, and PSMA-PET scan (if ≤5 metastases are detected I plan to perform SBRT as outlined in the Radiation section).
   - **Additional tests as needed:** CgA, BAP, Leptin, Adiponectin, CTx, P1NP, IGFBP-1, B12, folate, thyroid panel, cortisol, IL-6, E1, E3, etc.